RNA Interactome of Polycomb Repressive Complex 1 (PRC1)

TECHNICAL FIELD

This invention relates to the RNA interactome of Polycomb Repressive Complex 1 (PRC1) and methods of using inhibitory nucleic acids that bind RNAs and inhibit the PRC1-RNA interaction to modulate gene expression.

BACKGROUND

Transcriptome analyses have suggested that, although only 1-2% of the mammalian genome is protein-coding, 70-90% is transcriptionally active (Carninci et al., 2005; Kapranov et al., 2007; Mercer et al., 2009). Ranging from 100 nt to >100 kb, these transcripts are largely unknown in function, may originate within or between genes, and may be conserved and developmentally regulated (Kapranov et al., 2007; Guttman et al., 2009). Recent discoveries argue that a subset of these transcripts play crucial roles in epigenetic regulation.

RNA-mediated recruitment is especially attractive for Polycomb proteins. First identified in Drosophila as homeotic regulators, Polycomb proteins are conserved from flies to mammals and control many aspects of development (Ringrose and Paro, 2004; Boyer et al., 2006; Lee et al., 2006; Schuettengruber et al., 2007; Pietersen and van Lohuizen, 2008; Schwartz and Pirrotta, 2008).

Polycomb Repressive Complex 1 (PRC1) is the enzymatic complex that ubiquitylates histone H2A at lysine 119 (H2AK119Ub). In mammals, it is composed of multiple variable subunits, including (1) the catalytic subunit, Ring1b or Ring1a; (2) Bmi1 (which can be PCGF1, PCGF2, PCGF3, PCGF5, or PCGF6); (3) PH1 (or PH2, PH3); and (4) CBX2, 4, 6, 7, or 8. Action of PRC1 on chromatin results in chromatin compaction and transcriptional repression. The classical PRC1 complex exists in two forms in which either CBX and MPH or RYBP subunits associate with the catalytic core subunits RING1A/B and PCGF2/4. The PRC1 interacting protein, SCMLH1/2/3, is only weakly associated/substoichiometric and is considered an accessory factor, rather than a core component. The RanBP-ZF domain present in RYBP/YAF2 has an RNA binding function in some related proteins but apparently not in RYBP/YAF2. See, e.g., Brockdorff, RNA 19:429-442 (2013); Yap et al., Mol Cell. 38(5):662-74 (2010).

Although PRC1 binds thousands of sites in the mammalian genome, how PRC1 is targeted to chromatin has remained a mystery. YY1 and the H3K27me3 chromatin mark may recruit PRC1 in some contexts, but they are unlikely to be the general or only mechanisms. RNA-mediated targeting is another potential mechanism. PRC1 is known to interact with at least one RNA, ANRIL, likely via the chromodomain (CD) of the CBX7 protein (Yap et al., Mol Cell. 38(5):662-74 (2010)). ANRIL is an antisense non-coding RNA (ncRNA) at the INK4b/ARF/INK4a locus (Pasmant et al., Cancer Res 67: 3963-3969 (2007)). How many RNAs interact with PRC1 and whether they are a general recruiting tool for PRC1 has not previously been determined.

SUMMARY

A new ‘denaturing’ CLIP-seq method was developed using the biotin-avidin method, which enables washes in high salt and urea (i.e., protein denaturing conditions). Because the exemplified system includes two protein tags, FLAG and biotin, purification can be performed with either tag or conducted as a tandem affinity purification (e.g., FLAG purification first, followed by biotin pulldown). For the denaturing method, the biotin tag is preferably used. During CLIP, because the interacting RNAs are UV-crosslinked to RNA-binding proteins in a covalent fashion, the RNA-protein interactions survive the wash conditions, whereas nonspecific, low-affinity interactions are not preserved. These methods were used to identify genome-wide pools of polycomb repressive complex 1 (PRC1)-interacting RNAs (referred to herein as the “PRC1 transcriptome” or “PRC1 RNA interactome”) in several cell types, including embryonic stem cells and human fibroblast cells.

The results of the studies described herein demonstrated that PRC1 binds both noncoding RNA and coding RNA. The transcriptome includes antisense, intergenic, and promoter-associated transcripts, as well as many unannotated RNAs. A large number of transcripts occur within imprinted regions, oncogene and tumor suppressor loci, and stem-cell-related bivalent domains. Further evidence is provided that inhibitory oligonucleotides that specifically bind to these PRC1-interacting RNAs can successfully modulate gene expression in a variety of separate and independent examples, presumably by inhibiting PRC1-associated effects. PRC1 binding sites can be classified into several groups, including (i) 3′ untranslated region [3′ UTR], (ii) promoter-associated, (iii) gene body, (iv) antisense, and (v) intergenic. Inhibiting the PRC1-RNA interactions can lead to either activation or repression, depending on context.

Also provided herein are methods for isolating RNA sequences that interact with a selected protein, e.g., with chromatin complexes, in a cell; the methods include providing a cell expressing (i) a biotin ligase, e.g., BirA, and (ii) the protein of interest comprising a biotinylation sequence; exposing the cells to UV-crosslinking; lysing the cells, isolating protein-RNA complexes from the lysed cells, e.g., using avidin purification, e.g., streptavidin beads; washing the complexes in protein-denaturing conditions, e.g., high salt and detergent, e.g., using 8 M urea+0.1% SDS; and isolating the protein-RNA complexes.

In one aspect, described herein are methods for isolating RNA sequences that interact with a selected protein, e.g., with chromatin complexes. The methods include providing a cell expressing (i) a biotin ligase, e.g., BirA, and (ii) the protein of interest comprising a biotinylation sequence; exposing the cells to UV-crosslinking to crosslink the proteins to RNA, to create protein-RNA complexes; lysing the cells to obtain a sample comprising the protein-RNA complexes; isolating protein-RNA complexes from the lysed cells, e.g., using avidin purification, e.g., streptavidin beads; washing the complexes in protein-denaturing conditions, e.g., high salt and detergent, e.g., using 8 M urea+0.1% SDS; and isolating the protein-RNA complexes.

In some embodiments, the methods include optionally preparing a plurality of validated cDNAs complementary to the pool of ribonucleic acids (RNAs) that bind to the protein of interest; these methods include synthesizing DNA complementary to the RNAs to provide an initial population of cDNAs; PCR-amplifying, if necessary, using strand-specific primers; purifying the initial population of cDNAs to obtain a purified population of cDNAs that are at least about 20 nucleotides (nt) in length, e.g., at least 25, 50, 75, 100, 150, 200, or 250 nt in length; sequencing at least part or substantially all of the purified population of cDNAs; aligning reads to a reference genome and retaining only those that are aligned; selecting high-confidence cDNA sequences, optionally, based on criteria that (1) the candidate transcript has a minimum read density in reads per kilobase per million reads (RPKM) terms (e.g., above a desired threshold); and/or (2) the candidate transcript is enriched in the wildtype library versus a suitable control library (such as an IgG pulldown library or a protein-null pulldown library); thereby preparing the plurality of cDNAs. In some embodiments, the cDNAs are synthesized using strand-specific adaptors.

In some embodiments, the method is used to prepare a library representing a transcriptome associated with the protein of interest.

In some embodiments, the methods further include sequencing substantially all of the cDNAs.

In another aspect the invention features an inhibitory nucleic acid that specifically binds to, or is complementary to a region of an RNA that is known to bind to Polycomb repressive complex 1 (PRC1), wherein the sequence of the region is selected from the group consisting of SEQ ID NOs:1 to 5893 (human), 5894 to 17415 (human), and 17416 to 36368 (mouse) as set forth in Tables 1-3. Without being bound by a theory of invention, these inhibitory nucleic acids are able to interfere with the binding of and function of PRC1, by preventing recruitment of PRC1 to a specific chromosomal locus. For example, data herein shows that a single administration of inhibitory nucleic acids designed to specifically bind a RNA can alter expression of a gene associated with the RNA. Data provided herein also indicate that putative ncRNA binding sites for PRC1 show no conserved primary sequence motif, making it possible to design specific inhibitory nucleic acids that will interfere with PRC1 interaction with a single ncRNA, without generally disrupting PRC1 interactions with other ncRNAs. Further, data provided herein support that RNA can recruit PRC1 in a cis fashion, repressing gene expression at or near the specific chromosomal locus from which the RNA was transcribed, thus making it possible to design inhibitory nucleic acids that inhibit the function of PRC1 and increase the expression of a specific target gene.

In some embodiments, the inhibitory nucleic acid is provided for use in a method of modulating expression of a “gene targeted by the PRC1-binding RNA” (e.g., an intersecting or nearby gene, as set forth in Tables 1-3 below), meaning a gene whose expression is regulated by the PRC1-binding RNA. The term “PRC1-binding RNA” or “RNA that binds PRC1” is used interchangeably with “PRC1-associated RNA” and “PRC1-interacting RNA”, and refers to an RNA transcript or a region thereof (e.g., a Peak as described below) that binds the PRC1 complex, directly or indirectly. Such binding may be determined by dCLIP-SEQ techniques described herein using a component of the PRC1 complex, e.g., PRC1 itself. SEQ ID NOs: 1 to 5893 represent human RNA sequences containing portions that have been experimentally determined to bind PRC1 using the dCLIP-seq method described herein; SEQ ID NOs: 17416 to 36368 represent murine RNA sequences containing portions that have been experimentally determined to bind PRC1 using the dCLIP-seq method described herein; and SEQ ID NOs: 5894 to 17415 represent or human RNA sequences corresponding to the murine RNA sequences.

Such methods of modulating gene expression may be carried out in vitro, ex vivo, or in vivo. Tables 1-3 display genes targeted by the PRC1-binding RNA; the SEQ ID NOS: of the PRC1-associated RNA are set forth in the same row as the gene name. In some embodiments, the inhibitory nucleic acid is provided for use in a method of treating disease, e.g. a disease category as described herein. The treatment may involve modulating expression (either up or down) of a gene targeted by the PRC1-binding RNA, preferably upregulating gene expression. The inhibitory nucleic acid may be formulated as a sterile composition for parenteral administration. It is understood that any reference to uses of compounds throughout the description contemplates use of the compound in preparation of a pharmaceutical composition or medicament for use in the treatment of a disease. Thus, as one nonlimiting example, this aspect of the invention includes use of such inhibitory nucleic acids in the preparation of a medicament for use in the treatment of disease, wherein the treatment involves upregulating expression of a gene targeted by the PRC1-binding RNA.

Diseases, disorders or conditions that may be treated according to the invention include cardiovascular, metabolic, inflammatory, bone, neurological or neurodegenerative, pulmonary, hepatic, kidney, urogenital, bone, cancer, and/or protein deficiency disorders.

In a related aspect, the invention features a process of preparing an inhibitory nucleic acid that modulates gene expression, the process comprising the step of synthesizing an inhibitory nucleic acid of between 5 and 40 bases in length, or about 8 to 40, or about 5 to 50 bases in length, optionally single stranded, that specifically binds, or is complementary to, an RNA sequence that has been identified as binding to PRC1, optionally an RNA of any of Tables 1-3 or any one of SEQ ID NOs: 1 to 5893, or 5894 to 17415, or 17416 to 36368. This aspect of the invention may further comprise the step of identifying the RNA sequence as binding to PRC1, optionally through the dCLIP-seq method described herein.

In a further aspect of the present invention a process of preparing an inhibitory nucleic acid that specifically binds to an RNA that binds to Polycomb repressive complex 1 (PRC1) is provided, the process comprising the step of designing and/or synthesizing an inhibitory nucleic acid of between 5 and 40 bases in length, or about 8 to 40, or about 5 to 50 bases in length, optionally single stranded, that specifically binds to an RNA sequence that binds to PRC1, optionally an RNA of any of Tables 1-3 or any one of SEQ ID NOs: 1 to 5893, or 5894 to 17415, or 17416 to 36368.

In some embodiments prior to synthesizing the inhibitory nucleic acid the process further comprises identifying an RNA that binds to PRC1.

In some embodiments the RNA has been identified by a method involving identifying an RNA that binds to PRC1.

In some embodiments the inhibitory nucleic acid is at least 80% complementary to a contiguous sequence of between 5 and 40 bases, or about 8 to 40, or about 5 to 50 bases in said RNA sequence that binds to PRC1. In some embodiments the sequence of the designed and/or synthesized inhibitory nucleic acid is based on a said RNA sequence that binds to PRC1, or a portion thereof, said portion having a length of from 5 to 40 contiguous base pairs, or about 8 to 40 bases, or about 5 to 50 bases.

In some embodiments the sequence of the designed and/or synthesized inhibitory nucleic acid is based on a nucleic acid sequence that is complementary to said RNA sequence that binds to PRC1, or is complementary to a portion thereof, said portion having a length of from 5 to 40 contiguous base pairs, or about 8 to 40 base pairs, or about 5 to 50 base pairs.

The designed and/or synthesized inhibitory nucleic acid may be at least 80% complementary to (optionally one of at least 90%, 95%, 96%, 97%, 98%, 99% or 100% complementary to) the portion of the RNA sequence to which it binds or targets, or is intended to bind or target. In some embodiments it may contain 1, 2 or 3 base mismatches compared to the portion of the target RNA sequence or its complement respectively. In some embodiments it may have up to 3 mismatches over 15 bases, or up to 2 mismatches over 10 bases.

The inhibitory nucleic acid or portion of RNA sequence that binds to PRC1 may have a length of one of at least 8 to 40, or 10 to 50, or 5 to 50, or 5 to 40 bases, e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 bases. Where the inhibitory nucleic acid is based on an RNA sequence that binds to PRC1, a nucleic acid sequence that is complementary to said RNA sequence that binds to PRC1 or a portion of such a sequence, it may be based on information about that sequence, e.g. sequence information available in written or electronic form, which may include sequence information contained in publicly available scientific publications or sequence databases.

In some embodiments, the isolated single stranded oligonucleotide is of 5 to 40 nucleotides in length and has a region of complementarity that is complementary with at least 5 contiguous nucleotides of the PRC1-binding RNA that inhibits expression of the target gene, wherein the oligonucleotide is complementary to and binds specifically within a PRC1-binding region of the PRC1-binding RNA and interferes with binding of PRC1 to the PRC1-binding region without inducing degradation of the PRC1-binding RNA (e.g., wherein the PRC1-binding region has a nucleotide sequence identified using a denaturing cross-linking immunoprecipitation procedure using an a biotin-tagged PRC1 as described herein), and without interfering with binding of PRC2 to a PRC2-binding region of the RNA (as described in WO 2012/087983 or WO 2012/065143, wherein the PRC2-binding region has a nucleotide sequence protected from nucleases during an RNA immunoprecipitation procedure using an antibody directed against PRC2), optionally wherein the PRC1-binding RNA is transcribed from a sequence of the chromosomal locus of the target gene, and optionally wherein a decrease in recruitment of PRC1 to the target gene in the cell following delivery of the single stranded oligonucleotide to the cell, compared with an appropriate control cell to which the single stranded oligonucleotide has not been delivered, indicates effectiveness of the single stranded oligonucleotide.

Where the design and/or synthesis involves design and/or synthesis of a sequence that is complementary to a nucleic acid described by such sequence information the skilled person is readily able to determine the complementary sequence, e.g. through understanding of Watson-Crick base pairing rules which form part of the common general knowledge in the field.

In the methods described above the RNA that binds to PRC1 may be, or have been, identified, or obtained, by a method that involves identifying RNA that binds to PRC1.

Such methods may involve the following steps: providing a sample containing nuclear ribonucleic acids, contacting the sample with an agent that binds specifically to PRC1 or a subunit thereof, allowing complexes to form between the agent and protein in the sample, partitioning the complexes, synthesizing nucleic acid that is complementary to nucleic acid present in the complexes.

If necessary, the method may further comprise the steps of amplifying the synthesized nucleic acid, and/or purifying the nucleic acid (or amplified nucleic acid), and/or sequencing the nucleic acids so obtained, and/or filtering/analysing the nucleic acids so obtained to identify high-probability PRC1 (or subunit thereof)-interacting transcripts.

In one embodiment the method involves the dCLIP-Seq method described herein.

In accordance with the above, in some embodiments the RNA that binds to PRC1 may be one that is known to bind PRC1, e.g. information about the sequence of the RNA and/or its ability to bind PRC1 is available to the public in written or electronic form allowing the design and/or synthesis of the inhibitory nucleic acid to be based on that information. As such, an RNA that binds to PRC1 may be selected from known sequence information and used to inform the design and/or synthesis of the inhibitory nucleic acid.

In other embodiments the RNA that binds to PRC1 may be identified as one that binds PRC1 as part of the method of design and/or synthesis.

In preferred embodiments design and/or synthesis of an inhibitory nucleic acid involves manufacture of a nucleic acid from starting materials by techniques known to those of skill in the art, where the synthesis may be based on a sequence of an RNA (or portion thereof) that has been selected as known to bind to Polycomb repressive complex 2.

Methods of design and/or synthesis of an inhibitory nucleic acid may involve one or more of the steps of:

Identifying and/or selecting a portion of an RNA sequence that binds to PRC1 (e.g., as shown in Tables 1-3);

Designing a nucleic acid sequence having a desired degree of sequence identity or complementarity to an RNA sequence that binds to PRC1 or a portion thereof;

Synthesizing a nucleic acid to the designed sequence;

Mixing the synthesized nucleic acid with at least one pharmaceutically acceptable diluent, carrier or excipient to form a pharmaceutical composition or medicament.

Inhibitory nucleic acids so designed and/or synthesized may be useful in method of modulating gene expression as described herein.

As such, the process of preparing an inhibitory nucleic acid may be a process that is for use in the manufacture of a pharmaceutical composition or medicament for use in the treatment of disease, optionally wherein the treatment involves modulating expression of a gene targeted by the RNA binds to PRC1.

Thus, provided herein are methods for isolating RNA sequences that interact with a selected protein, e.g., with chromatin complexes, in a cell. The methods include providing a cell expressing (i) a biotin ligase, e.g., BirA, and (ii) the protein of interest comprising a biotinylation sequence; exposing the cells to UV-crosslinking; lysing the cells, isolating protein-RNA complexes from the lysed cells, e.g., using avidin purification, e.g., streptavidin beads; washing the complexes in protein-denaturing conditions, e.g., high salt and detergent, e.g., using 8 M urea+0.1% SDS; and isolating the protein-RNA complexes. In some embodiments, the methods include labelling the RNA in the RNA-protein complexes, e.g., by phosphorylation using ³²P-ATP. In some embodiments, the methods include purifying the RNA-protein complexes, preparing cDNA from the RNA, and deep sequencing the cDNA to identify the RNA sequences bound to the protein.

Also provided are kits for use in the methods described herein; these kits include an expression vector comprising a sequence encoding a biotin ligase, and an expression vector comprising a sequence encoding a biotinylation sequence, and optionally one or more buffers. In some embodiments, the the buffers include one or more of a high stringency denaturing buffer, e.g., comprising 8 M urea (range: 5-10 M, 6-10M, 7-10M, 7-9M, or 7.5-8.5M) plus 0.1% SDS (range: 0.0-2.0%); a wash buffer (e.g., PBS+2% SDS; and a high salt wash buffer (e.g., PBS+750 mM NaCl+1% NP40+0.5% NaDeoxycholate+0.1% SDS).

In yet another aspect, the invention provides isolated nucleic acids comprising a sequence referred to in any of Tables 1-3, or a fragment comprising at least 20 nt thereof. In some or any embodiments, the invention provides an isolated nucleic acid comprising (a) an RNA sequence as set forth in Tables 1-3 that targets a proto-oncogene or oncogene as set forth in Tables 1-3, or (b) a fragment of (a) that is at least 20 bases in length that retains PRC1-binding activity, or (c) a derivative of (a) or (b) that is at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% homologous thereto, or (d) a nucleic acid of (a), (b), or (c) in which one or more bases has been replaced with a base of similar base-pairing capacity, such as replacing U with T. In preferred embodiments, the isolated nucleic acid of (a), (b) or (c) is for use in a method of decreasing expression of an oncogene. In some embodiments, the isolated nucleic acid is synthetic. In some embodiments, the isolated RNA comprises a SEQ ID NO. associated with Pvt1 in Tables 1-3. Pvt1 is known in the art to be disrupted in some cases of Burkitt's lymphoma as well as in plasmacytomas (e.g., by translocations from another chromosome). Therefore, Pvt1 is likely to act by targeting PRC1 to c-Myc in order to repress its expression. Accordingly, exogenous administration of any of the RNA sequences associated with Pvt1 in Tables 1-3, or inhibitory nucleic acids complementary thereto, could rescue Pvt1 loss-of-function phenotypes contributing to various cancers.

In a further aspect, the invention provides methods for decreasing expression of an oncogene in a cell. In some embodiments, the methods include contacting the cell with a PRC1-binding fragment described in any of Tables 1-3, or a nucleic acid sequence that is at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% homologous to a PRC1-binding fragment as referred to in any of Tables 1-3. In exemplary methods, the RNA a nucleic acid in which one or more bases has been replaced with a base of similar base-pairing capacity, such as replacing U with T. PRC1-binding fragments of murine or orthologous ncRNAs, including human ncRNA, which retain the ncRNA's ability to bind PRC1, are contemplated.

In yet another aspect, the invention features methods for increasing expression of a tumor suppressor in a mammal, e.g. human, in need thereof. The methods include administering to said mammal an inhibitory nucleic acid that specifically binds, or is complementary, to a human PRC1-interacting RNA corresponding to a tumor suppressor locus of any of Tables 1-3 or a human RNA corresponding to an imprinted gene of any of Tables 1-3, or a related naturally occurring RNA that is othologous or at least 90%, (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%%, or 100%) identical over at least 15 (e.g., at least 20, 21, 25, 30, 100) nucoleobases thereof, in an amount effective to increase expression of the tumor suppressor or growth suppressing gene. It is understood that one method of determining human orthologous RNA that corresponds to murine RNA is to identify a corresponding human sequence at least 90% identical (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical) to at least 15 nucleobases of the murine sequence (or at least 20, 21, 25, 30, 40, 50, 60, 70, 80, 90 or 100 nucleobases).

In an additional aspect, the invention provides methods for inhibiting or suppressing tumor growth in a mammal, e.g. human, with cancer, comprising administering to said mammal an inhibitory nucleic acid that specifically binds, or is complementary, to a human PRC1-interacting RNA corresponding to a tumor suppressor locus of any of Tables 1-3, or a human RNA corresponding to an imprinted gene of any of Tables 1-3, or a related naturally-occurring RNA that is orthologous or at least 90%, (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) identical over at least 15 (e.g., at least 20, 21, 25, 30, 50, 70, 100) nucleobases thereof, in an amount effective to suppress or inhibit tumor growth.

In another aspect, the invention features methods for treating a mammal, e.g., a human, with cancer comprising administering to said mammal an inhibitory nucleic acid that specifically binds, or is complementary, to a human RNA corresponding to a tumor suppressor locus of any of Tables 1-3, or a human RNA corresponding to an imprinted gene of Tables 1-3, or a related naturally occurring RNA that is orthologous or at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical over at least 15 (e.g., at least 20, 21, 25, 30, 50, 70, 100) nucleobases thereof, in a therapeutically effective amount.

Also provided herein are inhibitory nucleic acids that specifically bind, or are complementary to, a region of an RNA that is known to bind to Polycomb repressive complex 1 (PRC1), wherein the sequence of the region is selected from the group consisting of SEQ ID NOs:1 to 5893 (human), 5894 to 17415 (human), and 17416 to 36368 (mouse) as set forth in Tables 1-3, for use in the treatment of disease, wherein the treatment involves modulating expression of a gene targeted by the RNA, wherein the inhibitory nucleic acid is between 5 and 40 bases in length, and wherein the inhibitory nucleic acid is formulated as a sterile composition.

Further described herein are processs for preparing an inhibitory nucleic acid that specifically binds, or is complementary to, an RNA that is known to bind to Polycomb repressive complex 1 (PRC1), selected from the group consisting of SEQ ID NOs:1 to 5893 (human), 5894 to 17415 (human), and 17416 to 36368 (mouse) as set forth in Tables 1-3; the processes include the step of designing and/or synthesizing an inhibitory nucleic acid of between 5 and 40 bases in length, optionally single stranded, that specifically binds to a region of the RNA that binds PRC1.

In some embodiments, the sequence of the designed and/or synthesized inhibitory nucleic acid is a nucleic acid sequence that is complementary to said RNA sequence that binds to PRC1, or is complementary to a portion thereof, said portion having a length of from 5 to 40 contiguous base pairs.

In some embodiments, the inhibitory nucleic acid is for use in the manufacture of a pharmaceutical composition or medicament for use in the treatment of disease, optionally wherein the treatment involves modulating expression of a gene targeted by the RNA binds to PRC1.

In some embodiments, the modulation is increasing expression of a gene and the region of the RNA that binds PRC1 can be in intergenic space mapping to a noncoding RNA, antisense to the coding gene, or in the promoter, 3′UTR, 5′UTR, exons, and introns of a coding gene.

In some embodiments, the modulation is decreasing expression of a gene and the region of the RNA that binds PRC1 can be in intergenic space mapping to a noncoding RNA, antisense to the coding gene, or in the promoter, 3′UTR, 5′UTR, exons, and introns of a coding gene.

In some embodiments, the modulation is to influence gene expression by altering splicing of a gene and the region of the RNA that binds PRC1 can be in intergenic space mapping to a noncoding RNA, antisense to the coding gene, or in the promoter, 3′UTR, 5′UTR, exons, and introns of a coding gene.

Also provided herein are sterile compositions comprising an inhibitory nucleic acid that specifically binds, or is complementary to, an RNA sequence of any one of SEQ ID NOs:1 to 5893 (human), 5894 to 17415 (human), and 17416 to 36368 (mouse) and is capable of modulating expression of a gene targeted by the RNA as set forth in Tables 1-3.

In some embodiments, the composition is for parenteral administration. In some embodiments, the RNA sequence is in the 3′UTR of a gene, and the inhibitory nucleic acid is capable of upregulating or downregulating expression of a gene targeted by the RNA.

Also provided herein is an inhibitory nucleic acid for use in the treatment of disease, wherein said inhibitory nucleic acid specifically binds, or is complementary to, an RNA sequence of any one of SEQ ID NOs:1 to 5893 (human) or 5894 to 17415 (human), and wherein the treatment involves modulating expression of a gene targeted by the RNA according to Tables 1-3.

The present disclosure also provides methods for modulating gene expression in a cell or a mammal comprising administering to the cell or the mammal an inhibitory nucleic acid that specifically binds, or is complementary to, an RNA sequence of any one of SEQ ID NOs:1 to 5893 (human) or 5894 to 17415 (human) or 17416 to 36368 (mouse), in an amount effective for modulating expression of a gene targeted by the RNA according to Table 1-3.

In addition, provided herein are inhibitory nucleic acids of about 5 to 50 bases in length that specifically bind, or are complementary to, a fragment of at least five consecutive bases within any of SEQ ID NOs:1 to 5893 (human) or 5894 to 17415 (human) or 17416 to 36368 (mouse), optionally for use in the treatment of disease, wherein the treatment involves modulating expression of a gene targeted by the RNA.

In addition, provided are methods for modulating expression of a gene comprising administering to a mammal an inhibitory nucleic acid as described herein in an amount effective for modulating expression of a gene targeted by the RNA as set forth in Tables 1-3.

In some embodiments, the modulation is upregulating or downregulating gene expression, optionally wherein the gene targeted by the RNA is selected from the group set forth in Tables 1-3, and wherein the RNA sequence is listed in the same row as the gene.

In some embodiments, the inhibitory nucleic acid is 5 to 40 bases in length (optionally 12-30, 12-28, or 12-25 bases in length).

In some embodiments, the inhibitory nucleic acid is 10 to 50 bases in length.

In some embodiments, the inhibitory nucleic acid comprises a base sequence at least 90% complementary to at least 10 bases of the RNA sequence.

In some embodiments, the inhibitory nucleic acid comprises a sequence of bases at least 80% or 90% complementary to, e.g., at least 5-30, 10-30, 15-30, 20-30, 25-30 or 5-40, 10-40, 15-40, 20-40, 25-40, or 30-40 bases of the RNA sequence.

In some embodiments, the inhibitory nucleic acid comprises a sequence of bases with up to 3 mismatches (e.g., up to 1, or up to 2 mismatches) in complementary base pairing over 10, 15, 20, 25 or 30 bases of the RNA sequence.

In some embodiments, the inhibitory nucleic acid comprises a sequence of bases at least 80% complementary to at least 10 bases of the RNA sequence.

In some embodiments, the inhibitory nucleic acid comprises a sequence of bases with up to 3 mismatches over 15 bases of the RNA sequence.

In some embodiments, the inhibitory nucleic acid is single stranded.

In some embodiments, the inhibitory nucleic acid is double stranded.

In some embodiments, the inhibitory nucleic acid is an antisense oligonucleotide, LNA molecule, PNA molecule, ribozyme or siRNA.

In some embodiments, the inhibitory nucleic acid is double stranded and comprises an overhang (optionally 2-6 bases in length) at one or both termini.

In some embodiments, the inhibitory nucleic acid is selected from the group consisting of antisense oligonucleotides, ribozymes, external guide sequence (EGS) oligonucleotides, siRNA compounds, micro RNAs (miRNAs); small, temporal RNAs (stRNA), and single- or double-stranded RNA interference (RNAi) compounds.

In some embodiments, the RNAi compound is selected from the group consisting of short interfering RNA (siRNA); or a short, hairpin RNA (shRNA); small RNA-induced gene activation (RNAa); and small activating RNAs (saRNAs).

In some embodiments, the antisense oligonucleotide is selected from the group consisting of antisense RNAs, antisense DNAs, and chimeric antisense oligonucleotides.

In some embodiments, the modified internucleoside linkage comprises at least one of: alkylphosphonate, phosphorothioate, phosphorodithioate, alkylphosphonothioate, phosphoramidate, carbamate, carbonate, phosphate triester, acetamidate, carboxymethyl ester, or combinations thereof.

In some embodiments, the modified sugar moiety comprises a 2′-O-methoxyethyl modified sugar moiety, a 2′-methoxy modified sugar moiety, a 2′-O-alkyl modified sugar moiety, or a bicyclic sugar moiety. In some embodiments, the inhibitory nucleic acids include 2′-OMe, 2′-F, LNA, PNA, FANA, ENA or morpholino modifications.

Further provided are sterile compositions comprising an isolated nucleic acid that is a mouse RNA sequence of any one of any one of SEQ ID NOs:1 to 5893 (human) or 5894 to 17415 (human) or 17416 to 36368 (mouse), or a fragment thereof at least 20 bases in length that retains PRC1-binding activity.

Also provided are isolated nucleic acids for use in a method of decreasing expression of an oncogene, comprising an RNA sequence as set forth in Tables 1-3 that targets a proto-oncogene or oncogene as set forth in Tables 1-3, or a fragment thereof at least 20 bases in length that retains PRC1-binding activity.

In addition, provided are methods for decreasing expression of an oncogene in a cell, the method comprising contacting the cell with an RNA sequence as set forth in Tables 1-3 that targets an oncogene as set forth in Tables 1-3, or a fragment thereof at least 20 bases in length that retains PRC1-binding activity.

Further, provided herein are methods of inducing expression of a target gene in a cell, the method comprising delivering to the cell a single stranded oligonucleotide of 5 to 40 nucleotides in length having a region of complementarity that is complementary with at least 5 contiguous nucleotides of a PRC1-binding RNA that inhibits expression of the target gene, wherein the oligonucleotide is complementary to and binds specifically to the PRC1-binding RNA, and wherein the PRC1-binding RNA is transcribed from a sequence of the chromosomal locus of the target gene.

In some embodiments, the RNA is a non-codingRNA.

In some embodiments, the methods include detecting expression of the PRC1-binding RNA in the cell, wherein expression of the PRC1-binding RNA in the cell indicates that the single stranded oligonucleotide is suitable for increasing expression of the target gene in the cell.

In some embodiments, the methods include detecting a change in expression of the target gene following delivery of the single stranded oligonucleotide to the cell, wherein an increase in expression of the target gene compared with an appropriate control cell indicates effectiveness of the single stranded oligonucleotide.

In some embodiments, the methods include detecting a change in recruitment of PRC1 to the target gene in the cell following delivery of the single stranded oligonucleotide to the cell, wherein a decrease in recruitment compared with an appropriate control cell indicates effectiveness of the single stranded oligonucleotide.

In some embodiments, the cell is in vitro.

In some embodiments, the cell is in vivo.

In some embodiments, at least one nucleotide of the oligonucleotide is a modified nucleotide.

In some embodiments, the PRC1-binding RNA is transcribed from the same strand as the target gene in a genomic region containing the target gene.

In some embodiments, the oligonucleotide has complementarity to a region of the PRC1-binding RNA transcribed from a portion of the target gene corresponding to an exon.

In some embodiments, the oligonucleotide has complementarity to a region of the PRC1-binding RNA transcribed from the same strand as the target gene within a chromosomal region within −2.0 kb to +0.001 kb of the transcription start site of the target gene.

In some embodiments, the oligonucleotide has complementarity to a region of the PRC1-binding RNA transcribed from the opposite strand of the target gene within a chromosomal region within −0.5 to +0.1 kb of the transcription start site of the target gene.

In some embodiments, the oligonucleotide has complementarity to the PRC1-binding RNA in a region of the PRC1-binding RNA that forms a stem-loop structure.

In some embodiments, at least one nucleotide of the oligonucleotide is an RNA or DNA nucleotide.

In some embodiments, at least one nucleotide of the oligonucleotide is a ribonucleic acid analogue comprising a ribose ring having a bridge between its 2′-oxygen and 4′-carbon.

In some embodiments, the ribonucleic acid analogue comprises a methylene bridge between the 2′-oxygen and the 4′-carbon.

In some embodiments, at least one nucleotide of the oligonucleotide comprises a modified sugar moiety.

In some embodiments, the oligonucleotide comprises at least one modified internucleoside linkage.

In some embodiments, the at least one modified internucleoside linkage is selected from phosphorothioate, phosphorodithioate, alkylphosphonothioate, phosphoramidate, carbamate, carbonate, phosphate triester, acetamidate, carboxymethyl ester, and combinations thereof.

In some embodiments, the oligonucleotide is configured such that hybridization of the single stranded oligonucleotide to the PRC1-binding RNA does not activate an RNAse H pathway in the cell.

In some embodiments, the oligonucleotide is configured such that hybridization of the single stranded oligonucleotide to the PRC1-binding RNA does not induce substantial cleavage or degradation of the PRC1-binding RNA in the cell.

In some embodiments, the oligonucleotide is configured such that hybridization of the single stranded oligonucleotide to the PRC1-binding RNA interferes with interaction of the RNA with PRC1 in the cell.

In some embodiments, the target gene is a protein-coding gene.

In some embodiments, the chromosomal locus of the target gene is an endogenous gene of an autosomal chromosome.

In some embodiments, the cell is a cell of a male subject.

In some embodiments, the oligonucleotide has complementarity to a region of the PRC1-binding RNA transcribed from a portion of the target gene corresponding to an intron-exon junction or an intron.

In some embodiments, the oligonucleotide has complementarity to a region of the PRC1-binding RNA transcribed from a portion of the target gene corresponding to a translation initiation region or a translation termination region.

In some embodiments, the oligonucleotide has complementarity to a region of the PRC1-binding RNA transcribed from a portion of the target gene corresponding to a promoter.

In some embodiments, the oligonucleotide has complementarity to a region of the PRC1-binding RNA transcribed from a portion of the target gene corresponding to a 5′-UTR.

In some embodiments, the oligonucleotide has complementarity to a region of the PRC1-binding RNA transcribed from a portion of the target gene corresponding to a 3′-UTR.

In some or any embodiments, the inhibitory nucleic acid is an oligomeric base compound or oligonucleotide mimetic that hybridizes to at least a portion of the target nucleic acid and modulates its function. In some or any embodiments, the inhibitory nucleic acid is single stranded or double stranded. A variety of exemplary inhibitory nucleic acids are known and described in the art. In some examples, the inhibitory nucleic acid is an antisense oligonucleotide, locked nucleic acid (LNA) molecule, peptide nucleic acid (PNA) molecule, ribozyme, siRNA, antagomirs, external guide sequence (EGS) oligonucleotide, microRNA (miRNA), small, temporal RNA (stRNA), or single- or double-stranded RNA interference (RNAi) compounds. It is understood that the term “LNA molecule” refers to a molecule that comprises at least one LNA modification; thus LNA molecules may have one or more locked nucleotides (conformationally constrained) and one or more non-locked nucleotides. It is also understood that the term “LNA” includes a nucleotide that comprises any constrained sugar that retains the desired properties of high affinity binding to complementary RNA, nuclease resistance, lack of immune stimulation, and rapid kinetics. Exemplary constrained sugars include those listed below. Similarly, it is understood that the term “PNA molecule” refers to a molecule that comprises at least one PNA modification and that such molecules may include unmodified nucleotides or internucleoside linkages.

In some or any embodiments, the inhibitory nucleic acid comprises at least one nucleotide and/or nucleoside modification (e.g., modified bases or with modified sugar moieties), modified internucleoside linkages, and/or combinations thereof. Thus, inhibitory nucleic acids can comprise natural as well as modified nucleosides and linkages. Examples of such chimeric inhibitory nucleic acids, including hybrids or gapmers, are described below.

In some embodiments, the inhibitory nucleic acid comprises one or more modifications comprising: a modified sugar moiety, and/or a modified internucleoside linkage, and/or a modified nucleotide and/or combinations thereof. In some embodiments, the modified internucleoside linkage comprises at least one of: alkylphosphonate, phosphorothioate, phosphorodithioate, alkylphosphonothioate, phosphoramidate, carbamate, carbonate, phosphate triester, acetamidate, carboxymethyl ester, or combinations thereof. In some embodiments, the modified sugar moiety comprises a 2′-O-methoxyethyl modified sugar moiety, a 2′-methoxy modified sugar moiety, a 2′-O-alkyl modified sugar moiety, or a bicyclic sugar moiety. Other examples of modifications include locked nucleic acid (LNA), peptide nucleic acid (PNA), arabinonucleic acid (ANA), optionally with 2′-F modification, 2′-fluoro-D-Arabinonucleic acid (FANA), phosphorodiamidate morpholino oligomer (PMO), ethylene-bridged nucleic acid (ENA), optionally with 2′-0,4′-C-ethylene bridge, and bicyclic nucleic acid (BNA). Yet other examples are described below and/or are known in the art.

In some embodiments, the inhibitory nucleic acid is 5-40 bases in length (e.g., 12-30, 12-28, 12-25). The inhibitory nucleic acid may also be 10-50, or 5-50 bases length. For example, the inhibitory nucleic acid may be one of any of 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 bases in length. In some embodiments, the inhibitory nucleic acid is double stranded and comprises an overhang (optionally 2-6 bases in length) at one or both termini. In other embodiments, the inhibitory nucleic acid is double stranded and blunt-ended. In some embodiments, the inhibitory nucleic acid comprises or consists of a sequence of bases at least 80% or 90% complementary to, e.g., at least 5, 10, 15, 20, 25 or 30 bases of, or up to 30 or 40 bases of, the target RNA, or comprises a sequence of bases with up to 3 mismatches (e.g., up to 1, or up to 2 mismatches) over 10, 15, 20, 25 or 30 bases of the target RNA.

Thus, the inhibitory nucleic acid can comprise or consist of a sequence of bases at least 80% complementary to at least 10 contiguous bases of the target RNA, or at least 80% complementary to at least 15, or 15-30, or 15-40 contiguous bases of the target RNA, or at least 80% complementary to at least 20, or 20-30, or 20-40 contiguous bases of the target RNA, or at least 80% complementary to at least 25, or 25-30, or 25-40 contiguous bases of the target RNA, or at least 80% complementary to at least 30, or 30-40 contiguous bases of the target RNA, or at least 80% complementary to at least 40 contiguous bases of the target RNA. Moreover, the inhibitory nucleic acid can comprise or consist of a sequence of bases at least 90% complementary to at least 10 contiguous bases of the target RNA, or at least 90% complementary to at least 15, or 15-30, or 15-40 contiguous bases of the target RNA, or at least 90% complementary to at least 20, or 20-30, or 20-40 contiguous bases of the target RNA, or at least 90% complementary to at least 25, or 25-30, or 25-40 contiguous bases of the target RNA, or at least 90% complementary to at least 30, or 30-40 contiguous bases of the target RNA, or at least 90% complementary to at least 40 contiguous bases of the target RNA. Similarly, the inhibitory nucleic acid can comprise or consist of a sequence of bases fully complementary to at least 5, 10, or 15 contiguous bases of the target RNA.

Complementarity can also be referenced in terms of the number of mismatches in complementary base pairing, as noted above. Thus, the inhibitory nucleic acid can comprise or consist of a sequence of bases with up to 3 mismatches over 10 contiguous bases of the target RNA, or up to 3 mismatches over 15 contiguous bases of the target RNA, or up to 3 mismatches over 20 contiguous bases of the target RNA, or up to 3 mismatches over 25 contiguous bases of the target RNA, or up to 3 mismatches over 30 contiguous bases of the target RNA. Similarly, the inhibitory nucleic acid can comprise or consist of a sequence of bases with up to 2 mismatches over 10 contiguous bases of the target RNA, or up to 2 mismatches over 15 contiguous bases of the target RNA, or up to 2 mismatches over 20 contiguous bases of the target RNA, or up to 2 mismatches over 25 contiguous bases of the target RNA, or up to 2 mismatches over 30 contiguous bases of the target RNA. Similarly, the the inhibitory nucleic acid can comprise or consist of a sequence of bases with one mismatch over 10, 15, 20, 25 or 30 contiguous bases of the target RNA.

As such, in some embodiments the inhibitory nucleic acid comprises or consists of a sequence of bases about 5 to 40, or 8 to 40, or 10 to 50, or 5 to 50 bases in length, comprising a base sequence at least 80% complementary to (optionally one of at least 90%, 95%, 96%, 97%, 98%, 99% or 100% complementary to) a contiguous sequence of at least 5 to 40 bases, or 8 to 40, or 10 to 50, or 5 to 50 bases (optionally one of at least 10, 15, 20, 25 or 30 bases, or one of 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 bases) of the target RNA. Thus, in some embodiments the inhibitory nucleic acid may comprise or consist of a sequence of at least 5 to 40, or 8 to 40, or 5 to 50, or 10 to 50, bases (optionally one of at least 10, 15, 20, 25 or 30 bases, or one of 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 bases) having at least 80% identity to (optionally one of at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identity to) a contiguous sequence of bases of the same length of an antisense nucleic acid that is completely complementary in sequence to the target RNA. In some embodiments the sequence of the inhibitory nucleic acid may contain 1, 2 or 3 mismatches in complementary base pairing compared to the target ncRNA sequence, over 10, 15, 20, 25 or 30 bases (optionally one of 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 bases) of the target RNA.

In some or any embodiments, the inhibitory nucleic acid is 5 to 40, or 8 to 40, or 10 to 50 bases in length (e.g., 12-30, 12-28, 12-25, 5-25, or 10-25, bases in length), and comprises a sequence of bases with up to 3 mismatches in complementary base pairing over 15 bases of, or up to 2 mismatches over 10 bases.

In some embodiments, gene expression is modulated in a cell. In some embodiments, the cell is a cancer cell, e.g., a tumor cell, in vitro or in vivo, e.g., in a subject. In other embodiments, the cell is a stem cell that is contacted with the inhibitory nucleic acid, PRC1-binding ncRNA, or fragment thereof, ex vivo, for example to enhance pluripotency, enhance differentiation, or induce the stem cell to differentiate to a particular cell type, e.g. nerve, neuron, dopaminergic neuron, muscle, skin, heart, kidney, liver, lung, neuroendocrine, retinal, retinal pigment epithelium, pancreatic alpha or beta cells, hematopoietic, chondrocyte, bone cells and/or blood cells (e.g., T-cells, B-cells, macrophages, erythrocytes, platelets, and the like).

In an additional aspect, the invention provides methods for enhancing pluripotency of a stem cell. The methods include contacting the cell with an inhibitory nucleic acid that specifically binds, or is complementary, to a nucleic acid sequence that is at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% homologous to a PRC1-binding fragment thereof, as referred to in Tables 1-3. PRC1-binding fragments of murine or orthologous RNAs, including human RNAs, are contemplated in the aforementioned method.

In a further aspect, the invention features methods for enhancing differentiation of a stem cell, the method comprising contacting the cell with an inhibitory nucleic acid that specifically binds, or is complementary, to a PRC1-binding RNA sequence as set forth in SEQ ID NOS. 17416 to 36368 [mouse Peaks] or 1 to 5893 [human Peaks] or 5894 to 17416 [human Peaks identified by LiftOver].

In some embodiments, the stem cell is an embryonic stem cell. In some embodiments, the stem cell is an iPS cell or an adult stem cell.

In an additional aspect, the invention provides sterile compositions including an inhibitory nucleic acid that specifically binds to or is at least 90% complementary to (e.g., at least 5, 10, 15, 20, 25 or 30 bases of, or up to 30 or 40 bases of) a sequence listed in any of Tables 1-3, or any one of SEQ ID NOs: 17416 to 36368 [mouse Peaks] or 1 to 5893 [human Peaks] or 5894 to 17416 [human Peaks identified by LiftOver], or a related naturally occurring RNA at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to at least 15 (e.g., at least 20, 21, 25, 30, 100) nucleobases of an ncRNA of any of Tables 1-3 or any one of SEQ ID NOs: 17416 to 36368 [mouse Peaks] or 1 to 5893 [human Peaks] or 5894 to 17416 [human Peaks identified by LiftOver], for parenteral administration. In some embodiments, the inhibitory nucleic acid is selected from the group consisting of antisense oligonucleotides, ribozymes, external guide sequence (EGS) oligonucleotides, siRNA compounds, micro RNAs (miRNAs); small, temporal RNAs (stRNA), and single- or double-stranded RNA interference (RNAi) compounds. In some embodiments, the RNAi compound is selected from the group consisting of short interfering RNA (siRNA); or a short, hairpin RNA (shRNA); small RNA-induced gene activation (RNAa); and small activating RNAs (saRNAs).

In some embodiments, the antisense oligonucleotide is selected from the group consisting of antisense RNAs, antisense DNAs, chimeric antisense oligonucleotides, and antisense oligonucleotides.

In some embodiments, the inhibitory nucleic acid comprises one or more modifications comprising: a modified sugar moiety, a modified internucleoside linkage, a modified nucleotide and/or combinations thereof. In some embodiments, the modified internucleoside linkage comprises at least one of: alkylphosphonate, phosphorothioate, phosphorodithioate, alkylphosphonothioate, phosphoramidate, carbamate, carbonate, phosphate triester, acetamidate, carboxymethyl ester, or combinations thereof. In some embodiments, the modified sugar moiety comprises a 2′-O-methoxyethyl modified sugar moiety, a 2′-methoxy modified sugar moiety, a 2′-O-alkyl modified sugar moiety, or a bicyclic sugar moiety. Other examples of modifications include locked nucleic acid (LNA), peptide nucleic acid (PNA), arabinonucleic acid (ANA), optionally with 2′-F modification, 2′-fluoro-D-Arabinonucleic acid (FANA), phosphorodiamidate morpholino oligomer (PMO), ethylene-bridged nucleic acid (ENA), optionally with 2′-0,4′-C-ethylene bridge, and bicyclic nucleic acid (BNA). Yet other examples are described below and/or are known in the art.

PRC1-binding fragments of any of the RNA sequences set forth in the sequence listing as summarized below are contemplated. In some aspects, the fragments may recruit PRC1 and enhance PRC1 activity, thereby repressing gene expression, while in other instances the fragments may interfere with PRC1 activity by masking the ncRNA-binding sites on PRC1. In particular, the invention features uses of fragments of the RNA below to modulate expression of any of the genes set forth in Tables 1-3, for use in treating a disease, disorder, condition or association (whether in the “opposite strand” column or the “same strand” column).

Moreover, inhibitory nucleic acids that specifically bind to any of the RNA peaks set forth in the sequence listing as summarized below, any one of SEQ ID NOs: 1 to 5893, 5894 to 17415, or 17416 to 36368, are also contemplated. In particular, the invention features uses of these inhibitory nucleic acids to upregulate expression of any of the genes set forth in Tables 1-3, for use in treating a disease, disorder, condition or association known in the art (whether in the “opposite strand” column or the “same strand”); upregulations of a set of genes grouped together in any one of the categories is contemplated. In some embodiments it is contemplated that expression may be increased by at least about 15-fold, 20-fold, 30-fold, 40-fold, 50-fold or 100-fold, or any range between any of the foregoing numbers. In other experiments, increased mRNA expression has been shown to correlate to increased protein expression.

Thus, in various aspects, the invention features inhibitory nucleic acids that specifically bind to any of the RNA sequences of any of Tables 1-3, for use in modulating expression of a group of reference genes that fall within any one or more of the categories set forth in the tables, and for treating corresponding diseases, disorders or conditions.

In another aspect, the invention also features inhibitory nucleic acids that specifically bind, or are complementary, to any of the RNA sequences of SEQ ID NOS: 17416 to 36368 [mouse Peaks] or 1 to 5893 [human Peaks] or 5894 to 17416 [human Peaks identified by LiftOver], whether in the “opposite strand” column or the “same strand” column of Tables 1-3. In some embodiments, the inhibitory nucleic acid is provided for use in a method of modulating expression of a gene targeted by the PRC1-binding RNA (e.g., an intersecting or nearby gene, as set forth in any of Tables 1-4 below). Such methods may be carried out in vitro, ex vivo, or in vivo. In some embodiments, the inhibitory nucleic acid is provided for use in methods of treating disease, e.g. as described below. The treatments may involve modulating expression (either up or down) of a gene targeted by the PRC1-binding RNA, preferably upregulating gene expression. In some embodiments, the inhibitory nucleic acid is formulated as a sterile composition for parenteral administration. Thus, in one aspect the invention describes a group of inhibitory nucleic acids that specifically bind, or are complementary to, a group of RNA sequences, i.e., Peaks, in any one of Tables 1, 2, or 3. In particular, the invention features uses of such inhibitory nucleic acids to upregulate expression of any of the reference genes set forth in Tables 1-3, for use in treating a disease, disorder, or condition.

It is understood that inhibitory nucleic acids of the invention may be complementary to, or specifically bind to, Peaks, or regions adjacent to (within 100, 200, 300, 400, or 500 nts of) Peaks, as shown in Tables 1-3.

Also provided herein are methods for treating a subject with MECP2 Duplication Syndrome. The methods include administering a therapeutically effective amount of an inhibitory nucleic acid targeting a PRC1-binding region on Mecp2 RNA, e.g., an inhibitory nucleic acid targeting a sequence within the 3′UTR of Mecp2. In some embodiments, inhibitory nucleic acid comprises any of SEQ ID NOs:36399 to 36404.

Further provided herein are methods for treating a subject with systemic lupus erythematosus. The methods include administering a therapeutically effective amount of an inhibitory nucleic acid targeting a PRC1-binding region on IRAK1 RNA, e.g., an inhibitory nucleci acid targeting a sequence within the 3′UTR of IRAK1.

In some embodiments, the inhibitory nucleic acid comprises any of SEQ ID NOs:36396 to 36398.

In some embodiments, the inhibitory nucleic acid comprises at least one locked nucleotide.

Also provided herein are inhibitory nucleic acids targeting a PRC1-binding region on Mecp2 RNA, preferably wherein the PRC1 binding region comprises SEQ ID NO:5876 or 5877, and/or preferably an inhibitory nucleic acid targeting a sequence within the 3′UTR of Mecp2, for use in treating a subject with MECP2 Duplication Syndrome, e.g., comprising any of SEQ ID NOs:36399 to 36404.

In addition, provided herein are inhibitory nucleic acids targeting a PRC1-binding region on IRAK1 RNA, preferably wherein the PRC1 binding region comprises SEQ ID NO:5874 or 5875, and/or preferably an inhibitory nucleic acid targeting a sequence within the 3′UTR of IRAK1, for use in treating a subject with systemic lupus erythematosus, e.g., an inhibitory nucleic acid comprising any of SEQ ID NOs:36396 to 36398.

In some or any embodiments, the inhibitory nucleic acids are, e.g., about 5 to 40, about 8 to 40, or 10 to 50 bases, or 5 to 50 bases in length. In some embodiments, the inhibitory nucleic acid comprises or consists of a sequence of bases at least 80% or 90% complementary to, e.g., at least 5, 10, 15, 20, 25 or 30 bases of, or up to 30 or 40 bases of, the target RNA (e.g., any one of SEQ ID NOs: 1 to 36,368), or comprises a sequence of bases with up to 3 mismatches (e.g., up to 1, or up to 2 mismatches) over 10, 15, 20, 25 or 30 bases of the target RNA.

Thus, as noted above, the inhibitory nucleic acid can comprise or consist of a sequence of bases at least 80% complementary to at least 10, or 10-30 or 10-40 contiguous bases of the target RNA, or at least 80% complementary to at least 15, or 15-30, or 15-40 contiguous bases of the target RNA, or at least 80% complementary to at least 20, or 20-30, or 20-40 contiguous bases of the target RNA, or at least 80% complementary to at least 25, or 25-30, or 25-40 contiguous bases of the target RNA, or at least 80% complementary to at least 30, or 30-40 contiguous bases of the target RNA, or at least 80% complementary to at least 40 contiguous bases of the target RNA. Moreover, the inhibitory nucleic acid can comprise or consist of a sequence of bases at least 90% complementary to at least 5, or 5-30 or 5-40 or 8-40 contiguous bases of the target RNA, or at least 90% complementary to at least 10, or 10-30, or 10-40 contiguous bases of the target RNA, or at least 90% complementary to at least 15, or 15-30, or 15-40 contiguous bases of the target RNA, or at least 90% complementary to at least 20, or 20-30, or 20-40 contiguous bases of the target RNA, or at least 90% complementary to at least 25, or 25-30, or 25-40 contiguous bases of the target RNA, or at least 90% complementary to at least 30, or 30-40 contiguous bases of the target RNA, or at least 90% complementary to at least 40 contiguous bases of the target RNA. Similarly, the inhibitory nucleic acid can comprise or consist of a sequence of bases fully complementary to at least 5, 10, or 15 contiguous bases of the target RNA. It is understood that some additional non-complementary bases may be included. It is understood that inhibitory nucleic acids that comprise such sequences of bases as described may also comprise other non-complementary bases. For example, an inhibitory nucleic acid can be 20 bases in total length but comprise a 15 base portion that is fully complementary to 15 bases of the target RNA. Similarly, an inhibitory nucleic acid can be 20 bases in total length but comprise a 15 base portion that is at least 80% complementary to 15 bases of the target RNA.

In some or any of the embodiments of inhibitory nucleic acids described herein (e.g. in the summary, detailed description, or examples of embodiments) or the processes for designing or synthesizing them, the inhibitory nucleic acids may optionally exclude (a) any LNA that disrupts binding of PRC2 to an RNA, e.g., as describe in WO 2012/087983 or WO 2012/065143; (b) any one or more of the specific inhibitory nucleic acids made or actually disclosed (i.e. specific chemistry, single or double-stranded, specific modifications, and specific base sequence), set forth in WO 2012/065143 or WO 2012/087983; and/or the general base sequence of any one or more of the inhibitory nucleic acids of (b); and/or (c) the group of inhibitory nucleic acids that specifically bind or are complementary to the same specific portion of RNA (a stretch of contiguous bases) as any one or more of the inhibitory nucleic acids of (a); as disclosed in any one or more of the following publications: as targeting ANRIL RNA (as described in Yap et al., Mol Cell. 2010 Jun. 11; 38(5):662-74) HOTAIR RNA (Rinn et al., 2007), Tsix, RepA, or Xist RNAs ((Zhao et al., 2008) [SEQ ID NOs: 936166-936170 of WO 2012/087983], or (Sarma et al., 2010) [SEQ ID NOs: 936177-936186 of WO 2012/087983] or (Zhao et al., 2010) [SEQ ID NOs: 936187-936188 of WO 2012/087983] or (Prasnath et al., 2005) [SEQ ID NOs: 936173-936176 of WO 2012/087983] or (Shamovsky et al., 2006) [SEQ ID NO: 936172 of WO 2012/087983] or (Mariner et al., 2008) [SEQ ID NO: 936171 of WO 2012/087983] or (Sunwoo et al., 2008) or (Bernard et al., 2010) [SEQ ID NO: 936189 of WO 2012/087983]; or as targeting short RNAs of 50-200 nt that are identified as candidate PRC2 regulators (Kanhere et al., 2010); or (Kuwabara et al., US 2005/0226848) [SEQ ID NOs: 936190-936191 of WO 2012/087983] or (Li et al., US 2010/0210707) [SEQ ID NOs: 936192-936227 of WO 2012/087983] or (Corey et al., U.S. Pat. No. 7,709,456) [SEQ ID NOs: 936228-936245] or (Mattick et al., WO 2009/124341), or (Corey et al., US 2010/0273863) [SEQ ID NOs: 936246-936265 of WO 2012/087983], or (Wahlstedt et al., US 2009/0258925) [SEQ ID NOs: 935060-935126 of WO 2012/087983], or BACE: US 2009/0258925 [SEQ ID NOs: 935060-935126 of WO 2012/087983]; ApoA1: US 2010/0105760/EP235283 [SEQ ID NOs: 935127-935299 of WO 2012/087983], P73, p53, PTEN, WO 2010/065787 A2/EP2370582 [SEQ ID NOs: 935300-935345 of WO 2012/087983]; SIRT1: WO 2010/065662 A2/EP09831068 [SEQ ID NOs: 935346-935392 of WO 2012/087983]; VEGF: WO 2010/065671 A2/EP2370581 [SEQ ID NOs: 935393-935403 of WO 2012/087983]; EPO: WO 2010/065792 A2/EP09831152 [SEQ ID NOs: 935404-935412 of WO 2012/087983]; BDNF: WO2010/093904 [SEQ ID NOs: 935413-935423 of WO 2012/087983], DLK1: WO 2010/107740 [SEQ ID NOs: 935424-935430 of WO 2012/087983]; NRF2/NFE2L2: WO 2010/107733 [SEQ ID NOs: 935431-935438 of WO 2012/087983]; GDNF: WO 2010/093906 [SEQ ID NOs: 935439-935476 of WO 2012/087983]; SOX2, KLF4, Oct3A/B, “reprogramming factors: WO 2010/135329 [SEQ ID NOs: 935477-935493 of WO 2012/087983]; Dystrophin: WO 2010/129861 [SEQ ID NOs: 935494-935525 of WO 2012/087983]; ABCA1, LCAT, LRP1, ApoE, LDLR, ApoA1: WO 2010/129799 [SEQ ID NOs: 935526-935804 of WO 2012/087983]; HgF: WO 2010/127195 [SEQ ID NOs: 935805-935809 of WO 2012/087983]; TTP/Zfp36: WO 2010/129746[SEQ ID NOs: 935810-935824 of WO 2012/087983]; TFE3, IRS2: WO 2010/135695 [SEQ ID NOs: 935825-935839 of WO 2012/087983]; RIG1, MDAS, IFNA1: WO 2010/138806 [SEQ ID NOs: 935840-935878 of WO 2012/087983]; PON1: WO 2010/148065 [SEQ ID NOs: 935879-935885 of WO 2012/087983]; Collagen: WO/2010/148050 [SEQ ID NOs: 935886-935918 of WO 2012/087983]; DyrklA, Dscrl, “Down Syndrome Gene”: WO/2010/151674 [SEQ ID NOs: 935919-935942 of WO 2012/087983]; TNFR2: WO/2010/151671 [SEQ ID NOs: 935943-935951 of WO 2012/087983]; Insulin: WO/2011/017516 [SEQ ID NOs: 935952-935963 of WO 2012/087983]; ADIPOQ: WO/2011/019815 [SEQ ID NOs: 935964-935992 of WO 2012/087983]; CHIP: WO/2011/022606 [SEQ ID NOs: 935993-936004 of WO 2012/087983]; ABCB1: WO/2011/025862 [SEQ ID NOs: 936005-936014 of WO 2012/087983]; NEUROD1, EUROD1, HNF4A, MAFA, PDX, KX6, “Pancreatic development gene”: WO/2011/085066 [SEQ ID NOs: 936015-936054 of WO 2012/087983]; MBTPS1: WO/2011/084455 [SEQ ID NOs: 936055-936059 of WO 2012/087983]; SHBG: WO/2011/085347 [SEQ ID NOs: 936060-936075 of WO 2012/087983]; IRF8: WO/2011/082409 [SEQ ID NOs: 936076-936080 of WO 2012/087983]; UCP2: WO/2011/079263 [SEQ ID NOs: 936081-936093 of WO 2012/087983]; HGF: WO/2011/079261 [SEQ ID NOs: 936094-936104 of WO 2012/087983]; GH: WO/2011/038205 [SEQ ID NOs: 936105-936110 of WO 2012/087983]; IQGAP: WO/2011/031482 [SEQ ID NOs: 936111-936116 of WO 2012/087983]; NRF1: WO/2011/090740 [SEQ ID NOs: 936117-936123 of WO 2012/087983]; P63: WO/2011/090741 [SEQ ID NOs: 936124-936128 of WO 2012/087983]; RNAseHl: WO/2011/091390 [SEQ ID NOs: 936129-936140 of WO 2012/087983]; ALOX12B: WO/2011/097582 [SEQ ID NOs: 936141-936146 of WO 2012/087983]; PYCR1: WO/2011/103528 [SEQ ID NOs: 936147-936151 of WO 2012/087983]; CSF3: WO/2011/123745 [SEQ ID NOs: 936152-936157 of WO 2012/087983]; FGF21: WO/2011/127337 [SEQ ID NOs: 936158-936165 of WO 2012/087983]; SIRTUIN (SIRT): WO2011/139387 [SEQ ID NOs: 936266-936369 and 936408-936425 of WO 2012/087983]; PAR4: WO2011/143640 [SEQ ID NOs: 936370-936376 and 936426 of WO 2012/087983]; LHX2: WO2011/146675 [SEQ ID NOs: 936377 936388 and 936427-936429 of WO 2012/087983]; BCL2L11: WO2011/146674 [SEQ ID NO: 936389-936398 and 936430-936431 of WO 2012/087983]; MSRA: WO2011/150007 [SEQ ID NOs: 936399-936405 and 936432 of WO 2012/087983]; ATOH1: WO2011/150005 [SEQ ID NOs: 936406-936407 and 936433 of WO 2012/087983] of which each of the foregoing is incorporated by reference in its entirety herein. In some or any of the embodiments, optionally excluded from the invention are of inhibitory nucleic acids that specifically bind to, or are complementary to, any one or more of the following regions: Nucleotides 1-932 of SEQ ID NO: 935128 of WO 2012/087983; Nucleotides 1-1675 of SEQ ID NO: 935306 of WO 2012/087983; Nucleotides 1-518 of SEQ ID NO: 935307 of WO 2012/087983; Nucleotides 1-759 of SEQ ID NO: 935308 of WO 2012/087983; Nucleotides 1-25892 of SEQ ID NO: 935309 of WO 2012/087983; Nucleotides 1-279 of SEQ ID NO: 935310 of WO 2012/087983; Nucleotides 1-1982 of SEQ ID NO: 935311 of WO 2012/087983; Nucleotides 1-789 of SEQ ID NO: 935312 of WO 2012/087983; Nucleotides 1-467 of SEQ ID NO: 935313 of WO 2012/087983; Nucleotides 1-1028 of SEQ ID NO: 935347 of WO 2012/087983; Nucleotides 1-429 of SEQ ID NO: 935348 of WO 2012/087983; Nucleotides 1-156 of SEQ ID NO: 935349 of WO 2012/087983; Nucleotides 1-593 of SEQ ID NO:935350 of WO 2012/087983; Nucleotides 1-643 of SEQ ID NO: 935395 of WO 2012/087983; Nucleotides 1-513 of SEQ ID NO: 935396 of WO 2012/087983; Nucleotides 1-156 of SEQ ID NO: 935406 of WO 2012/087983; Nucleotides 1-3175 of SEQ ID NO: 935414 of WO 2012/087983; Nucleotides 1-1347 of SEQ ID NO: 935426 of WO 2012/087983; Nucleotides 1-5808 of SEQ ID NO: 935433 of WO 2012/087983; Nucleotides 1-237 of SEQ ID NO: 935440 of WO 2012/087983; Nucleotides 1-1246 of SEQ ID NO: 935441 of WO 2012/087983; Nucleotides 1-684 of SEQ ID NO: 935442 of WO 2012/087983; Nucleotides 1-400 of SEQ ID NO: 935473 of WO 2012/087983; Nucleotides 1-619 of SEQ ID NO: 935474 of WO 2012/087983; Nucleotides 1-813 of SEQ ID NO: 935475 of WO 2012/087983; Nucleotides 1-993 of SEQ ID NO: 935480 of WO 2012/087983; Nucleotides 1-401 of SEQ ID NO: 935480 of WO 2012/087983; Nucleotides 1-493 of SEQ ID NO: 935481 of WO 2012/087983; Nucleotides 1-418 of SEQ ID NO: 935482 of WO 2012/087983; Nucleotides 1-378 of SEQ ID NO: 935496 of WO 2012/087983; Nucleotides 1-294 of SEQ ID NO: 935497 of WO 2012/087983; Nucleotides 1-686 of SEQ ID NO: 935498 of WO 2012/087983; Nucleotides 1-480 of SEQ ID NO: 935499 of WO 2012/087983; Nucleotides 1-501 of SEQ ID NO: 935500 of WO 2012/087983; Nucleotides 1-1299 of SEQ ID NO: 935533 of WO 2012/087983; Nucleotides 1-918 of SEQ ID NO: 935534 of WO 2012/087983; Nucleotides 1-1550 of SEQ ID NO: 935535 of WO 2012/087983; Nucleotides 1-329 of SEQ ID NO: 935536 of WO 2012/087983; Nucleotides 1-1826 of SEQ ID NO: 935537 of WO 2012/087983; Nucleotides 1-536 of SEQ ID NO: 935538 of WO 2012/087983; Nucleotides 1-551 of SEQ ID NO: 935539 of WO 2012/087983; Nucleotides 1-672 of SEQ ID NO: 935540 of WO 2012/087983; Nucleotides 1-616 of SEQ ID NO: 935541 of WO 2012/087983; Nucleotides 1-471 of SEQ ID NO: 935542 of WO 2012/087983; Nucleotides 1-707 of SEQ ID NO: 935543 of WO 2012/087983; Nucleotides 1-741 of SEQ ID NO: 935544 of WO 2012/087983; Nucleotides 1-346 of SEQ ID NO: 935545 of WO 2012/087983; Nucleotides 1-867 of SEQ ID NO: 935546 of WO 2012/087983; Nucleotides 1-563 of SEQ ID NO: 935547 of WO 2012/087983; Nucleotides 1-970 of SEQ ID NO: 935812 of WO 2012/087983; Nucleotides 1-1117 of SEQ ID NO: 935913 of WO 2012/087983; Nucleotides 1-297 of SEQ ID NO: 935814 of WO 2012/087983; Nucleotides 1-497 of SEQ ID NO: 935827 of WO 2012/087983; Nucleotides 1-1267 of SEQ ID NO: 935843 of WO 2012/087983; Nucleotides 1-586 of SEQ ID NO: 935844 of WO 2012/087983; Nucleotides 1-741 of SEQ ID NO: 935845 of WO 2012/087983; Nucleotides 1-251 of SEQ ID NO: 935846 of WO 2012/087983; Nucleotides 1-681 of SEQ ID NO: 935847 of WO 2012/087983; Nucleotides 1-580 of SEQ ID NO: 935848 of WO 2012/087983; Nucleotides 1-534 of SEQ ID NO: 935880 of WO 2012/087983; Nucleotides 1-387 of SEQ ID NO: 935889 of WO 2012/087983; Nucleotides 1-561 of SEQ ID NO: 935890 of WO 2012/087983; Nucleotides 1-335 of SEQ ID NO: 935891 of WO 2012/087983; Nucleotides 1-613 of SEQ ID NO: 935892 of WO 2012/087983; Nucleotides 1-177 of SEQ ID NO: 935893 of WO 2012/087983; Nucleotides 1-285 of SEQ ID NO: 935894 of WO 2012/087983; Nucleotides 1-3814 of SEQ ID NO: 935921 of WO 2012/087983; Nucleotides 1-633 of SEQ ID NO: 935922 of WO 2012/087983; Nucleotides 1-497 of SEQ ID NO: 935923 Nucleotides 1-545 of SEQ ID NO: 935924 of WO 2012/087983; Nucleotides 1-413 of SEQ ID NO: 935950 of WO 2012/087983; Nucleotides 1-413 of SEQ ID NO: 935951 of WO 2012/087983; Nucleotides 1-334 of SEQ ID NO: 935962 of WO 2012/087983; Nucleotides 1-582 of SEQ ID NO: 935963 of WO 2012/087983; Nucleotides 1-416 of SEQ ID NO: 935964 of WO 2012/087983; Nucleotides 1-3591 of SEQ ID NO: 935990 of WO 2012/087983; Nucleotides 1-875 of SEQ ID NO: 935991 of WO 2012/087983; Nucleotides 1-194 of SEQ ID NO: 935992 of WO 2012/087983; Nucleotides 1-2074 of SEQ ID NO: 936003 of WO 2012/087983; Nucleotides 1-1237 of SEQ ID NO: 936004 of WO 2012/087983; Nucleotides 1-4050 of SEQ ID NO: 936013 of WO 2012/087983; Nucleotides 1-1334 of SEQ ID NO: 936014 of WO 2012/087983; Nucleotides 1-1235 of SEQ ID NO: 936048 of WO 2012/087983; Nucleotides 1-17,964 of SEQ ID NO: 936049 of WO 2012/087983; Nucleotides 1-50,003 of SEQ ID NO: 936050 of WO 2012/087983; Nucleotides 1-486 of SEQ ID NO: 936051 of WO 2012/087983; Nucleotides 1-494 of SEQ ID NO: 936052 of WO 2012/087983; Nucleotides 1-1992 of SEQ ID NO: 936053 of WO 2012/087983; Nucleotides 1-1767 of SEQ ID NO: 936054 of WO 2012/087983; Nucleotides 1-1240 of SEQ ID NO: 936059 of WO 2012/087983; Nucleotides 1-3016 of SEQ ID NO: 936074 of WO 2012/087983; Nucleotides 1-1609 of SEQ ID NO: 936075 of WO 2012/087983; Nucleotides 1-312 of SEQ ID NO: 936080 of WO 2012/087983; Nucleotides 1-243 of SEQ ID NO: 936092 of WO 2012/087983; Nucleotides 1-802 of SEQ ID NO: 936093 of WO 2012/087983; Nucleotides 1-514 of SEQ ID NO: 936102 of WO 2012/087983; Nucleotides 1-936 of SEQ ID NO: 936103 of WO 2012/087983; Nucleotides 1-1075 of SEQ ID NO: 936104 of WO 2012/087983; Nucleotides 1-823 of SEQ ID NO: 936110 of WO 2012/087983; Nucleotides 1-979 of SEQ ID NO: 936116 of WO 2012/087983; Nucleotides 1-979 of SEQ ID NO: 936123 of WO 2012/087983; Nucleotides 1-288 of SEQ ID NO: 936128 of WO 2012/087983; Nucleotides 1-437 of SEQ ID NO: 936137 of WO 2012/087983; Nucleotides 1-278 of SEQ ID NO: 936138 of WO 2012/087983; Nucleotides 1-436 of SEQ ID NO: 936139 of WO 2012/087983; Nucleotides 1-1140 of SEQ ID NO: 936140 of WO 2012/087983; Nucleotides 1-2082 of SEQ ID NO: 936146 of WO 2012/087983; Nucleotides 1-380 of SEQ ID NO: 936151 of WO 2012/087983; Nucleotides 1-742 of SEQ ID NO: 936157 of WO 2012/087983; Nucleotides 1-4246 of SEQ ID NO: 936165 of WO 2012/087983; Nucleotides 1-1028 of SEQ ID NO: 936408 of WO 2012/087983; Nucleotides 1-429 of SEQ ID NO: 936409 of WO 2012/087983; Nucleotides 1-508 of SEQ ID NO: 936410 of WO 2012/087983; Nucleotides 1-593 of SEQ ID NO: 936411 of WO 2012/087983; Nucleotides 1-373 of SEQ ID NO: 936412 of WO 2012/087983; Nucleotides 1-1713 of SEQ ID NO: 936413 of WO 2012/087983; Nucleotides 1-660 of SEQ ID NO:936414 of WO 2012/087983; Nucleotides 1-589 of SEQ ID NO: 936415 of WO 2012/087983; Nucleotides 1-726 of SEQ ID NO: 936416 of WO 2012/087983; Nucletides 1-320 of SEQ ID NO: 936417 of WO 2012/087983; Nucletides 1-616 of SEQ ID NO: 936418 of WO 2012/087983; Nucletides 1-492 of SEQ ID NO: 936419 of WO 2012/087983; Nucletides 1-428 of SEQ ID NO: 936420 of WO 2012/087983; Nucletides 1-4041 of SEQ ID NO: 936421 of WO 2012/087983; Nucletides 1-705 of SEQ ID NO: 936422 of WO 2012/087983; Nucletides 1-2714 of SEQ ID NO: 936423 of WO 2012/087983; Nucletides 1-1757 of SEQ ID NO: 936424 of WO 2012/087983; Nucletides 1-3647 of SEQ ID NO: 936425 of WO 2012/087983; Nucleotides 1-354 of SEQ ID NO: 936426 of WO 2012/087983; Nucleotides 1-2145 of SEQ ID NO: 936427, Nucleotides 1-606 of SEQ ID NO: 936428 of WO 2012/087983; Nucleotides 1-480 of SEQ ID NO: 936429 of WO 2012/087983; Nucleotides 1-3026 of SEQ ID NO: 936430 of WO to 2012/087983; Nucleotides 1-1512 of SEQ ID NO: 936431 of WO 2012/087983; Nucleotides 1-3774 of SEQ ID NO: 936432 of WO 2012/087983; Nucleotides 1-589 of SEQ ID NO: 936433.

In some of the embodiments of inhibitory nucleic acids described herein, or processes for designing or synthesizing them, the inhibitory nucleic acids will upregulate gene expression and may specifically bind or specifically hybridize or be complementary to the PRC1-binding RNA that is transcribed from the same strand as a protein coding reference gene. The inhibitory nucleic acid may bind to a region of the PRC1-binding RNA, that originates within or overlaps an intron, exon, intron-exon junction, 5′ UTR, 3′ UTR, a translation initiation region, or a translation termination region of a protein-coding sense-strand of a reference gene (refGene).

In some or any of the embodiments of inhibitory nucleic acids described herein, or processes for designing or syntheisizing them, the inhibitory nucleic acids will upregulate gene expression and may specifically bind or specifically hybridize or be complementary to a PRC1 binding RNA that transcribed from the opposite strand (the antisense-strand) of a protein-coding reference gene.

The inhibitory nucleic acids described herein may be modified, e.g. comprise a modified sugar moiety, a modified internucleoside linkage, a modified nucleotide and/or combinations thereof. In addition, the inhibitory nucleic acids can exhibit one or more of the following properties: do not induce substantial cleavage or degradation of the target RNA; do not cause substantially complete cleavage or degradation of the target RNA; do not activate the RNAse H pathway; do not activate RISC; do not recruit any Argonaute family protein; are not cleaved by Dicer; do not mediate alternative splicing; are not immune stimulatory; are nuclease resistant; have improved cell uptake compared to unmodified oligonucleotides; are not toxic to cells or mammals; may have improved endosomal exit; do interfere with interaction of ncRNA with PRC1, preferably the Ezh2 subunit but optionally the Suz12, Eed, RbAp46/48 subunits or accessory factors such as Jarid2; do decrease histone H3-lysine27 methylation and/or do upregulate gene expression. In some or any of the embodiments of inhibitory nucleic acids described herein, or processes for designing or synthesizing them, the inhibitory nucleic acids may optionally exclude those that bind DNA of a promoter region, as described in Kuwabara et al., US 2005/0226848 or Li et al., US 2010/0210707 or Corey et al., U.S. Pat. No. 7,709,456 or Mattick et al., WO 2009/124341, or those that bind DNA of a 3′ UTR region, as described in Corey et al., US 2010/0273863.

Inhibitory nucleic acids that are designed to interact with RNA to modulate gene expression are a distinct subset of base sequences from those that are designed to bind a DNA target (e.g., are complementary to the underlying genomic DNA sequence from which the RNA is transcribed).

This application incorporates by reference the entire disclosures of U.S. provisional Nos. 61/425,174 filed on Dec. 20, 2010, and 61/512,754 filed on Jul. 28, 2011, and International Patent Application Nos. PCT/US2011/060493, filed Nov. 12, 2011, and PCT/US2011/065939, filed on Dec. 19, 2011.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Methods and materials are described herein for use in the present invention; other, suitable methods and materials known in the art can also be used. The materials, methods, and examples are illustrative only and not intended to be limiting. All publications, patent applications, patents, sequences, database entries, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control.

Other features and advantages of the invention will be apparent from the following detailed description and figures, and from the claims.

REFERENCE TO SEQUENCE LISTING

This application includes a Sequence Listing in .txt format, filed herewith as SL.txt, a file of 67.2 MB. The entire content of this file is hereby incorporated by reference.

DESCRIPTION OF DRAWINGS

FIGS. 1A-B are schematics of exemplary denaturing CLIP (dCLIP) pull-down methods (1A) and library preparation methods (1B).

FIGS. 2A-C show four test genes for effects of disrupting PRC1-3′UTR interactions. IGV screenshots shown for three Chromobox Homolog 7 (CBX7)-binding RNAs: (2A) Mouse DDB1 and CUL4 Associated Factor 12-Like 1 (Dcaf12L1); (2B) Mouse Calmodulin 2 (Calm2); (2C) Mouse methyl CpG binding protein 2 (Mecp2). For each gene, the RNA-seq profile shows the FPKM expression values of each gene. CLIP-seq profiles are then shown for various biological replicates (e.g., Cbx7 #1, #2, #3). For Dcaf12L1 and Calm2, statistically significant peaks (“Peak”, as called by PeakRanger software) shown as bars under each replicate's track. Two control (tag-only libraries) are shown for each gene. Only the relevant strand is shown (Watson or Crick). Note highly reproducible CLIP profiles and very clean control libraries. ASO LNA mixmers used for knockoff ananlysis are shown as black bars. The mixmers were pooled for the transfections.

FIGS. 3A-C are graphs showing gene upregulation as a result of disrupting PRC1-3′UTR interactions. 16.7 ES cells were nucleofected with pooled mixmer LNAs against Calmodulin 2 (Calm2) (leftmost bars) or DDB1 and CUL4 Associated Factor 12-Like 1 (Dcafl2L1) (middle bars); Dual-specific phosphatase 9 (Dusp9) was used as a negative control (right bars). Cells were harvested after 24 hours and whole cell RNA was used for quantitative gene expression analysis using real-time RT-PCR. Expression of specific transcripts was normalized to beta-actin as a reference gene.

FIGS. 4A-B shows the test gene, Tsix, and results of knocking off PRC1 from Tsix RNA. (4A) The RNA-seq profile shows the Fragments Per Kilobase of transcript per Million mapped reads (FPKM) expression values of each gene. CLIP-seq profiles are then shown for two biological replicates (Cbx7 #1, #2), with corresponding statistically significant peaks (“Peak”, as called by PeakRanger software) shown as bars under each replicate's track. Two control (tag-only libraries) are shown for each gene. Antisense oligonucleotide (ASO) LNA mixmers used for knockoff ananlysis are shown as black bars. The mixmers were pooled for the transfections. Only the Watson strand is shown in the figure. (4B) Tsix RNA is a repressor ofXist expression. Here we hypothesized that Tsix recruits PRC1 to repress Xist expression. The RT-qPCR analysis performed 6 hours after administering Tsix LNAs support this interaction. Xist upregulation was achieved specifically.

Table 1: Human CBX7-RNA binding sites as determined by denaturing CLIP-seq analysis in Human 293 cells. All coordinates in hg19. The columns (c) correspond to: c1, SEQ ID Number. c2, Chromosome number. c3, Read start position. c4, Read end position. c5, chromosome strand that the transcript is made from (+, top or Watson strand; −, bottom or Crick strand of each chromosome). C6, nearest gene name. c7, gene categories as defined in Example 2.

Table 2: Human LiftOver sequences corresponding to CBX7-RNA binding sites as determined by denaturing CLIP-seq analysis in mouse ES cells shown. All coordinates in hg19. CBX7-binding sites derived from CLIP-seq performed in the mouse ES cell line, 16.7, as shown in Table 3, are translated from mouse mm9 to human hg19 coordinates.

Table 3: Mouse CBX7-RNA binding sites as determined by denaturing CLIP-seq analysis in ES cells derived from Mus musculus. All coordinates in mm9. CLIP-seq performed in the mouse ES cell line, EL 16.7. CBX7 binding sites in the RNA are shown.

DETAILED DESCRIPTION

The new ‘denaturing’ CLIP-seq (dCLIP-seq) method, which utilizes a biotin tag to enable purification of RNA-protein complexes under denaturing conditions to increase the specificity of the purification scheme, was used to capture a genome-wide pool of transcripts (>30 nt) that bind with the PRC1 complex via the CBX7 subunit. Transcriptome characterization has identified classes of medically significant targets. Many if not all of the mouse PRC1-transcripts identified herein were shown by LiftOver analysis to have direct counterparts in the human epigenome.

As demonstrated herein, at least a subset of RNAs directly interacts with PRC1 in vivo and, in many cases, the interacting subunit is a CBX protein, e.g., CBX7. In some cases, the interacting subunit is CBX2, 4, 6, or 8. CBX7 is generally expressed earlier in development in less-differentiated cells, while CBX2, 4, 6, 8 are expressed in more differentiated cells and may be more tissue-specific. The CBX family is likely to have highly overlapping RNA interactomes, because the proteins are highly similar to each other and have RNA-binding domains.

The present analysis suggests that both cis and trans mechanisms may be utilized by RNAs in the PRC1 RNA interactome. As shown herein, PRC1 has a number of different cis-regulatory effects. PRC1 binding sites can be classified into several groups, including (i) 3′ untranslated region (3′ UTR), (ii) promoter-associated, (iii) gene body, (iv) antisense, and (v) intergenic. Disrupting the interaction between PRC1 and a binding RNA could lead to either activation or repression. For example, targeting the PRC1 binding sites within the 3′ UTR of Calm2 and Dcaf1211 results in upregulation of these coding genes (FIG. 3). Calm2 is a member of the calmodulin gene family, with three distinct calmodulin genes throughout the genome that encode an identical protein. CALM2 is a calcium binding protein that plays a role in signaling pathways, cell cycle progression and proliferation. Mutations are associated with long-QT syndrome (LQTS, life-threatening ventricular arrhythmias) with delayed neurodevelopment and epilepsy. By contrast, targeting various regions within Mecp2 and IRAK1 resulted in gene downregulation (FIGS. 5A-B). The present methods may be especially useful when one aims to titrate down but not eliminate gene expression, such as in the case of MECP2 Duplication Syndrome (a disease in which the MECP2 gene is duplicated and causes an Rett Syndrome-like disorder) or for treating autoimmune or inflammatory diseases, such as systemic lupus erythematosis (SLE), for which IRAK1 (interleukin 1 associated kinase 1) has been implicated.

As used herein, the 3′UTR is the last exon of a protein coding gene that usually includes the last few translated codons and the rest of the untranslated 3′ end of the mRNA encoded by the gene.

The evidence presented herein further demonstrates that RNA cofactors are a general feature of Polycomb regulation and that inhibitory nucleic acids as described herein that target RNAs in the PRC1 RNA interactome can successfully modulate (e.g., upregulate) gene expression, with effects dependent on the target site in the interacting transcript. The effects are presumed to be caused by inhibiting PRC1-RNA interactions. Genes in cis, in either antisense-strand orientation or same strand orientation, and extending 1 kb or more, e.g. 5 or 20 kb, from the location of the PRC1-binding RNA, can be regulated. Because chromatin modifiers such as PRC1 play a central role in maintaining stem cell pluripotency and in cancer, a genome-wide profile of regulatory RNAs will be a valuable resource in the quest to diagnose and treat disease. To downregulate gene expression, targeting RNA-PRC1 interactions by antisense oligonucleotides provides an alternative approach to RNAi methods, when one aims to titrate down but not eliminate gene expression, such as in the case of MECP2 Duplication Syndrome (a disease in which the MECP2 gene is duplicated and causes an Rett Syndrome-like disorder) or for treating autoimmune or inflammatory diseases, such as systemic lupus erythematosis (SLE), for which IRAK1 (interleukin 1 associated kinase 1) has been implicated.

Denaturing CLIP-Seq Methods (dCLIP-Seq)

Described herein are methods for pulling down RNAs that bind to a protein of interest, to produce libraries of those RNAs, and to identify regions of the RNAs to which the proteins bind. These methods were used to identify RNAs that bind the CBX7 portion of the PRC1 complex, but can be used with any proteins known or suspected to bind RNA. In some embodiments, the methods include the steps shown in FIGS. 1A and/or 1B; one of skill in the art will appreciate that other techniques can be substituted for those shown. These include conventional CLIP (see, e.g., Davidovich et al., Mol Cell. 2015 Feb. 5; 57(3):552-8), HITS-CLIP (Darnell, Wiley Interdiscip Rev RNA. 2010 September-October; 1(2): 266-286), PAR-CLIP, iCLIP (huppertz et al., Methods. 2014 February; 65(3): 274-287), and native RIP (Zhao et al., Mol Cell. 2010 Dec. 22; 40(6):939-53).

In preferred embodiments, the methods are practiced using cells, e.g., mammalian cells, that express the bacterial biotin ligase BirA, and an RNA-binding protein of interest, e.g., CBX2, CBX4, CBX6, CBX7, or CBX8, fused to a biotinylation tag sequence. In some embodiments, the BirA and RNA binding protein are on separate vectors, preferably separate vectors with different selectable markers, e.g., different antibiotic resistance genes, or different fluorescent proteins. In some embodiments, the BirA is expressed from a first vector under neomycin resistance, and the protein of interest fused to a biotinylation tag sequence is expressed from a second vector under puromycin resistance. Biotinylation tag sequences are known in the art, see, e.g., Schatz, Biotechnology (N Y). 1993 October; 11(10):1138-43; Tucker and Grisshammer, Biochem J. 1996 Aug. 1; 317 (Pt 3):891-9; and Beckett et al., Protein Sci. 1999 April; 8(4):921-9. An exemplary biotinylation sequence is GLNDIFEAQKIEWHE (SEQ ID NO: 36369); other sequences are known in the art, e.g., GLNDIFEAQKIEWH (SEQ ID NO: 36370); and others as disclosed in Beckett et al., Protein Science 1999, 8:921-929, e.g., in FIG. 5 and Table 2 therein. Sequences for BirA are also known in the art; see, e.g., Howard et al., Gene. 1985; 35(3):321-31. An exemplary protein sequence for BirA is as follows:

(SEQ ID NO: 36371)

10 20 30 40

MKDNTVPLKL IALLANGEFH SGEQLGETLG MSRAAINKHI

50 60 70 80

QTLRDWGVDV FTVPGKGYSL PEPIQLLNAK QILGQLDGGS

90 100 110 120

VAVLPVIDST NQYLLDRIGE LKSGDACIAE YQQAGRGRRG

130 140 150 160

RKWFSPFGAN LYLSMFWRLE QGPAAAIGLS LVIGIVMAEV

170 180 190 200

LRKLGADKVR VKWPNDLYLQ DRKLAGILVE LTGKTGDAAQ

210 220 230 240

IVIGAGINMA MRRVEESVVN QGWITLQEAG INLDRNTLAA

250 260 270 280

MLIRELRAAL ELFEQEGLAP YLSRWEKLDN FINRPVKLII

290 300 310 320

GDKEIFGISR GIDKQGALLL EQDGIIKPWM GGEISLRSAE

K

Additional exemplary sequences include those at GenBank Acc. No. NP_418404.1 and YP_491483.1; exemplary coding sequences can be found at NC_000913.3 and NC_007779.1.

Cells are crosslinked by exposure to ultraviolet (UV) light (e.g., preferably 254 nm, but a range of 200 nm to 400 nm may be possible), cellular lysates are prepared, then DNAsed to solubilize the chromatin, and protein-RNA complexes are pulled down using streptavidin beads. Importantly, the samples are then washed, preferably with a high stringency wash, e.g., using 8 M urea (range: 5-10 M, 6-10M, 7-10M, 7-9M, or 7.5-8.5M)+0.1% SDS (range: 0.0-2.0%). Other detergents may be used as substitutes for SDS, including Triton X-100 and NP40. Samples can then be further washed, e.g., in PBS+2% SDS and further in high salt buffer (e.g., PBS+750 mM NaCl+1% NP40+0.5% NaDeoxycholate+0.1% SDS; variations on salt/detergent conditions are possible). Under such suitable stringent conditions, most proteins are denatured, resulting in the loss of the nonspecific RNA-protein interactions. Only the extremely high-affinity biotin-avidin interaction survives. Thus, these steps can be used to effectively remove the vast majority of background RNA, resulting in extremely clean “peaks” of binding. The samples are then treated with DNAse to remove contaminating DNA. The RNA is phosphorylated using P32-ATP and run on SDS-PAGE and transferred onto membrane. Bands corresponding to the protein-RNA complex are then excised and eluted for cDNA preparation.

In some embodiments, the methods include contacting the sample with an agent, e.g., an antibody, that binds specifically to an RNA-binding protein or protein complex such as PRC1, e.g., to CBX7.

In some embodiments, the methods include some or all of the following: isolating the complexes; synthesizing DNA complementary to the RNAs to provide an initial population of cDNAs; PCR-amplifying, if necessary, using strand-specific primers; purifying the initial population of cDNAs to obtain a purified population of cDNAs that are at least 20 nucleotides (nt) in length; and high-throughput sequencing the purified population of cDNAs. Homopolymer reads are filtered, and reads matching the mitochondrial genome and ribosomal RNAs are excluded from all subsequent analyses. Reads that align to a reference genome with <1 mismatch are retained, excluding homopolymers, reads that align to the mitochondrial genome, and ribosomal RNAs. High probability PRC1-interacting transcripts are then called based on criteria that reads were significantly enriched in the wildtype library versus control library (such as a protein-null or tag-only control library, a minus-crosslinking library, or library made from an IgG pulldown done in parallel) for any given transcript. For example, under one set of criteria published in Zhao et al., 2010, the transcripts were enriched 3:1 in the wildtype library over the EZH2-null library, and each transcript had an RPKM minimum of 0.4. The criteria can be adjusted up or down based on empirical control data suggesting what cutoffs could be reasonably used. Statistical methods may also be used to call enrichment or “peaks” (binding sites) in the PRC1 library relative to control libraries, as has been used for the peaks called herein.

In general, to construct dCLIP-seq libraries, RNAs are extracted from the gel using standard techniques. To capture all RNAs (not just polyA RNAs) and to preserve strand information, 3′end-specific adapter is ligated to the extracted RNA fragments followed by hybridization with reverse transcription primer specific to 3′end adaptor and ligation of second adaptor specific to 5′ end. The subsequent reverse transcription step creates first strand cDNA sequence that contains sequences complementary to the 3′ and 5′ adapters. The resulting PCR using 3′- and 5′-adaptor specific primer pairs is then performed to amplify the cDNAs and the products sequenced via standard methods of high throughput sequencing. Prior to sequencing, a size-selection step is incorporated in which amplified PCR products of desired sizes are excised after separation by gel electrophoresis (e.g., on a Nu-Sieve agarose gel or in an acrylamide gel) in order to remove an undesirable side products such as adapter dimers.

Kits

Provided herein are kits for use in the dCLIP-seq methods described herein. The kits can include, but are not limited to, an expression vector for expressing the bacterial biotin ligase BirA in a cell type of interest, and an expression vector for expressing RNA-binding proteins of interest, e.g., mammalian (e.g., human or mouse) RNA-binding proteins of interest PRC1 components such as CBX2, CBX4, CBX6, CBX7, CBX8, or RYPB fused in-frame to a Flag-biotinylation tag sequence. In addition to PRC1 components, PRC2 components (EZH2, EZH1, SUZ12, etc) or any other RNA-binding protein (ATRX, YY1, CTCF, as three examples) may be used as bait and fused in frame to the biotin tag. In some embodiments, the kits include buffers, e.g., a high stringency denaturing buffer, e.g., comprising 8 M urea (range: 5-10 M, 6-10M, 7-10M, 7-9M, or 7.5-8.5M) plus 0.1% SDS (range: 0.0-2.0%); wash buffer (e.g., PBS+2% SDS; high salt wash buffer (e.g., PBS+750 mM NaCl+1% NP40+0.5% NaDeoxycholate+0.1% SDS. Other detergents may be used as substitutes for SDS, including Triton X-100 and NP40; variations on salt conditions are also possible. In some embodiments, the kits include cells expressing BirA.

PRC1-Interacting RNAs and RNA Libraries

The present invention includes the individual PRC1-binding regions of RNAs described herein, as well as libraries of RNAs produced by methods described herein. In some embodiments, the libraries are in solution, or are lyophilized. In some embodiments, the libraries are bound to a substrate, e.g., wherein each member of the library is bound to an individually addressable member, e.g., an individual area on an array (e.g., a microarray), or a bead. The PRC1 RNA interactome consists of both coding and noncoding transcripts. Non-coding PRC1-interacting RNA transcripts may also include a protein-coding sequence of bases, e.g., a distinct transcript that overlaps in position with a protein-coding reference gene (e.g., the gene whose expression is modulated in cis).

In one embodiment, an RNA includes a nucleotide sequence that is at least about 85% or more homologous or identical to the entire length of an RNA sequence shown herein, e.g., in any of Tables 1-4, or a fragment comprising at least 20 nt thereof (e.g., at least 25, 30, 35, 40, 50, 60, 70, 80, 90, or 100 nt thereof, e.g., at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 50% or more of the full length RNA). In some embodiments, the nucleotide sequence is at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% homologous or identical to an RNA sequence shown herein.

Mouse-to-human LiftOver analysis and analysis in the UCSC genome browser of syntenic positions indicate the existence of similar transcripts in the human genome. This process and LiftOver chains are generally described in Kent et al., Proc. Nat'l Acad. Sci., 100(20) 11484-11489 (2003). Given the geographic and sequence similarities between the mouse and human transcripts, we believe that a similar number of PRC1-interacting transcripts occur in the human system. The data suggest that many if not all of the mouse PRC1-transcripts have direct counterparts in the human epigenome. Such direct counterparts in other species are termed “orthologous” herein.

RNAs may be functionally conserved without being highly conserved at the level of overall nucleotide identity. For example, mouse Xist shows only 76% overall nucleotide identity with human XIST using sliding 21-bp windows, or an overall sequence identity of only 60%. However, within specific functional domains, the degree of conservation can be >70% between different mammalian species. The crucial motif in some RNAs (e.g., Repeat A of XIST) is the secondary structures formed by the repeat. An RNA interacting with PRC1 may therefore be similarly low in overall conservation but still have conservation in secondary structure within specific domains of the RNA, and thereby demonstrate functional conservation with respect to recruitment of PRC1.

Calculations of homology or sequence identity between sequences (the terms are used interchangeably herein) are performed as follows.

To determine the percent identity of two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). The length of a reference sequence aligned for comparison purposes is at least 80% of the length of the reference sequence, and in some embodiments is at least 90% or 100%. The nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein nucleic acid “identity” is equivalent to nucleic acid “homology”). The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.

For purposes of the present invention, the comparison of sequences and determination of percent identity between two sequences can be accomplished using a Blossum 62 scoring matrix with a gap penalty of 12, a gap extend penalty of 4, and a frameshift gap penalty of 5.

There are several potential uses for the RNAs described herein in the expanded PRC1 transcriptome: The RNAs themselves, or antagomirs and small molecules designed against them, can be utilized to modulate expression (either up or down) of Polycomb target genes.

In various related aspects, including with respect to the targeting of RNAs by LNA molecule, PRC1-binding RNAs can include endogenous coding and non-coding cellular RNAs, including but not limited to those RNAs that are greater than 60 nt in length, e.g., greater than 100 nt, e.g., greater than 200 nt, have no positive-strand open reading frames greater than 100 amino acids in length, are identified as ncRNAs by experimental evidence, and are distinct from known (smaller) functional-RNA classes (including but not limited to ribosomal, transfer, and small nuclear/nucleolar RNAs, siRNA, piRNA, and miRNA). See, e.g., Lipovich et al., “MacroRNA underdogs in a microRNA world: Evolutionary, regulatory, and biomedical significance of mammalian long non-protein-coding RNA” Biochimica et Biophysica Acta (2010) doi:10.1016/j.bbagrm.2010.10.001; Ponting et al., Cell 136(4):629-641 (2009), Jia et al., RNA 16 (8) (2010) 1478-1487, Dinger et al., Nucleic Acids Res. 37 1685 (2009) D122-D126 (database issue); and references cited therein. ncRNAs have also been referred to as, and can include, long non-coding RNA, long RNA, large RNA, macro RNA, intergenic RNA, and NonCoding Transcripts.

The methods described herein can be used to target both coding and non-coding RNAs. Known classes of RNAs include large intergenic non-coding RNAs (lincRNAs, see, e.g., Guttman et al., Nature. 2009 Mar. 12; 458(7235):223-7. Epub 2009 Feb. 1, which describes over a thousand exemplary highly conserved large non-coding RNAs in mammals; and Khalil et al., PNAS 106(28)₁₁₆₇₅-11680 (2009)); promoter associated short RNAs (PASRs; see, e.g., Seila et al., Science. 2008 Dec. 19; 322(5909):1849-51. Epub 2008 Dec. 4; Kanhere et al., Molecular Cell 38, 675-688, (2010)); endogenous antisense RNAs (see, e.g., Numata et al., BMC Genomics. 10:392 (2009); Okada et al., Hum Mol Genet. 17(11):1631-40 (2008); Numata et al., Gene 392(1-2):134-141 (2007); and Rosok and Sioud, Nat Biotechnol. 22(1):104-8 (2004)); and RNAs that bind chromatin modifiers such as PRC2 and LSD1 (see, e.g., Tsai et al., Science. 2010 Aug. 6; 329(5992):689-93. Epub 2010 Jul. 8; and Zhao et al., Science. 2008 Oct. 31; 322(5902):750-6).

Exemplary ncRNAs include XIST, TSIX, SRA1, and KCNQ1OT1. The sequences for more than 17,000 long human ncRNAs can be found in the NCode™ Long ncRNA Database on the Invitrogen website. Additional long ncRNAs can be identified using, e.g., manual published literature, Functional Annotation of Mouse (FANTOM3) project, Human Full-length cDNA Annotation Invitational (H-Invitational) project, antisense ncRNAs from cDNA and EST database for mouse and human using a computation pipeline (Zhang et al., Nucl. Acids Res. 35 (suppl 1): D156-D161 (2006); Engstrom et al., PLoS Genet. 2:e47 (2006)), human snoRNAs and scaRNAs derived from snoRNA-LBME-db, RNAz (Washietl et al. 2005), Noncoding RNA Search (Torarinsson, et al. 2006), and EvoFold (Pedersen et al. 2006).

Methods of Modulating Gene Expression

The RNAs described herein, including fragments thereof that are at least 20 nt in length, and inhibitory nucleic acids and small molecules targeting (e.g., complementary to) them, can be used to modulate gene expression in a cell, e.g., a cancer cell, a stem cell, or other normal cell types for gene or epigenetic therapy. The cells can be in vitro, including ex vivo, or in vivo (e.g., in a subject who has cancer, e.g., a tumor).

The methods described herein can be used for modulating expression of oncogenes and tumor suppressors in cells, e.g., cancer cells. For example, to decrease expression of an gene (e.g., an oncogene or imprinted gene) in a cell, the methods include introducing into the cell an inhibitory nucleic acid or small molecule that specifically binds, or is complementary, to a PRC1-binding region of an RNA that increases expression of the gene, e.g., an oncogene and/or an imprinted gene, set forth in Tables 1-3. As another example, to increase expression of a gene, e.g., a tumor suppressor, in a cell, the methods include introducing into the cell an inhibitory nucleic acid or small molecule that specifically binds, or is complementary, to a PRC1-binding region of an RNA that decreases expression of the gene, e.g., of a tumor suppressor gene, set forth in Tables 1-3, e.g., in subjects with cancer, e.g., lung adenocarcinoma patients.

In general, the methods include introducing into the cell an inhibitory nucleic acid that specifically binds, or is complementary, to a region of an RNA that modulated expression of a gene as set forth in Tables 1-3.

In preferred embodiments, the inhibitory nucleic acid binds to a region within or near (e.g., within 100, 200, 300, 400, 500, 600, 700, 1K, 2K, or 5K bases of) a PRC1-binding region of the RNA as set forth in Tables 1-3. The empirically-identified “peaks,” which are believed to represent PRC1-binding regions are shown in Table 1, with 500 nts of sequence on each side, so that in some the methods can include targeting a sequence as shown in one of the sequences in Tables 1-3, or a sequence that is between 500 nts from the start and 500 nts of the end of a sequence shown in Tables 1-3, or between 400 nts from the start and 400 nts of the end, 300 nts from the start and 300 nts of the end, between 200 nts from the start and 200 nts of the end, or between 100 nts from the start and 100 nts of the end, of a sequence shown in Tables 1-3. A nucleic acid that binds “specifically” binds primarily to the target RNA or related RNAs to inhibit regulatory function of the RNA but not of other non-target RNAs. The specificity of the nucleic acid interaction thus refers to its function (e.g., inhibiting the PRC1-associated repression of gene expression) rather than its hybridization capacity. Inhibitory nucleic acids may exhibit nonspecific binding to other sites in the genome or other RNAs, without interfering with binding of other regulatory proteins and without causing degradation of the non-specifically-bound RNA. Thus this nonspecific binding does not significantly affect function of other non-target RNAs and results in no significant adverse effects.

These methods can be used to treat a cancer in a subject by administering to the subject a composition (e.g., as described herein) comprising a PRC1-binding fragment of an RNA as described herein and/or an inhibitory nucleic acid that binds to an RNA (e.g., an inhibitory nucleic acid that binds to an RNA that inhibits a tumor suppressor, or cancer-suppressing gene, or imprinted gene and/or other growth-suppressing genes in any of Tables 1-3). Examples of cellular proliferative and/or differentiative disorders include cancer, e.g., carcinoma, sarcoma, metastatic disorders or hematopoietic neoplastic disorders, e.g., leukemias. A metastatic tumor can arise from a multitude of primary tumor types, including but not limited to those of prostate, colon, lung, breast and liver origin.

As used herein, treating includes “prophylactic treatment” which means reducing the incidence of or preventing (or reducing risk of) a sign or symptom of a disease in a patient at risk for the disease, and “therapeutic treatment”, which means reducing signs or symptoms of a disease, reducing progression of a disease, reducing severity of a disease, in a patient diagnosed with the disease. With respect to cancer, treating includes inhibiting tumor cell proliferation, increasing tumor cell death or killing, inhibiting rate of tumor cell growth or metastasis, reducing size of tumors, reducing number of tumors, reducing number of metastases, increasing 1-year or 5-year survival rate.

As used herein, the terms “cancer”, “hyperproliferative” and “neoplastic” refer to cells having the capacity for autonomous growth, i.e., an abnormal state or condition characterized by rapidly proliferating cell growth. Hyperproliferative and neoplastic disease states may be categorized as pathologic, i.e., characterizing or constituting a disease state, or may be categorized as non-pathologic, i.e., a deviation from normal but not associated with a disease state. The term is meant to include all types of cancerous growths or oncogenic processes, metastatic tissues or malignantly transformed cells, tissues, or organs, irrespective of histopathologic type or stage of invasiveness. “Pathologic hyperproliferative” cells occur in disease states characterized by malignant tumor growth. Examples of non-pathologic hyperproliferative cells include proliferation of cells associated with wound repair.

The terms “cancer” or “neoplasms” include malignancies of the various organ systems, such as affecting lung (e.g. small cell, non-small cell, squamous, adenocarcinoma), breast, thyroid, lymphoid, gastrointestinal, genito-urinary tract, kidney, bladder, liver (e.g. hepatocellular cancer), pancreas, ovary, cervix, endometrium, uterine, prostate, brain, as well as adenocarcinomas which include malignancies such as most colon cancers, colorectal cancer, renal-cell carcinoma, prostate cancer and/or testicular tumors, non-small cell carcinoma of the lung, cancer of the small intestine and cancer of the esophagus.

The term “carcinoma” is art recognized and refers to malignancies of epithelial or endocrine tissues including respiratory system carcinomas, gastrointestinal system carcinomas, genitourinary system carcinomas, testicular carcinomas, breast carcinomas, prostatic carcinomas, endocrine system carcinomas, and melanomas. In some embodiments, the disease is renal carcinoma or melanoma. Exemplary carcinomas include those forming from tissue of the cervix, lung, prostate, breast, head and neck, colon and ovary. The term also includes carcinosarcomas, e.g., which include malignant tumors composed of carcinomatous and sarcomatous tissues. An “adenocarcinoma” refers to a carcinoma derived from glandular tissue or in which the tumor cells form recognizable glandular structures.

The term “sarcoma” is art recognized and refers to malignant tumors of mesenchymal derivation.

Additional examples of proliferative disorders include hematopoietic neoplastic disorders. As used herein, the term “hematopoietic neoplastic disorders” includes diseases involving hyperplastic/neoplastic cells of hematopoietic origin, e.g., arising from myeloid, lymphoid or erythroid lineages, or precursor cells thereof. Preferably, the diseases arise from poorly differentiated acute leukemias, e.g., erythroblastic leukemia and acute megakaryoblastic leukemia. Additional exemplary myeloid disorders include, but are not limited to, acute promyeloid leukemia (APML), acute myelogenous leukemia (AML) and chronic myelogenous leukemia (CML) (reviewed in Vaickus, L. (1991) Crit Rev. in Oncol./Hemotol. 11:267-97); lymphoid malignancies include, but are not limited to acute lymphoblastic leukemia (ALL) which includes B-lineage ALL and T-lineage ALL, chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL), hairy cell leukemia (HLL) and Waldenstrom's macroglobulinemia (WM). Additional forms of malignant lymphomas include, but are not limited to non-Hodgkin lymphoma and variants thereof, peripheral T cell lymphomas, adult T cell leukemia/lymphoma (ATL), cutaneous T-cell lymphoma (CTCL), large granular lymphocytic leukemia (LGF), Hodgkin's disease and Reed-Sternberg disease.

In some embodiments, specific cancers that can be treated using the methods described herein include, but are not limited to: breast, lung, prostate, CNS (e.g., glioma), salivary gland, prostate, ovarian, and leukemias (e.g., ALL, CML, or AML). Associations of these genes with a particular cancer are known in the art, e.g., as described in Futreal et al., Nat Rev Cancer. 2004; 4; 177-83; and The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website, Bamford et al., Br J Cancer. 2004; 91; 355-8; see also Forbes et al., Curr Protoc Hum Genet. 2008; Chapter 10; Unit 10.11, and the COSMIC database, e.g., v. 50 (Nov. 30, 2010).

In addition, the methods described herein can be used for modulating (e.g., enhancing or decreasing) pluripotency of a stem cell and to direct stem cells down specific differentiation pathways to make endoderm, mesoderm, ectoderm, and their developmental derivatives. To increase, maintain, or enhance pluripotency, the methods include introducing into the cell an inhibitory nucleic acid that specifically binds to, or is complementary to, a PRC1-binding site on a non-coding RNA as set forth in any of Tables 1-3. Stem cells useful in the methods described herein include adult stem cells (e.g., adult stem cells obtained from the inner ear, bone marrow, mesenchyme, skin, fat, liver, muscle, or blood of a subject, e.g., the subject to be treated); embryonic stem cells, or stem cells obtained from a placenta or umbilical cord; progenitor cells (e.g., progenitor cells derived from the inner ear, bone marrow, mesenchyme, skin, fat, liver, muscle, or blood); and induced pluripotent stem cells (e.g., iPS cells).

Furthermore, the present methods can be used to treat Systemic Lupus erythematosus (SLE), an autoimmune disease that affects 1.5 million Americans (16,000 new cases per year). Ages 10-50 are the most affected, with more sufferers being female than male. SLE is a multi-organ disease; the effects include arthritis, joint pain & swelling, chest pain, fatigue, general malaise, hair loss, mouth sores, sensitivity to light, skin rash, and swollen lymph nodes. Current treatments include corticosteroids, immunosuppressants, and more recently belimumab (an inhibitor of B cell activating factor).

The causes of SLE are probably multiple, including HLA haplotypes. The interleukin 1 receptor associated kinase 1 (IRAK1) has been implicated in some patients. IRAK1 is X-linked (possibly explaining the female predominance of the disease) and is involved in immune response to foreign antigens and pathogens. IRAK1 has been associated with SLE in both adult and pediatric forms. Overexpression of IRAK1 in animal models causes SLE, and knocking out IRAK1 in mice alleviates symptoms of SLE. See, e.g., Jacob et al., Proc Natl Acad Sci USA. 2009 Apr. 14; 106(15):6256-61. The present methods can include treating a subject with SLE by administering an inhibitory nucleic acid that is complementary to a PRC1-binding region on IRAK1 RNA, e.g., an LNA targeting the 3′ UTR, e.g., as shown in Table 4.

The present methods can also be used to treat MECP2 Duplication Syndrome in a subject. This condition is characterized by mental retardation, weak muscle tone, and feeding difficulties, as well as poor/absent speech, seizures, and muscle spasticity. There are more reported cases in males than in females; female carriers may have skewed XCI. There is a 50% mortality rate by age 25 associated with this condition, which accounts for 1-2% of X-linked mental retardation. The real rate of incidence is unknown, as many go undiagnosed. Genetically, the cause is duplication (even triplication) of MECP2 gene. There is no current treatment. The present methods can include treating a subject with MECP2 Duplication Syndrome by administering an inhibitory nucleic acid that is complementary to a PRC1-binding region on Mecp2 RNA, e.g., an LNA targeting the 3′UTR of Mecp2 as shown in FIG. 2C, e.g., as shown in Table 4.

In some embodiments, the methods described herein include administering a composition, e.g., a sterile composition, comprising an inhibitory nucleic acid that is complementary to a PRC1-binding region on an RNA described herein, e.g., as set forth in any of Tables 1-3, or SEQ ID NOS:1-5893 (human) or 5894-17415 (human LiftOver). Inhibitory nucleic acids for use in practicing the methods described herein can be an antisense or small interfering RNA, including but not limited to an shRNA or siRNA. In some embodiments, the inhibitory nucleic acid is a modified nucleic acid polymer (e.g., a locked nucleic acid (LNA) molecule). The present methods can include administration of a

Inhibitory nucleic acids have been employed as therapeutic moieties in the treatment of disease states in animals, including humans. Inhibitory nucleic acids can be useful therapeutic modalities that can be configured to be useful in treatment regimes for the treatment of cells, tissues and animals, especially humans.

For therapeutics, an animal, preferably a human, suspected of having cancer is treated by administering an RNA or inhibitory nucleic acid in accordance with this invention. For example, in one non-limiting embodiment, the methods comprise the step of administering to the animal in need of treatment, a therapeutically effective amount of an RNA or inhibitory nucleic acid as described herein.

Inhibitory Nucleic Acids Inhibitory nucleic acids useful in the present methods and compositions include antisense oligonucleotides, ribozymes, external guide sequence (EGS) oligonucleotides, siRNA compounds, single- or double-stranded RNA interference (RNAi) compounds such as siRNA compounds, molecules comprising modified bases, locked nucleic acid molecules (LNA molecules), antagomirs, peptide nucleic acid molecules (PNA molecules), and other oligomeric compounds or oligonucleotide mimetics which hybridize to at least a portion of the target nucleic acid and modulate its function. In some embodiments, the inhibitory nucleic acids include antisense RNA, antisense DNA, chimeric antisense oligonucleotides, antisense oligonucleotides comprising modified linkages, interference RNA (RNAi), short interfering RNA (siRNA); a micro, interfering RNA (miRNA); a small, temporal RNA (stRNA); or a short, hairpin RNA (shRNA); small RNA-induced gene activation (RNAa); small activating RNAs (saRNAs), or combinations thereof. See, e.g., WO 2010040112.

In the present methods, the inhibitory nucleic acids are preferably designed to target a specific region of the RNA that binds to PRC1, as described herein (see Tables 1-3). These “inhibitory” nucleic acids are believed to work by inhibiting the interaction between the RNA and PRC1, and as described herein can be used to modulate expression of a gene.

In some embodiments, the inhibitory nucleic acids are 10 to 50, 13 to 50, or 13 to 30 nucleotides in length. One having ordinary skill in the art will appreciate that this embodies oligonucleotides having antisense (complementary) portions of 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleotides in length, or any range therewithin. It is understood that non-complementary bases may be included in such inhibitory nucleic acids; for example, an inhibitory nucleic acid 30 nucleotides in length may have a portion of 15 bases that is complementary to the targeted RNA. In some embodiments, the oligonucleotides are 15 nucleotides in length. In some embodiments, the antisense or oligonucleotide compounds of the invention are 12 or 13 to 30 nucleotides in length. One having ordinary skill in the art will appreciate that this embodies inhibitory nucleic acids having antisense (complementary) portions of 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 nucleotides in length, or any range therewithin.

Preferably the inhibitory nucleic acid comprises one or more modifications comprising: a modified sugar moiety, and/or a modified internucleoside linkage, and/or a modified nucleotide and/or combinations thereof. It is not necessary for all positions in a given oligonucleotide to be uniformly modified, and in fact more than one of the modifications described herein may be incorporated in a single oligonucleotide or even at within a single nucleoside within an oligonucleotide.

In some embodiments, the inhibitory nucleic acids are chimeric oligonucleotides that contain two or more chemically distinct regions, each made up of at least one nucleotide. These oligonucleotides typically contain at least one region of modified nucleotides that confers one or more beneficial properties (such as, for example, increased nuclease resistance, increased uptake into cells, increased binding affinity for the target) and a region that is a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. Chimeric inhibitory nucleic acids of the invention may be formed as composite structures of two or more oligonucleotides, modified oligonucleotides, oligonucleosides and/or oligonucleotide mimetics as described above. Such compounds have also been referred to in the art as hybrids or gapmers. Representative United States patents that teach the preparation of such hybrid structures comprise, but are not limited to, U.S. Pat. Nos. 5,013,830; 5,149,797; 5,220,007; 5,256,775; 5,366,878; 5,403,711; 5,491,133; 5,565,350; 5,623,065; 5,652,355; 5,652,356; and 5,700,922, each of which is herein incorporated by reference.

In some embodiments, the inhibitory nucleic acid comprises at least one nucleotide modified at the 2′ position of the sugar, most preferably a 2′-O-alkyl, 2′-O-alkyl-O-alkyl or 2′-fluoro-modified nucleotide. In other preferred embodiments, RNA modifications include 2′-fluoro, 2′-amino and 2′ O-methyl modifications on the ribose of pyrimidines, abasic residues or an inverted base at the 3′ end of the RNA. Such modifications are routinely incorporated into oligonucleotides and these oligonucleotides have been shown to have a higher Tm (i.e., higher target binding affinity) than; 2′-deoxyoligonucleotides against a given target.

A number of nucleotide and nucleoside modifications have been shown to make the oligonucleotide into which they are incorporated more resistant to nuclease digestion than the native oligodeoxynucleotide; these modified oligos survive intact for a longer time than unmodified oligonucleotides. Specific examples of modified oligonucleotides include those comprising modified backbones, for example, phosphorothioates, phosphotriesters, methyl phosphonates, short chain alkyl or cycloalkyl intersugar linkages or short chain heteroatomic or heterocyclic intersugar linkages. Most preferred are oligonucleotides with phosphorothioate backbones and those with heteroatom backbones, particularly CH₂—NH—O—CH₂, CH, ˜N(CH₃)˜O˜CH₂(known as a methylene(methylimino) or MMI backbone], CH₂—O—N(CH₃)—CH₂, CH₂—N(CH₃)—N(CH₃)—CH₂and 0-N(CH₃)— CH₂—CH₂backbones, wherein the native phosphodiester backbone is represented as O— P— O— CH); amide backbones (see De Mesmaeker et al. Ace. Chem. Res. 1995, 28:366-374); morpholino backbone structures (see Summerton and Weller, U.S. Pat. No. 5,034,506); peptide nucleic acid (PNA) backbone (wherein the phosphodiester backbone of the oligonucleotide is replaced with a polyamide backbone, the nucleotides being bound directly or indirectly to the aza nitrogen atoms of the polyamide backbone, see Nielsen et al., Science 1991, 254, 1497). Phosphorus-containing linkages include, but are not limited to, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates comprising 3′alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates comprising 3′-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3′-5′ linkages, 2′-5′ linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3′-5′ to 5′-3′ or 2′-5′ to 5′-2′; see U.S. Pat. Nos. 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455, 233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563, 253; 5,571,799; 5,587,361; and 5,625,050.

Morpholino-based oligomeric compounds are described in Dwaine A. Braasch and David R. Corey, Biochemistry, 2002, 41(14), 4503-4510); Genesis, volume 30, issue 3, 2001; Heasman, J., Dev. Biol., 2002, 243, 209-214; Nasevicius et al., Nat. Genet., 2000, 26, 216-220; Lacerra et al., Proc. Natl. Acad. Sci., 2000, 97, 9591-9596; and U.S. Pat. No. 5,034,506, issued Jul. 23, 1991. In some embodiments, the morpholino-based oligomeric compound is a phosphorodiamidate morpholino oligomer (PMO) (e.g., as described in Iverson, Curr. Opin. Mol. Ther., 3:235-238, 2001; and Wang et al., J. Gene Med., 12:354-364, 2010; the disclosures of which are incorporated herein by reference in their entireties).

Cyclohexenyl nucleic acid oligonucleotide mimetics are described in Wang et al., J. Am. Chem. Soc., 2000, 122, 8595-8602.

Modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These comprise those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH2 component parts; see U.S. Pat. Nos. 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264, 562; 5, 264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; and 5,677,439, each of which is herein incorporated by reference.

Modified oligonucleotides are also known that include oligonucleotides that are based on or constructed from arabinonucleotide or modified arabinonucleotide residues. Arabinonucleosides are stereoisomers of ribonucleosides, differing only in the configuration at the 2′-position of the sugar ring. In some embodiments, a 2′-arabino modification is 2′-F arabino. In some embodiments, the modified oligonucleotide is 2′-fluoro-D-arabinonucleic acid (FANA) (as described in, for example, Lon et al., Biochem., 41:3457-3467, 2002 and Min et al., Bioorg. Med. Chem. Lett., 12:2651-2654, 2002; the disclosures of which are incorporated herein by reference in their entireties). Similar modifications can also be made at other positions on the sugar, particularly the 3′ position of the sugar on a 3′ terminal nucleoside or in 2′-5′ linked oligonucleotides and the 5′ position of 5′ terminal nucleotide.

PCT Publication No. WO 99/67378 discloses arabinonucleic acids (ANA) oligomers and their analogues for improved sequence specific inhibition of gene expression via association to complementary messenger RNA.

Other preferred modifications include ethylene-bridged nucleic acids (ENAs) (e.g., International Patent Publication No. WO 2005/042777, Morita et al., Nucleic Acid Res., Suppl 1:241-242, 2001; Surono et al., Hum. Gene Ther., 15:749-757, 2004; Koizumi, Curr. Opin. Mol. Ther., 8:144-149, 2006 and Horie et al., Nucleic Acids Symp. Ser (Oxf), 49:171-172, 2005; the disclosures of which are incorporated herein by reference in their entireties). Preferred ENAs include, but are not limited to, 2′-O,4′-C-ethylene-bridged nucleic acids.

Examples of LNAs are described in WO 2008/043753 and include compounds of the following formula.

embedded image

where X and Y are independently selected among the groups —O—,

—S—, —N(H)—, N(R)—,—CH2- or —CH— (if part of a double bond),

—CH₂—O—, —CH₂—S—, —CH₂—N(H)—, —CH₂—N(R)—, —CH₂—CH₂— or —CH₂—CH— (if part of a double bond),

—CH═CH—, where R is selected from hydrogen and C_1-4-alkyl; Z and Z* are independently selected among an internucleoside linkage, a terminal group or a protecting group; B constitutes a natural or non-natural nucleotide base moiety; and the asymmetric groups may be found in either orientation.

Preferably, the LNA used in the oligomer of the invention comprises at least one LNA unit according any of the formulas

embedded image

wherein Y is —O—, —S—, —NH—, or N(R^H); Z and Z* are independently selected among an internucleoside linkage, a terminal group or a protecting group; B constitutes a natural or non-natural nucleotide base moiety, and RH is selected from hydrogen and C_1-4-alkyl.

Preferably, the Locked Nucleic Acid (LNA) used in the oligomeric compound, such as an antisense oligonucleotide, of the invention comprises at least one nucleotide comprises a Locked Nucleic Acid (LNA) unit according any of the formulas shown in Scheme 2 of PCT/DK2006/000512.

Preferably, the LNA used in the oligomer of the invention comprises internucleoside linkages selected from -0-P(O)₂—O—, —O—P(O,S)—O—, -0-P(S)₂—O—, —S—P(O)₂—O—, —S—P(O,S)—O—, —S—P(S)₂—O—, -0-P(O)₂—S—, —O—P(O,S)—S—, —S—P(O)₂—S—, —O—PO(R^H)—O—, O—PO(OCH₃)—O—, —O—PO(NR^H)—O—, —O—PO(OCH₂CH₂S—R)—O—, —O—PO(BH₃)—O—, —O—PO(NHR^H)—O—, —O—P(O)₂—NR^H—, —NR^H—P(O)₂—O—, —NR^H—CO—O—, where R^His selected from hydrogen and C_1-4-alkyl.

Specifically preferred LNA units are shown in scheme 2:

embedded image

The term “thio-LNA” comprises a locked nucleotide in which at least one of X or Y in the general formula above is selected from S or —CH2-S—. Thio-LNA can be in both beta-D and alpha-L-configuration.

The term “amino-LNA” comprises a locked nucleotide in which at least one of X or Y in the general formula above is selected from —N(H)—, N(R)—, CH₂—N(H)—, and —CH₂—N(R)— where R is selected from hydrogen and C_1-4-alkyl. Amino-LNA can be in both beta-D and alpha-L-configuration.

The term “oxy-LNA” comprises a locked nucleotide in which at least one of X or Y in the general formula above represents —O— or —CH₂—O—. Oxy-LNA can be in both beta-D and alpha-L-configuration.

The term “ena-LNA” comprises a locked nucleotide in which Y in the general formula above is —CH₂—O— (where the oxygen atom of —CH₂—O— is attached to the 2′-position relative to the base B).

LNAs are described in additional detail below.

One or more substituted sugar moieties can also be included, e.g., one of the following at the 2′ position: OH, SH, SCH₃, F, OCN, OCH₃OCH₃, OCH₃O(CH₂)n CH₃, O(CH₂)n NH₂or O(CH₂)n CH₃where n is from 1 to about 10; Ci to C10 lower alkyl, alkoxyalkoxy, substituted lower alkyl, alkaryl or aralkyl; Cl; Br; CN; CF3; OCF3; O—, S—, or N-alkyl; O-, S-, or N-alkenyl; SOCH3; SO2 CH3; ONO2; NO2; N3; NH2; heterocycloalkyl; heterocycloalkaryl; aminoalkylamino; polyalkylamino; substituted silyl; an RNA cleaving group; a reporter group; an intercalator; a group for improving the pharmacokinetic properties of an oligonucleotide; or a group for improving the pharmacodynamic properties of an oligonucleotide and other substituents having similar properties. A preferred modification includes 2′-methoxyethoxy [2′-O—CH₂CH₂OCH₃, also known as 2′-O-(2-methoxyethyl)] (Martin et al, Helv. Chim. Acta, 1995, 78, 486). Other preferred modifications include 2′-methoxy (2′-O—CH₃), 2′-propoxy (2′-OCH₂CH₂CH₃) and 2′-fluoro (2′-F). Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3′ position of the sugar on the 3′ terminal nucleotide and the 5′ position of 5′ terminal nucleotide. Oligonucleotides may also have sugar mimetics such as cyclobutyls in place of the pentofuranosyl group.

Inhibitory nucleic acids can also include, additionally or alternatively, nucleobase (often referred to in the art simply as “base”) modifications or substitutions. As used herein, “unmodified” or “natural” nucleobases include adenine (A), guanine (G), thymine (T), cytosine (C) and uracil (U). Modified nucleobases include nucleobases found only infrequently or transiently in natural nucleic acids, e.g., hypoxanthine, 6-methyladenine, 5-Me pyrimidines, particularly 5-methylcytosine (also referred to as 5-methyl-2′ deoxycytosine and often referred to in the art as 5-Me-C), 5-hydroxymethylcytosine (HMC), glycosyl HMC and gentobiosyl HMC, isocytosine, pseudoisocytosine, as well as synthetic nucleobases, e.g., 2-aminoadenine, 2-(methylamino)adenine, 2-(imidazolylalkyl)adenine, 2-(aminoalklyamino)adenine or other heterosubstituted alkyladenines, 2-thiouracil, 2-thiothymine, 5-bromouracil, 5-hydroxymethyluracil, 5-propynyluracil, 8-azaguanine, 7-deazaguanine, N6 (6-aminohexyl)adenine, 6-aminopurine, 2-aminopurine, 2-chloro-6-aminopurine and 2,6-diaminopurine or other diaminopurines. See, e.g., Kornberg, “DNA Replication,” W. H. Freeman & Co., San Francisco, 1980, pp 75-77; and Gebeyehu, G., et al. Nucl. Acids Res., 15:4513 (1987)). A “universal” base known in the art, e.g., inosine, can also be included. 5-Me-C substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2<0>C. (Sanghvi, in Crooke, and Lebleu, eds., Antisense Research and Applications, CRC Press, Boca Raton, 1993, pp. 276-278) and are presently preferred base substitutions.

It is not necessary for all positions in a given oligonucleotide to be uniformly modified, and in fact more than one of the modifications described herein may be incorporated in a single oligonucleotide or even at within a single nucleoside within an oligonucleotide.

In some embodiments, both a sugar and an internucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups. The base units are maintained for hybridization with an appropriate nucleic acid target compound. One such oligomeric compound, an oligonucleotide mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar-backbone of an oligonucleotide is replaced with an amide containing backbone, for example, an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. Representative United States patents that teach the preparation of PNA compounds include, but are not limited to, U.S. Pat. Nos. 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference. Further teaching of PNA compounds can be found in Nielsen et al, Science, 1991, 254, 1497-1500.

Inhibitory nucleic acids can also include one or more nucleobase (often referred to in the art simply as “base”) modifications or substitutions. As used herein, “unmodified” or “natural” nucleobases comprise the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified nucleobases comprise other synthetic and natural nucleobases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudo-uracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylquanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine.

Further, nucleobases comprise those disclosed in U.S. Pat. No. 3,687,808, those disclosed in “The Concise Encyclopedia of Polymer Science And Engineering”, pages 858-859, Kroschwitz, ed. John Wiley & Sons, 1990; those disclosed by Englisch et al., Angewandle Chemie, International Edition, 1991, 30, page 613, and those disclosed by Sanghvi, Chapter 15, Antisense Research and Applications,” pages 289-302, Crooke, and Lebleu, eds., CRC Press, 1993. Certain of these nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds of the invention. These include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and 0-6 substituted purines, comprising 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2<0>C (Sanghvi, et al., eds, “Antisense Research and Applications,” CRC Press, Boca Raton, 1993, pp. 276-278) and are presently preferred base substitutions, even more particularly when combined with 2′-O-methoxyethyl sugar modifications. Modified nucleobases are described in U.S. Pat. No. 3,687,808, as well as U.S. Pat. Nos. 4,845,205; 5,130,302; 5,134,066; 5,175, 273; 5, 367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,596,091; 5,614,617; 5,750,692, and 5,681,941, each of which is herein incorporated by reference.

In some embodiments, the inhibitory nucleic acids are chemically linked to one or more moieties or conjugates that enhance the activity, cellular distribution, or cellular uptake of the oligonucleotide. For example, one or more inhibitory nucleic acids, of the same or different types, can be conjugated to each other; or inhibitory nucleic acids can be conjugated to targeting moieties with enhanced specificity for a cell type or tissue type. Such moieties include, but are not limited to, lipid moieties such as a cholesterol moiety (Letsinger et al., Proc. Natl. Acad. Sci. USA, 1989, 86, 6553-6556), cholic acid (Manoharan et al., Bioorg. Med. Chem. Let., 1994, 4, 1053-1060), a thioether, e.g., hexyl-S— tritylthiol (Manoharan et al, Ann. N. Y. Acad. Sci., 1992, 660, 306-309; Manoharan et al., Bioorg. Med. Chem. Let., 1993, 3, 2765-2770), a thiocholesterol (Oberhauser et al., Nucl. Acids Res., 1992, 20, 533-538), an aliphatic chain, e.g., dodecandiol or undecyl residues (Kabanov et al., FEBS Lett., 1990, 259, 327-330; Svinarchuk et al., Biochimie, 1993, 75, 49-54), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., Tetrahedron Lett., 1995, 36, 3651-3654; Shea et al., Nucl. Acids Res., 1990, 18, 3777-3783), a polyamine or a polyethylene glycol chain (Mancharan et al., Nucleosides & Nucleotides, 1995, 14, 969-973), or adamantane acetic acid (Manoharan et al., Tetrahedron Lett., 1995, 36, 3651-3654), a palmityl moiety (Mishra et al., Biochim. Biophys. Acta, 1995, 1264, 229-237), or an octadecylamine or hexylamino-carbonyl-t oxycholesterol moiety (Crooke et al., J. Pharmacol. Exp. Ther., 1996, 277, 923-937). See also U.S. Pat. Nos. 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552, 538; 5,578,717, 5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486, 603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762, 779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082, 830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5, 245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241, 5,391, 723; 5,416,203, 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5, 565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599, 928 and 5,688,941, each of which is herein incorporated by reference.

These moieties or conjugates can include conjugate groups covalently bound to functional groups such as primary or secondary hydroxyl groups. Conjugate groups of the invention include intercalators, reporter molecules, polyamines, polyamides, polyethylene glycols, polyethers, groups that enhance the pharmacodynamic properties of oligomers, and groups that enhance the pharmacokinetic properties of oligomers. Typical conjugate groups include cholesterols, lipids, phospholipids, biotin, phenazine, folate, phenanthridine, anthraquinone, acridine, fluoresceins, rhodamines, coumarins, and dyes. Groups that enhance the pharmacodynamic properties, in the context of this invention, include groups that improve uptake, enhance resistance to degradation, and/or strengthen sequence-specific hybridization with the target nucleic acid. Groups that enhance the pharmacokinetic properties, in the context of this invention, include groups that improve uptake, distribution, metabolism or excretion of the compounds of the present invention. Representative conjugate groups are disclosed in International Patent Application No. PCT/US92/09196, filed Oct. 23, 1992, and U.S. Pat. No. 6,287,860, which are incorporated herein by reference. Conjugate moieties include, but are not limited to, lipid moieties such as a cholesterol moiety, cholic acid, a thioether, e.g., hexyl-5-tritylthiol, a thiocholesterol, an aliphatic chain, e.g., dodecandiol or undecyl residues, a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate, a polyamine or a polyethylene glycol chain, or adamantane acetic acid, a palmityl moiety, or an octadecylamine or hexylamino-carbonyl-oxy cholesterol moiety. See, e.g., U.S. Pat. Nos. 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717, 5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241, 5,391,723; 5,416,203, 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and 5,688,941.

The inhibitory nucleic acids useful in the present methods are sufficiently complementary to the target RNA, e.g., hybridize sufficiently well and with sufficient biological functional specificity, to give the desired effect. “Complementary” refers to the capacity for pairing, through base stacking and specific hydrogen bonding, between two sequences comprising naturally or non-naturally occurring (e.g., modified as described above) bases (nucleosides) or analogs thereof. For example, if a base at one position of an inhibitory nucleic acid is capable of hydrogen bonding with a base at the corresponding position of an RNA, then the bases are considered to be complementary to each other at that position. 100% complementarity is not required. As noted above, inhibitory nucleic acids can comprise universal bases, or inert abasic spacers that provide no positive or negative contribution to hydrogen bonding. Base pairings may include both canonical Watson-Crick base pairing and non-Watson-Crick base pairing (e.g., Wobble base pairing and Hoogsteen base pairing). It is understood that for complementary base pairings, adenosine-type bases (A) are complementary to thymidine-type bases (T) or uracil-type bases (U), that cytosine-type bases (C) are complementary to guanosine-type bases (G), and that universal bases such as such as 3-nitropyrrole or 5-nitroindole can hybridize to and are considered complementary to any A, C, U, or T. Nichols et al., Nature, 1994; 369:492-493 and Loakes et al., Nucleic Acids Res., 1994; 22:4039-4043. Inosine (I) has also been considered in the art to be a universal base and is considered complementary to any A, C, U, or T. See Watkins and SantaLucia, Nucl. Acids Research, 2005; 33 (19): 6258-6267.

In some embodiments, the location on a target RNA to which an inhibitory nucleic acids hybridizes is defined as a region to which a protein binding partner binds, as shown in Tables 1-3. Routine methods can be used to design an inhibitory nucleic acid that binds to this sequence with sufficient specificity. In some embodiments, the methods include using bioinformatics methods known in the art to identify regions of secondary structure, e.g., one, two, or more stem-loop structures, or pseudoknots, and selecting those regions to target with an inhibitory nucleic acid. For example, methods of designing oligonucleotides similar to the inhibitory nucleic acids described herein, and various options for modified chemistries or formats, are exemplified in Lennox and Behlke, Gene Therapy (2011) 18: 1111-1120, which is incorporated herein by reference in its entirety, with the understanding that the present disclosure does not target miRNA ‘seed regions’.

While the specific sequences of certain exemplary target segments are set forth herein, one of skill in the art will recognize that these serve to illustrate and describe particular embodiments within the scope of the present invention. Additional target segments are readily identifiable by one having ordinary skill in the art in view of this disclosure. Target segments 5-500 nucleotides in length comprising a stretch of at least five (5) consecutive nucleotides within the protein binding region, or immediately adjacent thereto, are considered to be suitable for targeting as well. Target segments can include sequences that comprise at least the 5 consecutive nucleotides from the 5 ‘-terminus of one of the protein binding regions (the remaining nucleotides being a consecutive stretch of the same RNA beginning immediately upstream of the 5’-terminus of the binding segment and continuing until the inhibitory nucleic acid contains about 5 to about 100 nucleotides). Similarly preferred target segments are represented by RNA sequences that comprise at least the 5 consecutive nucleotides from the 3 ‘-terminus of one of the illustrative preferred target segments (the remaining nucleotides being a consecutive stretch of the same RNA beginning immediately downstream of the 3’-terminus of the target segment and continuing until the inhibitory nucleic acid contains about 5 to about 100 nucleotides). One having skill in the art armed with the sequences provided herein will be able, without undue experimentation, to identify further preferred protein binding regions to target with complementary inhibitory nucleic acids.

In the context of the present disclosure, hybridization means base stacking and hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary nucleoside or nucleotide bases. For example, adenine and thymine are complementary nucleobases which pair through the formation of hydrogen bonds. Complementary, as the term is used in the art, refers to the capacity for precise pairing between two nucleotides. For example, if a nucleotide at a certain position of an oligonucleotide is capable of hydrogen bonding with a nucleotide at the same position of a RNA molecule, then the inhibitory nucleic acid and the RNA are considered to be complementary to each other at that position. The inhibitory nucleic acids and the RNA are complementary to each other when a sufficient number of corresponding positions in each molecule are occupied by nucleotides that can hydrogen bond with each other through their bases. Thus, “specifically hybridizable” and “complementary” are terms which are used to indicate a sufficient degree of complementarity or precise pairing such that stable and specific binding occurs between the inhibitory nucleic acid and the RNA target. For example, if a base at one position of an inhibitory nucleic acid is capable of hydrogen bonding with a base at the corresponding position of a RNA, then the bases are considered to be complementary to each other at that position. 100% complementarity is not required.

It is understood in the art that a complementary nucleic acid sequence need not be 100% complementary to that of its target nucleic acid to be specifically hybridizable. A complementary nucleic acid sequence for purposes of the present methods is specifically hybridizable when binding of the sequence to the target RNA molecule interferes with the normal function of the target RNA to cause a loss of activity (e.g., inhibiting PRC1-associated repression with consequent up-regulation of gene expression) and there is a sufficient degree of complementarity to avoid non-specific binding of the sequence to non-target RNA sequences under conditions in which avoidance of the non-specific binding is desired, e.g., under physiological conditions in the case of in vivo assays or therapeutic treatment, and in the case of in vitro assays, under conditions in which the assays are performed under suitable conditions of stringency. For example, stringent salt concentration will ordinarily be less than about 750 mM NaCl and 75 mM trisodium citrate, preferably less than about 500 mM NaCl and 50 mM trisodium citrate, and more preferably less than about 250 mM NaCl and 25 mM trisodium citrate. Low stringency hybridization can be obtained in the absence of organic solvent, e.g., formamide, while high stringency hybridization can be obtained in the presence of at least about 35% formamide, and more preferably at least about 50% formamide. Stringent temperature conditions will ordinarily include temperatures of at least about 30° C., more preferably of at least about 37° C., and most preferably of at least about 42° C. Varying additional parameters, such as hybridization time, the concentration of detergent, e.g., sodium dodecyl sulfate (SDS), and the inclusion or exclusion of carrier DNA, are well known to those skilled in the art. Various levels of stringency are accomplished by combining these various conditions as needed. In a preferred embodiment, hybridization will occur at 30° C. in 750 mM NaCl, 75 mM trisodium citrate, and 1% SDS. In a more preferred embodiment, hybridization will occur at 37° C. in 500 mM NaCl, 50 mM trisodium citrate, 1% SDS, 35% formamide, and 100 μg/ml denatured salmon sperm DNA (ssDNA). In a most preferred embodiment, hybridization will occur at 42° C. in 250 mM NaCl, 25 mM trisodium citrate, 1% SDS, 50% formamide, and 200 μg/ml ssDNA. Useful variations on these conditions will be readily apparent to those skilled in the art.

For most applications, washing steps that follow hybridization will also vary in stringency. Wash stringency conditions can be defined by salt concentration and by temperature. As above, wash stringency can be increased by decreasing salt concentration or by increasing temperature. For example, stringent salt concentration for the wash steps will preferably be less than about 30 mM NaCl and 3 mM trisodium citrate, and most preferably less than about 15 mM NaCl and 1.5 mM trisodium citrate. Stringent temperature conditions for the wash steps will ordinarily include a temperature of at least about 25° C., more preferably of at least about 42° C., and even more preferably of at least about 68° C. In a preferred embodiment, wash steps will occur at 25° C. in 30 mM NaCl, 3 mM trisodium citrate, and 0.1% SDS. In a more preferred embodiment, wash steps will occur at 42° C. in 15 mM NaCl, 1.5 mM trisodium citrate, and 0.1% SDS. In a more preferred embodiment, wash steps will occur at 68° C. in 15 mM NaCl, 1.5 mM trisodium citrate, and 0.1% SDS. Additional variations on these conditions will be readily apparent to those skilled in the art. Hybridization techniques are well known to those skilled in the art and are described, for example, in Benton and Davis (Science 196:180, 1977); Grunstein and Hogness (Proc. Natl. Acad. Sci., USA 72:3961, 1975); Ausubel et al. (Current Protocols in Molecular Biology, Wiley Interscience, New York, 2001); Berger and Kimmel (Guide to Molecular Cloning Techniques, 1987, Academic Press, New York); and Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, New York.

In general, the inhibitory nucleic acids useful in the methods described herein have at least 80% sequence complementarity to a target region within the target nucleic acid, e.g., 90%, 95%, or 100% sequence complementarity to the target region within an RNA. For example, an antisense compound in which 18 of 20 nucleobases of the antisense oligonucleotide are complementary, and would therefore specifically hybridize, to a target region would represent 90 percent complementarity. Percent complementarity of an inhibitory nucleic acid with a region of a target nucleic acid can be determined routinely using basic local alignment search tools (BLAST programs) (Altschul et al., J. Mol. Biol., 1990, 215, 403-410; Zhang and Madden, Genome Res., 1997, 7, 649-656). Antisense and other compounds of the invention that hybridize to an RNA are identified through routine experimentation. In general the inhibitory nucleic acids must retain specificity for their target, i.e., either do not directly bind to, or do not directly significantly affect expression levels of, transcripts other than the intended target.

Target-specific effects, with corresponding target-specific functional biological effects, are possible even when the inhibitory nucleic acid exhibits non-specific binding to a large number of non-target RNAs. For example, short 8 base long inhibitory nucleic acids that are fully complementary to a RNA may have multiple 100% matches to hundreds of sequences in the genome, yet may produce target-specific effects, e.g. upregulation of a specific target gene through inhibition of PRC1 activity. 8-base inhibitory nucleic acids have been reported to prevent exon skipping with with a high degree of specificity and reduced off-target effect. See Singh et al., RNA Biol., 2009; 6(3): 341-350. 8-base inhibitory nucleic acids have been reported to interfere with miRNA activity without significant off-target effects. See Obad et al., Nature Genetics, 2011; 43: 371-378.

For further disclosure regarding inhibitory nucleic acids, please see US2010/0317718 (antisense oligos); US2010/0249052 (double-stranded ribonucleic acid (dsRNA)); US2009/0181914 and US2010/0234451 (LNA molecules); US2007/0191294 (siRNA analogues); US2008/0249039 (modified siRNA); and WO2010/129746 and WO2010/040112 (inhibitory nucleic acids).

Antisense

In some embodiments, the inhibitory nucleic acids are antisense oligonucleotides. Antisense oligonucleotides are typically designed to block expression of a DNA or RNA target by binding to the target and halting expression at the level of transcription, translation, or splicing. Antisense oligonucleotides of the present invention are complementary nucleic acid sequences designed to hybridize under stringent conditions to an RNA in vitro, and are expected to inhibit the activity of PRC1 in vivo. Thus, oligonucleotides are chosen that are sufficiently complementary to the target, i.e., that hybridize sufficiently well and with sufficient biological functional specificity, to give the desired effect.

Modified Base, Including Locked Nucleic Acids (LNAs)

In some embodiments, the inhibitory nucleic acids used in the methods described herein comprise one or more modified bonds or bases. Modified bases include phosphorothioate, methylphosphonate, peptide nucleic acids, or locked nucleic acids (LNAs). Preferably, the modified nucleotides are part of locked nucleic acid molecules, including [alpha]-L-LNAs. LNAs include ribonucleic acid analogues wherein the ribose ring is “locked” by a methylene bridge between the 2′-oxgygen and the 4′-carbon—i.e., oligonucleotides containing at least one LNA monomer, that is, one 2′-O,4′-C-methylene-β-D-ribofuranosyl nucleotide. LNA bases form standard Watson-Crick base pairs but the locked configuration increases the rate and stability of the basepairing reaction (Jepsen et al., Oligonucleotides, 14, 130-146 (2004)). LNAs also have increased affinity to base pair with RNA as compared to DNA. These properties render LNAs especially useful as probes for fluorescence in situ hybridization (FISH) and comparative genomic hybridization, as knockdown tools for miRNAs, and as antisense oligonucleotides to target mRNAs or other RNAs, e.g., RNAs as described herien.

The modified base/LNA molecules can include molecules comprising 10-30, e.g., 12-24, e.g., 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides in each strand, wherein one of the strands is substantially identical, e.g., at least 80% (or more, e.g., 85%, 90%, 95%, or 100%) identical, e.g., having 3, 2, 1, or 0 mismatched nucleotide(s), to a target region in the RNA. The modified base/LNA molecules can be chemically synthesized using methods known in the art.

The modified base/LNA molecules can be designed using any method known in the art; a number of algorithms are known, and are commercially available (e.g., on the internet, for example at exiqon.com). See, e.g., You et al., Nuc. Acids. Res. 34:e60 (2006); McTigue et al., Biochemistry 43:5388-405 (2004); and Levin et al., Nuc. Acids. Res. 34:e142 (2006). For example, “gene walk” methods, similar to those used to design antisense oligos, can be used to optimize the inhibitory activity of a modified base/LNA molecule; for example, a series of oligonucleotides of 10-30 nucleotides spanning the length of a target RNA can be prepared, followed by testing for activity. Optionally, gaps, e.g., of 5-10 nucleotides or more, can be left between the LNAs to reduce the number of oligonucleotides synthesized and tested. GC content is preferably between about 30₇60%. General guidelines for designing modified base/LNA molecules are known in the art; for example, LNA sequences will bind very tightly to other LNA sequences, so it is preferable to avoid significant complementarity within an LNA molecule. Contiguous runs of three or more Gs or Cs, or more than four LNA residues, should be avoided where possible (for example, it may not be possible with very short (e.g., about 9-10 nt) oligonucleotides). In some embodiments, the LNAs are xylo-LNAs.

For additional information regarding LNA molecules see U.S. Pat. Nos. 6,268,490; 6,734,291; 6,770,748; 6,794,499; 7,034,133; 7,053,207; 7,060,809; 7,084,125; and 7,572,582; and U.S. Pre-Grant Pub. Nos. 20100267018; 20100261175; and 20100035968; Koshkin et al. Tetrahedron 54, 3607-3630 (1998); Obika et al. Tetrahedron Lett. 39, 5401-5404 (1998); Jepsen et al., Oligonucleotides 14:130-146 (2004); Kauppinen et al., Drug Disc. Today 2(3):287-290 (2005); and Ponting et al., Cell 136(4):629-641 (2009), and references cited therein.

As demonstrated herein and previously (see, e.g., WO 2012/065143 and WO 2012/087983, incorporated herein by reference), LNA molecules can be used as a valuable tool to manipulate and aid analysis of RNAs. Advantages offered by an LNA molecule-based system are the relatively low costs, easy delivery, and rapid action. While other inhibitory nucleic acids may exhibit effects after longer periods of time, LNA molecules exhibit effects that are more rapid, e.g., a comparatively early onset of activity, are fully reversible after a recovery period following the synthesis of new RNA, and occur without causing substantial or substantially complete RNA cleavage or degradation. One or more of these design properties may be desired properties of the inhibitory nucleic acids of the invention. Additionally, LNA molecules make possible the systematic targeting of domains within much longer nuclear transcripts. Although a PNA-based system has been described earlier, the effects on Xi were apparent only after 24 hours (Beletskii et al., Proc Natl Acad Sci USA. 2001; 98:9215-9220). The LNA technology enables high-throughput screens for functional analysis of non-coding RNAs and also provides a novel tool to manipulate chromatin states in vivo for therapeutic applications.

In various related aspects, the methods described herein include using LNA molecules to target RNAs for a number of uses, including as a research tool to probe the function of a specific RNA, e.g., in vitro or in vivo. The methods include selecting one or more desired RNAs, designing one or more LNA molecules that target the RNA, providing the designed LNA molecule, and administering the LNA molecule to a cell or animal. The methods can optionally include selecting a region of the RNA and designing one or more LNA molecules that target that region of the RNA.

Aberrant imprinted gene expression is implicated in several diseases including Long QT syndrome, Beckwith-Wiedemann, Prader-Willi, and Angelman syndromes, as well as behavioral disorders and carcinogenesis (see, e.g., Falls et al., Am. J. Pathol. 154:635-647 (1999); Lalonde, Annu Rev Genet 30:173-195 (1996); Hall Annu Rev Med. 48:35-44 (1997)). LNA molecules can be created to treat such imprinted diseases. As one example, the long QT Syndrome can be caused by a K+ gated Calcium-channel encoded by Kcnql. This gene is regulated by its antisense counterpart, the long noncoding RNA, Kcnqlotl (Pandey et al., Mol Cell. 2008 Oct. 24; 32(2):232-46). Disease arises when Kcnqlotl is aberrantly expressed. LNA molecules can be created to downregulate Kcnqlotl, thereby restoring expression of Kcnql. As another example, LNA molecules could inhibit RNA cofactors for polycomb complex chromatin modifiers to reverse the imprinted defect.

From a commercial and clinical perspective, the timepoints between about 1 to 24 hours potentially define a window for epigenetic reprogramming. The advantage of the LNA system is that it works quickly, with a defined half-life, and is therefore reversible upon degradation of LNAs, at the same time that it provides a discrete timeframe during which epigenetic manipulations can be made. By targeting nuclear long RNAs, LNA molecules or similar polymers, e.g., xylo-LNAs, might be utilized to manipulate the chromatin state of cells in culture or in vivo, by transiently eliminating the regulatory RNA and associated proteins long enough to alter the underlying locus for therapeutic purposes. In particular, LNA molecules or similar polymers that specifically bind to, or are complementary to, PRC1-binding RNA can prevent recruitment of PRC1 to a specific chromosomal locus, in a gene-specific fashion.

LNA molecules might also be administered in vivo to treat other human diseases, such as but not limited to cancer, neurological disorders, infections, inflammation, and myotonic dystrophy. For example, LNA molecules might be delivered to tumor cells to downregulate the biologic activity of a growth-promoting or oncogenic long nuclear RNA (e.g., Gt12 or MALAT1 (Luo et al., Hepatology. 44(4):1012-24 (2006)), a RNA associated with metastasis and is frequently upregulated in cancers). Repressive RNAs downregulating tumor suppressors can also be targeted by LNA molecules to promote reexpression. For example, expression of the INK4b/ARF/INK4a tumor suppressor locus is controlled by Polycomb group proteins including PRC1 and PRC1 and repressed by the antisense noncoding RNA ANRIL (Yap et al., Mol Cell. 2010 Jun. 11; 38(5):662-74). PRC1-binding regions described herein in ANRIL can be targeted by LNA molecules to promote reexpression of the INK4b/ARF/INK4a tumor suppressor. Some ncRNAs may be positive regulators of oncogenes. Such “activating ncRNAs” have been described recently (e.g., Jpx (Tian et al., Cell. 143(3):390-403 (2010) and others (from et al., Cell. 143(1):46-58 (2010)). Therefore, LNA molecules could be directed at these activating ncRNAs to downregulate oncogenes. LNA molecules could also be delivered to inflammatory cells to downregulate regulatory ncRNA that modulate the inflammatory or immune response. (e.g., LincRNA-Cox2, see Guttman et al., Nature. 458(7235):223-7. Epub 2009 Feb. 1 (2009)).

In still other related aspects, the LNA molecules targeting PRC1-binding regions in RNAs described herein can be used to create animal or cell models of conditions associated with altered gene expression (e.g., as a result of altered epigenetics).

The methods described herein may also be useful for creating animal or cell models of other conditions associated with aberrant imprinted gene expression, e.g., as noted above.

In various related aspects, the results described herein demonstrate the utility of LNA molecules for targeting RNA, for example, to transiently disrupt chromatin for purposes of reprogramming chromatin states ex vivo. Because LNA molecules stably displace RNA for hours and chromatin does not rebuild for hours thereafter, LNA molecules create a window of opportunity to manipulate the epigenetic state of specific loci ex vivo, e.g., for reprogramming of hiPS and hESC prior to stem cell therapy. For example, Gt12 controls expression of DLK1, which modulates the pluripotency of iPS cells. Low Gt12 and high DLK1 is correlated with increased pluripotency and stability in human iPS cells. Thus, LNA molecules targeting Gt12 can be used to inhibit differentiation and increase pluripotency and stability of iPS cells.

See also PCT/US11/60493, which is incorporated by reference herein in its entirety.

Interfering RNA, Including siRNA/shRNA

In some embodiments, the inhibitory nucleic acid sequence that is complementary to an RNA can be an interfering RNA, including but not limited to a small interfering RNA (“siRNA”) or a small hairpin RNA (“shRNA”). Methods for constructing interfering RNAs are well known in the art. For example, the interfering RNA can be assembled from two separate oligonucleotides, where one strand is the sense strand and the other is the antisense strand, wherein the antisense and sense strands are self-complementary (i.e., each strand comprises nucleotide sequence that is complementary to nucleotide sequence in the other strand; such as where the antisense strand and sense strand form a duplex or double stranded structure); the antisense strand comprises nucleotide sequence that is complementary to a nucleotide sequence in a target nucleic acid molecule or a portion thereof (i.e., an undesired gene) and the sense strand comprises nucleotide sequence corresponding to the target nucleic acid sequence or a portion thereof. Alternatively, interfering RNA is assembled from a single oligonucleotide, where the self-complementary sense and antisense regions are linked by means of nucleic acid based or non-nucleic acid-based linker(s). The interfering RNA can be a polynucleotide with a duplex, asymmetric duplex, hairpin or asymmetric hairpin secondary structure, having self-complementary sense and antisense regions, wherein the antisense region comprises a nucleotide sequence that is complementary to nucleotide sequence in a separate target nucleic acid molecule or a portion thereof and the sense region having nucleotide sequence corresponding to the target nucleic acid sequence or a portion thereof. The interfering can be a circular single-stranded polynucleotide having two or more loop structures and a stem comprising self-complementary sense and antisense regions, wherein the antisense region comprises nucleotide sequence that is complementary to nucleotide sequence in a target nucleic acid molecule or a portion thereof and the sense region having nucleotide sequence corresponding to the target nucleic acid sequence or a portion thereof, and wherein the circular polynucleotide can be processed either in vivo or in vitro to generate an active siRNA molecule capable of mediating RNA interference.

In some embodiments, the interfering RNA coding region encodes a self-complementary RNA molecule having a sense region, an antisense region and a loop region. Such an RNA molecule when expressed desirably forms a “hairpin” structure, and is referred to herein as an “shRNA.” The loop region is generally between about 2 and about 10 nucleotides in length. In some embodiments, the loop region is from about 6 to about 9 nucleotides in length. In some embodiments, the sense region and the antisense region are between about 15 and about 20 nucleotides in length. Following post-transcriptional processing, the small hairpin RNA is converted into a siRNA by a cleavage event mediated by the enzyme Dicer, which is a member of the RNase III family. The siRNA is then capable of inhibiting the expression of a gene with which it shares homology. For details, see Brummelkamp et al., Science 296:550-553, (2002); Lee et al, Nature Biotechnol., 20, 500-505, (2002); Miyagishi and Taira, Nature Biotechnol 20:497-500, (2002); Paddison et al. Genes & Dev. 16:948-958, (2002); Paul, Nature Biotechnol, 20, 505-508, (2002); Sui, Proc. Natl. Acad. Sd. USA, 99(6), 5515-5520, (2002); Yu et al. Proc NatlAcadSci USA 99:6047-6052, (2002).

The target RNA cleavage reaction guided by siRNAs is highly sequence specific. In general, siRNA containing a nucleotide sequences identical to a portion of the target nucleic acid are preferred for inhibition. However, 100% sequence identity between the siRNA and the target gene is not required to practice the present invention. Thus the invention has the advantage of being able to tolerate sequence variations that might be expected due to genetic mutation, strain polymorphism, or evolutionary divergence. For example, siRNA sequences with insertions, deletions, and single point mutations relative to the target sequence have also been found to be effective for inhibition. Alternatively, siRNA sequences with nucleotide analog substitutions or insertions can be effective for inhibition. In general the siRNAs must retain specificity for their target, i.e., must not directly bind to, or directly significantly affect expression levels of, transcripts other than the intended target.

Ribozymes

In some embodiments, the inhibitory nucleic acids are ribozymes. Trans-cleaving enzymatic nucleic acid molecules can also be used; they have shown promise as therapeutic agents for human disease (Usman & McSwiggen, 1995 Ann. Rep. Med. Chem. 30, 285-294; Christoffersen and Marr, 1995 J. Med. Chem. 38, 2023-2037). Enzymatic nucleic acid molecules can be designed to cleave specific RNA targets within the background of cellular RNA. Such a cleavage event renders the RNA non-functional.

In general, enzymatic nucleic acids with RNA cleaving activity act by first binding to a target RNA. Such binding occurs through the target binding portion of a enzymatic nucleic acid which is held in close proximity to an enzymatic portion of the molecule that acts to cleave the target RNA. Thus, the enzymatic nucleic acid first recognizes and then binds a target RNA through complementary base pairing, and once bound to the correct site, acts enzymatically to cut the target RNA. Strategic cleavage of such a target RNA will destroy its ability to direct synthesis of an encoded protein. After an enzymatic nucleic acid has bound and cleaved its RNA target, it is released from that RNA to search for another target and can repeatedly bind and cleave new targets.

Several approaches such as in vitro selection (evolution) strategies (Orgel, 1979, Proc. R. Soc. London, B 205, 435) have been used to evolve new nucleic acid catalysts capable of catalyzing a variety of reactions, such as cleavage and ligation of phosphodiester linkages and amide linkages, (Joyce, 1989, Gene, 82, 83-87; Beaudry et al., 1992, Science 257, 635-641; Joyce, 1992, Scientific American 267, 90-97; Breaker et al, 1994, TIBTECH 12, 268; Bartel et al, 1993, Science 261:1411-1418; Szostak, 1993, TIBS 17, 89-93; Kumar et al, 1995, FASEB J., 9, 1183; Breaker, 1996, Curr. Op. Biotech., 1, 442). The development of ribozymes that are optimal for catalytic activity would contribute significantly to any strategy that employs RNA-cleaving ribozymes for the purpose of regulating gene expression. The hammerhead ribozyme, for example, functions with a catalytic rate (kcat) of about 1 min⁻¹in the presence of saturating (10 MM) concentrations of Mg²⁺ cofactor. An artificial “RNA ligase” ribozyme has been shown to catalyze the corresponding self-modification reaction with a rate of about 100 min⁻¹. In addition, it is known that certain modified hammerhead ribozymes that have substrate binding arms made of DNA catalyze RNA cleavage with multiple turn-over rates that approach 100 min⁻¹.

Making and Using Inhibitory Nucleic Acids

The nucleic acid sequences used to practice the methods described herein, whether RNA, cDNA, genomic DNA, vectors, viruses or hybrids thereof, can be isolated from a variety of sources, genetically engineered, amplified, and/or expressed/generated recombinantly. If desired, nucleic acid sequences of the invention can be inserted into delivery vectors and expressed from transcription units within the vectors. The recombinant vectors can be DNA plasmids or viral vectors. Generation of the vector construct can be accomplished using any suitable genetic engineering techniques well known in the art, including, without limitation, the standard techniques of PCR, oligonucleotide synthesis, restriction endonuclease digestion, ligation, transformation, plasmid purification, and DNA sequencing, for example as described in Sambrook et al. Molecular Cloning: A Laboratory Manual. (1989)), Coffin et al. (Retroviruses. (1997)) and “RNA Viruses: A Practical Approach” (Alan J. Cann, Ed., Oxford University Press, (2000)).

Preferably, inhibitory nucleic acids of the invention are synthesized chemically. Nucleic acid sequences used to practice this invention can be synthesized in vitro by well-known chemical synthesis techniques, as described in, e.g., Adams (1983) J. Am. Chem. Soc. 105:661; Belousov (1997) Nucleic Acids Res. 25:3440-3444; Frenkel (1995) Free Radic. Biol. Med. 19:373-380; Blommers (1994) Biochemistry 33:7886-7896; Narang (1979) Meth. Enzymol. 68:90; Brown (1979) Meth. Enzymol. 68:109; Beaucage (1981) Tetra. Lett. 22:1859; U.S. Pat. No. 4,458,066; WO/2008/043753 and WO/2008/049085, and the references cited therein.

Nucleic acid sequences of the invention can be stabilized against nucleolytic degradation such as by the incorporation of a modification, e.g., a nucleotide modification. For example, nucleic acid sequences of the invention includes a phosphorothioate at least the first, second, or third internucleotide linkage at the 5′ or 3′ end of the nucleotide to sequence. As another example, the nucleic acid sequence can include a 2′-modified nucleotide, e.g., a 2′-deoxy, 2′-deoxy-2′-fluoro, 2′-O-methyl, 2′-O-methoxyethyl (2′-O-MOE), 2′-O-aminopropyl (2′-O-AP), 2′-O-dimethylaminoethyl (2′-O-DMAOE), 2′-O-dimethylaminopropyl (2′-O-DMAP), 2′-O-dimethylaminoethyloxyethyl (2′-O-DMAEOE), or 2′-O—N-methylacetamido (2′-O—NMA). As another example, the nucleic acid sequence can include at least one 2′-O-methyl-modified nucleotide, and in some embodiments, all of the nucleotides include a 2′-O-methyl modification. In some embodiments, the nucleic acids are “locked,” i.e., comprise nucleic acid analogues in which the ribose ring is “locked” by a methylene bridge connecting the 2′-O atom and the 4′-C atom (see, e.g., Kaupinnen et al., Drug Disc. Today 2(3):287-290 (2005); Koshkin et al., J. Am. Chem. Soc., 120(50):13252-13253 (1998)). For additional modifications see US 20100004320, US 20090298916, and US 20090143326.

It is understood that any of the modified chemistries or formats of inhibitory nucleic acids described herein can be combined with each other, and that one, two, three, four, five, or more different types of modifications can be included within the same molecule.

Techniques for the manipulation of nucleic acids used to practice this invention, such as, e.g., subcloning, labeling probes (e.g., random-primer labeling using Klenow polymerase, nick translation, amplification), sequencing, hybridization and the like are well described in the scientific and patent literature, see, e.g., Sambrook et al., Molecular Cloning; A Laboratory Manual 3d ed. (2001); Current Protocols in Molecular Biology, Ausubel et al., eds. (John Wiley & Sons, Inc., New York 2010); Kriegler, Gene Transfer and Expression: A Laboratory Manual (1990); Laboratory Techniques In Biochemistry And Molecular Biology: Hybridization With Nucleic Acid Probes, Part I. Theory and Nucleic Acid Preparation, Tijssen, ed. Elsevier, N.Y. (1993).

Pharmaceutical Compositions

The methods described herein can include the administration of pharmaceutical compositions and formulations comprising inhibitory nucleic acid sequences designed to target an RNA.

In some embodiments, the compositions are formulated with a pharmaceutically acceptable carrier. The pharmaceutical compositions and formulations can be administered parenterally, topically, orally or by local administration, such as by aerosol or transdermally. The pharmaceutical compositions can be formulated in any way and can be administered in a variety of unit dosage forms depending upon the condition or disease and the degree of illness, the general medical condition of each patient, the resulting preferred method of administration and the like. Details on techniques for formulation and administration of pharmaceuticals are well described in the scientific and patent literature, see, e.g., Remington: The Science and Practice of Pharmacy, 21st ed., 2005.

The inhibitory nucleic acids can be administered alone or as a component of a pharmaceutical formulation (composition). The compounds may be formulated for administration, in any convenient way for use in human or veterinary medicine. Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.

Formulations of the compositions of the invention include those suitable for intradermal, inhalation, oral/nasal, topical, parenteral, rectal, and/or intravaginal administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. The amount of active ingredient (e.g., nucleic acid sequences of this invention) which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, the particular mode of administration, e.g., intradermal or inhalation. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect, e.g., an antigen specific T cell or humoral response.

Pharmaceutical formulations of this invention can be prepared according to any method known to the art for the manufacture of pharmaceuticals. Such drugs can contain sweetening agents, flavoring agents, coloring agents and preserving agents. A formulation can be admixtured with nontoxic pharmaceutically acceptable excipients which are suitable for manufacture. Formulations may comprise one or more diluents, emulsifiers, preservatives, buffers, excipients, etc. and may be provided in such forms as liquids, powders, emulsions, lyophilized powders, sprays, creams, lotions, controlled release formulations, tablets, pills, gels, on patches, in implants, etc.

Pharmaceutical formulations for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in appropriate and suitable dosages. Such carriers enable the pharmaceuticals to be formulated in unit dosage forms as tablets, pills, powder, dragees, capsules, liquids, lozenges, gels, syrups, slurries, suspensions, etc., suitable for ingestion by the patient. Pharmaceutical preparations for oral use can be formulated as a solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable additional compounds, if desired, to obtain tablets or dragee cores. Suitable solid excipients are carbohydrate or protein fillers include, e.g., sugars, including lactose, sucrose, mannitol, or sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxy-methylcellulose; and gums including arabic and tragacanth; and proteins, e.g., gelatin and collagen. Disintegrating or solubilizing agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate. Push-fit capsules can contain active agents mixed with a filler or binders such as lactose or starches, lubricants such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active agents can be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycol with or without stabilizers.

Aqueous suspensions can contain an active agent (e.g., nucleic acid sequences of the invention) in admixture with excipients suitable for the manufacture of aqueous suspensions, e.g., for aqueous intradermal injections. Such excipients include a suspending agent, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia, and dispersing or wetting agents such as a naturally occurring phosphatide (e.g., lecithin), a condensation product of an alkylene oxide with a fatty acid (e.g., polyoxyethylene stearate), a condensation product of ethylene oxide with a long chain aliphatic alcohol (e.g., heptadecaethylene oxycetanol), a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol (e.g., polyoxyethylene sorbitol mono-oleate), or a condensation product of ethylene oxide with a partial ester derived from fatty acid and a hexitol anhydride (e.g., polyoxyethylene sorbitan mono-oleate). The aqueous suspension can also contain one or more preservatives such as ethyl or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents and one or more sweetening agents, such as sucrose, aspartame or saccharin. Formulations can be adjusted for osmolarity.

In some embodiments, oil-based pharmaceuticals are used for administration of nucleic acid sequences of the invention. Oil-based suspensions can be formulated by suspending an active agent in a vegetable oil, such as arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin; or a mixture of these. See e.g., U.S. Pat. No. 5,716,928 describing using essential oils or essential oil components for increasing bioavailability and reducing inter- and intra-individual variability of orally administered hydrophobic pharmaceutical compounds (see also U.S. Pat. No. 5,858,401). The oil suspensions can contain a thickening agent, such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents can be added to provide a palatable oral preparation, such as glycerol, sorbitol or sucrose. These formulations can be preserved by the addition of an antioxidant such as ascorbic acid. As an example of an injectable oil vehicle, see Minto (1997) J. Pharmacol. Exp. Ther. 281:93-102.

Pharmaceutical formulations can also be in the form of oil-in-water emulsions. The oily phase can be a vegetable oil or a mineral oil, described above, or a mixture of these. Suitable emulsifying agents include naturally-occurring gums, such as gum acacia and gum tragacanth, naturally occurring phosphatides, such as soybean lecithin, esters or partial esters derived from fatty acids and hexitol anhydrides, such as sorbitan mono-oleate, and condensation products of these partial esters with ethylene oxide, such as polyoxyethylene sorbitan mono-oleate. The emulsion can also contain sweetening agents and flavoring agents, as in the formulation of syrups and elixirs. Such formulations can also contain a demulcent, a preservative, or a coloring agent. In alternative embodiments, these injectable oil-in-water emulsions of the invention comprise a paraffin oil, a sorbitan monooleate, an ethoxylated sorbitan monooleate and/or an ethoxylated sorbitan trioleate.

The pharmaceutical compounds can also be administered by in intranasal, intraocular and intravaginal routes including suppositories, insufflation, powders and aerosol formulations (for examples of steroid inhalants, see e.g., Rohatagi (1995) J. Clin. Pharmacol. 35:1187-1193; Tjwa (1995) Ann. Allergy Asthma Immunol. 75:107-111). Suppositories formulations can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at body temperatures and will therefore melt in the body to release the drug. Such materials are cocoa butter and polyethylene glycols.

In some embodiments, the pharmaceutical compounds can be delivered transdermally, by a topical route, formulated as applicator sticks, solutions, suspensions, emulsions, gels, creams, ointments, pastes, jellies, paints, powders, and aerosols.

In some embodiments, the pharmaceutical compounds can also be delivered as microspheres for slow release in the body. For example, microspheres can be administered via intradermal injection of drug which slowly release subcutaneously; see Rao (1995) J. Biomater Sci. Polym. Ed. 7:623-645; as biodegradable and injectable gel formulations, see, e.g., Gao (1995) Pharm. Res. 12:857-863 (1995); or, as microspheres for oral administration, see, e.g., Eyles (1997) J. Pharm. Pharmacol. 49:669-674.

In some embodiments, the pharmaceutical compounds can be parenterally administered, such as by intravenous (IV) administration or administration into a body cavity or lumen of an organ. These formulations can comprise a solution of active agent dissolved in a pharmaceutically acceptable carrier. Acceptable vehicles and solvents that can be employed are water and Ringer's solution, an isotonic sodium chloride. In addition, sterile fixed oils can be employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid can likewise be used in the preparation of injectables. These solutions are sterile and generally free of undesirable matter. These formulations may be sterilized by conventional, well known sterilization techniques. The formulations may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents, e.g., sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate and the like. The concentration of active agent in these formulations can vary widely, and will be selected primarily based on fluid volumes, viscosities, body weight, and the like, in accordance with the particular mode of administration selected and the patient's needs. For IV administration, the formulation can be a sterile injectable preparation, such as a sterile injectable aqueous or oleaginous suspension. This suspension can be formulated using those suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation can also be a suspension in a nontoxic parenterally-acceptable diluent or solvent, such as a solution of 1,3-butanediol. The administration can be by bolus or continuous infusion (e.g., substantially uninterrupted introduction into a blood vessel for a specified period of time).

In some embodiments, the pharmaceutical compounds and formulations can be lyophilized. Stable lyophilized formulations comprising an inhibitory nucleic acid can be made by lyophilizing a solution comprising a pharmaceutical of the invention and a bulking agent, e.g., mannitol, trehalose, raffinose, and sucrose or mixtures thereof. A process for preparing a stable lyophilized formulation can include lyophilizing a solution about 2.5 mg/mL protein, about 15 mg/mL sucrose, about 19 mg/mL NaCl, and a sodium citrate buffer having a pH greater than 5.5 but less than 6.5. See, e.g., U.S. 20040028670.

The compositions and formulations can be delivered by the use of liposomes. By using liposomes, particularly where the liposome surface carries ligands specific for target cells, or are otherwise preferentially directed to a specific organ, one can focus the delivery of the active agent into target cells in vivo. See, e.g., U.S. Pat. Nos. 6,063,400; 6,007,839; Al-Muhammed (1996) J. Microencapsul. 13:293-306; Chonn (1995) Curr. Opin. Biotechnol. 6:698-708; Ostro (1989) Am. J. Hosp. Pharm. 46:1576-1587. As used in the present invention, the term “liposome” means a vesicle composed of amphiphilic lipids arranged in a bilayer or bilayers. Liposomes are unilamellar or multilamellar vesicles that have a membrane formed from a lipophilic material and an aqueous interior that contains the composition to be delivered. Cationic liposomes are positively charged liposomes that are believed to interact with negatively charged DNA molecules to form a stable complex. Liposomes that are pH-sensitive or negatively-charged are believed to entrap DNA rather than complex with it. Both cationic and noncationic liposomes have been used to deliver DNA to cells.

Liposomes can also include “sterically stabilized” liposomes, i.e., liposomes comprising one or more specialized lipids. When incorporated into liposomes, these specialized lipids result in liposomes with enhanced circulation lifetimes relative to liposomes lacking such specialized lipids. Examples of sterically stabilized liposomes are those in which part of the vesicle-forming lipid portion of the liposome comprises one or more glycolipids or is derivatized with one or more hydrophilic polymers, such as a polyethylene glycol (PEG) moiety. Liposomes and their uses are further described in U.S. Pat. No. 6,287,860.

The formulations of the invention can be administered for prophylactic and/or therapeutic treatments. In some embodiments, for therapeutic applications, compositions are administered to a subject who is need of reduced triglyceride levels, or who is at risk of or has a disorder described herein, in an amount sufficient to cure, alleviate or partially arrest the clinical manifestations of the disorder or its complications; this can be called a therapeutically effective amount. For example, in some embodiments, pharmaceutical compositions of the invention are administered in an amount sufficient to decrease serum levels of triglycerides in the subject.

The amount of pharmaceutical composition adequate to accomplish this is a therapeutically effective dose. The dosage schedule and amounts effective for this use, i.e., the dosing regimen, will depend upon a variety of factors, including the stage of the disease or condition, the severity of the disease or condition, the general state of the patient's health, the patient's physical status, age and the like. In calculating the dosage regimen for a patient, the mode of administration also is taken into consideration.

The dosage regimen also takes into consideration pharmacokinetics parameters well known in the art, i.e., the active agents' rate of absorption, bioavailability, metabolism, clearance, and the like (see, e.g., Hidalgo-Aragones (1996) J. Steroid Biochem. Mol. Biol. 58:611-617; Groning (1996) Pharmazie 51:337-341; Fotherby (1996) Contraception 54:59-69; Johnson (1995) J. Pharm. Sci. 84:1144-1146; Rohatagi (1995) Pharmazie 50:610-613; Brophy (1983) Eur. J. Clin. Pharmacol. 24:103-108; Remington: The Science and Practice of Pharmacy, 21st ed., 2005). The state of the art allows the clinician to determine the dosage regimen for each individual patient, active agent and disease or condition treated. Guidelines provided for similar compositions used as pharmaceuticals can be used as guidance to determine the dosage regiment, i.e., dose schedule and dosage levels, administered practicing the methods of the invention are correct and appropriate.

Single or multiple administrations of formulations can be given depending on for example: the dosage and frequency as required and tolerated by the patient, the degree and amount of therapeutic effect generated after each administration (e.g., effect on tumor size or growth), and the like. The formulations should provide a sufficient quantity of active agent to effectively treat, prevent or ameliorate conditions, diseases or symptoms.

In alternative embodiments, pharmaceutical formulations for oral administration are in a daily amount of between about 1 to 100 or more mg per kilogram of body weight per day. Lower dosages can be used, in contrast to administration orally, into the blood stream, into a body cavity or into a lumen of an organ. Substantially higher dosages can be used in topical or oral administration or administering by powders, spray or inhalation. Actual methods for preparing parenterally or non-parenterally administrable formulations will be known or apparent to those skilled in the art and are described in more detail in such publications as Remington: The Science and Practice of Pharmacy, 21st ed., 2005.

Various studies have reported successful mammalian dosing using complementary nucleic acid sequences. For example, Esau C., et al., (2006) Cell Metabolism, 3(2):87-98 reported dosing of normal mice with intraperitoneal doses of miR-122 antisense oligonucleotide ranging from 12.5 to 75 mg/kg twice weekly for 4 weeks. The mice appeared healthy and normal at the end of treatment, with no loss of body weight or reduced food intake. Plasma transaminase levels were in the normal range (AST ¾ 45, ALT ¾ 35) for all doses with the exception of the 75 mg/kg dose of miR-122 ASO, which showed a very mild increase in ALT and AST levels. They concluded that 50 mg/kg was an effective, non-toxic dose. Another study by Krützfeldt J., et al., (2005) Nature 438, 685-689, injected anatgomirs to silence miR-122 in mice using a total dose of 80, 160 or 240 mg per kg body weight. The highest dose resulted in a complete loss of miR-122 signal. In yet another study, locked nucleic acid molecules (“LNA molecules”) were successfully applied in primates to silence miR-122. Elmen J., et al., (2008) Nature 452, 896-899, report that efficient silencing of miR-122 was achieved in primates by three doses of 10 mg kg-1 LNA-antimiR, leading to a long-lasting and reversible decrease in total plasma cholesterol without any evidence for LNA-associated toxicities or histopathological changes in the study animals.

In some embodiments, the methods described herein can include co-administration with other drugs or pharmaceuticals, e.g., compositions for providing cholesterol homeostasis. For example, the inhibitory nucleic acids can be co-administered with drugs for treating or reducing risk of a disorder described herein.

EXAMPLES

The invention is further described in the following examples, which do not limit the scope of the invention described in the claims.

Example 1. A Denaturing CLIP-Seq Method for Identifying RNA Interactomes of Chromatin Complexes with High Specificity

PRC1 is Polycomb Repressive Complex 1, a Polycomb complex that is biochemically distinct from PRC2. PRC1 is the ezymatic complex that ubiquitylates histone H2A at lysine 119 (H2AK119Ub). Action of PRC1 on chromatin results in chromatin compaction and transcriptional repression. Although PRC1 binds thousands of sites in the mammalian genome, how PRC1 is targeted to chromatin has remained a mystery. YY1 may recruit PRC1 in some contexts, but is unlikely to be the general mechanism. RNA-mediated targeting is another potential mechanism. PRC1 is known to interact with at least one RNA—ANRIL (Yap et al., Mol Cell. 2010 Jun. 11; 38(5):662-74). This example describes methods that were developed to determing how many RNAs interact with PRC1 and whether they are a general recruiting tool for PRC1.

These “denaturing” CLIP-seq methods (also referred to herein as dCLIP-seq) utilize a biotin tag to enable purification of RNA-protein complexes under denaturing conditions to increase the specificity of the purification scheme. As shown in FIGS. 1A-B, for the to denaturing CLIP method, cell lines stably expressing two vectors were prepared: vector #1-expressing bacterial biotin ligase BirA under neomycin resistance; and vector #2—expressing a protein of interest (here, PRC1) fused to a biotinylation tag or control vector under puromycin resistance. Both human HEK 293 kidney cells and mouse 16.7 ES cells were used. Cells were crosslinked by exposure to ultraviolet (UV) light (254 nm) at 150-400 mJ/cm²on ice depending on cell layer thickness, cellular lysates are prepared, then treated with DNAse to solubilize the chromatin, and protein-RNA complexes were pulled down using streptavidin beads. Importantly, the samples were then washed with a high stringency wash using 8 M urea+0.1% SDS (range: 0.0-2.0%) at room temperature. Samples were then further washed in PBS+2% SDS and further in high salt buffer (PBS+750 mM NaCl+1% NP40+0.5% NaDeoxycholate+0.1% SDS), each at room temperature. Under such stringent conditions, most proteins are denatured, resulting in the loss of the nonspecific RNA-protein interactions. Only the extremely high-affinity biotin-avidin interaction survives. Thus, these steps can be used to effectively remove the vast majority of background RNA, resulting in extremely clean “peaks” of binding. The samples are then treated with DNAse to remove contaminating DNA. The RNA was phosphorylated using ³²P-ATP and run on SDS-PAGE and transferred onto a membrane. Broad bands corresponding to the RNA-PRC1 complex were identified by the presence of radioactive labeling (hot smear on the membrane) and then excised and eluted for cDNA preparation preparation prior to deep sequencing.

Peaks (high-frequency sequences, believed to correlate with protein binding sites on the RNA), were called by the following methods. About 40 million paired-end 50 nucleotide (nt) reads were generated for every dCLIP-seq sample. Adaptor sequences were trimmed with either Trim Galore! v0.3.3 (for dCLIP-seq; stringency 15 and allowed error rate 0.2), or cutadapt (v1.0). Identical sequences (PCR duplicates) were removed by custom programs prior to alignment. To account for the M. mus (mus)/M. castaneus (cas) hybrid character of mouse 16.7 ES cell line used for a dCLIP-seq, reads were first aligned to custom mus/129 and cas genomes, and then mapped back to the reference mm9 genome (Pinter et al., Genome Res 22, 1864-1876, 2012). For dCLIP-seq data obtained from human HEK293 cell line, alignments were performed to hg19 human reference genome. All alignments were performed with Tophat (v2.0.11) (Kim et al., Genome Biol 14, R36, 2013). Post-processing of alignments was performed with custom scripts using SAMtools (Li et al., Bioinformatics 25, 2078-2079, 2009), and BEDtools v2.17.0 (Quinlan and Hall, Bioinformatics 26, 841-842, 2010). These included accounting, alignment file-type conversion, extracting and sorting reads (SAMtools), and obtaining wig coverage files (SAMtools depth).

Fragment per million (fpm) wig files were then created by scaling uniquely aligned wig files to total number of fragments per million in each library (determined by SAMtools flagstat combining reads “with itself and mate mapped” and “singletons”). Then consecutive wig entries of equal coverage were merged forming bed files that were used for peak calling. The peak caller software peakranger (v. 16) (Uren et al., Bioinformatics 28, 3013-3020, 2012) was used. The software peakranger requires an even distribution of watson/crick entries, so prior to calling, strand specific bed file entries were randomized for strand. The software peakranger was called with arguments ranger −p 0.01—format bed—gene_annot_file (either mm9 or hg19 appropriate), −d experiment and −c mock-transfected control, to find narrow peaks with p-value 0.01 or less. To extract more uniquely aligned reads, a second round of peak calling was performed from the mus track, this time including “pegged” reads attained using tophat2 with the option −g 100. Pegged reads are singletons extracted from the reps track where the locus of one end is fixed locus and other varies. We then merged the results with the previous method.

Example 2. Human CBX7-RNA Binding Sites as Determined by Denaturing CLIP-Seq Analysis in Human 293 Cells

CLIP-seq performed in human female embryonic kidney fibroblast line, HEK293, as described above in Example 1. CBX7 binding sites in the RNA are shown in Table 1. Peaks were called from uniquely mapped reads using the software peakranger (p=0.01). The resulting strand specific bed files were then converted to their respective strands. To produce non-overlapping peaks, entries, from two biological replicate bed files were expanded by 500 nucleotides on each side and merged. The envelope of 500 bases was added because RNA-protein interactions could be affected by changes in nucleic acid folding nearby, which in turn could cause allosteric effects on the RNA-protein interaction. Then the closest gene was determined for each entry (bedtools closest) and categorized as “Imprinted” gene, “Oncogene”, and/or “Tumor Suppressor”.

Our analysis turned up 5893 binding sites in RNA for human CBX7. The columns (c) in Table 1 correspond to: c1, SEQ ID Number. c2, Chromosome number. c3, Read start position. c4, Read end position. c5, chromosome strand that the transcript is made from (+, top or Watson strand; −, bottom or Crick strand of each chromosome). C₆, nearest gene name. c7, gene categories as defined in the following way.

The hexadecimal code is used in Table 1 to indicate the number of categories satisfied by each gene: The 4 bit represents an Imprinted gene (IM). The 2 bit represents an Oncogene (OC). The 1 bit represents a Tumor Suppressor (TS). The hexadecimal code can be translated to binary. Each bit represents the condition (1) or absence (0) of the condition.

Thus:

Value
binary
meaning

0x1
0 0 1
TS

0x2
0 1 0
OC

0x3
0 1 1
TS and OC

0x4
1 0 0
IM

0x5
1 0 1
IM and TS

0x6
1 1 0
IM and OC

0x7
1 1 1
IM and OC and TS

Example 3. Mouse CBX7-RNA Binding Sites as Determined by Denaturing CLIP-Seq Analysis in ES Cells Derived from Mus musculus

CLIP-seq was performed as described in Example 1 in the mouse ES cell line, EL 16.7. CBX7 binding sites in the RNA are shown in Table 3. Peaks were called from uniquely mapped reads using the software peakranger (p=0.01). The resulting strand specific bed files were then converted to their respective strand. To produce non-overlapping peaks entries, 3 biological replicates of undifferentiated and 1 biological replicate of day 7-differentiated ES cells were expanded by 500 nucleotides on each side and merged. The envelope of 500 bases was added because RNA-protein interactions could be affected by changes in nucleic acid folding nearby, which in turn could cause allosteric effects on the RNA-protein interaction. Then the closest gene was determined for each entry (bedtools closest) and categorized as “Imprinted” gene, “Oncogene”, and/or “Tumor Suppressor”.

Our analysis revealed 18,953 binding sites (peaks) in RNA for mouse ES cells. The columns (c) in Table 3 correspond to: c1, SEQ ID Number. c2, Chromosome number. c3, Read start position. c4, Read end position. c5, chromosome strand that the transcript is made from (+, top or Watson strand; −, bottom or Crick strand of each chromosome). C6, nearest gene name. c7, gene categories as defined above in Example 2.

Example 4. Human LiftOver Sequences Corresponding to CBX7-RNA Binding Sites as Determined by Denaturing CLIP-Seq Analysis in Mouse ES Cells

CBX7-binding sites shown in Table 2 were derived from dCLIP-seq performed in the mouse ES cell line, 16.7, as shown in Table 3, translated from mouse mm9 to human hg19 coordinates. The software UCSC Liftover was used to convert mouse mm9 coordinates from the mouse sub-sheet to human hg19 in the human liftover sub-sheet, prior to the envelope extension and merge step. The analysis led to 11,522 binding sites in human RNA. The columns (c) in Table 2 correspond to: c1, SEQ ID Number. c2, Chromosome number. c3, Read start position. c4, Read end position. c5, chromosome strand that the transcript is made from (+, top or Watson strand; −, bottom or Crick strand of each chromosome). C6, nearest gene name. c7, gene categories as defined in Example 2.

Example 5. Targeting the PRC1-RNA Interaction to Modulate Gene Expression

Analysis of the results described above indicated that PRC1 binding sites can be classified into several groups, including (i) 3′ untranslated region [3′ UTR], (ii) promoter-associated, (iii) gene body, (iv) antisense, and (v) intergenic. In order to block the identified interactions between Cbx7 and specific RNA transcripts, antisense oligonucleotides (ASO) LNAs were administered to cells in culture, to determine whether targeting the interaction between PRC1 and each of these RNA classes would change gene expression in cis.

First, the effects of disrupting PRC1-3′UTR interactions were examined. Potential Cbx7 binding sites (identified as described above) that were within 3′UTRs of three selected transcripts were identified based on CLIP-seq data, including (FIG. 2A) Mouse DDB1 and CUL4 Associated Factor 12-Like 1 (Dcaf12L1); (FIG. 2B) Mouse Calmodulin 2 (Calm2); (FIG. 2C) Mouse Mecp2; and Human IRAK1. 22-mer mixmer LNAs targeting selected binding sites (FIG. 3) were designed with the following sequences:

TABLE 4

Sequences of LNAs targeting Dusp9,

Dcaf12L1, IRAK1, Mecp2, and Calm2

Target

LNA
SEQ ID

Gene
LNA I.D
sequence
NO:

Dusp9
Dusp9-1-
CCTACAGTTCC
36372

a
AAGAAGTCTAA

Dusp9-1-
GAAGCAGGAAG
36373

b
GAGTCTACACG

Dusp9-2-
CAGTTTGACCA
36374

a
CCCTCAGTCAC

Dusp9-2-
AAAGAAACAGT
36375

b
CAGGGCACCAG

Dusp9-3-
CACAGGTATTG
36376

a
CCAGCTCCAGG

Dusp9-3-
CACACACACAG
36377

b
AGTCTACAACG

Dcaf12L1
Dcaf12L1-
CCTGTCTGCCA
36378

1
TACATTCTACA

Dcaf12L1-
GCTCAGACTTC
36379

2
TTCCTTTGCAC

Dcaf12L1-
GTAACAGATCT
36380

3
ATTCTACTTGA

Dcaf12L1-
CATTATCTCTA
36381

4-a
TTTATCTGAAC

Dcaf12L1-
GGAGAAAACCA
36382

4-b
ATCTATCCGCA

Calm2
Calm2-1-
GCCAGAGTAAG
36383

a
CCACATGCAAC

Calm2-1-
TTAGATGTGCA
36384

b
GACGGGCTTAG

Calm2-2-
TTACAGCTCCA
36385

a
CACTTCAACAA

C

Calm2-2-
ACATGCTGACA
36386

b
GTTCCTAAAAG

Scrambled
LNA-Scr
GTGTAACACGT
36387

control

CTATACGCCCA

Tsix
Tsix-
AGAGTACAGTT
36388

region-1
AACAAGCTGGG

T

Tsix-
TGTTTTGTGAC
36389

region-2
AGGGATTCT

Tsix-
TTCTTCCTTGC
36390

region-
ATTGTGTCTA

3a

Tsix-
GGTGTGTCCTA
36391

region-
TGGTCCTATGT

3b

Tsix-
CCATGTAACAG
36392

region-
AATGTTGAGAT

3c

Tsix-
CATAATCTGTG
36393

region-
ACCAGTACCTC

4a

Tsix-
CATCAGAAGAG
36394

region-
GTTAGATAT

4b

Tsix-
TGGAGGCAGGT
36395

region-
GGATTTCTAAC

4c

IRAK1
IRAK1-a
CCAACATGCGC
36396

CAGCCTCCTCA

IRAK1-b
AAGTGCTGGGA
36397

TTACAGGCGTG

IRAK1-c
ATCATGACTCA
36398

CTGCAGCCTCG

Mecp2
Mecp2-
TCGCTATACCA
36399

reg1-a
CAGTCCACAGG

Mecp2-
TGAAGCAGAGA
36400

reg1-b
GCAGGAAGAAG

Mecp2-
ACACCTCAAAT
36401

reg1-c
CTCAAGAGGCT

Mecp2-
GATTACTCCCT
36402

reg2-a
AGAGCAAGGCC

Mecp2-
CACAAGGAAAG
36403

reg2-b
GGCTCGGCACA

Mecp2-
CCACTTCCCTC
36404

reg2-c
CCTTCAAATGC

Phosphate residues were replaced with phosphorothioate residues for increased stability. Multiple LNA oligonucleotides (LNAs) targeting the same transcript were pooled together to the final concentration of 50 μM. Following trypsinization and feeder removal, a total of 2×10⁶EL16.7 mouse ES cells were resuspended in 100 μM of ES cell nucleofector solution (Lonza) supplemented with 2 μM LNAs. The cells were transfected using the A-030 program. A 0.5 mL of culture medium was added to the cells and 250 μL of this suspension was plated on gelatinized 6-well tissue culture dish with 2 ml of fibroblast-conditioned media. Per time point, whole cell RNA was extracted using a Trizol reagent and expression of the target genes was estimated using quantitative real-time RT-PCR (normalized to beta-actin as a reference gene).

The effect of LNAs on gene expression was represented as a ratio between specific LNAs and scrambled control. The results are shown in FIGS. 3 and 5A-B. To test the specificity of LNA pools, two unrelated amplicons were tested for every LNA pool along with a specific one. There was a specific increase in Dcaf12L1 gene expression 24 hrs after nucleofection with the Dcaf12L1-specific LNA pool as compared to unrelated Calm2 or to Dusp9 genes (FIG. 3, right). The same was true for the LNA pool against Calm2, which resulted in a specific increase in Calm2 mRNA levels as compared to unrelated Dsup9 and Dcaf12L1 genes 24 hrs after nucleofection (FIG. 3, left). These results indicate that targeting the RNA interaction with PRC1 lead to an increase in gene expression.

In contrast, LNAs targeting Mecp2 and IRAK1 interaction with PRC1-binding RNA resulted in gene downregulation, presumably as a result of disrupting PRC1 RNA interactions. Mouse embryonic fibroblasts (MEFs) were nucleofected with pooled LNAs and harvested after 24 hours for qRT-PCR analysis of Mecp2 expression. Downregulation was seen after Mecp2-specific LNA treatment, but not seen with LNAs against Tsix or scrambled control. In addition, human PC3 cells were transfected with pooled IRAK1-specific LNA or control scrambled LNA, then harvested after 24 hours or 36 hours for qRT-PCR analysis of IRAK1 expression. Specific downregulation was seen for IRAK1-specific LNA. Thus, these LNAs caused downregulation but not elimination of gene expression in cis. Thus, targeting 3′ UTR-PRC1 interactions by antisense oligonucleotides provides an alternative approach to RNAi methods and may be especially useful when one aims to titrate down but not eliminate gene expression, such as in the case of MECP 2 Duplication Syndrome.

Second, we examined the effects of disrupting PRC1-antisense RNA interactions. As an example, Tsix RNA is antisense to Xist and binds PRC1 via CBX7 at both Tsix's 5′ and 3′ ends. Tsix RNA is a known repressor ofXist expression but the mechanisms of repression have not be fully elucidated. Here we hypothesized that Tsix in part recruits PRC1 to repress Xist expression. Targeting Tsix RNA with ASO mixmers led to increased Xist expression even after just 6 hours of treatment (FIG. 4A,B), consistent with a derepression of Xist when PRC1 cannot be recruited. Furthermore, ANRIL is antisense to INK4a and interacts with CBX7. Targeting ANRIL is expected to lead to derepression of the linked coding gene INK4a, consistent with loss of ANRIL-PRC1 interactions. Thus, antisense RNAs interact with PRC1 and serve as recruiting tools for PRC1 in cis.

Third, we examined the effects of disrupting PRC1-intergenic RNA interactions. Genes can either be turned up or down. For example, Xist is a CBX7 target. Xist recruits PRC1 via CBX7 to the rest of the X-chromosome. Targeting Xist binding sites is expected to prevent PRC1 recruitment and leads to failure of X-inactivation or higher likelihood of X-reactivation. As an opposite example, Pvt1 is a long noncoding RNA located next to c-Myc and is a frequent site of translocations in B-cell lymphomas (e.g., Burkitt's). Pvt1 and to cMyc are both associated with oncogenesis. Pvt1 appears to be a positive regulator of cMyc expression. Our analysis shows that Pvt1 is a PRC1 target. Pvt1 may recruit PRC1 and result in upregulation of cMyc.

These data indicate that PRC1-RNA interactions may serve different functions within cells and genes may be up- or down-regulated by disrupting these CBX7-RNA interactions.

Gene

SEQ ID NO.
Chromosome
Start (bp)
Stop (bp)
strand
Nearest gene
category

1
chr1
840144
841315
+
SAMD11
0x0

2
chr1
852326
853425
−
LOC100130417
0x0

3
chr1
864967
866163
+
SAMD11
0x0

4
chr1
879290
880468
−
NOC2L
0x0

5
chr1
893660
894797
−
NOC2L
0x0

6
chr1
933795
934971
−
HES4
0x0

7
chr1
939820
940963
+
ISG15
0x1

8
chr1
941875
943019
+
ISG15
0x1

9
chr1
990208
992002
+
AGRN
0x0

10
chr1
1018302
1019453
−
C1orf159
0x0

11
chr1
1042955
1044169
−
C1orf159
0x0

12
chr1
1155610
1156790
−
SDF4
0x0

13
chr1
1221945
1223142
+
SCNN1D
0x0

14
chr1
1240971
1242078
−
ACAP3
0x0

15
chr1
1244270
1245370
−
ACAP3
0x0

16
chr1
1244824
1245997
−
PUSL1
0x0

17
chr1
1250751
1251923
−
CPSF3L
0x0

18
chr1
1253901
1255113
−
CPSF3L
0x0

19
chr1
1257950
1259068
−
CPSF3L
0x0

20
chr1
1270872
1272024
−
DVL1
0x4

21
chr1
1287069
1288262
+
TAS1R3
0x0

22
chr1
1327280
1328568
−
CCNL2
0x0

23
chr1
1482465
1483678
−
SSU72
0x0

24
chr1
1497825
1498974
−
SSU72
0x0

25
chr1
1499242
1500446
−
SSU72
0x0

26
chr1
1531126
1532227
−
C1orf233
0x0

27
chr1
1534005
1535150
−
C1orf233
0x0

28
chr1
1554365
1555575
+
MIB2
0x0

29
chr1
1717245
1718531
−
GNB1
0x0

30
chr1
2087331
2088452
+
PRKCZ
0x0

31
chr1
2186545
2187672
+
SKI
0x0

32
chr1
2258187
2259377
−
MORN1
0x0

33
chr1
2970525
2971680
−
FU42875
0x0

34
chr1
3696643
3697775
−
LRRC47
0x0

35
chr1
3712359
3713583
−
LRRC47
0x0

36
chr1
5221620
5222816
+
AJAP1
0x0

37
chr1
6244753
6246027
−
RPL22
0x6

38
chr1
6257275
6258424
−
RPL22
0x6

39
chr1
6283411
6284533
−
ICMT
0x0

40
chr1
6438381
6439534
−
ACOT7
0x0

41
chr1
6584050
6585244
−
NOL9
0x0

42
chr1
6605037
6606171
−
NOL9
0x0

43
chr1
6651267
6652348
−
KLHL21
0x0

44
chr1
6695045
6696146
−
DNAJC11
0x1

45
chr1
6709976
6711146
−
DNAJC11
0x1

46
chr1
6844973
6846190
+
CAMTA1
0x1

47
chr1
8387551
8388748
+
SLC45A1
0x0

48
chr1
8411950
8413097
−
RERE
0x0

49
chr1
8556917
8558157
−
RERE
0x0

50
chr1
8667679
8668827
−
RERE
0x0

51
chr1
8922743
8923838
−
ENO1
0x0

52
chr1
8924945
8926044
−
ENO1
0x0

53
chr1
8926640
8927823
−
ENO1
0x0

54
chr1
9364627
9365824
+
SPSB1
0x0

55
chr1
9648465
9649637
+
TMEM201
0x0

56
chr1
9797015
9798190
−
CLSTN1
0x0

57
chr1
10006837
10008034
+
NMNAT1
0x0

58
chr1
10210619
10211845
+
UBE4B
0x1

59
chr1
10212128
10213323
+
UBE4B
0x1

60
chr1
10219898
10221032
+
UBE4B
0x1

61
chr1
10437072
10438185
+
KIF1B
0x1

62
chr1
10517254
10518437
−
DFFA
0x0

63
chr1
10519910
10521155
−
DFFA
0x0

64
chr1
11082896
11084096
+
TARDBP
0x0

65
chr1
11086612
11087712
+
TARDBP
0x0

66
chr1
11114167
11115339
−
SRM
0x0

67
chr1
11166821
11168000
−
MTOR
0x0

68
chr1
11190033
11191197
−
MTOR
0x0

69
chr1
11845848
11847032
−
MTHFR
0x0

70
chr1
11967643
11968911
+
PLOD1
0x0

71
chr1
11969319
11970555
−
KIAA2013
0x0

72
chr1
12024759
12025894
+
PLOD1
0x0

73
chr1
12071654
12072919
+
MFN2
0x0

74
chr1
12081168
12082397
+
MIIP
0x0

75
chr1
12337286
12338484
+
VPS13D
0x0

76
chr1
12496061
12497240
−
DHRS3
0x0

77
chr1
12534409
12535606
+
VPS13D
0x0

78
chr1
12828806
12829927
+
PRAMEF12
0x0

79
chr1
15931136
15932327
+
DDI2
0x0

80
chr1
16046315
16047483
+
PLEKHM2
0x0

81
chr1
16158644
16159843
−
FU37453
0x0

82
chr1
16163602
16164745
+
SPEN
0x0

83
chr1
16176405
16177587
+
SPEN
0x0

84
chr1
16198975
16200210
+
SPEN
0x0

85
chr1
16202208
16203403
+
SPEN
0x0

86
chr1
16256261
16257458
+
SPEN
0x0

87
chr1
16263796
16264969
+
SPEN
0x0

88
chr1
16265815
16266883
+
SPEN
0x0

89
chr1
16780855
16781964
−
CROCCP3
0x0

90
chr1
16846525
16847742
−
CROCCP3
0x0

91
chr1
16871860
16873033
−
NBPF1
0x0

92
chr1
17004176
17005430
−
ESPNP
0x0

93
chr1
17053194
17054426
+
MIR3675
0x0

94
chr1
17186168
17187363
+
CROCC
0x2

95
chr1
17187862
17189092
+
CROCC
0x2

96
chr1
17733274
17734587
−
RCC2
0x0

97
chr1
17748766
17749972
−
RCC2
0x0

98
chr1
19207589
19208765
−
ALDH4A1
0x0

99
chr1
19407485
19408666
−
UBR4
0x0

100
chr1
19467661
19468839
−
UBR4
0x0

101
chr1
19480827
19482021
−
UBR4
0x0

102
chr1
19510062
19511162
−
UBR4
0x0

103
chr1
19518563
19519634
−
UBR4
0x0

104
chr1
19625557
19627771
−
AKR7A2
0x0

105
chr1
19934145
19935669
+
C1orf151-NBL1
0x0

106
chr1
19934145
19935669
+
MINOS1
0x0

107
chr1
21068879
21070073
−
HP1BP3
0x0

108
chr1
21101451
21102605
−
HP1BP3
0x0

109
chr1
21112219
21113345
−
HP1BP3
0x0

110
chr1
21180924
21182129
−
EIF4G3
0x0

111
chr1
21219529
21220598
−
EIF4G3
0x0

112
chr1
21357497
21358722
−
EIF4G3
0x0

113
chr1
21368009
21369192
−
EIF4G3
0x0

114
chr1
21469103
21470320
−
EIF4G3
0x0

115
chr1
21483420
21484575
−
EIF4G3
0x0

116
chr1
21499884
21501032
−
EIF4G3
0x0

117
chr1
22022042
22023220
−
USP48
0x0

118
chr1
22090919
22092045
−
USP48
0x0

119
chr1
22175614
22176789
−
H5PG2
0x0

120
chr1
22418197
22419329
+
CDC42
0x2

121
chr1
22438373
22439541
+
CDC42
0x2

122
chr1
23604893
23606066
−
HNRNPR
0x0

123
chr1
23611267
23612409
−
HNRNPR
0x0

124
chr1
23636297
23637464
−
HNRNPR
0x0

125
chr1
23664466
23665686
−
HNRNPR
0x0

126
chr1
23696173
23697372
+
C1orf213
0x0

127
chr1
24018563
24019764
+
RPL11
0x0

128
chr1
24035667
24036809
+
RPL11
0x0

129
chr1
24053341
24054440
+
TCEB3
0x0

130
chr1
24055464
24056625
+
TCEB3
0x0

131
chr1
24086902
24088096
−
LOC100506963
0x0

132
chr1
24121383
24122585
+
LYPLA2
0x0

133
chr1
24321543
24322767
+
PNRC2
0x0

134
chr1
24795527
24796626
+
NIPAL3
0x0

135
chr1
25168610
25169758
+
CLIC4
0x0

136
chr1
25686991
25688242
+
TMEM50A
0x0

137
chr1
26142500
26144914
+
SEPN1
0x0

138
chr1
26226551
26228033
−
STMN1
0x0

139
chr1
26799856
26800971
+
HMGN2
0x0

140
chr1
27212259
27213402
−
GPN2
0x0

141
chr1
27435519
27436813
−
SLC9A1
0x0

142
chr1
27586882
27588101
+
WDTC1
0x0

143
chr1
27632491
27633959
+
WDTC1
0x0

144
chr1
27730967
27732179
−
WASF2
0x0

145
chr1
27732345
27740500
−
WASF2
0x0

146
chr1
28240102
28241240
−
RPA2
0x0

147
chr1
28298923
28300079
−
EYA3
0x0

148
chr1
28352695
28353858
−
EYA3
0x0

149
chr1
28833307
28835831
+
RCC1
0x0

150
chr1
28833307
28835831
+
SNHG3
0x0

151
chr1
28904692
28908087
−
SNHG12
0x0

152
chr1
28904692
28908087
−
SNORA16A
0x0

153
chr1
28904692
28908087
−
SNORA44
0x0

154
chr1
28904692
28908087
−
SNORA61
0x0

155
chr1
28904692
28908087
−
SNORD99
0x0

156
chr1
28974564
28975822
+
RNU11
0x0

157
chr1
29247305
29248543
+
EPB41
0x1

158
chr1
29308535
29309673
−
TMEM200B
0x0

159
chr1
29444554
29446232
+
EPB41
0x1

160
chr1
29474230
29475417
−
SRSF4
0x0

161
chr1
29480719
29481895
−
SRSF4
0x0

162
chr1
30305391
30306547
−
MECR
0x0

163
chr1
31316149
31317342
+
LOC100129196
0x0

164
chr1
31467449
31468593
−
PUM1
0x0

165
chr1
31478154
31479311
−
PUM1
0x0

166
chr1
32203368
32204547
−
BAI2
0x1

167
chr1
32228432
32229591
−
BAI2
0x1

168
chr1
32507902
32509306
+
KHDRBS1
0x0

169
chr1
32640327
32641537
+
KPNA6
0x0

170
chr1
32661663
32662812
+
TXLNA
0x0

171
chr1
32689077
32690271
+
EIF3I
0x0

172
chr1
32800031
32801234
−
MARCKSL1
0x0

173
chr1
33051782
33052957
−
ZBTB8A
0x0

174
chr1
33086866
33088028
−
Z8TB8OS
0x0

175
chr1
33474529
33475637
−
AK2
0x0

176
chr1
33765318
33766520
+
ZNF362
0x0

177
chr1
34029443
34030618
−
CSMD2
0x0

178
chr1
35316677
35317863
−
C1orf212
0x0

179
chr1
35648193
35650636
−
SFPQ
0x2

180
chr1
35651800
35652899
−
SFPQ
0x2

181
chr1
35656343
35657533
−
SFPQ
0x2

182
chr1
36031642
36032886
+
NCDN
0x0

183
chr1
36063797
36064965
−
PSMB2
0x0

184
chr1
36307953
36309152
+
EIF2C4
0x0

185
chr1
36388167
36389851
+
EIF2C1
0x0

186
chr1
36614384-
36615568
−
TRAPPC3
0x0

187
chr1
36807748
36808925
−
STK40
0x0

188
chr1
39469513
39470715
+
AKIRIN1
0x0

189
chr1
39493910
39495136
+
NDUFS5
0x0

190
chr1
40029630
40030729
−
PABPC4
0x0

191
chr1
40032527
40033665
−
PABPC4
0x0

192
chr1
40032527
40033665
−
SNORA55
0x0

193
chr1
40041718
40042871
−
PABPC4
0x0

194
chr1
40413156
40414381
+
MFSD2A
0x1

195
chr1
40428168
40429524
+
MFSD2A
0x1

196
chr1
40537396
40538555
+
CAP1
0x0

197
chr1
40537899
40539087
−
PPT1
0x0

198
chr1
40598294
40599496
+
RLF
0x0

199
chr1
40930541
40931733
+
ZNF643
0x0

200
chr1
41476871
41478119
+
CTPS
0x0

201
chr1
41608008
41609172
−
SCMH1
0x0

202
chr1
41919561
41920665
+
LOC100507178
0x0

203
chr1
42641695
42642843
−
FOXJ3
0x0

204
chr1
42643332
42644469
−
FOXJ3
0x0

205
chr1
43161880
43162989
+
YBX1
0x0

206
chr1
43167147
43168350
+
YBX1
0x0

207
chr1
44125402
44126640
+
KDM4A
0x0

208
chr1
44170298
44171502
+
KDM4A
0x0

209
chr1
44369888
44371081
+
ST3GAL3
0x0

210
chr1
44371265
44372436
+
ST3GAL3
0x0

211
chr1
44442659
44443906
+
ATP6V0B
0x0

212
chr1
44911247
44912431
+
RNF220
0x0

213
chr1
45062534
45063657
−
TMEM53
0x0

214
chr1
45186916
45188147
−
TMEM53
0x0

215
chr1
45196159
45197386
−
BEST4
0x0

216
chr1
45240987
45242949
+
RPS8
0x0

217
chr1
45240987
45242949
+
SNORD46
0x0

218
chr1
45240987
45242949
+
SNORD55
0x0

219
chr1
45242965
45244687
+
RPS8
0x0

220
chr1
45242965
45244687
+
SNORD38A
0x0

221
chr1
45242965
45244687
+
SNORD38B
0x0

222
chr1
45284993
45286220
−
PTCH2
0x1

223
chr1
46125981
46127259
−
GPBP1L1
0x0

224
chr1
46148262
46149412
−
GPBP1L1
0x0

225
chr1
46654276
46655502
−
POMGNT1
0x0

226
chr1
46859410
46860537
+
FAAH
0x0

227
chr1
47745459
47746710
−
STIL
0x0

228
chr1
47774668
47775846
−
STIL
0x0

229
chr1
49275861
49277039
−
BEND5
0x0

230
chr1
51049850
51051026
−
FAF1
0x0

231
chr1
51189287
51190509
−
FAF1
0x0

232
chr1
51715868
51717079
−
TTC39A
0x0

233
chr1
51787282
51788462
−
TTC39A
0x0

234
chr1
52379262
52380464
−
RAB3B
0x0

235
chr1
52438512
52439715
+
BTF3L4
0x0

236
chr1
52826661
52827803
−
CC2D1B
0x0

237
chr1
52837435
52838617
−
ORC1
0x2

238
chr1
53336515
53337624
+
ZYG11A
0x0

239
chr1
53349000
53350130
+
ZYG11A
0x0

240
chr1
53367018
53368216
+
ZYG11A
0x0

241
chr1
53491985
53493213
+
SCP2
0x0

242
chr1
53716288
53717467
−
LRP8
0x0

243
chr1
55315885
55317555
−
DHCR24
0x0

244
chr1
57129718
57130907
+
PRKAA2
0x0

245
chr1
59248014
59249266
−
JUN
0x2

246
chr1
60868316
60869493
+
HOOK1
0x0

247
chr1
61663674
61664848
+
NFIA
0x0

248
chr1
63182476
63183613
−
DOCK7
0x0

249
chr1
65008049
65009293
+
CACHD1
0x0

250
chr1
65234621
65235845
+
RAVER2
0x0

251
chr1
65523304
65524453
−
MIR101-1
0x1

252
chr1
65523304
65524453
−
MIR3671
0x0

253
chr1
67873676
67875700
−
SERBP1
0x0

254
chr1
67878205
67879389
−
SERBP1
0x0

255
chr1
67887368
67888559
−
SERBP1
0x0

256
chr1
68166950
68168313
−
GNG12
0x0

257
chr1
68273081
68274225
−
GNG12
0x0

258
chr1
70067427
70068625
+
LRRC7
0x0

259
chr1
70686727
70688033
+
SRSF11
0x2

260
chr1
76252214
76253404
+
RABGGTB
0x0

261
chr1
76252214
76253404
+
SNORD45C
0x0

262
chr1
77554193
77555417
−
PIGK
0x0

263
chr1
78170124
78171311
−
USP33
0x0

264
chr1
78410310
78411448
−
FUBP1
0x2

265
chr1
78434297
78435474
−
FUBP1
0x2

266
chr1
82403020
82404264
+
LPHN2
0x2

267
chr1
84570348
84571545
+
PRKACB
0x0

268
chr1
84966968
84968146
−
GNG5
0x0

269
chr1
85330676
85331965
−
LPAR3
0x0

270
chr1
85610552
85611775
−
SYDE2
0x0

271
chr1
86057408
86058620
+
CYR61
0x0

272
chr1
86079240
86080418
−
ZNHIT6
0x0

273
chr1
87426543
87427773
+
HS2ST1
0x0

274
chr1
87511146
87512431
+
HS2ST1
0x0

275
chr1
89255594
89256826
+
PKN2
0x0

276
chr1
89259619
89260755
+
PKN2
0x0

277
chr1
89270987
89272231
+
PKN2
0x0

278
chr1
90341079
90342295
+
LRRC8D
0x0

279
chr1
90472119
90473511
+
ZNF326
0x0

280
chr1
91363596
91364776
−
ZNF644
0x0

281
chr1
91852202
91853725
−
HFM1
0x0

282
chr1
92326566
92327783
−
TGFBR3
0x1

283
chr1
92724108
92725226
−
GLMN
0x0

284
chr1
92975994
92977194
−
EVI5
0x0

285
chr1
93588727
93590210
+
MTF2
0x0

286
chr1
93618375
93619763
−
TMED5
0x0

287
chr1
93803508
93804686
−
LOC100131564
0x0

288
chr1
93810953
93812167
+
DR1
0x0

289
chr1
94312549
94313776
+
MIR760
0x0

290
chr1
94899930
94901140
+
ABCD3
0x0

291
chr1
95401336
95402708
+
LOC729970
0x0

292
chr1
96690973
96692200
+
PTBP2
0x0

293
chr1
96911938
96913259
+
PTBP2
0x0

294
chr1
98628031
98629273
+
LOC729987
0x0

295
chr1
100139712
100140929
+
PALMD
0x0

296
chr1
100547299
100548483
+
HIAT1
0x0

297
chr1
101486719
101487914
−
DPH5
0x0

298
chr1
102251585
102252999
−
OLFM3
0x0

299
chr1
103507706
103508886
−
COL11A1
0x2

300
chr1
108112882
108114057
−
VAV3
0x0

301
chr1
109241985
109243695
+
PRPF38B
0x0

302
chr1
109604746
109605960
−
TAF13
0x0

303
chr1
109642240
109643797
+
SCARNA2
0x0

304
chr1
109852954
109854306
−
SORT1
0x0

305
chr1
110563994
110565230
+
AHCYL1
0x0

306
chr1
110881918
110883020
+
RBM15
0x2

307
chr1
110889786
110890938
+
RBM15
0x2

308
chr1
111983105
111984257
−
WDR77
0x0

309
chr1
112001663
112002811
+
ATP5F1
0x0

310
chr1
112186658
112187879
+
RAP1A
0x1

311
chr1
112198778
112199981
+
RAP1A
0x1

312
chr1
113212803
113214334
+
CAPZA1
0x0

313
chr1
113454053
113456912
−
SLC16A1
0x0

314
chr1
113459502
113460782
−
SLC16A1
0x0

315
chr1
113552218
113553398
+
LRIG2
0x0

316
chr1
113711026
113712272
+
LRIG2
0x0

317
chr1
114216414
114217630
+
MAGI3
0x0

318
chr1
115248058
115249362
−
NRAS
0x2

319
chr1
115259278
115261005
−
CSDE1
0x0

320
chr1
115259278
115261005
−
NRAS
0x2

321
chr1
115268298
115269476
−
CSDE1
0x0

322
chr1
115269811
115271040
+
SYCP1
0x0

323
chr1
115272477
115273735
−
CSDE1
0x0

324
chr1
115277451
115278611
−
CSDE1
0x0

325
chr1
116915330
116916732
+
ATP1A1
0x0

326
chr1
116926045
116927247
+
ATP1A1
0x0

327
chr1
116932313
116933518
+
ATP1A1
0x0

328
chr1
116946522
116947737
+
ATP1A1
0x0

329
chr1
117452059
117453257
+
PTGFRN
0x0

330
chr1
117640591
117641790
+
TTF2
0x0

331
chr1
117910253
117911401
+
MAN1A2
0x0

332
chr1
117944308
117945714
+
MAN1A2
0x0

333
chr1
117993522
117994752
+
MAN1A2
0x0

334
chr1
118530435
118531631
−
SPAG17
0x0

33S
chr1
120543418
120544633
−
NOTCH2
0x2

336
chr1
144055799
144057061
+
SRGAP2P2
0x0

337
chr1
144857432
144858775
−
PDE4DIP
0x2

338
chr1
144881054
144882227
−
PDE4DIP
0x2

339
chr1
144900376
144901530
−
PDE4DIP
0x2

340
chr1
144921748
144923136
−
PDE4DIP
0x2

341
chr1
145115870
145116991
+
SEC22B
0x0

312
chr1
145382265
145383487
+
NBPF10
0x0

343
chr1
145394939
145396145
−
POLR3GL
0x0

344
chr1
145508701
145509914
+
RBM8A
0x0

34S
chr1
145510390
145511633
+
RBM8A
0x0

346
chr1
145577621
145578843
+
PIAS3
0x0

347
chr1
146555618
146556791
−
LOC728989
0x0

348
chr1
147510499
147511710
−
PDZK1P1
0x0

349
chr1
147825129
147826328
+
GPR89C
0x0

350
chr1
147993651
147994895
+
GPR89C
0x0

351
chr1
148240938
148242186
+
NBPF15
0x0

352
chr1
148247512
148248779
+
NBPF15
0x0

353
chr1
148344173
148345590
−
PPIAL4D
0x0

354
chr1
148344173
148345590
−
PPIAL4F
0x0

355
chr1
149193532
149194786
−
HIST2H2BF
0x0

356
chr1
149223492
149224764
−
HIST2H2BF
0x0

357
chr1
149229993
149231191
−
HIST2H2BF
0x0

358
chr1
149294107
149295294
−
HIST2H2BF
0x0

359
chr1
149298025
149299210
−
HIST2H2BF
0x0

360
chr1
149513523
149514749
−
HIST2H2BF
0x0

361
chr1
149803642
149804974
+
HIST2H4A
0x0

362
chr1
149803642
149804974
+
HIST2H4B
0x0

363
chr1
149822551
149824705
+
HIST2H2AA3
0x0

364
chr1
149822551
149824705
+
HIST2H2AA4
0x0

365
chr1
149822551
149824705
+
HIST2H3A
0x0

366
chr1
149822551
149824705
+
HIST2H3C
0x0

367
chr1
149857574
149858794
−
HIST2H2BE
0x0

368
chr1
149858006
149859450
+
HIST2H2AC
0x0

369
chr1
150190301
150191593
−
ANP32E
0x0

370
chr1
150208744
150210050
+
CA14
0x0

371
chr1
150324926
150326093
+
PRPF3
0x0

372
chr1
150418223
150419437
+
RPRD2
0x0

373
chr1
150445729
150446920
+
RPRD2
0x0

374
chr1
150464353
150465522
+
TARS2
0x0

375
chr1
150470489
150471707
+
TARS2
0x0

376
chr1
150548808
150549982
−
MCL1
0x0

377
chr1
150592648
150593816
−
ENSA
0x0

378
chr1
150594619
150595719
−
ENSA
0x0

379
chr1
150815378
150816598
−
ARNT
0x2

380
chr1
150901999
150903198
+
SETDB1
0x0

381
chr1
150937624
150938971
−
CERS2
0x0

382
chr1
151024631
151025836
−
CDC42SE1
0x0

383
chr1
151148459
151149816
−
TMOD4
0x0

384
chr1
151148459
151149816
−
VPS72
0x0

385
chr1
151214030
151215213
+
PIP5K1A
0x0

386
chr1
151377945
151379168
−
POGZ
0x0

387
chr1
151415600
151416737
−
POGZ
0x0

388
chr1
151424674
151425882
−
POGZ
0x0

389
chr1
151669554
151671784
+
SNX27
0x0

390
chr1
153608927
153610327
+
CHTOP
0x0

391
chr1
153637282
153638518
−
ILF2
0x0

392
chr1
153949216
153950397
−
JTB
0x0

393
chr1
154179204
154180520
−
C1orf43
0x0

394
chr1
154223078
154224555
+
UBAP2L
0x0

395
chr1
154229465
154230671
+
UBAP2L
0x0

396
chr1
154231629
154232898
+
UBAP2L
0x0

397
chr1
154554155
154556592
−
ADAR
0x0

398
chr1
154573661
154574860
−
ADAR
0x0

399
chr1
154744040
154745218
−
KCNN3
0x2

400
chr1
155092389
155093588
+
EFNA1
0x1

401
chr1
155216724
155217968
−
FAM189B
0x0

402
chr1
155222866
155224055
−
FAM189B
0x0

403
chr1
155238484
155239665
−
CLK2
0x0

404
chr1
155281808
155283956
+
FDPS
0x0

405
chr1
155387707
155388905
−
ASH1L
0x0

406
chr1
155392166
155393369
−
ASH1L
0x0

407
chr1
155628831
155630008
−
YY1AP1
0x0

408
chr1
155717315
155718435
−
GON4L
0x0

409
chr1
155734656
155735997
−
GON4L
0x0

410
chr1
155889121
155890387
−
SNORA42
0x0

411
chr1
155895194
155896426
−
KIAA0907
0x0

412
chr1
155895194
155896426
−
SCARNA4
0x0

413
chr1
155978393
155979751
−
SSR2
0x0

414
chr1
156005184
156006501
−
UBQLN4
0x0

415
chr1
156046144
156047385
−
MEX3A
0x0

416
chr1
156049971
156051157
−
MEX3A
0x0

417
chr1
156083983
156085214
+
LMNA
0x0

418
chr1
156711443
156713262
−
HDGF
0x0

419
chr1
159147726
159148925
+
CADM3
0x1

420
chr1
159887640
159888903
−
TAGLN2
0x0

421
chr1
160247969
160249354
−
PEX19
0x0

422
chr1
160323451
160324651
+
NCSTN
0x0

423
chr1
160964965
160966160
−
F11R
0x0

424
chr1
160967011
160968217
−
F11R
0x0

425
chr1
161140861
161142038
−
B4GALT3
0x0

426
chr1
161195560
161196876
+
TOMM40L
0x0

427
chr1
161287359
161288596
+
SDHC
0x2

428
chr1
161296677
161298830
+
SDHC
0x2

429
chr1
161409368
161410591
−
C1orf192
0x0

430
chr1
161500321
161501624
+
HSPA6
0x4

431
chr1
161581923
161583137
+
HSPA7
0x0

432
chr1
161590868
161592139
+
HSPA7
0x0

433
chr1
162470267
162471488
+
UHMK1
0x0

434
chr1
164569061
164570291
+
PBX1
0x2

435
chr1
165825882
165827031
+
UCK2
0x0

436
chr1
165878681
165880175
+
UCK2
0x0

437
chr1
166245062
166246377
−
FAM78B
0x0

438
chr1
166716741
166718458
+
POGK
0x0

439
chr1
166822396
166823563
+
POGK
0x0

440
chr1
167876363
167877573
−
ADCY10
0x0

441
chr1
168024779
168025960
−
GPR161
0x0

442
chr1
168218537
168219697
+
SFT2D2
0x0

443
chr1
169894169
169895391
−
KIFAP3
0x0

444
chr1
171470726
171471915
+
PRRC2C
0x0

445
chr1
171509758
171510953
+
PRRC2C
0x0

446
chr1
173760137
173761357
+
KLHL20
0x0

447
chr1
173832715
173837436
−
GAS5
0x1

448
chr1
173832715
173837436
−
SNORD44
0x0

449
chr1
173832715
173837436
−
SNORD47
0x0

450
chr1
173832715
173837436
−
SNORD74
0x0

451
chr1
173832715
173837436
−
SNORD75
0x0

452
chr1
173832715
173837436
−
SNORD76
0x0

453
chr1
173832715
173837436
−
SNORD77
0x0

454
chr1
173832715
173837436
−
SNORD78
0x0

455
chr1
173832715
173837436
−
SNORD79
0x0

456
chr1
173832715
173837436
−
SNORD80
0x0

457
chr1
173832715
173837436
−
SNORD81
0x0

458
chr1
173903892
173905070
−
RC3H1
0x0

459
chr1
173906989
173908288
−
RC3H1
0x0

460
chr1
174158307
174159546
+
RABGAP1L
0x0

461
chr1
178567950
178569162
+
C1orf220
0x0

462
chr1
178842862
178844097
+
RALGPS2
0x0

463
chr1
178886248
178887421
+
RALGPS2
0x0

464
chr1
179189773
179190983
−
ABL2
0x2

465
chr1
179813512
179814723
−
TOR1AIP2
0x0

466
chr1
179833159
179835492
−
TOR1AIP2
0x0

467
chr1
180080290
180081489
+
CEP350
0x0

468
chr1
180245669
180246855
−
LOC100527964
0x0

469
chr1
180737011
180738229
+
XPR1
0x0

470
chr1
180751452
180752652
+
XPR1
0x0

471
chr1
180944787
180946000
−
STX6
0x0

472
chr1
182352152
182354225
−
GLUL
0x0

473
chr1
182357155
182358347
−
GLUL
0x0

474
chr1
182822589
182823780
+
DHX9
0x0

475
chr1
182843646
182844797
+
DHX9
0x0

476
chr1
183451618
183452866
+
SMG7
0x0

477
chr1
183521166
183522365
+
SMG7
0x0

478
chr1
183599093
183600275
−
ARPC5
0x0

479
chr1
185029958
185031201
+
RNF2
0x0

480
chr1
185266746
185267923
−
IVNS1ABP
0x0

481
chr1
186341227
186342433
+
C1orf27
0x0

482
chr1
190328252
190329522
−
FAM5C
0x0

483
chr1
193054036
193055950
+
TROVE2
0x0

484
chr1
194881379
194882556
−
KCNT2
0x0

485
chr1
196246079
196247256
−
KCNT2
0x0

486
chr1
196454168
196455378
−
KCNT2
0x0

487
chr1
197123904
197125081
−
ZBTB41
0x2

488
chr1
198189561
198190790
+
NEK7
0x0

489
chr1
201104044
201105241
−
TMEM9
0x0

490
chr1
201263563
201264762
+
PKP1
0x0

491
chr1
201844844
201846017
+
IPO9
0x0

492
chr1
201846540
201847715
+
IPO9
0x0

493
chr1
202102898
202104120
−
ARL8A
0x0

494
chr1
202112029
202113216
−
ARL8A
0x0

495
chr1
202428654
202429874
+
PPP1R12B
0x0

496
chr1
203292770
203293990
+
BTG2
0x1

497
chr1
203765008
203766264
+
ZC3H11A
0x0

498
chr1
204061645
204062843
+
SOX13
0x0

499
chr1
204082926
204084098
+
SOX13
0x0

500
chr1
204475098
204476336
+
MDM4
0x2

501
chr1
204475595
204476748
−
PIK3C2B
0x0

502
chr1
204506187
204507372
+
MDM4
0x2

503
chr1
204522274
204523452
+
MDM4
0x2

504
chr1
204530962
204532206
−
LRRN2
0x0

505
chr1
205217339
205218722
+
TMCC2
0x0

506
chr1
205273122
205274318
−
NUAK2
0x0

507
chr1
205592298
205593497
−
ELK4
0x2

508
chr1
205682685
205686265
−
NUCKS1
0x0

509
chr1
205686535
205687953
−
NUCKS1
0x0

510
chr1
205718529
205719853
−
NUCKS1
0x0

511
chr1
206518541
206519779
+
SRGAP2
0x0

512
chr1
206895521
206896732
+
MAPKAPK2
0x0

513
chr1
206905648
206907237
+
MAPKAPK2
0x0

514
chr1
207285121
207286300
+
C4BPA
0x0

515
chr1
210029291
210030488
+
DIEXF
0x0

516
chr1
211712199
211713383
−
SLC30A1
0x0

517
chr1
212265961
212267203
+
DTL
0x0

518
chr1
212273532
212274725
+
DTL
0x0

519
chr1
212792678
212793986
+
ATF3
0x0

520
chr1
212964633
212965882
+
TATDN3
0x0

521
chr1
214371742
214372972
+
SMYD2
0x0

522
chr1
214529737
214530959
−
PTPN14
0x4

523
chr1
215758835
215760082
+
KCTD3
0x0

524
chr1
216707533
216708744
−
ESRRG
0x0

525
chr1
216938284
216939482
+
SPATA17
0x0

526
chr1
217781474
217782701
−
GPATCH2
0x0

527
chr1
219464873
219466060
+
LYPIAL1
0x0

528
chr1
220290576
220291740
+
RNU5F-1
0x0

529
chr1
220343726
220344909
−
RAB3GAP2
0x0

530
chr1
220373343
220374520
−
MIR664
0x0

531
chr1
220373343
220374520
−
SNORA36B
0x0

532
chr1
220411787
220412985
−
RAB3GAP2
0x0

533
chr1
224186371
224187597
+
FBXO28
0x0

534
chr1
224458091
224459318
−
NVL
0x0

535
chr1
224487715
224488892
−
NVL
0x0

536
chr1
224621339
224622694
−
WDR26
0x0

537
chr1
224632047
224633294
+
CNIH4
0x0

538
chr1
225227059
225228271
+
DNAH14
0x0

539
chr1
225395058
225396267
+
DNAH14
0x0

540
chr1
225589675
225591446
−
LBR
0x0

541
chr1
225683421
225684835
−
ENAH
0x0

542
chr1
225699878
225701146
−
ENAH
0x0

543
chr1
225832972
225834130
−
ENAH
0x0

544
chr1
225839667
225840854
−
ENAH
0x0

545
chr1
225840886
225842085
−
ENAH
0x0

546
chr1
225976535
225978191
+
SRP9
0x0

547
chr1
226053350
226054557
−
TMEM63A
0x0

548
chr1
226231274
226232493
+
H3F3A
0x0

549
chr1
226308957
226310189
+
H3F3A
0x0

550
chr1
226308957
226310189
+
H3F3AP4
0x0

551
chr1
226332364
226333539
−
ACBD3
0x0

552
chr1
226548198
226550310
−
PARP1
0x0

553
chr1
226633087
226634318
+
C1orf95
0x0

554
chr1
226764909
226766092
+
C1orf95
0x0

555
chr1
227174238
227175480
+
ADCK3
0x0

556
chr1
228246176
228247405
+
WNT3A
0x0

557
chr1
228268372
228269597
−
C1orf35
0x0

558
chr1
228286031
228287395
+
ARF1
0x1

559
chr1
228460035
228461227
+
OBSCN
0x6

560
chr1
228464213
228465383
+
OBSCN
0x6

561
chr1
228479225
228480392
+
OBSCN
0x6

562
chr1
228588834
228589997
−
TRIM11
0x0

563
chr1
228742937
228744191
+
RHOU
0x0

564
chr1
228763318
228764571
−
HIST3H2A
0x0

565
chr1
228822584
228823835
+
DUSP5P
0x0

566
chr1
229452464
229453715
+
SPHAR
0x0

567
chr1
229829043
229830261
+
URB2
0x0

568
chr1
230376361
230377564
+
GALNT2
0x0

569
chr1
231076229
231077435
−
TTC13
0x0

570
chr1
231089569
231090749
−
TTC13
0x0

571
chr1
231113282
231114478
−
TTC13
0x0

572
chr1
231400510
231401943
+
GNPAT
0x0

573
chr1
231694808
231696046
+
TSNAX
0x0

574
chr1
231694808
231696046
+
TSNAX-DISC1
0x0

575
chr1
231990122
231991288
+
DISC1
0x0

576
chr1
233514316
233515555
+
KIAA1804
0x2

577
chr1
233518262
233519476
+
KIAA1804
0x2

578
chr1
233520067
233521316
+
KIAA1804
0x2

579
chr1
234492209
234493429
−
TARBP1
0x0

580
chr1
234496426
234497849
+
C1orf31
0x0

581
chr1
234563407
234565919
−
TARBP1
0x0

582
chr1
234585710
234586893
−
TARBP1
0x0

583
chr1
234605372
234606597
−
TARBP1
0x0

584
chr1
234610314
234611484
−
TARBP1
0x0

585
chr1
234613342
234614518
−
TARBP1
0x0

586
chr1
234741314
234743389
−
IRF2BP2
0x0

587
chr1
234745312
234746411
−
IRF2BP2
0x0

588
chr1
235272366
235273548
−
TOMM20
0x0

589
chr1
235273910
235275525
−
TOMM20
0x0

590
chr1
235290593
235291716
−
SNORA14B
0x0

591
chr1
235460844
235462024
−
ARID4B
0x0

592
chr1
235601456
235602682
+
TBCE
0x0

593
chr1
235796415
235797938
−
GNG4
0x0

594
chr1
236380467
236381595
−
ERO1LB
0x0

595
chr1
236430556
236431809
+
GPR137B
0x0

596
chr1
236646542
236647719
+
EDARADD
0x0

597
chr1
236706956
236708213
−
HEATR1
0x0

598
chr1
236961224
236962464
+
MTR
0x0

599
chr1
236975460
236976657
+
MTR
0x0

600
chr1
237007214
237008501
+
MTR
0x0

601
chr1
237765743
237767229
+
RYR2
0x2

602
chr1
243663467
243665403
−
AKT3
0x2

603
chr1
244586559
244587735
−
ADSS
0x0

604
chr1
244871059
244872312
+
PPPDE1
0x0

605
chr1
245013374
245014444
−
HNRNPU
0x2

606
chr1
245016406
245017772
−
HNRNPU
0x2

607
chr1
245020748
245021936
−
HNRNPU
0x2

608
chr1
245026904
245028090
−
HNRNPU
0x2

609
chr1
245106873
245108219
+
EFCAB2
0x0

610
chr1
245382092
245383296
+
KIF26B
0x0

611
chr1
246197368
246198550
−
SMYD3
0x0

612
chr1
246349541
246350748
−
SMYD3
0x0

613
chr1
246636841
246638018
−
SMYD3
0x0

614
chr1
247318878
247320068
−
ZNF124
0x0

615
chr1
247322465
247323700
−
ZNF124
0x0

616
chr1
247326069
247327168
−
ZNF124
0x0

617
chr1
247453655
247454860
−
ZNF496
0x0

618
chr1
247613596
247614816
+
NLRP3
0x2

619
chr1
249167501
249168976
+
ZNF672
0x0

620
chr10
327413
328640
−
DIP2C
0x0

621
chr10
666729
667894
−
DIP2C
0x0

622
chr10
717319
718546
−
DIP2C
0x0

623
chr10
851188
852361
−
LARP4B
0x0

624
chr10
857811
858983
−
LARP4B
0x0

625
chr10
897946
899153
−
LARP4B
0x0

626
chr10
915522
916733
−
LARP4B
0x0

627
chr10
1037878
1039077
+
GTPBP4
0x1

628
chr10
1177466
1178635
+
WDR37
0x0

629
chr10
3143076
3144273
+
PFKP
0x2

630
chr10
5498718
5499855
+
NET1
0x0

631
chr10
5894873
5896267
−
ANKRD16
0x0

632
chr10
7284973
7286228
−
SFMBT2
0x4

633
chr10
7318329
7319540
−
SFMBT2
0x4

634
chr10
7327265
7328458
−
SFMBT2
0x4

635
chr10
7361094
7362349
−
SFMBT2
0x4

636
chr10
7388629
7389823
−
SFMBT2
0x4

637
chr10
7884436
7885634
+
TAF3
0x0

638
chr10
8034661
8035813
+
TAF3
0x0

639
chr10
10817881
10819050
−
SFTA1P
0x0

640
chr10
11375072
11376197
+
CELF2
0x0

641
chr10
11529210
11530389
−
USP6NL
0x0

642
chr10
12139258
12140488
+
DHTKD1
0x0

643
chr10
12141598
12142790
+
DHTKD1
0x0

644
chr10
12193739
12194931
+
SEC61A2
0x0

645
chr10
13769281
13770472
+
PRPF18
0x0

646
chr10
15254670
15255759
−
FAM171A1
0x0

647
chr10
15677400
15678528
−
ITGA8
0x0

648
chr10
15885198
15886387
−
FAM188A
0x1

649
chr10
16512344
16513511
+
PTER
0x0

650
chr10
16517452
16518631
+
PTER
0x0

651
chr10
17271274
17272447
+
VIM
0x0

652
chr10
17278801
17280000
+
VIM
0x0

653
chr10
17658065
17659244
−
PTPLA
0x0

654
chr10
17693625
17694846
+
StAM
0x0

655
chr10
18731218
18732413
+
CACNB2
0x0

656
chr10
18969440
18970539
+
ARL5B
0x0

657
chr10
21442123
21443301
−
C10orf113
0x0

658
chr10
21453958
21455156
+
LOC100128511
0x0

659
chr10
21934560
21935750
+
MLLT10
0x0

660
chr10
21944578
21945780
+
MLLT10
0x0

661
chr10
21974309
21975409
+
MLLT10
0x0

662
chr10
22221492
22222711
+
MLLT10
0x0

663
chr10
22517892
22519075
−
EBLN1
0x0

664
chr10
27046890
27048090
+
PDSS1
0x0

665
chr10
27112344
27113521
−
ABI1
0x2

666
chr10
27414860
27416037
−
YME1L1
0x0

667
chr10
27422424
27423599
−
YME1L1
0x0

668
chr10
27430769
27431910
−
YME1L1
0x0

669
chr10
27484861
27486047
−
ACBD5
0x0

670
chr10
27529727
27530930
−
ACBD5
0x0

671
chr10
27828011
27829181
+
RAB18
0x0

672
chr10
28840201
28841312
+
WAC
0x0

673
chr10
28896605
28897768
+
WAC
0x0

674
chr10
30601620
30602784
−
MTPAP
0x0

675
chr10
32197132
32198312
−
ARHGAP12
0x0

676
chr10
32298882
32300844
−
KIF5B
0x2

677
chr10
32307631
32308819
−
KIF5B
0x2

678
chr10
32599864
32601121
−
EPC1
0x2

679
chr10
33532312
33533462
−
NRP1
0x0

680
chr10
34682668
34684029
−
PARD3
0x0

681
chr10
34931805
34940500
−
PARD3
0x0

682
chr10
35005954
35007146
−
PARD3
0x0

683
chr10
35674327
35675517
+
CCNY
0x0

684
chr10
38104286
38105423
−
ZNF248
0x0

685
chr10
38410549
38411702
+
ZNF37A
0x2

686
chr10
38726021
38727193
+
LOC399744
0x0

687
chr10
42987909
42989114
+
LOC848S6
0x0

688
chr10
43047320
43048711
−
ZNF37BP
0x0

689
chr10
45950107
45951270
−
MARCH8
0x0

690
chr10
48205645
48206744
+
AGAP9
0x0

691
chr10
49862031
49863217
−
ARHGAP22
0x0

692
chr10
50910581
50911972
−
OGDHL
0x0

693
chr10
51387116
51388251
+
MSMB
0x1

694
chr10
51591654
51592946
−
TIMM23
0x0

695
chr10
51748030
51749191
+
AGAP6
0x0

696
chr10
52141798
52142974
−
SGMS1
0x0

697
chr10
52789097
52790200
+
PRKG1
0x0

698
chr10
52938396
52939541
+
PRKG1
0x0

699
chr10
52980093
52981305
+
PRKG1
0x0

700
chr10
52999596
53000733
+
MIR605
0x0

701
chr10
53089007
53090231
+
MIR605
0x0

702
chr10
53134151
53135349
+
MIR605
0x0

703
chr10
53342480
53343660
+
PRKG1
0x0

704
chr10
53412101
53413200
+
PRKG1
0x0

70S
chr10
53426903
53428121
+
PRKG1
0x0

706
chr10
57419102
57420322
−
ZWINT
0x0

707
chr10
57526788
57528007
−
ZWINT
0x0

708
chr10
58117180
58118473
−
ZWINT
0x0

709
chr10
61550012
61551187
−
CCDC6
0x0

710
chr10
61646660
61647838
−
CCDC6
0x0

711
chr10
61799473
61800681
−
ANK3
0x2

712
chr10
62471757
62472934
−
ANK3
0x2

713
chr10
62553173
62554457
−
CDK1
0x0

714
chr10
62670575
62671753
−
RHOBTB1
0x0

715
chr10
63447839
63449050
+
C10orf107
0x0

716
chr10
63976408
63977620
−
RTKN2
0x0

717
chr10
65006684
65007886
−
JMJD1C
0x0

718
chr10
65256338
65257454
−
JMJD1C
0x0

719
chr10
65283600
65284816
+
REEP3
0x0

720
chr10
65358845
65360025
+
REEP3
0x0

721
chr10
65381754
65383090
+
REEP3
0x0

722
chr10
67420760
67421880
−
CTNNA3
0x4

723
chr10
69090896
69092095
−
CTNNA3
0x4

724
chr10
69523738
69525755
+
SIRT1
0x0

725
chr10
69556175
69557381
−
DNAJC12
0x0

726
chr10
70101826
70103014
+
HNRNPH3
0x0

727
chr10
70128501
70129686
−
RUFY2
0x0

728
chr10
70153037
70154136
−
RUFY2
0x0

729
chr10
70227468
70228610
−
DNA2
0x0

730
chr10
70286378
70287515
−
SLC25A16
0x0

731
chr10
70416334
70417482
+
TET1
0x0

732
chr10
70425287
70426442
+
TET1
0x0

733
chr10
70458278
70459445
+
TET1
0x0

734
chr10
70514348
70515593
+
CCAR1
0x0

735
chr10
70514348
70515593
+
SNORD98
0x0

736
chr10
70521337
70522505
+
CCAR1
0x0

737
chr10
70526118
70527353
+
CCAR1
0x0

738
chr10
70547382
70548611
+
CCAR1
0x0

739
chr10
70719311
70720548
+
DDX21
0x0

740
chr10
70742633
70743716
+
DDX21
0x0

741
chr10
71213672
71214905
+
TSPAN15
0x0

742
chr10
71968827
71969932
−
PPA1
0x0

743
chr10
72090161
72091301
−
LRRC20
0x0

744
chr10
72179181
72180412
+
EIF4EBP2
0x0

745
chr10
72182095
72183256
+
EIF4EBP2
0x0

746
chr10
72186344
72188291
+
EIF4EBP2
0x0

747
chr10
72226248
72227487
+
KIAA1274
0x0

748
chr10
72327126
72328451
+
KIAA1274
0x0

749
chr10
72603792
72604923
+
SGPL1
0x0

750
chr10
72638485
72639719
+
SGPL1
0x0

751
chr10
73059524
73060994
+
UNC5B
0x1

752
chr10
73575664
73577723
−
PSAP
0x0

753
chr10
73769977
73771076
+
CHST3
0x0

754
chr10
73771572
73773721
+
CHST3
0x0

755
chr10
74226979
74228171
−
MICU1
0x0

756
chr10
74645466
74646663
+
MCU
0x0

757
chr10
74761035
74762200
−
P4HA1
0x0

758
chr10
74853987
74855251
−
P4HA1
0x0

759
chr10
75008449
75009792
−
MRPS16
0x0

760
chr10
75262821
75263997
−
USP54
0x0

761
chr10
75433909
75435129
−
AGAP5
0x0

762
chr10
75456729
75457933
−
AGAP5
0x0

763
chr10
75536646
75537837
+
FUT11
0x0

764
chr10
75545273
75546461
+
KIAA0913
0x0

765
chr10
75558239
75559455
+
KIAA0913
0x0

766
chr10
75623611
75624834
−
CAMK2G
0x0

767
chr10
75828203
75829447
+
VCL
0x1

768
chr10
76102005
76103155
+
ADK
0x0

769
chr10
76602446
76603781
+
KAT6B
0x2

770
chr10
76870831
76872021
+
SAMD8
0x0

771
chr10
76936412
76937545
+
SAMD8
0x0

772
chr10
76983205
76984301
+
VDAC2
0x0

773
chr10
76994299
76995499
−
COMTD1
0x0

774
chr10
76995165
76996322
+
VDAC2
0x0

775
chr10
77160413
77161591
−
ZNF503
0x0

776
chr10
77550216
77551415
+
C10orf11
0x0

777
chr10
79514310
79515493
−
DLG5
0x2

778
chr10
79550701
79552113
−
DLG5
0x2

779
chr10
79580656
79581853
−
DLG5
0x2

780
chr10
79729156
79730355
−
POLR3A
0x2

781
chr10
79794606
79795831
+
RPS24
0x0

782
chr10
79796462
79797625
+
RPS24
0x0

783
chr10
79799824
79800997
+
RPS24
0x0

784
chr10
80146596
80147772
−
POLR3A
0x2

785
chr10
81572099
81573257
−
SFTPD
0x0

786
chr10
81686310
81687409
+
MBL1P
0x0

787
chr10
81885271
81886500
+
PLAC9
0x0

788
chr10
85911939
85913402
+
GHITM
0x0

789
chr10
87571839
87573088
−
GRID1
0x2

790
chr10
87811722
87812914
+
LOC100507470
0x0

791
chr10
88126165
88127381
+
OPN4
0x0

792
chr10
88256073
88257291
−
WAPAL
0x0

793
chr10
88266884
88268077
−
WAPAL
0x0

794
chr10
88648778
88650011
+
BMPR1A
0x2

795
chr10
89312084
89313511
+
MINPP1
0x0

796
chr10
89512707
89513915
−
ATAD1
0x0

797
chr10
89542693
89544610
−
ATAD1
0x0

798
chr10
89727592
89728794
+
PTEN
0x1

799
chr10
90999167
91000389
+
LIPA
0x0

800
chr10
91144482
91145707
−
SLC16A12
0x0

801
chr10
92986428
92987533
+
PCGF5
0x0

802
chr10
93576218
93577444
+
TNKS2
0x0

803
chr10
93756841
93758040
+
BTAF1
0x0

804
chr10
94044068
94045250
−
CPEB3
0x0

805
chr10
94092672
94093873
+
MARCH5
0x0

806
chr10
94193802
94195017
−
MARK2P9
0x0

807
chr10
94685206
94686408
+
EXOC6
0x0

808
chr10
96108489
96109640
−
NOC3L
0x0

809
chr10
96117423
96118595
−
NOC3L
0x0

810
chr10
96122067
96123244
−
NOC3L
0x0

811
chr10
96349622
96350815
+
HELLS
0x0

812
chr10
96362603
96364743
+
HELLS
0x0

813
chr10
96370239
96371467
+
HELLS
0x0

814
chr10
97888941
97890188
+
ZNF518A
0x2

815
chr10
98038160
98039356
+
DNTT
0x0

816
chr10
98281270
98282442
−
TM9SF3
0x0

817
chr10
98352618
98353841
−
PIK3AP1
0x0

818
chr10
98560827
98562069
−
PIK3AP1
0x0

819
chr10
98619000
98620163
+
LCOR
0x0

820
chr10
98697481
98698689
+
LCOR
0x0

821
chr10
99200150
99201299
−
EXOSC1
0x0

822
chr10
99211300
99212538
+
ZDHHC16
0x0

823
chr10
99220768
99221879
−
MMS19
0x0

824
chr10
99257035
99258187
−
MMS19
0x0

825
chr10
99434051
99435229
−
AVPI1
0x2

826
chr10
99486666
99487852
+
MARVELD1
0x0

827
chr10
99620012
99621179
+
GOLGA7B
0x0

828
chr10
101106408
101107648
+
CNNM1
0x0

829
chr10
101189707
101190895
−
GOT1
0x0

830
chr10
101198213
101199432
+
CNNM1
0x0

831
chr10
101446019
101447252
+
ENTPD7
0x0

832
chr10
101909566
101910739
−
ERLIN1
0x0

833
chr10
101996380
101997710
−
CWF19L1
0x0

834
chr10
101996380
101997710
−
SNORA12
0x0

835
chr10
102012574
102013761
−
CWF19L1
0x0

836
chr10
102121124
102123864
+
SCD
0x0

837
chr10
102123929
102124967
+
SCD
0x0

838
chr10
102312573
102313722
+
HIF1AN
0x0

839
chr10
102510249
102511465
+
PAX2
0x0

840
chr10
102588417
102589613
+
PAX2
0x0

841
chr10
102740219
102741347
−
MRPL43
0x0

842
chr10
102746626
102747726
−
MRPL43
0x0

843
chr10
102826216
102827396
+
KAZALD1
0x0

844
chr10
103066793
103067972
−
BTRC
0x0

845
chr10
103124035
103125312
−
LBX1
0x0

846
chr10
103432736
103433950
−
FBXW4
0x0

847
chr10
103732741
103733962
−
C10orf76
0x0

848
chr10
103870177
103871418
−
LDB1
0x6

849
chr10
103903555
103904683
+
PPRC1
0x0

850
chr10
104350740
104351950
+
SUFU
0x1

851
chr10
104391364
104392863
+
SUFU
0x1

852
chr10
104618319
104619522
+
C10orf32
0x0

853
chr10
104618319
104619522
+
C10orf32-AS3MT
0x0

854
chr10
104703041
104704186
+
CNNM2
0x0

855
chr10
104841572
104842768
+
CNNM2
0x0

856
chr10
104929881
104931142
−
NT5C2
0x0

857
chr10
104936094
104937308
+
LOC729020
0x0

858
chr10
104966476
104967641
−
NT5C2
0x0

859
chr10
105071657
105072830
−
PCGF6
0x0

860
chr10
105236366
105237543
−
CALHM3
0x0

861
chr10
105354565
105355675
−
SH3PXD2A
0x0

862
chr10
105359058
105360157
−
SH3PXO2A
0x0

863
chr10
105402766
105403933
−
SH3PXD2A
0x0

864
chr10
105753471
105754685
+
SLK
0x0

865
chr10
105797373
105798600
+
SLK
0x0

866
chr10
108729213
108730449
+
SORCS3
0x0

867
chr10
111825059
111826221
+
ADD3
0x0

868
chr10
112045697
112046917
+
MXI1
0x1

869
chr10
112541004
112542127
+
RBM20
0x0

870
chr10
112556693
112557891
+
RBM20
0x0

871
chr10
112601898
112603122
−
LOC282997
0x0

872
chr10
114300308
114301485
+
VTI1A
0x2

873
chr10
114430666
114431996
+
VTI1A
0x2

874
chr10
114575897
114577131
+
VTI1A
0x2

875
chr10
114803679
114804834
+
TCF7L2
0x1

876
chr10
114810783
114812085
+
TCF7L2
0x1

877
chr10
114832960
114834173
+
TCF7L2
0x1

878
chr10
114994467
114995686
+
TCF7L2
0x1

879
chr10
116191291
116192572
−
ABLIM1
0x0

880
chr10
116192892
116194131
−
ABLIM1
0x0

881
chr10
116194170
116195533
−
ABLIM1
0x0

882
chr10
116482750
116483970
+
FAM160B1
0x0

883
chr10
116726306
116727502
+
TRUB1
0x0

884
chr10
118432853
118434126
−
HSPA12A
0x0

885
chr10
118659202
118660345
−
KIAA1598
0x0

886
chr10
118672336
118673543
−
KIAA1598
0x0

887
chr10
119040865
119042286
−
PDZD8
0x0

888
chr10
119133806
119134993
−
PDZD8
0x0

889
chr10
119613911
119615133
−
RAB11FIP2
0x0

890
chr10
120444662
120445977
−
C10orf46
0x0

891
chr10
120801317
120802788
−
EIF3A
0x2

892
chr10
120827133
120828353
+
NANOS1
0x0

893
chr10
120829962
120831338
−
EIF3A
0x2

894
chr10
120928180
120929329
−
PRDX3
0x0

895
chr10
121334411
121335594
−
TIAL1
0x0

896
chr10
121335956
121337136
−
TIAL1
0x0

897
chr10
121608403
121609588
−
MCMBP
0x0

898
chr10
123310751
123311964
−
FGFR2
0x2

899
chr10
123324439
123325692
−
FGFR2
0x2

900
chr10
123663896
123665105
−
ATE1
0x0

901
chr10
123718953
123720157
−
NSMCE4A
0x0

902
chr10
124913829
124915052
+
BUB3
0x0

903
chr10
124924070
124925428
+
BUB3
0x0

904
chr10
124934702
124936353
+
BUB3
0x0

905
chr10
124991437
124992665
+
BUB3
0x0

906
chr10
125025863
125027036
+
BUB3
0x0

907
chr10
125114673
125115921
+
BUB3
0x0

908
chr10
125164937
125166171
+
BUB3
0x0

909
chr10
125198504
125199751
+
GPR26
0x0

910
chr10
125664056
125665258
−
CPXM2
0x0

911
chr10
125774837
125776019
−
CHST15
0x0

912
chr10
125830388
125831664
−
CHST15
0x0

913
chr10
126308995
126312062
−
FAM53B
0x0

914
chr10
126369856
126371487
−
FAM53B
0x0

915
chr10
126464474
126465618
−
METTL10
0x0

916
chr10
126475775
126476905
−
METTL10
0x0

917
chr10
126496071
126497298
+
FAM175B
0x0

918
chr10
126700536
126701714
−
CTBP2
0x1

919
chr10
126800984
126802132
−
CTBP2
0x1

920
chr10
126816411
126817597
−
CTBP2
0x1

921
chr10
127411064
127412263
+
C10orf137
0x2

922
chr10
127705459
127706666
−
ADAM12
0x2

923
chr10
128854346
128855588
+
DOCK1
0x0

924
chr10
129894800
129896956
−
MKI67
0x0

925
chr10
129905232
129906521
−
MKI67
0x0

926
chr10
129913111
129914504
−
MKI67
0x0

927
chr10
131634425
131635894
−
EBF3
0x0

928
chr10
131642924
131644143
+
MGMT
0x0

929
chr10
132107642
132108887
+
GLRX3
0x0

930
chr10
132179372
132180570
−
LOC387723
0x0

931
chr10
134109868
134111045
−
STK32C
0x0

932
chr10
134754867
134756042
−
TTC40
0x0

933
chr10
135095771
135096937
−
TUBGCP2
0x0

934
chr10
135115703
135116996
−
TUBGCP2
0x0

935
chr10
135121757
135122955
−
TUBGCP2
0x0

936
chr10
135222774
135224017
+
MTG1
0x0

937
chr11
290224
291416
+
ATHL1
0x0

938
chr11
439910
441128
−
ANO9
0x0

939
chr11
642177
643361
−
DEAF1
0x0

940
chr11
671065
672334
−
DEAF1
0x0

941
chr11
769924
771342
−
PDDC1
0x0

942
chr11
790565
791735
−
SLC25A22
0x0

943
chr11
809719
810944
+
RPLP2
0x0

944
chr11
811175
813388
+
RPLP2
0x0

945
chr11
811175
813388
+
SNORA52
0x0

946
chr11
988708
989919
+
AP2A2
0x0

947
chr11
1773934
1775128
−
CTSD
0x0

948
chr11
2393292
2394489
+
CD81
0x4

949
chr11
2417707
2419006
+
CD81
0x4

950
chr11
2984521
2985619
−
SNORA54
0x0

951
chr11
3383623
3384799
−
ZNF195
0x0

952
chr11
3716135
3717338
−
NUP98
0x2

953
chr11
6631438
6632537
−
TAF10
0x0

954
chr11
8125426
8126565
+
TUB
0x0

955
chr11
8538631
8539771
−
STK33
0x0

956
chr11
8689247
8690420
−
TRIM66
0x0

957
chr11
8705244
8706446
+
RPL27A
0x0

958
chr11
8705244
8706446
+
SNORA3
0x0

959
chr11
8706452
8707671
+
RPL27A
0x0

960
chr11
8706452
8707671
+
SNORA45
0x0

961
chr11
9310545
9311720
−
TMEM41B
0x0

962
chr11
9431002
9432103
+
IPO7
0x0

963
chr11
9449754
9451088
+
IPO7
0x0

964
chr11
9449754
9451088
+
SNORA23
0x0

965
chr11
9461513
9462627
+
IPO7
0x0

966
chr11
9609488
9610703
+
WEE1
0x0

967
chr11
10264434
10265657
−
SBF2
0x0

968
chr11
10529526
10530696
−
MIR4485
0x0

969
chr11
10529526
10530696
−
MTRNR2L8
0x0

970
chr11
10818436
10819796
−
EIF4G2
0x0

971
chr11
10822497
10823700
−
EIF4G2
0x0

972
chr11
10822497
10823700
−
SNORD97
0x0

973
chr11
12962124
12963416
+
TEAD1
0x0

974
chr11
13434590
13435724
−
BTBD10
0x0

975
chr11
13440526
13441707
−
BTBd10
0x0

976
chr11
14478587
14479807
−
COPB1
0x0

977
chr11
16760098
16761286
+
C11or158
0x0

978
chr11
16995727
16997058
−
PLEKHA7
0x0

979
chr11
17095623
17098089
−
RPS13
0x0

980
chr11
17098092
17099231
−
RPS13
0x0

981
chr11
17225281
17226466
−
PIK3C2A
0x0

982
chr11
17399390
17400490
+
B7H6
0x0

983
chr11
18428322
18429599
+
LDHA
0x0

984
chr11
19422875
19424100
−
NAV2-AS4
0x0

985
chr11
22248369
22249579
+
ANO5
0x0

986
chr11
22709343
22710553
+
GAS2
0x0

987
chr11
22795836
22797053
+
GAS2
0x0

988
chr11
23427115
23428335
+
GAS2
0x0

989
chr11
28191782
28193016
+
METTL15
0x0

990
chr11
28592373
28593592
+
METTL15
0x0

991
chr11
32608006
32609259
+
EIF3M
0x0

992
chr11
33100090
33101473
+
LINC00294
0x0

993
chr11
33160995
33162510
−
CSTF3
0x0

994
chr11
33690488
33691795
+
C11orf41
0x0

995
chr11
34073293
34074505
+
CAPRIN1
0x0

996
chr11
34117590
34118706
+
CAPRIN1
0x0

997
chr11
34121064
34122602
+
CAPRIN1
0x0

998
chr11
34368183
34369357
−
ABTB2
0x0

999
chr11
35473459
35474657
−
PAMR1
0x0

1000
chr11
36248223
36249497
+
LDLRAD3
0x0

1001
chr11
38594065
38595243
+
C11orf74
0x0

1002
chr11
43465120
43466265
+
TTC17
0x0

1003
chr11
43701813
43703100
+
HSD17B12
0x0

1004
chr11
43710889
43712096
+
HSD17B12
0x0

1005
chr11
43713719
43714879
+
HSD17B12
0x0

1006
chr11
44104241
44105440
+
ACCS
0x0

1007
chr11
44147814
44149025
+
EXT2
0x1

1008
chr11
44950191
44951341
+
TSPAN18
0x0

1009
chr11
44953860
44955070
−
TP53I11
0x0

1010
chr11
45923521
45924726
+
MAPK8IP1
0x0

1011
chr11
46449763
46450915
−
AMBRA1
0x0

1012
chr11
46514646
46515836
−
AMBRA1
0x0

1013
chr11
46699392
46700538
−
ARHGAP1
0x0

1014
chr11
46772535
46773582
−
CKAP5
0x0

1015
chr11
47489352
47490908
−
CELF1
0x0

1016
chr11
47499886
47501080
−
CELF1
0x0

1017
chr11
47509722
47511032
−
CELF1
0x0

1018
chr11
47600235
47601463
+
NDUFS3
0x0

1019
chr11
47799968
47801080
−
NUP160
0x0

1020
chr11
47833349
47834567
−
NUP160
0x0

1021
chr11
50048802
50050001
+
OR4C13
0x2

1022
chr11
57083573
57084694
−
TNKS1BP1
0x0

1023
chr11
57092908
57094413
−
SSRP1
0x0

1024
chr11
57101422
57102590
−
SSRP1
0x0

1025
chr11
57507709
57508876
+
C11orf31
0x0

1026
chr11
57507709
57508876
+
TMX2
0x0

1027
chr11
57538522
57539710
+
CTNND1
0x1

1028
chr11
57575280
57576487
+
CTNND1
0x1

1029
chr11
57575280
57575487
+
TMX2-CTNND1
0x0

1030
chr11
57585111
57586193
+
CTNND1
0x1

1031
chr11
57585111
57586193
+
TMX2-CTNND1
0x0

1032
chr11
58385311
58385651
+
ZFP91
0x0

1033
chr11
59382267
59383461
−
OSBP
0x0

1034
chr11
60657745
60658974
−
PRPF19
0x0

1035
chr11
60673362
60574576
−
PRPF19
0x0

1036
chr11
60905662
60907001
−
VPS37C
0x0

1037
chr11
61080978
61082137
−
DDB1
0x0

1038
chr11
61094557
61095688
−
DDB1
0x0

1039
chr11
61103262
61104457
+
DAK
0x0

1040
chr11
61116305
61117482
−
CYBASC3
0x0

1041
chr11
61171066
61172241
−
CPSF7
0x0

1042
chr11
61570746
61572017
−
FADS1
0x0

1043
chr11
61633292
61634749
+
FADS2
0x0

1044
chr11
61731955
61733169
−
FTH1
0x0

1045
chr11
61918917
61920151
+
INCENP
0x0

1046
chr11
62326613
62327797
−
EEF1G
0x0

1047
chr11
62326613
62327797
−
MIR3654
0x0

1048
chr11
62328614
62329742
−
EEF1G
0x0

1049
chr11
62334335
62335539
−
EEF1G
0x0

1050
chr11
62360207
62361316
−
MTA2
0x2

1051
chr11
62364348
62365556
−
MTA2
0x2

1052
chr11
62383240
62384372
−
B3GAT3
0x0

1053
chr11
62400036
62401262
−
GANAB
0x0

1054
chr11
62431867
62433201
−
C11orf48
0x0

1055
chr11
62432354
62433550
−
METTL12
0x0

1056
chr11
62432354
62433550
+
SNORA57
0x0

1057
chr11
62489249
62490426
+
HNRNPUL2
0x0

1058
chr11
62489249
62490426
−
HNRNPUL2-BSCL2
0x0

1059
chr11
62510820
62512038
+
TTC9C
0x0

1060
chr11
62532031
62533274
+
POLR2G
0x0

1061
chr11
62542758
62543857
+
TAF6L
0x0

1062
chr11
62549124
62550223
+
TAF6L
0x0

1063
chr11
62567012
62568190
−
NXF1
0x2

1064
chr11
62608541
62609849
−
WDR74
0x0

1065
chr11
62618968
62621378
−
SNHG1
0x0

1066
chr11
62618968
62621378
−
SNORD22
0x0

1067
chr11
62618968
62621378
−
SNORD29
0x0

1068
chr11
62618968
62621378
−
SNORD30
0x0

1069
chr11
62618968
62621378
−
SNORD31
0x0

1070
chr11
62622051
62623625
−
SNHG1
0x0

1071
chr11
62622051
62623625
−
SNORD25
0x0

1072
chr11
62622051
62623625
−
SNORD26
0x0

1073
chr11
62622051
62623625
−
SNORD27
0x0

1074
chr11
62622051
62623625
−
SNORD28
0x0

1075
chr11
63423115
63424290
−
ATL3
0x0

1076
chr11
63596428
63597649
+
C11orf84
0x0

1077
chr11
63785551
63786757
−
MACROD1
0x0

1078
chr11
64005477
64006741
+
VEGFB
0x0

1079
chr11
64013805
64014998
−
PPP1R14B
0x0

1080
chr11
64018832
64019978
+
PLCB3
0x1

1081
chr11
64063003
64064157
+
KCNK4
0x0

1082
chr11
64083247
64084373
+
ESRRA
0x0

1083
chr11
64083656
64084870
−
TRMT112
0x0

1084
chr11
64532206
64533405
−
SF1
0x0

1085
chr11
64574182
64575360
−
MEN1
0x1

1086
chr11
64845803
64846957
−
CDCA5
0x0

1087
chr11
64878887
64880037
+
C11orf2
0x0

1088
chr11
64878887
64880037
+
TM7SF2
0x0

1089
chr11
64880221
64881320
+
TM7SF2
0x0

1090
chr11
64914487
64915767
+
MRPL49
0x0

1091
chr11
64978362
64979722
+
CAPN1
0x0

1092
chr11
65197873
65199078
+
NEAT1
0x0

1093
chr11
65202147
65203375
+
NEAT1
0x0

1094
chr11
65205474
65206618
+
MIR612
0x0

1095
chr11
65211102
65213301
+
MIR612
0x0

1096
chr11
65267086
65272491
+
MALAT1
0x0

1097
chr11
65272670
65273959
+
MALAT1
0x0

1098
chr11
65303924
65305111
+
SCYL1
0x0

1099
chr11
65318518
65319691
−
LTBP3
0x0

1100
chr11
65340337
65341462
+
FAM89B
0x0

1101
chr11
65382895
65384217
+
PCNXL3
0x0

1102
chr11
65403876
65405283
+
PCNXL3
0x0

1103
chr11
65420601
65421743
−
RELA
0x0

1104
chr11
65606663
65607901
+
SNX32
0x0

1105
chr11
65621762
65623097
−
CFL1
0x0

1106
chr11
65657684
65658871
+
CCDC85B
0x0

1107
chr11
65732857
65734198
+
SART1
0x0

1108
chr11
66040462
66041680
+
RAB1B
0x4

1109
chr11
66115021
66116249
+
TMEM151A
0x0

1110
chr11
66412944
66414301
+
RBM14-RBM4
0x0

1111
chr11
66412944
66414301
+
RBM4
0x0

1112
chr11
66458249
66459396
−
SPTBN2
0x0

1113
chr11
66477558
66478690
−
SPTBN2
0x0

1114
chr11
66998612
66999821
+
KDM2A
0x0

1115
chr11
67129304
67130537
+
LOC100130987
0x0

1116
chr11
67171122
67172325
+
PPP1CA
0x1

1117
chr11
67888092
67889195
−
CHKA
0x0

1118
chr11
68114944
68116240
+
LRP5
0x2

1119
chr11
68124695
68125868
+
LRP5
0x2

1120
chr11
68178330
68179614
+
LRP5
0x2

1121
chr11
68380749
68381958
+
PPP6R3
0x0

1122
chr11
68457842
68459072
+
GAL
0x0

1123
chr11
69465610
69466793
+
CCND1
0x2

1124
chr11
69468028
69469207
+
CCND1
0x2

1125
chr11
70260296
70261444
+
CTTN
0x0

1126
chr11
70266096
70267236
+
CTTN
0x0

1127
chr11
70281342
70282887
+
CTTN
0x0

1128
chr11
70487751
70488908
−
SHANK2
0x0

1129
chr11
71719638
71720823
−
NUMA1
0x2

1130
chr11
72396112
72397289
−
ARAP1
0x0

1131
chr11
72465381
72466597
−
STARD10
0x0

1132
chr11
72533951
72535153
+
ATG16L2
0x0

1133
chr11
73089519
73090913
+
RELT
0x0

1134
chr11
73102560
73103766
+
RELT
0x0

1135
chr11
73113207
73114421
−
FAM168A
0x0

1136
chr11
73292950
73294141
−
FAM168A
0x0

1137
chr11
73471139
73472306
−
RA86A
0x0

1138
chr11
73686049
73687204
−
UCP2
0x0

1139
chr11
73692040
73693221
−
UCP2
0x0

1140
chr11
74395754
74397001
+
POLD3
0x0

1141
chr11
74459371
74460563
+
RNF169
0x0

1142
chr11
74548402
74549680
+
RNF169
0x0

1143
chr11
74953752
74954991
+
LOC100507050
0x0

1144
chr11
74973123
74974469
−
ARRB1
0x0

1145
chr11
75114637
75115718
+
RPS3
0x0

1146
chr11
75114637
75115718
+
SNORD15B
0x0

1147
chr11
75116122
75117284
+
RPS3
0x0

1148
chr11
75946310
75947433
−
WNT11
0x1

1149
chr11
76188233
76189474
+
C11orf30
0x2

1150
chr11
77445397
77446524
−
RSF1
0x0

1151
chr11
77596958
77598370
+
C11or167
0x0

1152
chr11
78203348
78204744
−
NARS2
0x0

1153
chr11
78281988
78283213
−
NARS2
0x0

1154
chr11
79158852
79160049
+
USP35
0x0

1155
chr11
82400096
82401484
+
C11orf82
0x0

1156
chr11
85194521
85195729
+
TMEM126B
0x0

1157
chr11
85372133
85373311
−
CREBZF
0x0

1158
chr11
85374978
85376093
−
CREBZF
0x0

1159
chr11
85955600
85956820
+
EED
0x0

1160
chr11
86781990
86783149
+
TMEM135
0x0

1161
chr11
87035894
87037074
+
TMEM135
0x0

1162
chr11
87173935
87175142
+
TMEM135
0x0

1163
chr11
88115883
88117057
+
TYR
0x0

1164
chr11
88601325
88602522
−
GRM5
0x2

1165
chr11
90016508
90017736
+
NAALAD2
0x0

1166
chr11
92628475
92629717
+
FAT3
0x2

1167
chr11
93430080
93431249
+
KIAA1731
0x0

1168
chr11
93431321
93432559
+
KIAA1731
0x0

1169
chr11
93454277
93455631
+
KIAA1731
0x0

1170
chr11
93454277
93455631
+
SCARNA9
0x0

1171
chr11
93463172
93467318
−
MIR1304
0x0

1172
chr11
93463172
93467318
−
SNORA1
0x0

1173
chr11
93463172
93467318
−
SNORA18
0x0

1174
chr11
93463172
93467318
−
SNORA25
0x0

1175
chr11
93463172
93467318
−
SNORA32
0x0

1176
chr11
93463172
93467318
−
SNORA8
0x0

1177
chr11
93463172
93467318
−
SNORD5
0x0

1178
chr11
93463172
93467318
−
SNORD6
0x0

1179
chr11
93467776
93468906
−
SNORA40
0x0

1180
chr11
93471932
93473313
−
TAF1D
0x0

1181
chr11
93710378
93711559
−
VSTM5
0x0

1182
chr11
93951439
93952636
−
GPR83
0x0

1183
chr11
94150949
94152169
−
MRE11A
0x2

1184
chr11
94191674
94192852
−
MRE11A
0x2

1185
chr11
94626721
94627940
+
AMOTL1
0x0

1186
chr11
94901765
94902876
−
SESN3
0x0

1187
chr11
94905459
94906618
−
SESN3
0x0

1188
chr11
95825694
95826915
−
MAML2
0x2

1189
chr11
97636450
97637649
−
CCDC82
0x0

1190
chr11
102165160
102166359
+
BIRC3
0x2

1191
chr11
102267092
102268404
−
TMEM123
0x0

1192
chr11
103002798
103004000
+
DYNC2H1
0x2

1193
chr11
103027441
103028540
+
DYNC2H1
0x2

1194
chr11
103174765
103176006
+
DYNC2H1
0x2

1195
chr11
105633446
105634654
+
GRIA4
0x0

1196
chr11
105968338
105969437
+
AASDHPPT
0x0

1197
chr11
108002424
108003642
+
ACAT1
0x0

1198
chr11
108047167
108048374
−
NPAT
0x0

1199
chr11
108344138
108345359
−
KDELC2
0x0

1200
chr11
108788410
108789619
+
DDX10
0x0

1201
chr11
110100605
110101959
−
RDX
0x0

1202
chr11
110165437
110166631
−
RDX
0x0

1203
chr11
111611018
111612348
−
PPP2R1B
0x1

1204
chr11
111630786
111631964
−
PPP2R1B
0x1

1205
chr11
111692090
111693298
−
ALG9
0x0

1206
chr11
111911615
111912858
+
DLAT
0x0

1207
chr11
113692674
113693849
−
USP28
0x2

1208
chr11
113737800
113739046
+
HTR3B
0x0

1209
chr11
114293964
114295180
+
RBM7
0x0

1210
chr11
115046086
115047511
−
CADM1
0x1

1211
chr11
115148719
115149902
−
CADM1
0x1

1212
chr11
115342456
115343604
−
CADM1
0x1

1213
chr11
115471774
115472976
+
FAM55B
0x0

1214
chr11
115692620
115693820
−
APOC3
0x0

1215
chr11
117708156
117709359
−
FXYD6
0x0

1216
chr11
118279246
118280394
+
ATP5L
0x0

1217
chr11
118342606
118343847
+
MLL
0x2

1218
chr11
118393102
118394257
+
MLL
0x2

1219
chr11
118427130
118428283
−
IFT46
0x0

1220
chr11
118470924
118472083
+
ARCN1
0x0

1221
chr11
118527620
118528782
+
PHLDB1
0x0

1222
chr11
118619817
118620995
−
DDX6
0x0

1223
chr11
118894521
118895926
−
SLC37A4
0x0

1224
chr11
118914425
118916307
−
HYOU1
0x0

1225
chr11
118964055
118965438
−
H2AFX
0x0

1226
chr11
120219784
120220989
+
ARHGEF12
0x1

1227
chr11
120346835
120347953
+
ARHGEF12
0x1

1228
chr11
120356530
120357629
+
ARHGEF12
0x1

1229
chr11
120901672
120902820
−
TBCEL
0x0

1230
chr11
122928226
122929337
−
HSPA8
0x0

1231
chr11
122929463
122930664
−
HSPA8
0x0

1232
chr11
123050799
123052002
−
CLMP
0x0

1233
chr11
123595631
123596826
−
ZNF202
0x0

1234
chr11
123634095
123635377
+
GRAMD1B
0x0

1235
chr11
124505785
124507034
+
TBRG1
0x1

1236
chr11
124923736
124924915
−
TMEM218
0x0

1237
chr11
125169906
125171066
+
PKNOX2
0x0

1238
chr11
125453376
125454570
+
EI24
0x1

1239
chr11
125490149
125491346
+
STT3A
0x0

1240
chr11
125547115
125548337
+
CHEK1
0x1

1241
chr11
126076638
126077817
−
RPUSD4
0x0

1242
chr11
126147179
126148335
+
FOXRED1
0x0

1243
chr11
129297040
129298265
+
BARX2
0x0

1244
chr11
130013182
130015087
+
APLP2
0x0

1245
chr11
133768160
133769577
−
LOC283174
0x0

1246
chr11
133768160
133769577
−
MIR4697
0x0

1247
chr11
133775128
133776296
−
LOC283174
0x0

1248
chr11
133801584
133802941
−
IGSF9B
0x0

1249
chr11
133905644
133907090
−
IGSF9B
0x0

1250
chr11
134207878
134209110
+
GLB1L2
0x0

1251
chr11
134244503
134245731
+
GLB1L2
0x0

1252
chr12
364481
365671
−
SLC6A13
0x0

1253
chr12
392498
393756
−
KDMSA
0x2

1254
chr12
413102
414299
+
CCDC77
0x0

1255
chr12
973775
975079
+
WNK1
0x0

1256
chr12
1038335
1039518
−
RAD52
0x0

1257
chr12
1136736
1137951
+
ERC1
0x2

1258
chr12
2364481
2365782
+
CACNA1C
0x0

1259
chr12
2675917
2677086
+
CACNA1C
0x0

1260
chr12
2912189
2913544
+
FKBP4
0x0

1261
chr12
2927125
2928323
+
ITFG2
0x0

1262
chr12
2986248
2987433
+
C12orf32
0x0

1263
chr12
2997913
2999053
+
C12orf32
0x0

1264
chr12
3008519
3009671
+
TULP3
0x0

1265
chr12
3079751
3080900
+
TEAD4
0x0

1266
chr12
3153592
3154803
+
TEAD4
0x0

1267
chr12
4399756
4400906
+
CCND2
0x2

1268
chr12
4411084
4412957
+
CCND2
0x2

1269
chr12
4772532
4773729
+
NDUFA9
0x0

1270
chr12
6618969
6620370
+
NCAPD2
0x0

1271
chr12
6618969
6620370
+
SCARNA10
0x0

1272
chr12
6626244
6627393
+
NCAPD2
0x0

1273
chr12
6646283
6647637
+
GAPDH
0x0

1274
chr12
6652008
6653217
−
IFFO1
0x0

1275
chr12
6678923
6680015
−
CHD4
0x2

1276
chr12
6690067
6691369
−
CHD4
0x2

1277
chr12
6690067
6691369
−
SCARNA11
0x0

1278
chr12
6709165
6710346
−
CHD4
0x2

1279
chr12
6775774
6776986
−
ZNF384
0x2

1280
chr12
6879192
6880496
+
PTMS
0x2

1281
chr12
7052424
7053623
+
C12orf57
0x0

1282
chr12
7074110
7075210
−
PHB2
0x0

1283
chr12
7076077
7077300
−
PHB2
0x0

1284
chr12
7076077
7077300
−
SCARNA12
0x0

1285
chr12
7079104
7080280
−
PHB2
0x0

1286
chr12
7362702
7363899
+
PEX5
0x0

1287
chr12
9451079
9452259
+
LOC642846
0x0

1288
chr12
9572828
9574121
−
DDX12P
0x0

1289
chr12
10865278
10866425
−
CSDA
0x0

1290
chr12
11283034
11284164
−
TAS2R30
0x0

1291
chr12
12396929
12398082
−
LRP6
0x0

1292
chr12
12693877
12695074
−
DUSP16
0x0

1293
chr12
12843359
12844568
+
CDKN1B
0x2

1294
chr12
12882447
12883597
+
APOLD1
0x0

1295
chr12
13349667
13350884
+
EMP1
0x1

1296
chr12
14553333
14554482
+
ATF7IP
0x0

1297
chr12
14576917
14578148
+
ATF7IP
0x0

1298
chr12
16034899
16035998
+
STRAP
0x0

1299
chr12
19459402
19460532
+
PLEKHA5
0x0

1300
chr12
19609180
19610356
−
PLCZ1
0x0

1301
chr12
19646275
19647461
+
AEBP2
0x0

1302
chr12
19667021
19668250
+
AEBP2
0x0

1303
chr12
19787207
19788406
+
AEBP2
0x0

1304
chr12
20703858
20705060
+
PDE3A
0x0

1305
chr12
21787731
21789097
−
LDHB
0x0

1306
chr12
21796330
21797498
−
LDHB
0x0

1307
chr12
21806910
21808112
−
LDHB
0x0

1308
chr12
22841550
22842755
−
ETNK1
0x0

1309
chr12
24302800
24303994
−
SOX5
0x2

1310
chr12
25359335
25360441
−
KRAS
0x2

1311
chr12
26799681
26800860
−
ITPR2
0x0

1312
chr11
27182459
27183558
+
MED21
0x0

1313
chr12
28416937
28418091
+
CCDC91
0x0

1314
chr12
29318753
29320044
+
FAR2
0x0

1315
chr12
31255183
31256382
+
DDX11
0x2

1316
chr12
32329775
32330974
+
BICD1
0x0

1317
chr12
34358128
34359328
+
ALG10
0x0

1318
chr12
38554688
38555905
−
CPNE8
0x0

1319
chr12
38556667
38557854
−
CPNE8
0x0

1320
chr12
40306319
40307450
−
SLC2A13
0x2

1321
chr12
41291889
41293092
+
CNTN1
0x2

1322
chr12
42802927
42804130
+
PPHLN1
0x0

1323
chr12
44112475
44113668
−
PUS7L
0x0

1324
chr11
46210804
46211974
−
ARID2
0x1

1325
chr12
46348079
46349248
−
SCAF11
0x0

1326
chr12
46578570
46579679
−
SLC38A1
0x0

1327
chr12
46580852
46583054
−
SLC38A1
0x0

1328
chr12
46662262
46663408
−
SLC38A1
0x0

1329
chr12
46753993
46755126
−
SLC38A2
0x0

1330
chr12
47028778
47029926
+
MIR4698
0x0

1331
chr12
48211842
48213021
−
HDAC7
0x0

1332
chr12
48361676
48362943
+
TMEM106C
0x0

1333
chr12
48929861
48931073
−
LALBA
0x0

1334
chr11
49047617
49048857
−
KANSL2
0x0

1335
chr12
49047617
49048857
−
MIR1291
0x0

1336
chr12
49047617
49048857
−
SNORA34
0x0

1337
chr12
49049902
49051113
−
SNORA2A
0x0

1338
chr12
49053651
49054832
−
KANSL2
0x0

1339
chr12
49318110
49319282
−
FKBP11
0x0

1340
chr12
49329445
49332620
−
ARF3
0x0

1341
chr12
49414410
49415621
−
MLL2
0x2

1342
chr12
49435603
49436758
−
MLL2
0x2

1343
chr12
49529532
49530765
+
TUBA1C
0x0

1344
chr12
49548759
49550000
+
TUBA1C
0x0

1345
chr12
49666456
49667619
+
TUBA1C
0x0

1346
chr12
49920100
49921328
+
SPATS2
0x0

1347
chr12
49985589
49986795
+
PRPF40B
0x0

1348
chr12
50128781
50130000
−
FMNL3
0x2

1349
chr12
50134767
50135968
+
TMBIM6
0x0

1350
chr12
50145699
50146862
+
TMBIM6
0x0

1351
chr12
50156264
50157519
+
TMBIM6
0x0

1352
chr12
50157722
50158819
+
TMBIM6
0x0

1353
chr12
50184490
50185694
−
NCKAP5L
0x0

1354
chr12
50491552
50492780
+
SMARCD1
0x2

1355
chr12
50849813
50851143
+
LARP4
0x0

1356
chr12
51090319
51091513
+
DIP28
0x0

1357
chr12
51498676
51499900
−
TFCP2
0x0

1358
chr12
51634102
51635201
+
DAZAP2
0x0

1359
chr12
51636316
51637386
+
DAZAP2
0x0

1360
chr12
52401840
52403056
+
GRASP
0x0

1361
chr12
53415744
53416893
+
EIF4B
0x0

1362
chr12
53427832
53429067
+
EIF4B
0x0

1363
chr12
53434475
53435740
+
EIF4B
0x0

1364
chr12
53440754
53442110
−
LOC283335
0x0

1365
chr12
53677339
53678467
+
ESPL1
0x2

1366
chr12
53861998
53863198
+
PCBP2
0x0

1367
chr12
53872702
53873900
+
PCBP2
0x0

1368
chr12
53925841
53927016
−
ATF7
0x0

1369
chr12
53959188
53960365
−
ATF7
0x0

1370
chr12
54058406
54059659
−
ATP5G2
0x0

1371
chr12
54105636
54106848
−
CALCOCO1
0x0

1372
chr12
54116856
54118029
−
CALCOCO1
0x0

1373
chr12
54624276
54625822
−
CBX5
0x0

1374
chr12
54624276
54625822
−
MIR3198-2
0x0

1375
chr12
54626334
54627796
−
CBX5
0x0

1376
chr12
54632554
54633647
−
CBX5
0x0

1377
chr12
54678040
54679244
+
HNRNPA1
0x0

1378
chr12
54678040
54679244
+
HNRNPA1P10
0x0

1379
chr12
54680244
54681745
+
HNRNPA1
0x0

1380
chr12
54744020
54745227
+
COPZ1
0x0

1381
chr12
56144734
56145888
+
GDF11
0x0

1382
chr12
56214650
56215827
−
DNAJC14
0x0

1383
chr12
56319123
56320301
−
WIBG
0x0

1384
chr12
56509912
56511132
+
RPL41
0x0

1385
chr12
56529980
56531185
+
ESYT1
0x0

1386
chr12
56554648
56555864
+
MYL6
0x0

1387
chr12
56567925
56569100
−
SMARCC2
0x0

1388
chr12
56574409
56575535
−
SMARCC2
0x0

1389
chr12
56631521
56633609
−
ANKRD52
0x0

1390
chr12
56650675
56651839
−
ANKRD52
0x0

1391
chr12
56665418
56666553
−
CS
0x0

1392
chr12
56669294
56670401
−
CS
0x0

1393
chr12
56904854
56906036
+
RBMS2
0x0

1394
chr12
56983285
56984504
+
RBMS2
0x0

1395
chr12
56990790
56991985
−
BAZ2A
0x0

1396
chr12
56998428
56999593
−
BAZ2A
0x0

1397
chr12
57031567
57032662
−
ATP5B
0x0

1398
chr12
57038251
57039453
−
ATP5B
0x0

1399
chr12
57038251
57039453
−
SNORD59A
0x0

1400
chr12
57057255
57058446
−
PTGES3
0x0

1401
chr12
57106012
57107208
−
NACA
0x2

1402
chr12
57452030
57453472
−
TMEM194A
0x0

1403
chr12
57557543
57558713
+
LRP1
0x0

1404
chr12
57650492
57651591
−
R3HDM2
0x0

1405
chr12
57677230
57678420
−
R3HDM2
0x0

1406
chr12
57764748
57765913
−
R3HDM2
0x0

1407
chr12
57923781
57924975
−
DCTN2
0x0

1408
chr12
57998635
57999786
+
DTX3
0x0

1409
chr12
59270638
59271817
−
LRIG3
0x1

1410
chr12
62948534
62949723
−
MON2
0x0

1411
chr12
63327834
63329011
−
PPM1H
0x0

1412
chr12
63358577
63359800
+
MIRLET7I
0x1

1413
chr12
65603419
65604657
−
LEMD3
0x0

1414
chr12
67285540
67286640
−
GRIP1
0x0

1415
chr12
67296512
67297691
−
GRIP1
0x0

1416
chr12
67431752
67432968
−
GRIP1
0x0

1417
chr12
67698510
67699685
+
CAND1
0x0

1418
chr12
69005201
69006430
+
RAP1B
0x0

1419
chr12
69649981
69651119
+
CPSF6
0x0

1420
chr12
69994544
69995776
+
CCT2
0x0

1421
chr12
70194830
70196046
+
RAB3IP
0x0

1422
chr12
70679838
70681070
+
CNOT2
0x0

1423
chr12
71896974
71898191
+
LGR5
0x0

1424
chr11
72004583
72005719
−
ZFC3H1
0x0

1425
chr12
72005992
72007142
−
ZFC3H1
0x0

1426
chr12
72180935
72182073
+
RAB21
0x0

1427
chr12
74850635
74851794
+
ATXN7L3B
0x0

1428
chr12
75679900
75681078
−
CAPS2
0x0

1429
chr12
75891366
75892543
+
GLIPR1
0x1

1430
chr12
75892900
75894150
−
KRR1
0x0

1431
chr12
76430189
76431289
−
PHLDA1
0x0

1432
chr12
76439331
76440505
−
NAP1L1
0x0

1433
chr12
76443863
76444966
−
NAP1L1
0x0

1434
chr12
76451371
76460500
−
NAP1L1
0x0

1435
chr12
76461818
76462967
−
NAP1L1
0x0

1436
chr12
77224354
77225520
+
ZDHHC17
0x1

1437
chr12
77423288
77424487
−
E2F7
0x4

1438
chr12
79454116
79455268
−
PAWR
0x1

1439
chr12
79545435
79546544
−
PAWR
0x1

1440
chr12
80065464
80066629
−
PAWR
0x1

1441
chr12
81938745
81939922
−
PPFIA2
0x0

1442
chr12
82111266
82112433
−
PPFIA2
0x0

1443
chr12
82763997
82765204
+
C12orf26
0x0

1444
chr12
83250305
83251851
+
TMTC2
0x0

1445
chr12
83445406
83446612
+
TMTC2
0x0

1446
chr12
85275664
85276792
−
SLC6A15
0x2

1447
chr12
85689617
85690718
+
ALX1
0x0

1448
chr12
88478022
88479168
−
CEP290
0x0

1449
chr12
88823643
88824885
+
TMTC3
0x0

1450
chr12
89912721
89913853
−
GALNT4
0x0

1451
chr12
89912721
89913853
−
POC1B-GALNT4
0x0

1452
chr12
90013416
90014561
−
ATP2B1
0x0

1453
chr12
90082996
90084168
−
ATP2B1
0x0

1454
chr12
92120144
92121361
+
CLLU1
0x0

1455
chr12
92734804
92736003
+
CLLU1
0x0

1456
chr12
93795485
93796681
+
NUDT4
0x0

1457
chr12
93795485
93796681
+
NUDT4P1
0x0

1458
chr12
93801835
93803801
−
UBE2N
0x0

1459
chr12
93895618
93896756
+
MRPL42
0x0

1460
chr12
93898154
93899253
+
MRPL42
0x0

1461
chr12
93902860
93904057
+
MRPL42
0x0

1462
chr12
94033987
94035163
−
LOC144481
0x0

1463
chr12
94270786
94271995
+
CRADD
0x0

1464
chr12
95449301
95450478
−
NR2C1
0x0

1465
chr12
95694283
95695450
+
VEZT
0x0

1466
chr12
95838385
95839584
−
USP44
0x0

1467
chr12
95907272
95908503
+
METAP2
0x2

1468
chr12
95945210
95946388
−
USP44
0x0

1469
chr12
96131748
96132931
−
NTN4
0x0

1470
chr12
96679370
96680544
−
CDK17
0x0

1471
chr12
98896705
98897950
+
TMPO
0x0

1472
chr12
98909061
98910417
+
TMPO
0x0

1473
chr12
98928615
98929958
+
TMPO
0x0

1474
chr12
98988112
98989361
+
SLC25A3
0x0

1475
chr12
98992887
98994230
+
SLC25A3
0x0

1476
chr12
98992887
98994230
+
SNORA53
0x0

1477
chr12
99477048
99478198
−
ANKS1B
0x0

1478
chr12
100497710
100498916
−
UHRF1BP1L
0x0

1479
chr12
100562243
100563428
−
GOLGA2P5
0x0

1480
chr12
100672654
100673917
+
SCYL2
0x0

1481
chr12
102599508
102600903
+
PARPBP
0x0

1482
chr12
102606561
102607720
−
PARPBP
0x0

1483
chr12
102819646
102820849
−
IGF1
0x0

1484
chr12
104167901
104169068
−
NTSDCS
0x0

1485
chr12
104324745
104325987
+
HSP90B1
0x0

1486
chr12
104381637
104382863
+
TDG
0x2

1487
chr12
104658682
104659889
+
TXNRD1
0x0

1488
chr12
104714376
104715825
+
TXNRD1
0x0

1489
chr12
104732514
104733718
+
TXNRD1
0x0

1490
chr12
104742733
104744033
+
TXNRD1
0x0

1491
chr12
105283361
105284557
+
C12orf45
0x0

1492
chr12
105392116
105393273
+
C12orf45
0x0

1493
chr12
105397776
105398870
+
C12orf45
0x0

1494
chr12
105503187
105504415
+
KIAA1033
0x0

1495
chr12
106631295
106632921
−
CKAP4
0x0

1496
chr12
106872290
106873478
+
POLR3B
0x0

1497
chr12
107347778
107348955
−
MTERFD3
0x0

1498
chr12
107384669
107385818
−
CRY1
0x0

1499
chr12
107951247
107952444
−
BTBD11
0x0

1500
chr12
108917140
108918239
−
SART3
0x0

1501
chr12
108953954
108955214
−
SART3
0x0

1502
chr12
109038635
109040230
−
CORO1C
0x0

1503
chr12
109312158
109313375
+
DAO
0x0

1504
chr12
109636634
109637824
+
ACACB
0x0

1505
chr12
109724629
109725961
−
FOXN4
0x0

1506
chr12
109740686
109741911
−
FOXN4
0x0

1507
chr12
109761616
109762830
+
ACACB
0x0

1508
chr12
109973462
109974663
+
UBE3B
0x0

1509
chr12
109994373
109995568
−
MMAB
0x0

1510
chr12
110763655
110764854
+
ATP2A2
0x2

1511
chr12
110777915
110779112
+
ATP2A2
0x2

1512
chr12
110783912
110785278
+
ATP2A2
0x2

1513
chr12
110824490
110826195
−
ANAPC7
0x0

1514
chr12
111157924
111159308
−
PPP1CC
0x0

1515
chr12
111855661
111856775
+
SH2B3
0x0

1516
chr12
111948470
111949661
−
ATXN2
0x0

1517
chr12
111958175
111959274
−
ATXN2
0x0

1518
chr12
112460151
112461345
+
ERP29
0x0

1519
chr12
112466354
112467513
−
NAA25
0x0

1520
chr12
112467833
112468970
−
NAA25
0x0

1521
chr12
112504368
112505565
−
NAA25
0x0

1522
chr12
112510461
112511674
−
NAA25
0x0

1523
chr12
112637375
112638555
−
C12orf51
0x2

1524
chr12
112704325
112705613
+
TRAFD1
0x0

1525
chr12
112746050
112747202
−
C12orf51
0x2

1526
chr12
112911069
112912282
+
PTPN11
0x2

1527
chr12
112944565
112946176
+
PTPN11
0x2

1528
chr12
113673828
113675053
+
TPCN1
0x0

1529
chr12
113735248
113736378
+
TPCN1
0x0

1530
chr12
113874548
113875949
+
SDSL
0x0

1531
chr12
115129856
115131062
+
LOC255480
0x0

1532
chr12
116398477
116399619
−
MED13L
0x0

1533
chr12
116433823
116435006
−
MED13L
0x0

1534
chr12
117152663
117154080
−
C12orf49
0x0

1535
chr12
117365284
117366523
+
FBXW8
0x0

1536
chr12
118683520
118685251
+
PEBP1
0x0

1537
chr12
119266964
119268147
+
SRRM4
0x0

1538
chr12
120123558
120130500
−
CIT
0x2

1539
chr12
120574832
120576057
−
GCN1L1
0x0

1540
chr12
120592597
120594106
−
GCN1L1
0x0

1541
chr12
120592597
120594106
−
MIR4498
0x0

1542
chr12
120600352
120601529
−
GCN1L1
0x0

1543
chr12
120636369
120637807
−
RPLPO
0x0

1544
chr12
120659813
120661023
−
PXN
0x0

1545
chr12
120719700
120720918
+
S1RT4
0x0

1546
chr12
120729010
120730242
−
PXN
0x0

1547
chr12
120730321
120731569
−
PXN
0x0

1548
chr12
120779154
120780474
−
MSI1
0x0

1549
chr12
120875360
120876560
+
COX6A1
0x0

1550
chr12
120877815
120879006
+
COX6A1
0x0

1551
chr12
120884509
120885705
+
GATC
0x0

1552
chr12
120935439
120936770
+
DYNLL1
0x0

1553
chr12
121124410
121125575
+
MLEC
0x0

1554
chr12
121138015
121139114
+
MLEC
0x0

1555
chr12
121159111
121160851
+
UNC119B
0x0

1556
chr12
121201895
121203019
−
SPPL3
0x0

1557
chr12
121308258
121309467
−
SPPL3
0x0

1558
chr12
121314068
121315243
−
SPPL3
0x0

1559
chr12
121676294
121677456
−
CAMKK2
0x0

1560
chr12
122496860
122497973
+
BCL7A
0x2

1561
chr12
122627621
122628772
+
MLXIP
0x0

1562
chr12
122779092
122780309
−
CLIP1
0x2

1563
chr12
122825134
122826272
−
CLIP1
0x2

1564
chr12
123120516
123121672
+
KNTC1
0x0

1565
chr12
123444050
123445230
−
ABCB9
0x0

1566
chr12
123745288
123746440
−
CDK2AP1
0x1

1567
chr12
123801208
123802366
−
SBNO1
0x0

1568
chr12
123943066
123944289
+
SNRNP35
0x0

1569
chr12
124081212
124082349
+
TMED2
0x0

1570
chr12
124100782
124101965
+
DDX55
0x0

1571
chr12
124145169
124146424
+
GTF2H3
0x0

1572
chr12
124219151
124220344
+
ATP6V0A2
0x0

1573
chr12
124854201
124855376
−
NCOR2
0x0

1574
chr12
124903987
124905161
−
NCOR2
0x0

1575
chr12
124915360
124916735
−
NCOR2
0x0

1576
chr12
124922826
124924510
−
NCOR2
0x0

1577
chr12
124979296
124980474
−
NCOR2
0x0

1578
chr12
125261806
125262989
−
SCARB1
0x0

1579
chr12
125339397
125340559
−
SCARB1
0x0

1580
chr12
125397675
125398874
−
UBC
0x0

1581
chr12
127649925
127651531
−
LOC440117
0x0

1582
chr12
131358620
131359786
+
RAN
0x0

1583
chr12
131359882
131362107
+
RAN
0x0

1584
chr12
132589229
132590362
+
EP400NL
0x0

1585
chr12
132638091
132639288
+
NOC4L
0x0

1586
chr12
133159939
133161159
+
FBRSL1
0x4

1587
chr12
133235503
133236603
−
POLE
0x0

1588
chr12
133249065
133250242
−
POLE
0x0

1589
chr12
133286628
133287809
+
PGAM5
0x0

1590
chr12
133297027
133298212
+
PGAM5
0x0

1591
chr12
133302273
133303436
−
ANKLE2
0x0

1592
chr12
133340445
133341593
+
PGAM5
0x0

1593
chr12
133346386
133347715
−
GOLGA3
0x0

1594
chr12
133401746
133403135
+
PGAM5
0x0

1595
chr13
20182187
20183387
+
MPHOSPH8
0x0

1596
chr13
20198790
20199958
+
MPHOSPH8
0x0

1597
chr13
21185776
21187001
+
IFT88
0x1

1598
chr13
21535345
21536549
+
SAP18
0x0

1599
chr13
21946854
21948041
−
ZDHHC20
0x0

1600
chr13
21948636
21949812
−
ZDHHC20
0x0

1601
chr13
21994684
21995835
−
ZDHHC20
0x0

1602
chr13
23903680
23904855
−
SACS
0x0

1603
chr13
23934784
23935912
−
SACS
0x0

1604
chr13
24434695
24435873
−
MIPEP
0x0

1605
chr13
24699699
24700878
−
C1QTNF9B
0x0

1606
chr13
24796585
24798913
+
SPATA13
0x2

1607
chr13
25470098
25471258
−
CENPJ
0x0

1608
chr13
25670480
25671744
+
PABPC3
0x2

1609
chr13
26853541
26854689
+
CDK8
0x0

1610
chr13
26936737
26937942
+
CDK8
0x0

1611
chr13
27694168
27695357
−
USP12
0x0

1612
chr13
27827796
27830192
+
RPL21
0x0

1613
chr13
27827796
27830192
+
RPL21P28
0x0

1614
chr13
27827796
27830192
+
SNORA27
0x0

1615
chr13
27827796
27830192
+
SNORD102
0x0

1616
chr13
28007054
28008244
+
GTF3A
0x0

1617
chr13
28563055
28564262
−
PRHOXNB
0x0

1618
chr13
28712198
28713431
+
PAN3
0x0

1619
chr13
30085991
30087580
−
SLC7A1
0x0

1620
chr13
30106461
30107604
−
SLC7A1
0x0

1621
chr13
30109547
30110829
−
SLC7A1
0x0

1622
chr13
30814590
30815735
−
KATNAL1
0x0

1623
chr13
31712045
31713225
−
HSPH1
0x0

1624
chr13
34410120
34411619
+
RFC3
0x0

1625
chr13
34497437
34498845
+
RFCS
0x0

1626
chr13
34526824
34527999
+
RFCS
0x0

1627
chr13
35939677
35940865
+
NBEA
0x0

1628
chr13
37427215
37428396
−
SMAD9
0x0

1629
chr13
37439099
37440278
−
SMAD9
0x0

1630
chr13
41132450
41133622
−
FOXO1
0x1

1631
chr13
41155039
41156154
−
FOXO1
0x1

1632
chr13
41494897
41496052
−
LOC100616668
0x0

1633
chr13
41494897
41496052
−
SUGT1P3
0x0

1634
chr13
42352226
42353364
−
KIAA0564
0x0

1635
chr13
42439523
42440727
−
KIAA0564
0x0

1636
chr13
42893974
42895101
+
AKAP11
0x2

1637
chr13
44168571
44169757
−
ENOX1
0x0

1638
chr13
45575759
45576957
+
KIAA1704
0x0

1639
chr13
45825141
45826367
+
GTF2F2
0x0

1640
chr13
45910549
45912314
−
SNORA31
0x0

1641
chr13
45910549
45912314
−
TPT1
0x0

1642
chr13
46948034
46949263
−
KIAA0226L
0x0

1643
chr13
49561491
49562687
+
FNDC3A
0x0

1644
chr13
50587746
50588962
−
DLEU2
0x1

1645
chr13
50656526
50657696
+
DLEU1
0x1

1646
chr13
51323418
51324638
+
RNASEH2B
0x0

1647
chr13
51837909
51839104
+
FAM124A
0x0

1648
chr13
52987379
52988940
−
VPS36
0x0

1649
chr13
53190495
53191693
+
HNRNPA1L2
0x0

1650
chr13
60651419
60652765
−
DIAPH3
0x0

1651
chr13
61015885
61017092
+
TDRD3
0x0

1652
chr13
61125023
61126193
+
TDRD3
0x0

1653
chr13
61363164
61364351
+
TDRD3
0x0

1654
chr13
67840715
67841891
−
PCDH9
0x0

1655
chr13
72228968
72230115
−
DACH1
0x0

1656
chr13
72252217
72253358
−
DACH1
0x0

1657
chr13
72388884
72389994
−
DACH1
0x0

1658
chr13
72419172
72420352
−
DACH1
0x0

1659
chr13
73282402
73283576
−
MZT1
0x0

1660
chr13
73301105
73302258
−
MZT1
0x0

1661
chr13
73308096
73309322
+
BORA
0x0

1662
chr13
74505335
74506483
−
KLF12
0x0

1663
chr13
75883686
75884853
−
TBC1D4
0x0

1664
chr13
75935627
75936804
−
TBC1D4
0x0

1665
chr13
76134337
76135485
+
UCHL3
0x0

1666
chr13
76142156
76143379
+
UCHL3
0x0

1667
chr13
76179345
76180503
+
UCHL3
0x0

1668
chr13
76791681
76792834
+
LMO7
0x2

1669
chr13
77459623
77460867
−
KCTD12
0x0

1670
chr13
77581326
77582522
−
FBXL3
0x0

1671
chr13
77592190
77593366
−
FBXL3
0x0

1672
chr13
77730560
77731688
−
MYCBP2
0x2

1673
chr13
79176171
79177675
−
POU4F1
0x0

1674
chr13
79188083
79189266
−
RNF219
0x0

1675
chr13
79888041
79889331
−
RBM26
0x0

1676
chr13
79939705
79940928
−
RBM26
0x0

1677
chr13
80071204
80072474
+
NDFIP2
0x0

1678
chr13
92252899
92254129
+
GPC5
0x0

1679
chr13
95840472
95841650
−
ABCC4
0x0

1680
chr13
95868999
95870171
−
ABCC4
0x0

1681
chr13
96293455
96294610
−
DZIP1
0x0

1682
chr13
96855475
96856610
+
HS6ST3
0x0

1683
chr13
97601125
97602326
−
OXGR1
0x0

1684
chr13
98652227
98653437
+
IPO5
0x0

1685
chr13
99104245
99105441
−
STK24
0x0

1686
chr13
99205745
99206936
−
STK24
0x0

1687
chr13
99323732
99324883
+
FARP1
0x0

1688
chr13
99857416
99858783
+
UBAC2
0x0

1689
chr13
99866861
99868315
−
MIR548AN
0x0

1690
chr13
102651242
102652440
+
ITGBL1
0x0

1691
chr13
103278915
103280017
−
TPP2
0x0

1692
chr13
103355620
103356795
−
METTL21C
0x0

1693
chr13
107210710
107211839
−
ARGLU1
0x0

1694
chr13
108076427
108077608
−
FAM155A
0x0

1695
chr13
108161143
108162342
−
FAM155A
0x0

1696
chr13
108264790
108265967
−
FAM155A
0x0

1697
chr13
108299224
108300407
−
FAM155A
0x0

1698
chr13
109513961
109515157
−
LIG4
0x0

1699
chr13
110435906
110437076
−
IRS2
0x0

1700
chr13
110566925
110568267
+
COL4A2
0x2

1701
chr13
111348428
111349606
−
CARS2
0x0

1702
chr13
113598283
113599440
−
MCF2L-AS1
0x0

1703
chr13
113833527
113834684
−
PCID2
0x0

1704
chr13
113917507
113918650
+
CUL4A
0x1

1705
chr13
113931038
113932264
+
CUL4A
0x1

1706
chr13
114183681
114184915
+
TMCO3
0x0

1707
chr13
114294691
114295879
+
TFDP1
0x0

1708
chr14
20742356
20743528
−
TTC5
0x0

1709
chr14
20790801
20792085
−
CCNB1IP1
0x0

1710
chr14
20810712
20812122
−
RPPH1
0x0

1711
chr14
20882556
20883783
+
APEX1
0x0

1712
chr14
21081438
21082537
−
RNASE12
0x0

1713
chr14
21100650
21101887
+
ANG
0x0

1714
chr14
21120694
21121938
−
OR6S1
0x0

1715
chr14
21127573
21128700
−
OR6S1
0x0

1716
chr14
21130773
21132001
−
OR6S1
0x0

1717
chr14
21149336
21150513
+
ANG
0x0

1718
chr14
21150862
21152183
+
ANG
0x0

1719
chr14
21701758
21702922
−
HNRNPC
0x0

1720
chr14
21819168
21820374
−
SUPT16H
0x0

1721
chr14
21883441
21884661
−
CHD8
0x0

1722
chr14
21927022
21928341
−
RAB2B
0x0

1723
chr14
21970840
21972169
−
METTL3
0x2

1724
chr14
23398370
23399587
+
REM2
0x0

1725
chr14
23534766
23535940
−
ACIN1
0x2

1726
chr14
23539764
23541105
−
ACIN1
0x2

1727
chr14
23794361
23795539
+
BCL2L2-PABPN1
0x0

1728
chr14
23794361
23795539
+
PABPN1
0x0

1729
chr14
23947343
23948545
+
NGDN
0x0

1730
chr14
24736302
24737477
−
RABGGTA
0x0

1731
chr14
24783279
24784402
+
LTB4R
0x0

1732
chr14
24842532
24843745
+
NFATC4
0x0

1733
chr14
24910543
24911763
−
SDR39U1
0x0

1734
chr14
26150011
26151194
−
5TXBP6
0x0

1735
chr14
28733778
28735048
+
FOXG1
0x4

1736
chr14
30270786
30271961
−
PRKD1
0x2

1737
chr14
31070268
31071668
+
G2E3
0x0

1738
chr14
31481080
31482291
−
MIR624
0x0

1739
chr14
31585380
31586544
−
HECTD1
0x0

1740
chr14
31919046
31920232
−
C14orf126
0x0

1741
chr14
32589428
32590647
+
ARHGAP5
0x0

1742
chr14
32803437
32804634
+
AKAP6
0x2

1743
chr14
32853729
32854962
+
AKAP6
0x2

1744
chr14
34929007
34930135
−
SPTSSA
0x0

1745
chr14
35328000
35329104
+
BAZ1A
0x0

1746
chr14
35857231
35858622
−
NFKBIA
0x2

1747
chr14
36231437
36232687
−
RALGAPA1
0x0

1748
chr14
39455981
39457143
+
GEMIN2
0x0

1749
chr14
39617080
39618404
−
TRAPPC6B
0x0

1750
chr14
39650236
39651971
+
PNN
0x1

1751
chr14
39837183
39838385
+
CTAGE5
0x0

1752
chr14
44660534
44661689
−
FSCB
0x0

1753
chr14
45429705
45430918
−
KLHL28
0x0

1754
chr14
45513128
45514344
+
FAM179B
0x0

1755
chr14
45571192
45572327
+
PRPF39
0x0

1756
chr14
45669258
45670454
+
FANCM
0x2

1757
chr14
45860772
45861964
+
FANCM
0x2

1758
chr14
50052744
50054179
+
LRR1
0x0

1759
chr14
50072238
50073452
+
LRR1
0x0

1760
chr14
50252419
50253619
−
NEMF
0x0

1761
chr14
50283121
50284320
−
NEMF
0x0

1762
chr14
50319903
50321149
−
NEMF
0x0

1763
chr14
50328727
50329939
−
NEMF
0x0

1764
chr14
50534715
50536100
+
ARF6
0x0

1765
chr14
50867418
50868611
−
CDKL1
0x0

1766
chr14
51255767
51256946
−
NIN
0x2

1767
chr14
51464045
51465182
−
TRIM9
0x0

1768
chr14
51574132
51575351
+
TMX1
0x0

1769
chr14
51712422
51713625
+
TMX1
0x0

1770
chr14
51715602
51716791
+
TMX1
0x0

1771
chr14
51721809
51723001
+
TMX1
0x0

1772
chr14
53010501
53011643
−
TXNDC16
0x0

1773
chr14
53052610
53053853
+
GPR137C
0x0

1774
chr14
53084258
53085453
+
GPR137C
0x0

1775
chr14
53517339
53518466
−
DDHD1
0x0

1776
chr14
54893869
54895013
−
CNIH
0x0

1777
chr14
55119067
55120298
+
SAMD4A
0x0

1778
chr14
56166774
56167972
+
KTN1
0x2

1779
chr14
57746954
57748160
+
MUDENG
0x0

1780
chr14
58645963
58647181
+
ACTR10
0x0

1781
chr14
58706021
58707218
−
FLJ31306
0x0

1782
chr14
60582184
60583444
+
C14orf135
0x0

1783
chr14
60590498
60591850
+
C14orf135
0x0

1784
chr14
60715423
60716633
+
PPM1A
0x0

1785
chr14
60728399
60729605
+
PPM1A
0x0

1786
chr14
63589788
63590983
+
RHOJ
0x0

1787
chr14
64481686
64482836
+
SYNE2
0x0

1788
chr14
64595923
64597126
+
SYNE2
0x0

1789
chr14
64640181
64641308
+
SYNE2
0x0

1790
chr14
64749029
64750351
−
ESR2
0x1

1791
chr14
65590559
65591762
−
MAX
0x0

1792
chr14
68265192
68266392
+
RAD51B
0x2

1793
chr14
69259066
69260239
−
ZFP36L1
0x2

1794
chr14
70235277
70236409
+
SR5F5
0x0

1795
chr14
70827039
70828233
+
ADAM21
0x0

1796
chr14
71050827
71051971
−
MEDS
0x0

1797
chr14
73395835
73397193
−
DPF3
0x0

1798
chr14
73637050
73638259
+
PSEN1
0x0

1799
chr14
73658933
73660059
+
PSEN1
0x0

1800
chr14
73750395
73751600
−
NUMB
0x0

1801
chr14
75068529
75069738
−
LTBP2
0x2

1802
chr14
75358451
75359654
+
DLST
0x0

1803
chr14
75496694
75497909
−
MLH3
0x0

1804
chr14
75575913
75577091
−
NEK9
0x2

1805
chr14
75600401
75601539
−
TMED10
0x0

1806
chr14
76528971
76530189
+
IFT43
0x0

1807
chr14
76637656
76638879
+
C14orf118
0x0

1808
chr14
76663629
76664745
+
C14orf118
0x0

1809
chr14
77256334
77257559
−
ANGEL1
0x0

1810
chr14
78173934
78175091
+
SLIRP
0x0

1811
chr14
81668501
81669733
−
SNORA79
0x0

1812
chr14
85737717
85738922
+
FLRT2
0x0

1813
chr14
89043389
89044605
+
ZC3H14
0x0

1814
chr14
89078709
89079907
+
ZC3H14
0x0

1815
chr14
89299285
89300522
+
TTC8
0x0

1816
chr14
90051483
90052669
+
PRO1768
0x0

1817
chr14
90178358
90179578
+
PRO1768
0x0

1818
chr14
90564181
90565327
−
EFCAB11
0x0

1819
chr14
91816631
91817828
−
CCDC88C
0x0

1820
chr14
93406578
93408201
−
ITPK1
0x0

1821
chr14
95192789
95194001
+
SERPINA13
0x0

1822
chr14
95999181
96000528
−
SCARNA13
0x0

1823
chr14
95999181
96000528
−
SNHG10
0x0

1824
chr14
96428328
96429515
−
TCL1A
0x0

1825
chr14
96788184
96789377
−
ATG2B
0x0

1826
chr14
96850446
96851673
+
C14orf129
0x0

1827
chr14
97003083
97004318
+
PAPOLA
0x0

1828
chr14
97299331
97300523
+
VRK1
0x0

1829
chr14
97303953
97305166
+
VRK1
0x0

1830
chr14
97588455
97589675
+
VRK1
0x0

1831
chr14
99438779
99440087
−
BCL11B
0x2

1832
chr14
99871011
99872156
−
SETD3
0x0

1833
chr14
99927008
99928201
−
SETD3
0x0

1834
chr14
99978119
99979271
−
CCDC85C
0x0

1835
chr14
99980306
99981513
−
CCDC85C
0x0

1836
chr14
100704883
100706065
+
YY1
0x0

1837
chr14
102451533
102452778
+
DYNC1H1
0x0

1838
chr14
102485774
102486912
+
DYNC1H1
0x0

1839
chr14
102513570
102514767
+
DYNC1H1
0x0

1840
chr14
102515579
102516643
+
DYNC1H1
0x0

1841
chr14
102547003
102548556
−
HSP90AA1
0x2

1842
chr14
102551792
102552968
−
HSP90AA1
0x2

1843
chr14
102792163
102793304
+
ZNF839
0x0

1844
chr14
102797439
102798576
+
ZNF839
0x0

1845
chr14
102972147
102973298
−
ANKRD9
0x0

1846
chr14
103284894
103286072
+
TRAF3
0x2

1847
chr14
103375057
103376164
+
TRAF3
0x2

1848
chr14
103601516
103602707
+
TNFAIP2
0x0

1849
chr14
103803650
103804881
+
EIF5
0x0

1850
chr14
103803650
103804881
+
SNORA28
0x0

1851
chr14
103985494
103987405
−
CKB
0x0

1852
chr14
104131617
104132836
−
KLC1
0x0

1853
chr14
104378332
104379524
−
C14orf2
0x0

1854
chr14
104479474
104480652
+
TDRD9
0x0

1855
chr14
105235359
105236649
−
AKT1
0x2

1856
chr14
105715971
105717135
−
BRF1
0x1

1857
chr14
105716708
105717810
+
BTBD6
0x0

1858
chr14
105752951
105754079
−
BRF1
0x1

1859
chr14
105849686
105850785
+
PACS2
0x0

1860
chr14
105926114
105927310
+
MTA1
0x2

1861
chr14
105934900
105936046
+
MTA1
0x2

1862
chr15
21936754
21937923
−
LOC646214
0x0

1863
chr15
24925724
24926901
+
C15orf2
0x2

1864
chr15
25683452
25684651
−
UBE3A
0x4

1865
chr15
25781530
25782728
+
SNORD109A
0x4

1866
chr15
25781530
25782728
+
SNORD109B
0x4

1867
chr15
28491389
28492502
−
HERC2
0x2

1868
chr15
28505439
28506582
−
HERC2
0x2

1869
chr15
29335946
29337183
+
APBA2
0x0

1870
chr15
29345646
29346846
+
APBA2
0x0

1871
chr15
31745052
31746201
−
OTUD7A
0x0

1872
chr15
34251063
34252240
−
AVEN
0x0

1873
chr15
34633527
34634962
−
NOP10
0x0

1874
chr15
34781617
34782779
−
GOLGA8B
0x0

1875
chr15
37014652
37015883
+
C15orf41
0x0

1876
chr15
37255197
37256324
−
MEIS2
0x0

1877
chr15
40833292
40834457
−
MRPL42P5
0x0

1878
chr15
41036799
41038022
−
FAM82A2
0x0

1879
chr15
41270810
41271987
−
INO80
0x0

1880
chr15
41315423
41316571
−
INO80
0x0

1881
chr15
41683649
41684911
−
NDUFAF1
0x0

1882
chr15
41987838
41989218
+
MGA
0x2

1883
chr15
42002771
42004041
+
MGA
0x2

1884
chr15
42620396
42621594
−
GANC
0x0

1885
chr15
42706180
42707487
−
ZFP106
0x0

1886
chr15
42962748
42963944
+
STARD9
0x0

1887
chr15
43283722
43284928
−
UBR1
0x2

1888
chr15
44038200
44039385
+
PDIA3
0x0

1889
chr15
44093201
44094397
+
C15orf63
0x0

1890
chr15
44093201
44094397
+
SERF2-C15ORF63
0x0

1891
chr15
44243568
44244787
−
FRMD5
0x0

1892
chr15
44707143
44708328
+
CASC4
0x0

1893
chr15
44853224
44854435
+
EIF3J
0x0

1894
chr15
44855288
44856463
+
EIF3J
0x0

1895
chr15
45039370
45040570
+
TRIM69
0x0

1896
chr15
45490204
45491403
−
SHF
0x0

1897
chr15
45492010
45493176
−
SHF
0x0

1898
chr15
45492781
45493978
+
DUOX1
0x0

1899
chr15
47619874
47621023
+
SEMA6D
0x0

1900
chr15
47699587
47700788
+
SEMA6D
0x0

1901
chr15
48729413
48730591
−
FBN1
0x0

1902
chr15
49170975
49172607
+
EID1
0x2

1903
chr15
51223596
51224840
+
AP4E1
0x0

1904
chr15
52841907
52843027
−
ARPP13
0x0

1905
chr15
55874281
55875380
−
PYGO1
0x0

1906
chr15
59040732
59041932
−
ADAM10
0x2

1907
chr15
59431774
59432875
+
CCNB2
0x0

1908
chr15
59968844
59970052
−
BNIP2
0x0

1909
chr15
60576764
60577938
+
FOXB1
0x0

1910
chr15
61501060
61510500
+
RORA
0x0

1911
chr15
64791589
64792900
+
ZNF609
0x0

1912
chr15
64856192
64857385
+
ZNF609
0x0

1913
chr15
65587813
65589092
+
KBTBD13
0x0

1914
chr15
65596449
65597712
+
KBTBD13
0x0

1915
chr15
66433059
66434274
−
MEGF11
0x0

1916
chr15
66496826
66498012
−
MEGF11
0x0

1917
chr15
66637503
66638647
−
SCARNA14
0x0

1918
chr15
66639053
66640252
−
SCARNA14
0x0

1919
chr15
66792791
66794211
−
RPL4
0x0

1920
chr15
66792791
66794211
−
SNORD18C
0x0

1921
chr15
66794418
66796231
−
RPL4
0x0

1922
chr15
66794418
66796231
−
SNORD16
0x0

1923
chr15
66794418
66796231
−
SNORD18A
0x0

1924
chr15
66794418
66796231
−
SNORD18B
0x0

1925
chr15
67511428
67512557
−
AAGAB
0x0

1926
chr15
68496759
68497953
−
CALML4
0x0

1927
chr15
68499340
68500439
−
CLN6
0x0

1928
chr15
68572922
68574070
+
FEM1B
0x0

1929
chr15
69070758
69072796
−
ANP32A
0x1

1930
chr15
69079609
69080756
−
ANP32A
0x1

1931
chr15
69100468
69101612
−
ANP32A-IT1
0x0

1932
chr15
69494074
69495240
+
MIR548H4
0x0

1933
chr15
69738521
69739744
+
KIF23
0x0

1934
chr15
69747224
69748423
+
RPLP1
0x0

1935
chr15
70389486
70390685
−
TLE3
0x0

1936
chr15
70481875
70483051
+
C15orf50
0x0

1937
chr15
71456865
71458080
−
CT62
0x0

1938
chr15
72337357
72338555
+
SENP8
0x0

1939
chr15
72486311
72487490
−
GRAMD2
0x0

1940
chr15
72490926
72492479
−
PKM2
0x0

1941
chr15
72546097
72547249
−
PARP6
0x0

1942
chr15
72766136
72767238
+
ARIH1
0x0

1943
chr15
73043229
73044383
−
ADPGK
0x0

1944
chr15
73408453
73409650
+
NEO1
0x1

1945
chr15
74851876
74853097
+
ARID3B
0x1

1946
chr15
75132127
75133316
−
ULK3
0x0

1947
chr15
75628401
75629629
+
COMMD4
0x0

1948
chr15
76584313
76585531
−
ETFA
0x0

1949
chr15
77224273
77225393
+
RCN2
0x1

1950
chr15
77337848
77339156
−
TSPAN3
0x0

1951
chr15
77362838
77363961
−
TSPAN3
0x0

1952
chr15
77969913
77971109
−
LINGO1
0x0

1953
chr15
78833666
78834832
+
PSMA4
0x0

1954
chr15
78881867
78883066
+
CHRNA5
0x0

1955
chr15
78884931
78886120
+
CHRNA5
0x0

1956
chr15
79152336
79153574
+
MORF4L1
0x0

1957
chr15
80993689
80994882
+
FAM108C1
0x0

1958
chr15
81270066
81271359
−
MESDC2
0x0

1959
chr15
81557467
81558641
−
STARD5
0x0

1960
chr15
82466075
82467253
−
EFTUD1
0x0

1961
chr15
83684818
83686067
−
BTBD1
0x0

1962
chr15
83857545
83858740
−
HDGFRP3
0x0

1963
chr15
84515575
84516733
−
LOC388152
0x0

1964
chr15
84819674
84820905
+
LOC100505679
0x0

1965
chr15
85234210
85235385
−
SEC11A
0x0

1966
chr15
85337100
85338312
+
ZNF592
0x0

1967
chr15
85628321
85629513
+
PDE8A
0x0

1968
chr15
86111157
86112347
+
AKAP13
0x2

1969
chr15
86260146
86261296
+
AKAP13
0x2

1970
chr15
88654304
88655504
+
LOC283738
0x0

1971
chr15
89743411
89744512
+
ABHD2
0x0

1972
chr15
89825525
89826904
+
FANCI
0x0

1973
chr15
89859503
89860736
+
FANCI
0x0

1974
chr15
89877748
89878974
+
FANCI
0x0

1975
chr15
90146668
90147889
+
C15orf42
0x0

1976
chr15
90610429
90611599
+
ZNF710
0x0

1977
chr15
90814312
90815850
+
NGRN
0x0

1978
chr15
90907212
90908788
+
ZNF774
0x0

1979
chr15
91185812
91187013
+
CRTC3
0x2

1980
chr15
91425207
91426364
+
FURIN
0x0

1981
chr15
91432876
91434053
−
HDDC3
0x0

1982
chr15
91478248
91479432
+
UNC45A
0x0

1983
chr15
91516850
91517974
−
PRC1
0x2

1984
chr15
93255471
93256642
+
ASB9P1
0x0

1985
chr15
93586832
93588055
−
RGMA
0x0

1986
chr15
96288506
96289758
+
LOC145820
0x0

1987
chr15
100648661
100649816
−
ADAMTS17
0x0

1988
chr15
100765299
100766413
−
ADAMTS17
0x0

1989
chr15
100870564
100871790
−
ADAMTS17
0x0

1990
chr15
101480773
101482171
+
LRRK1
0x2

1991
chr15
101825007
101826228
−
SNRPA1
0x0

1992
chr15
102181636
102182846
−
TM2D3
0x0

1993
chr16
143816
144957
+
MPG
0x0

1994
chr16
235472
236640
−
LUC7L
0x0

1995
chr16
342848
344050
−
AXIN1
0x1

1996
chr16
396145
397340
−
AXIN1
0x1

1997
chr16
448859
451026
+
NME4
0x0

1998
chr16
589506
590634
+
MIR3176
0x0

1999
chr16
595185
596399
+
SOLH
0x0

2000
chr16
601507
602707
+
SOLH
0x0

2001
chr16
683792
685117
−
C16orf13
0x0

2002
chr16
723557
724706
+
RHOT2
0x0

2003
chr16
733573
734707
−
JMJD8
0x0

2004
chr16
733573
734707
−
WDR24
0x0

2005
chr16
783112
784246
−
NARFL
0x0

2006
chr16
787182
788296
−
NARFL
0x0

2007
chr16
841316
842543
+
CHTF18
0x0

2008
chr16
941830
943035
−
LMF1
0x0

2009
chr16
1419680
1420859
−
UNKL
0x0

2010
chr16
1509920
1511053
−
CLCN7
0x0

2011
chr16
1793752
1795078
+
MAPK8IP3
0x2

2012
chr16
2011358
2012506
+
NDUFB10
0x0

2013
chr16
2012334
2013692
−
RPS2
0x0

2014
chr16
2012334
2013692
−
SNORA10
0x0

2015
chr16
2012334
2013692
−
SNORA64
0x0

2016
chr16
2127155
2128344
+
TSC2
0x1

2017
chr16
2129738
2130819
+
TSC2
0x1

2018
chr16
2204448
2205682
−
SNORD60
0x0

2019
chr16
2262814
2263925
−
PGP
0x0

2020
chr16
2302820
2304024
−
RNPS1
0x0

2021
chr16
2325778
2326930
−
ABCA3
0x0

2022
chr16
2507661
2508867
+
CCNF
0x0

2023
chr16
2551481
2552720
+
TBC1D24
0x0

2024
chr16
2669190
2670380
−
ERVK13-1
0x0

202S
chr16
2816749
2818757
+
SRRM2
0x0

2026
chr16
3103594
3104769
−
CCDC64B
0x0

2027
chr16
3135604
3136834
+
IL32
0x0

2028
chr16
3183893
3185039
−
MGC3771
0x0

2029
chr16
3206822
3207998
−
MGC3771
0x0

2030
chr16
3707612
3708771
−
TRAP1
0x0

2031
chr16
3738655
3739754
−
TRAP1
0x0

2032
chr16
3776638
3777807
−
CREBBP
0x1

2033
chr16
3853492
3854682
−
CREBBP
0x1

2034
chr16
3899742
3901495
−
CREBBP
0x1

2035
chr16
4312072
4313247
−
TFAP4
0x0

2036
chr16
4585148
4586317
−
C16orf5
0x0

2037
chr16
4631453
4632577
−
FAM100A
0x0

2038
chr16
4780498
4781691
−
ANKS3
0x0

2039
chr16
4809968
4811154
−
ZNF500
0x0

2040
chr16
4930725
4931953
+
UBN1
0x0

2041
chr16
9202390
9203489
+
C16orf72
0x0

2042
chr16
9732686
9733886
+
MIR548X
0x0

2043
chr16
10623788
10625100
−
EMP2
0x0

2044
chr16
11118150
11119355
+
CLEC16A
0x0

2045
chr16
11795285
11796473
−
TXNDC11
0x0

2046
chr16
11982629
11983709
−
GSPT1
0x0

2047
chr16
11989914
11991031
−
GSPT1
0x0

2048
chr16
14247481
14248682
+
MKL2
0x0

2049
chr16
15154201
15155400
−
RRN3
0x0

2050
chr16
15224518
15225828
−
MIR3180-4
0x0

2051
chr16
15959530
15960686
−
FOPNL
0x0

2052
chr16
16103077
16104257
+
ABCC1
0x0

2053
chr16
16180120
16181312
+
ABCC1
0x0

2054
chr16
16231673
16232855
+
ABCC1
0x0

2055
chr16
18367186
18368355
+
ABCC6P1
0x0

2056
chr16
18795494
18796703
−
RPS15A
0x0

2057
chr16
21964106
21965352
−
UQCRC2
0x2

2058
chr16
22206429
22207666
−
CDR2
0x0

2059
chr16
22236504
22237625
−
EEF2K
0x0

2060
chr16
23154325
23155505
−
USP31
0x0

2061
chr16
23443115
23444292
+
SCNN1B
0x0

2062
chr16
23455520
23456673
−
COG7
0x0

2063
chr16
23518784
23519913
−
GGA2
0x0

2064
chr16
26772167
26773347
−
NSMCE1
0x0

2065
chr16
28109306
28110513
−
XPO6
0x0

2066
chr16
28165013
28166113
−
XPO6
0x0

2067
chr16
28172868
28174090
+
SBK1
0x0

2068
chr16
28178211
28179388
−
XPO6
0x0

2069
chr16
28222170
28223312
−
XPO6
0x0

2070
chr16
28488127
28489342
−
CLN3
0x0

2071
chr16
28502619
28503773
−
CLN3
0x0

2072
chr16
28735596
28736768
+
EIF3C
0x0

2073
chr16
28735596
28736768
+
EIF3CL
0x0

2074
chr16
29620126
29621279
−
SLC7A5P1
0x0

2075
chr16
29818410
29819625
+
MAZ
0x0

2076
chr16
29821157
29822740
+
MAZ
0x0

2077
chr16
29830643
29831878
+
C16orf53
0x0

2078
chr16
29830643
29831878
+
MVP
0x0

2079
chr16
30076596
30077792
+
ALDOA
0x0

2080
chr16
30078033
30079171
+
ALDOA
0x0

2081
chr16
30079608
30080725
+
ALDOA
0x0

2082
chr16
30345960
30347162
−
LOC595101
0x0

2083
chr16
30367895
30369061
−
TBC1D10B
0x0

2084
chr16
30369950
30371830
−
TBC1D10B
0x0

2085
chr16
30482481
30483615
+
ITGAL
0x0

2086
chr16
30662533
30663730
+
PRR14
0x0

2087
chr16
30680929
30682096
+
FBRS
0x0

2088
chr16
30721321
30722534
+
SNORA30
0x0

2089
chr16
30721321
30722534
+
SRCAP
0x0

2090
chr16
30734492
30735698
+
SRCAP
0x0

2091
chr16
30749886
30751115
+
SRCAP
0x0

2092
chr16
30762261
30763449
+
PHKG2
0x0

2093
chr16
30785855
30786949
+
RNF40
0x0

2094
chr16
30898461
30899560
−
BCL7C
0x0

2095
chr16
30995147
30996395
+
SETD1A
0x0

2096
chr16
31055455
31056660
+
STX4
0x0

2097
chr16
31101627
31103190
−
VKORC1
0x0

2098
chr16
33959014
33960199
−
LINC00273
0x0

2099
chr16
33963060
33964589
+
LOC283914
0x0

2100
chr16
46946475
46947651
+
GPT2
0x0

2101
chr16
46949560
46950994
+
GPT2
0x0

2102
chr16
47161753
47162900
−
NETO2
0x0

2103
chr16
47176155
47177315
−
NETO2
0x0

2104
chr16
47502596
47503917
+
PHKB
0x0

2105
chr16
47530809
47531908
+
PHKB
0x0

2106
chr16
48277848
48278972
+
LONP2
0x0

2107
chr16
48387030
48388180
+
LONP2
0x0

2108
chr16
49557027
49558211
−
ZNF423
0x0

2109
chr16
49604532
49605679
−
ZNF423
0x0

2110
chr16
50138880
50140042
+
HEATR3
0x0

2111
chr16
53468212
53469426
+
RBL2
0x1

2112
chr16
54018126
54019355
+
FTO
0x0

2113
chr16
57333351
57334551
+
ARL2BP
0x0

2114
chr16
57333796
57335000
−
PLLP
0x0

2115
chr16
57770451
57771687
+
KATNB1
0x0

2116
chr16
58194850
58196051
−
CSNK2A2
0x0

2117
chr16
58506204
58507370
+
NDRG4
0x1

2118
chr16
58581850
58583095
−
SNORA46
0x0

2119
chr16
58593207
58594416
−
CNOT1
0x2

2120
chr16
58593207
58594416
−
SNORA50
0x0

2121
chr16
58636236
58637361
−
CNOT1
0x2

2122
chr16
59573507
59574718
+
SETD6
0x0

2123
chr16
61776537
61777739
−
CDH8
0x0

2124
chr16
66583830
66585064
+
CKLF
0x0

2125
chr16
66583830
66585064
+
CKLF-CMTM1
0x0

2126
chr16
66651623
66652756
−
CMTM4
0x0

2127
chr16
66857453
66858552
−
NAE1
0x0

2128
chr16
67355018
67356243
−
KCTD19
0x0

2129
chr16
67644395
67645577
−
ACD
0x4

2130
chr16
67644742
67646514
+
CTCF
0x1

2131
chr16
67670055
67671257
+
CTCF
0x1

2132
chr16
68155794
68157476
+
NFATC3
0x0

2133
chr16
68537173
68538388
+
ZFP90
0x0

2134
chr16
69362090
69363244
−
COG8
0x0

2135
chr16
69362090
69363244
−
PDF
0x0

2136
chr16
69375976
69377216
+
NIP7
0x0

2137
chr16
69641676
69642775
+
NFAT5
0x0

2138
chr16
70282376
70283535
−
EXOSC6
0x0

2139
chr16
70380666
70382034
+
DDX19A
0x0

2140
chr16
70412278
70413437
−
ST3GAL2
0x0

2141
chr16
70567748
70568934
+
SF3B3
0x0

2142
chr16
70598735
70599882
+
SF3B3
0x0

2143
chr16
70600812
70601947
+
SF3B3
0x0

2144
chr16
70724351
70725450
−
VAC14
0x0

2145
chr16
72238271
72239450
−
PMFBP1
0x0

2146
chr16
72984070
72985255
−
ZFHX3
0x1

2147
chr16
72990914
72992079
−
ZFHX3
0x1

2148
chr16
72992940
72994069
−
ZFHX3
0x1

2149
chr16
73047809
73049165
−
ZFHX3
0x1

2150
chr16
74714271
74715389
−
MLKL
0x0

2151
chr16
75289855
75291011
−
BCAR1
0x0

2152
chr16
79630494
79631584
−
MAF
0x1

2153
chr16
81030333
81031467
−
CMC2
0x0

2154
chr16
81744479
81745663
+
CMIP
0x0

2155
chr16
81995033
81996350
+
PLCG2
0x2

2156
chr16
82195015
82196190
−
MPHOSPH6
0x0

2157
chr16
84216501
84217600
−
TAF1C
0x0

2158
chr16
84734892
84736093
+
USP10
0x0

2159
chr16
84778008
84779365
+
USP10
0x0

2160
chr16
85244625
85245831
+
LOC400548
0x0

2161
chr16
85394186
85395412
+
LINC00311
0x0

2162
chr16
85443986
85445195
+
LINC00311
0x0

2163
chr16
85660061
85661260
+
KIAA0182
0x0

2164
chr16
85808485
85809616
−
COX4NB
0x0

2165
chr16
87364296
87365490
−
FBXO31
0x1

2166
chr16
87398201
87399306
−
FBXO31
0x1

2167
chr16
87469465
87470642
−
ZCCHC14
0x0

2168
chr16
87737922
87739118
−
KLHDC4
0x0

2169
chr16
88060540
88061765
+
BANP
0x1

2170
chr16
88083221
88084320
+
BANP
0x1

2171
chr16
88817646
88818825
−
PIEZO1
0x0

2172
chr16
88872808
88873963
+
CDT1
0x0

2173
chr16
89164503
89165709
+
ACSF3
0x0

2174
chr16
89371092
89372297
−
ANKRD11
0x0

2175
chr16
89497144
89498290
−
ANKRD11
0x0

2176
chr16
89543379
89550500
−
ANKRD11
0x0

2177
chr16
89595342
89596458
+
SPG7
0x0

2178
chr16
89627259
89628503
+
RPL13
0x0

2179
chr16
89627259
89628503
+
SNORD68
0x0

2180
chr16
89629746
89630946
+
RPL13
0x0

2181
chr16
89720957
89722136
+
C16orf55
0x0

2182
chr16
89759982
89761224
+
CDK10
0x0

2183
chr16
89762227
89763431
−
SPATA2L
0x0

2184
chr16
89783657
89784775
+
LOC100128881
0x0

2185
chr16
89803908
89805002
+
ZNF276
0x0

2186
chr16
89804541
89805669
−
FANCA
0x2

2187
chr16
89830638
89831758
−
FANCA
0x2

2188
chr16
89835725
89837364
−
FANCA
0x2

2189
chr16
89851003
89852132
−
FANCA
0x2

2190
chr16
89960891
89962086
+
TCF25
0x0

2191
chr16
89966465
89967671
+
TCF25
0x0

2192
chr16
89975246
89976652
−
TCF25
0x0

2193
chr16
90019017
90020436
+
DEF8
0x0

2194
chr16
90027401
90028606
+
DEF8
0x0

2195
chr16
90071461
90072626
−
DBNDD1
0x0

2196
chr16
90094687
90095934
+
GAS8
0x0

2197
chr17
420039
421215
−
VPS53
0x1

2198
chr17
421588
422752
−
VPS53
0x1

2199
chr17
809734
810881
−
NXN
0x0

2200
chr17
877224
878419
+
TIMM22
0x0

2201
chr17
906054
907251
+
TIMM22
0x0

2202
chr17
907914
909091
−
ABR
0x0

2203
chr17
975303
976505
−
ABR
0x0

2204
chr17
1247548
1249295
−
YWHAE
0x2

2205
chr17
1302901
1304079
−
YWHAE
0x2

2206
chr17
1367797
1369135
−
MYO1C
0x0

2207
chr17
1870297
1871457
−
RTN4RL1
0x0

2208
chr17
2091648
2092874
+
SRR
0x0

2209
chr17
2202637
2203736
−
SMG6
0x0

2210
chr17
2231890
2233069
−
SNORD91B
0x0

2211
chr17
2231890
2233069
−
TSR1
0x0

2212
chr17
2289272
2290479
−
MNT
0x0

2213
chr17
2758169
2759392
+
RAP1GAP2
0x0

2214
chr17
3727428
3728604
−
C17orf85
0x0

2215
chr17
3774868
3776203
−
CAMKK1
0x0

2216
chr17
3989255
3990394
−
ZZEF1
0x2

2217
chr17
4848985
4850149
−
PFN1
0x1

2218
chr17
4927219
4928332
+
KIF1C
0x2

2219
chr17
5011951
5013308
−
ZNF232
0x0

2220
chr17
5192114
5193285
+
RABEP1
0x2

2221
chr17
5347087
5348274
−
DHX33
0x0

2222
chr17
7128624
7130033
−
DVL2
0x0

2223
chr17
7143329
7144561
−
GABARAP
0x1

2224
chr17
7214768
7215867
+
EIF5A
0x2

2225
chr17
7310728
7311838
+
NLGN2
0x0

2226
chr17
7477573
7478698
+
EIF4A1
0x0

2227
chr17
7477573
7478598
+
SENP3-EIF4A1
0x0

2228
chr17
7477573
7478698
+
SNORA48
0x0

2229
chr17
7479570
7481901
+
EIF4A1
0x0

2230
chr17
7479570
7481901
+
SENP3-EIF4A1
0x0

2231
chr17
7479570
7481901
+
SNORA67
0x0

2232
chr17
7479570
7481901
+
SNORD10
0x0

2233
chr17
7571798
7572976
−
TP53
0x1

2234
chr17
7759946
7761139
−
LSMD1
0x0

2235
chr17
7809090
7810209
+
CHD3
0x2

2236
chr17
7809090
7810209
+
SCARNA21
0x0

2237
chr17
7848570
7849762
+
CNTROB
0x0

2238
chr17
8023063
8024273
−
HES7
0x0

2239
chr17
8023683
8024894
+
MIR4314
0x0

2240
chr17
8076195
8077469
−
TMEM107
0x0

2241
chr17
8089692
8090869
+
MIR3676
0x0

2242
chr17
8089692
8090869
+
MIR4521
0x0

2243
chr17
8377996
8379137
−
MYH10
0x0

2244
chr17
14608210
14609470
−
CDRT15
0x0

2245
chr17
15918092
15919219
+
TTC19
0x0

2246
chr17
16132196
16133391
+
PIGL
0x0

2247
chr17
16343991
16345208
+
C17orf76-AS1
0x0

2248
chr17
16343991
16345208
+
SNORD65
0x0

2249
chr17
17089072
17090238
+
MPRIP
0x0

2250
chr17
17286493
17287902
−
C0PS3
0x2

2251
chr17
17634942
17636091
+
RAI1
0x0

2252
chr17
17999746
18000896
+
DRG2
0x0

2253
chr17
18111909
18113101
+
ALKBH5
0x0

2254
chr17
18177405
18178544
−
TOP3A
0x0

2255
chr17
18562696
18563882
+
ZNF286B
0x0

2256
chr17
18964696
18965964
+
SLC5A10
0x0

2257
chr17
19015303
19016503
−
GRAP
0x0

2258
chr17
19090777
19092061
+
GRAPL
0x0

2259
chr17
19092840
19094050
−
GRAP
0x0

2260
chr17
19349188
19350394
−
MFAP4
0x0

2261
chr17
19355037
19356234
+
RNF112
0x0

2262
chr17
19568464
19569565
+
ALDH3A2
0x0

2263
chr17
20903023
20904171
−
USP22
0x0

2264
chr17
26368250
26369432
+
NLK
0x0

2265
chr17
26794566
26795779
+
SLC13A2
0x0

2266
chr17
26918992
26920362
−
SPAG5
0x0

2267
chr17
26959602
26960700
−
KIAA0100
0x0

2268
chr17
27047016
27048207
+
RPL23A
0x0

2269
chr17
27047016
27048207
+
SNORD42B
0x0

2270
chr17
27049068
27051266
+
RPL23A
0x0

2271
chr17
27049068
27051266
+
SNORD42A
0x0

2272
chr17
27049068
27051266
+
SNORD4A
0x0

2273
chr17
27049068
27051266
+
SNORD4B
0x0

2274
chr17
27076052
27077263
+
TRAF4
0x0

2275
chr17
27134427
27135693
−
C17orf63
0x0

2276
chr17
27206815
27207989
−
FLOT2
0x0

2277
chr17
27250434
27251617
−
PHF12
0x0

2278
chr17
27330860
27332058
−
SEZ6
0x0

2279
chr17
27586017
27587151
−
NUFIP2
0x0

2280
chr17
27589485
27590890
−
NUFIP2
0x0

2281
chr17
27597552
27598763
−
NUFIP2
0x0

2282
chr17
27613073
27614247
−
NUFIP2
0x0

2283
chr17
27620125
27621304
−
NUFIP2
0x0

2284
chr17
27876749
27877967
+
TAOK1
0x0

2285
chr17
28793244
28794488
+
CPD
0x2

2286
chr17
29151064
29152280
−
CRLF3
0x0

2287
chr17
29876577
29877796
+
MIR193A
0x0

2288
chr17
30178363
30179685
−
C17orf79
0x0

2289
chr17
30322093
30323192
+
SUZ12
0x2

2290
chr17
30323258
30324460
+
SUZ12
0x2

2291
chr17
30327053
30328256
+
SUZ12
0x2

2292
chr17
30701748
30703107
+
ZNF207
0x0

2293
chr17
30729721
30730945
+
ZNF207
0x0

2294
chr17
31149233
31150434
+
TMEM98
0x0

2295
chr17
33338521
33339709
−
RAD51L3-RFFL
0x0

2296
chr17
33338521
33339709
−
RFFL
0x0

2297
chr17
33477601
33478846
−
NLE1
0x0

2298
chr17
34005816
34007062
+
AP281
0x0

2299
chr17
34051812
34052960
+
AP281
0x0

2300
chr17
34216112
34217346
+
TAF15
0x0

2301
chr17
34867890
34869254
−
MYO19
0x0

2302
chr17
35463729
35464880
−
ACACA
0x0

2303
chr17
35609261
35610459
−
ACACA
0x0

2304
chr17
36907500
36908659
−
PCGF2
0x1

2305
chr17
36923201
36924315
−
PIP4K2B
0x0

2306
chr17
36933509
36934767
−
PIP4K2B
0x0

2307
chr17
37008384
37009879
−
RPL23
0x0

2308
chr17
37008384
37009879
−
SNORA21
0x0

2309
chr17
37310065
37311369
−
ARL5C
0x0

2310
chr17
37360307
37361530
+
RPL19
0x0

2311
chr17
38187243
38188407
−
MED24
0x0

2312
chr17
38292372
38293524
+
MSL1
0x0

2313
chr17
38544516
38546023
−
TOP2A
0x0

2314
chr17
38546963
38548087
−
TOP2A
0x0

2315
chr17
38555669
38556813
−
TOP2A
0x0

2316
chr17
39623661
39624919
+
LOC100505782
0x0

2317
chr17
39682054
39683217
−
KRT19
0x0

2318
chr17
39919253
39920390
−
JUP
0x1

2319
chr17
39976137
39977291
+
FKBP10
0x0

2320
chr17
40022691
40023931
−
ACLY
0x0

2321
chr17
40041357
40042582
−
ACLY
0x0

2322
chr17
40051029
40052128
−
ACLY
0x0

2323
chr17
40066060
40067304
−
ACLY
0x0

2324
chr17
40150541
40151724
−
DNAJC7
0x0

2325
chr17
40276463
40277602
−
RAB5C
0x0

2326
chr17
40997873
40999063
+
AOC2
0x0

2327
chr17
41166535
41167621
−
VAT1
0x0

2328
chr17
41464126
41465330
−
LOC100130581
0x0

2329
chr17
41477626
41478857
+
ARL4D
0x0

2330
chr17
41893195
41894405
−
MPP3
0x1

2331
chr17
42124839
42126012
−
LSM12
0x0

2332
chr17
42143070
42144243
−
LSM12
0x0

2333
chr17
42269530
42270800
−
ATXN7L3
0x0

2334
chr17
42283758
42284942
−
UBTF
0x0

2335
chr17
42291123
42292222
−
UBTF
0x0

2336
chr17
42429663
42430895
−
GRN
0x0

2337
chr17
42472130
42475225
−
GPATCH8
0x0

2338
chr17
42563669
42564836
−
GPATCH8
0x0

2339
chr17
42858464
42859563
−
ADAM11
0x0

2340
chr17
42927693
42928792
−
EFTUD2
0x0

2341
chr17
43011561
43012778
−
KIF18B
0x0

2342
chr17
43112655
43113866
−
DCAKD
0x0

2343
chr17
43127402
43129550
−
DCAKD
0x0

2344
chr17
43158651
43159849
+
NMT1
0x0

2345
chr17
43188503
43189680
−
PLCD3
0x0

2346
chr17
43552039
43553599
−
MIR4315-1
0x0

2347
chr17
43552039
43553599
−
MIR4315-2
0x0

2348
chr17
43552039
43553599
−
PLEKHM1
0x0

2349
chr17
44107289
44109182
−
KANSL1
0x0

2350
chr17
44121458
44122619
−
KANSL1
0x0

2351
chr17
44143350
44144558
−
KANSL1
0x0

2352
chr17
44235813
44236965
−
KANSL1
0x0

2353
chr17
44248825
44250127
−
KANSL1
0x0

2354
chr17
44892011
44893187
+
WNT9B
0x0

2355
chr17
45700639
45701871
+
NPEPPS
0x0

2356
chr17
45740976
45743040
+
KPNB1
0x0

2357
chr17
45749870
45751463
+
KPNB1
0x0

2358
chr17
45759557
45760750
+
KPNB1
0x0

2359
chr17
46048089
46049200
+
CDK5RAP3
0x0

2360
chr17
46146996
46148371
−
CBX1
0x0

2361
chr17
46555948
46557104
+
HOXB-AS3
0x0

2362
chr17
46672630
46673780
−
HOXB6
0x0

2363
chr17
46674823
46676013
−
HOXB6
0x0

2364
chr17
46689629
46690750
−
HOXB8
0x0

2365
chr17
46698671
46699886
−
HOXB9
0x0

2366
chr17
47026177
47027373
−
SNF8
0x0

2367
chr17
47102139
47103238
+
IGF2BP1
0x0

2368
chr17
47103331
47104443
+
IGF2BP1
0x0

2369
chr17
47128290
47131034
+
IGF2BP1
0x0

2370
chr17
47269322
47270552
+
ABI3
0x2

2371
chr17
47370381
47371514
−
ZNF652
0x0

2372
chr17
47438823
47439984
−
ZNF652
0x0

2373
chr17
47698699
47699875
−
SPOP
0x2

2374
chr17
48211639
48212824
−
PPP1R9B
0x0

2375
chr17
48458394
48459935
−
LRRC59
0x0

2376
chr17
49238557
49239765
+
NME1
0x1

2377
chr17
49238557
49239765
+
NME1-NME2
0x0

2378
chr17
49243309
49244511
+
NME1-NME2
0x0

2379
chr17
49243309
49244511
+
NME2
0x0

2380
chr17
50173256
50174452
+
UTP18
0x0

2381
chr17
54908462
54909643
−
C17orf67
0x0

2382
chr17
54965631
54966927
−
TRIM25
0x0

2383
chr17
55536824
55538020
+
MSI2
0x0

2384
chr17
55756729
55757945
+
MSI2
0x0

2385
chr17
55760969
55762149
+
MSI2
0x0

2386
chr17
55866332
55867485
+
MSI2
0x0

2387
chr17
56078023
56079230
−
SRSF1
0x2

2388
chr17
56081814
56083329
−
SRSF1
0x2

2389
chr17
56083848
56084941
−
SRSF1
0x2

2390
chr17
56566533
56567635
−
MTMR4
0x0

2391
chr17
56902493
56903592
+
PPM1E
0x2

2392
chr17
57188247
57189567
−
SKA2
0x0

2393
chr17
57317303
57318598
+
GDPD1
0x0

2394
chr17
57474126
57475693
+
YPEL2
0x0

2395
chr17
57684974
57686173
+
DHX40
0x0

2396
chr17
57771333
57772704
+
CLTC
0x2

2397
chr17
57808269
57809459
+
VMP1
0x0

2398
chr17
57957769
57958998
−
TUBD1
0x0

2399
chr17
58010067
58011229
+
RPS6KB1
0x2

2400
chr17
58308321
58309557
−
SCARNA20
0x0

2401
chr17
58448595
58449725
−
USP32
0x0

2402
chr17
58710732
58711871
+
PPM1D
0x2

2403
chr17
59275968
59277116
+
BCAS3
0x0

2404
chr17
59316760
59318001
+
BCAS3
0x0

2405
chr17
59432076
59433255
−
NACA2
0x0

2406
chr17
59821357
59822521
−
BRIP1
0x2

2407
chr17
60023113
60024212
−
MED13
0x0

2408
chr17
60086819
60087918
−
MED13
0x0

2409
chr17
60100732
60101884
−
MED13
0x0

2410
chr17
60458542
60459757
+
EFCAB3
0x0

2411
chr17
60480366
60481496
−
TBC1D3P2
0x0

2412
chr17
60555248
60556357
−
TBC1D3P2
0x0

2413
chr17
60610210
60611437
+
TLK2
0x0

2414
chr17
60641806
60643010
+
TLK2
0x0

2415
chr17
61043429
61044634
+
TANC2
0x0

2416
chr17
61554766
61555995
−
ACE
0x2

2417
chr17
61668036
61669123
+
DCAF7
0x0

2418
chr17
61706281
61707494
−
MAP3K3
0x0

2419
chr17
61799111
61800221
−
STRADA
0x0

2420
chr17
61823148
61824382
−
CCDC47
0x0

2421
chr17
61909439
61910644
−
SMARCD2
0x0

2422
chr17
62134563
62135698
−
ERN1
0x0

2423
chr17
62222870
62224324
+
SNORA76
0x0

2424
chr17
62222870
62224324
+
SNORD104
0x0

2425
chr17
62247937
62249096
−
TEX2
0x0

2426
chr17
62496606
62498485
−
DDX5
0x2

2427
chr17
62496606
62498485
−
MIR3064
0x0

2428
chr17
62496606
62498485
−
MIR5047
0x0

2429
chr17
62498499
62499684
−
DDX5
0x2

2430
chr17
62575922
62577102
−
SMURF2
0x2

2431
chr17
62942866
62944035
−
AMZ2P1
0x0

2432
chr17
64263301
64264539
+
PRKCA
0x0

2433
chr17
64436881
64438060
+
PRKCA
0x0

2434
chr17
64530427
64531606
+
PRKCA
0x0

2435
chr17
65168688
65169857
−
HELZ
0x0

2436
chr17
65292355
65293532
−
PSMD12
0x0

2437
chr17
65336211
65337416
−
PSMD12
0x0

2438
chr17
65409593
65410812
+
PITPNC1
0x0

2439
chr17
65736243
65737466
+
SNORA38B
0x0

2440
chr17
65821694
65822893
+
BPTF
0x2

2441
chr17
65849813
65851009
+
BPTF
0x2

2442
chr17
65959757
65960975
+
BPTF
0x2

2443
chr17
66015434
66016611
−
C17orf58
0x0

2444
chr17
66042188
66043393
+
KPNA2
0x0

2445
chr17
66122069
66123217
+
LOC100499466
0x0

2446
chr17
66527202
66528626
+
PRKAR1A
0x1

2447
chr17
72199262
72200454
+
RPL38
0x0

2448
chr17
72833367
72834565
+
TMEM104
0x0

2449
chr17
73029927
73031118
−
ATP5H
0x0

2450
chr17
73037405
73038494
+
KCTD2
0x0

2451
chr17
73131557
73132694
−
HN1
0x0

2452
chr17
73178426
73179605
−
SUMO2
0x0

2453
chr17
73218498
73219694
+
NUP85
0x0

2454
chr17
73227391
73228588
+
NUP85
0x0

2455
chr17
73313814
73314889
−
GRB2
0x2

2456
chr17
73455722
73456919
+
KIAA0195
0x0

2457
chr17
73773957
73775044
−
H3F3B
0x0

2458
chr17
73807721
73808921
+
UNK
0x0

2459
chr17
73895087
73896240
−
MRPL38
0x0

2460
chr17
73937435
73938595
−
ACOX1
0x0

2461
chr17
74077015
74078380
−
EXOC7
0x0

2462
chr17
74084980
74086079
−
EXOC7
0x0

2463
chr17
74086438
74087537
−
EXOC7
0x0

2464
chr17
74138610
74139786
−
RNF157
0x0

2465
chr17
74140038
74141515
−
RNF157
0x0

2466
chr17
74288029
74289169
−
QRICH2
0x0

2467
chr17
74326348
74327468
−
PRPSAP1
0x0

2468
chr17
74391748
74392886
−
UBE2O
0x2

2469
chr17
74554334
74555523
+
LOC100507246
0x0

2470
chr17
74554334
74555523
+
SNORD1C
0x0

2471
chr17
74559655
74561651
+
LOC100507246
0x0

2472
chr17
74670186
74671261
−
MXRA7
0x0

2473
chr17
74671792
74672890
−
MXRA7
0x0

2474
chr17
74731497
74732605
−
MIR636
0x0

2475
chr17
74731497
74732605
−
SRSF2
0x2

2476
chr17
75084818
75086125
+
LINC00338
0x0

2477
chr17
75084818
75086125
+
SCARNA16
0x0

2478
chr17
75084818
75086125
+
SEC14L1
0x0

2479
chr17
75157550
75158929
−
MIR4316
0x0

2480
chr17
75437613
75438794
+
SEPT9
0x2

2481
chr17
75495129
75496821
+
SEPT9
0x2

2482
chr17
75816292
75817394
+
FLJ45079
0x0

2483
chr17
76027252
76028462
+
TNRC6C
0x0

2484
chr17
76105054
76106203
+
TNRC6C
0x0

2485
chr17
76219271
76221106
+
BIRC5
0x0

2486
chr17
76396238
76397436
+
PGS1
0x0

2487
chr17
76670230
76671405
−
CYTH1
0x0

2488
chr17
76706536
76707691
−
CYTH1
0x0

2489
chr17
76810010
76811142
−
USP36
0x0

2490
chr17
76848640
76849834
−
TIMP2
0x0

2491
chr17
76968262
76969430
−
LGALS3BP
0x0

2492
chr17
76987582
76988709
−
CANT1
0x2

2493
chr17
77081695
77082911
+
ENGASE
0x0

2494
chr17
77751447
77752559
+
CBX2
0x0

2495
chr17
77908923
77910604
−
TBC1D16
0x0

2496
chr17
77911036
77912202
−
TBC1D16
0x0

2497
chr17
78079141
78080240
+
GAA
0x0

2498
chr17
78441438
78444535
−
NPTX1
0x0

2499
chr17
78518341
78519546
+
RPTOR
0x0

2500
chr17
78521208
78522403
+
RPTOR
0x0

2501
chr17
78900830
78902034
+
RPTOR
0x0

2502
chr17
79180215
79181398
−
AZI1
0x0

2503
chr17
79222243
79223442
+
C17orf89
0x0

2504
chr17
79224181
79225386
−
SLC38A10
0x0

2505
chr17
79231888
79233044
−
SLC38A10
0x0

2506
chr17
79249251
79250465
−
SLC38A10
0x0

2507
chr17
79362635
79363814
−
MIR4740
0x0

2508
chr17
79431650
79432774
+
BAHCC1
0x0

2509
chr17
79476602
79478114
−
ACTG1
0x0

2510
chr17
79480417
79481633
−
ACTG1
0x0

2511
chr17
79503071
79504238
−
C17orf70
0x0

2512
chr17
79516997
79518173
−
C17orf70
0x0

2513
chr17
79524060
79525921
−
NPLOC4
0x0

2514
chr17
79538509
79539655
−
NPLOC4
0x0

2515
chr17
79571064
79572231
−
NPLOC4
0x0

2516
chr17
79660352
79661562
+
HGS
0x0

2517
chr17
79668356
79669552
+
HGS
0x0

2518
chr17
79686704
79687912
+
SLC25A10
0x0

2519
chr17
79766882
79768094
+
GCGR
0x0

2520
chr17
79779775
79780909
−
FAM195B
0x0

2521
chr17
79785791
79787099
−
FAM195B
0x0

2522
chr17
79800553
79801723
−
P4HB
0x0

2523
chr17
79802990
79804345
−
P4HB
0x0

2524
chr17
79824534
79825654
+
ANAPC11
0x0

2525
chr17
79839418
79840516
−
ALYREF
0x0

2526
chr17
79842416
79844483
−
ALYREF
0x0

2527
chr17
79845379
79846425
−
ALYREF
0x0

2528
chr17
79851805
79853110
+
ANAPC11
0x0

2529
chr17
79872229
79873547
−
SIRT7
0x0

2530
chr17
79957605
79958704
+
ASPSCR1
0x0

2531
chr17
79990233
79991418
+
RAC3
0x0

2532
chr17
80007055
80008185
−
RFNG
0x0

2533
chr17
80008514
80009655
−
RFNG
0x0

2534
chr17
80020966
80022173
−
DUS1L
0x0

2535
chr17
80035753
80036898
−
FASN
0x0

2536
chr17
80038577
80039772
−
FASN
0x0

2537
chr17
80041094
80042193
−
FASN
0x0

2538
chr17
80048397
80049582
−
FASN
0x0

2539
chr17
80051030
80052507
−
FASN
0x0

2540
chr17
80055526
80056564
−
FASN
0x0

2541
chr17
80093530
80094678
−
CCDC57
0x0

2542
chr17
80111293
80112455
−
CCDC57
0x0

2543
chr17
80203472
80204534
−
CSNK1D
0x0

2544
chr17
80212410
80213512
−
CSNK1D
0x0

2545
chr17
80221639
80222776
−
CSNK1D
0x0

2546
chr17
80540194
80541386
+
FOXK2
0x0

2547
chr17
80552134
80553370
+
FOXK2
0x0

2548
chr17
80559523
80560801
+
FOXK2
0x0

2549
chr17
80572648
80573867
−
WDR45L
0x0

2550
chr17
80675431
80676530
+
FN3KRP
0x0

2551
chr17
80723624
80724793
+
TBCD
0x0

2552
chr17
80725741
80726938
+
TBCD
0x0

2553
chr17
80879768
80880945
+
TBCD
0x0

2554
chr17
80922711
80923915
−
B3GNTL1
0x0

2555
chr18
261064
262183
−
THOC1
0x0

2556
chr18
319122
320335
−
COLEC12
0x0

2557
chr18
421767
422978
−
COLEC12
0x0

2558
chr18
721629
722906
−
YES1
0x0

2559
chr18
759931
761128
−
YES1
0x0

2560
chr18
2380851
2382070
+
NDC80
0x2

2561
chr18
5840188
5841409
+
MIR3976
0x0

2562
chr18
6301429
6302684
−
L3MBTL4
0x1

2563
chr18
6310997
6312174
−
L3MBTL4
0x1

2564
chr18
9399920
9401153
+
TWSG1
0x0

2565
chr18
9524016
9525208
+
RALBP1
0x0

2566
chr18
9535748
9536953
+
RALBP1
0x0

2567
chr18
9569916
9571148
−
PPP4R1
0x0

2568
chr18
9710586
9711734
+
RAB31
0x0

2569
chr18
9861621
9862813
+
RAB31
0x0

2570
chr18
9953971
9955154
+
VAPA
0x0

2571
chr18
10532844
10534018
+
NAPG
0x0

2572
chr18
12309965
12311147
+
TUBB6
0x0

2573
chr18
12446096
12447328
−
SPIRE1
0x0

2574
chr18
12455237
12456416
−
SPIRE1
0x0

2575
chr18
12546141
12547368
−
SPIRE1
0x0

2576
chr18
12934265
12935389
+
SEH1L
0x0

2577
chr18
13681472
13682627
−
FAM210A
0x0

2578
chr18
19348091
19349274
+
MIB1
0x0

2579
chr18
19353015
19354226
+
MIB1
0x0

2580
chr18
19358990
19360117
+
MIB1
0x0

2581
chr18
19409262
19410364
+
MIB1
0x0

2582
chr18
19446390
19447573
+
MIB1
0x0

2583
chr18
20714978
20716166
+
CABLES1
0x1

2584
chr18
20780816
20782005
+
CABLES1
0x1

2585
chr18
21191142
21192365
+
LAMA3
0x0

2586
chr18
21938451
21939627
−
OSBPL1A
0x0

2587
chr18
23597385
23598512
−
SS18
0x0

2588
chr18
29204767
29205899
−
B4GALT6
0x0

2589
chr18
29298411
29299551
+
TTR
0x0

2590
chr18
29451847
29452976
−
TRAPPC8
0x0

2591
chr18
29691209
29692408
+
RNF138
0x0

2592
chr18
31433808
31435029
−
NOL4
0x0

2593
chr18
31608188
31609387
−
ASXL3
0x0

2594
chr18
32470630
32471818
+
DTNA
0x2

2595
chr18
33571402
33572486
−
RPRD1A
0x0

2596
chr18
33594761
33595888
−
RPRD1A
0x0

2597
chr18
34478931
34480136
+
KIAA1328
0x0

2598
chr18
34701645
34702810
+
KIAA1328
0x0

2599
chr18
36880605
36881780
−
LOC647946
0x0

2600
chr18
37308446
37309672
−
LOC647946
0x0

2601
chr18
37324791
37325970
−
LOC647946
0x0

2602
chr18
42374366
42375584
−
SETBP1
0x0

2603
chr18
43668976
43670384
−
ATP5A1
0x0

2604
chr18
43671168
43672337
−
ATP5A1
0x0

2605
chr18
43953766
43954965
+
RNF165
0x0

2606
chr18
45422404
45423676
−
SMAD2
0x1

2607
chr18
47015074
47016220
−
RPL17
0x0

2608
chr18
47015074
47016220
−
RPL17-C18ORF32
0x0

2609
chr18
47015074
47016220
−
SNORD58C
0x0

2610
chr18
47017102
47018645
−
RPL17
0x0

2611
chr18
47017102
47018645
−
RPL17-C18ORF32
0x0

2612
chr18
47017102
47018645
−
SNORD58A
0x0

2613
chr18
47017102
47018645
−
SNORD58B
0x0

2614
chr18
47340026
47341285
+
SCARNA17
0x0

2615
chr18
48558068
48559169
+
SMAD4
0x1

2616
chr18
48702628
48703803
−
MEX3C
0x0

2617
chr18
51748117
51749303
−
SNORA37
0x0

2618
chr18
54269694
54270879
−
TXNL1
0x0

2619
chr18
54433380
54434591
+
WDR7
0x0

2620
chr18
55143632
55144824
+
ONECUT2
0x0

2621
chr18
55150433
55151555
+
ONECUT2
0x0

2622
chr18
55269173
55270333
−
NARS
0x0

2623
chr18
56806600
56807800
+
SEC11C
0x0

2624
chr18
56995198
56996412
−
LMAN1
0x0

2625
chr18
60865174
60866368
−
BCL2
0x2

2626
chr18
60997925
60999189
−
KDSR
0x0

2627
chr18
61056709
61057890
−
VPS4B
0x0

2628
chr18
65183056
65184215
−
DSEL
0x0

2629
chr18
66525652
66526789
+
CCDC102B
0x0

2630
chr18
67140788
67141996
+
DOK6
0x0

2631
chr18
68179463
68180631
+
SOCS6
0x0

2632
chr18
71958541
71959718
−
CYB5A
0x0

2633
chr18
72370379
72371580
+
ZNF407
0x2

2634
chr18
72673866
72675068
+
ZNF407
0x2

2635
chr18
74153275
74154425
−
ZNF516
0x0

2636
chr18
77169917
77171163
+
NFATC1
0x0

2637
chr18
77226859
77228067
+
NFATC1
0x0

2638
chr18
77740134
77741271
−
TXNL4A
0x0

2639
chr18
77772388
77773636
+
RBFA
0x0

2640
chr18
77869933
77871914
+
ADNP2
0x0

2641
chr19
433713
434965
−
SHC2
0x0

2642
chr19
572067
573237
+
BSG
0x0

2643
chr19
582401
583822
+
BSG
0x0

2644
chr19
647243
648413
−
RNF126
0x0

2645
chr19
660054
661181
−
RNF126
0x0

2646
chr19
738533
739809
+
PALM
0x0

2647
chr19
797449
798548
+
PTBP1
0x0

2648
chr19
807100
808347
+
PTBP1
0x0

2649
chr19
811324
812518
+
PTBP1
0x0

2650
chr19
863453
864557
−
MED16
0x0

2651
chr19
864586
865775
−
MED16
0x0

2652
chr19
876524
877713
−
MED16
0x0

2653
chr19
896103
897244
−
R3HDM4
0x0

2654
chr19
916775
917954
+
KISS1R
0x0

2655
chr19
974159
975320
+
ARID3A
0x0

2656
chr19
1009824
1010928
−
C19orf6
0x0

2657
chr19
1087248
1088492
−
POLR2E
0x0

2658
chr19
1106011
1107109
+
GPX4
0x0

2659
chr19
1144281
1145432
−
SBNO2
0x0

2660
chr19
1159004
1160170
−
SBNO2
0x0

2661
chr19
1231861
1233081
−
C19orf26
0x0

2662
chr19
1252042
1253161
−
C19orf26
0x0

2663
chr19
1258064
1259192
+
MIDN
0x0

2664
chr19
1271892
1273420
+
CIRBP
0x0

2665
chr19
1383048
1384244
+
NDUFS7
0x0

2666
chr19
1408226
1409407
+
DAZAP1
0x0

2667
chr19
1576222
1578329
−
MBD3
0x0

2668
chr19
1584613
1587222
−
MBD3
0x0

2669
chr19
1591066
1592308
−
MBD3
0x0

2670
chr19
1609021
1611339
−
TCF3
0x2

2671
chr19
1852619
1853804
−
KLF16
0x0

2672
chr19
1985081
1986305
−
BTBD2
0x0

2673
chr19
2037117
2039388
−
MKNK2
0x0

2674
chr19
2194712
2195943
+
DOT1L
0x0

2675
chr19
2206903
2208036
+
DOT1L
0x0

2676
chr19
2230429
2232621
+
DOT1L
0x0

2677
chr19
2232946
2234118
−
MIR1227
0x0

2678
chr19
2232946
2234118
−
PLEKHJ1
0x0

2679
chr19
2248798
2250016
+
AMH
0x1

2680
chr19
2271337
2273780
+
OAZ1
0x0

2681
chr19
2323614
2324827
−
LSM7
0x0

2682
chr19
2327666
2328831
−
LSM7
0x0

2683
chr19
2426336
2427443
−
TIMM13
0x0

2684
chr19
2428253
2431164
−
LMNB2
0x0

2685
chr19
2754228
2756106
−
SGTA
0x0

2686
chr19
3023431
3024607
−
TLE2
0x0

2687
chr19
3121993
3123177
+
GNA11
0x2

2688
chr19
3208205
3209304
+
NCLN
0x0

2689
chr19
3434561
3435750
+
NFIC
0x0

2690
chr19
3621899
3623077
−
C19orf29
0x0

2691
chr19
3660460
3661587
−
PIP5K1C
0x0

2692
chr19
3975699
3978729
−
EEF2
0x0

2693
chr19
3978771
3979956
−
EEF2
0x0

2694
chr19
3980845
3983477
−
EEF2
0x0

2695
chr19
3980845
3983477
−
SNORD37
0x0

2696
chr19
4027433
4028579
+
PIAS4
0x0

2697
chr19
4034724
4035823
+
PIAS4
0x0

2698
chr19
4047304
4048448
−
ZBTB7A
0x0

2699
chr19
4055272
4056464
−
ZBTB7A
0x0

2700
chr19
4062229
4063364
−
ZBTB7A
0x0

2701
chr19
4101878
4102995
−
MAP2K2
0x0

2702
chr19
4110028
4111458
−
MAP2K2
0x0

2703
chr19
4116961
4118119
−
MAP2K2
0x0

2704
chr19
4310496
4311645
+
FSD1
0x0

2705
chr19
4322332
4323445
+
FSD1
0x0

2706
chr19
4359894
4360966
−
SH3GL1
0x2

2707
chr19
4366582
4367670
−
SH3GL1
0x2

2708
chr19
4429995
4431094
+
CHAF1A
0x0

2709
chr19
4440953
4442054
+
CHAF1A
0x0

2710
chr19
4561124
4562302
−
SEMA6B
0x0

2711
chr19
4654640
4655802
+
TNFAIP8L1
0x0

2712
chr19
4657317
4658465
−
C19orf10
0x0

2713
chr19
4917576
4918740
+
UHRF1
0x0

2714
chr19
4939459
4940559
+
UHRF1
0x0

2715
chr19
4944246
4945392
+
UHRF1
0x0

2716
chr19
4985938
4987096
+
KDM4B
0x0

2717
chr19
5046939
5048139
+
KDM4B
0x0

2718
chr19
5133469
5134656
+
KDM4B
0x0

2719
chr19
5134771
5135966
+
KDM4B
0x0

2720
chr19
5205586
5206716
−
PTPRS
0x2

2721
chr19
5266837
5267994
−
PTPRS
0x2

2722
chr19
5273735
5274901
−
PTPRS
0x2

2723
chr19
5325308
5326490
−
PTPRS
0x2

2724
chr19
5336090
5337290
−
PTPRS
0x2

2725
chr19
5566085
5567294
−
PLAC2
0x0

2726
chr19
5652831
5654001
+
SAFB
0x1

2727
chr19
5667676
5668949
+
SAFB
0x1

2728
chr19
5667701
5668881
−
C19orf70
0x0

2729
chr19
5679163
5680303
−
C19orf70
0x0

2730
chr19
5689972
5692190
+
RPL36
0x0

2731
chr19
5709498
5710708
−
LONP1
0x0

2732
chr19
5805513
5806703
+
NRTN
0x0

2733
chr19
6012390
6013607
−
RFX2
0x2

2734
chr19
6210117
6211258
−
MLLT1
0x2

2735
chr19
6211446
6213296
−
MLLT1
0x2

2736
chr19
6221935
6223135
−
MLLT1
0x2

2737
chr19
6413133
6415362
−
KHSRP
0x2

2738
chr19
6453951
6455214
−
SLC25A23
0x0

2739
chr19
6493985
6495204
−
TUBB4A
0x0

2740
chr19
7114169
7115339
−
INSR
0x0

2741
chr19
7124438
7125655
−
INSR
0x0

2742
chr19
7988914
7990981
−
CTXN1
0x0

2743
chr19
7991707
7992856
−
TIMM44
0x0

2744
chr19
8024767
8025863
−
ELAVL1
0x0

2745
chr19
8026719
8028012
−
ELAVL1
0x0

2746
chr19
8468497
8469678
+
RAB11B
0x0

2747
chr19
8553318
8554417
+
HNRNPM
0x0

2748
chr19
9680260
9681437
−
ZNF121
0x0

2749
chr19
9784612
9785787
−
ZNF562
0x0

2750
chr19
9937238
9938414
−
FBXL12
0x0

2751
chr19
9938053
9939209
+
UBL5
0x0

2752
chr19
9950227
9951326
+
PIN1
0x0

2753
chr19
10217776
10218974
+
PPAN
0x0

2754
chr19
10217776
10218974
+
PPAN-P2RY11
0x0

2755
chr19
10217776
10218974
+
SNORD105
0x0

2756
chr19
10227061
10228280
−
EIF3G
0x0

2757
chr19
10243711
10244899
−
DNMT1
0x4

2758
chr19
10250997
10252088
−
DNMT1
0x4

2759
chr19
10369710
10370861
+
MRPL4
0x0

2760
chr19
10421479
10422676
−
FDX1L
0x0

2761
chr19
10427503
10428656
−
RAVER1
0x0

2762
chr19
10463325
10464506
−
TYK2
0x0

2763
chr19
10501355
10502667
−
CDC37
0x0

2764
chr19
10777886
10779078
+
ILF3
0x0

2765
chr19
10795337
10796433
+
ILF3
0x0

2766
chr19
10800973
10802039
+
ILF3
0x0

2767
chr19
11032246
11033452
+
CARM1
0x0

2768
chr19
11082469
11083677
+
SMARCA4
0x1

2769
chr19
11107671
11108841
+
SMARCA4
0x1

2770
chr19
11133693
11134778
+
SMARCA4
0x1

2771
chr19
11223722
11224919
+
LDLR
0x0

2772
chr19
11257228
11258356
−
SPC24
0x0

2773
chr19
11455424
11456815
−
TMEM205
0x0

2774
chr19
11474649
11475822
+
LPPR2
0x0

2775
chr19
11518907
11520144
+
PRKCSH
0x0

2776
chr19
11546281
11547487
+
PRKCSH
0x0

2777
chr19
11560498
11562101
+
PRKCSH
0x0

2778
chr19
11663922
11665073
−
ELOF1
0x0

2779
chr19
11925496
11926700
+
ZNF440
0x0

2780
chr19
12698834
12699974
−
ZNF490
0x0

2781
chr19
12809813
12812031
−
TNPO2
0x0

2782
chr19
12813855
12815063
−
TNPO2
0x0

2783
chr19
12821562
12822732
−
TNPO2
0x0

2784
chr19
12825352
12826594
−
TNPO2
0x0

2785
chr19
12840942
12842171
−
C19orf43
0x0

2786
chr19
13038666
13039865
−
FARSA
0x0

2787
chr19
13040558
13041695
−
FARSA
0x0

2788
chr19
13054508
13055694
+
CALR
0x2

2789
chr19
13135373
13136566
+
NFIX
0x0

2790
chr19
13219864
13221182
−
TRMT1
0x0

2791
chr19
13229656
13230815
+
NACC1
0x0

2792
chr19
13249505
13250603
+
NACC1
0x0

2793
chr19
13264394
13265575
+
IER2
0x0

2794
chr19
13883248
13884372
+
MRI1
0x0

2795
chr19
13923224
13924434
+
ZSWIM4
0x0

2796
chr19
14198159
14199558
−
SAMD1
0x0

2797
chr19
14200909
14202105
−
SAMD1
0x0

2798
chr19
14293844
14294997
−
LPHN1
0x2

2799
chr19
14579728
14580828
+
PKN1
0x2

2800
chr19
14581976
14583102
+
PKN1
0x2

2801
chr19
14588668
14589819
−
GIPC1
0x0

2802
chr19
14625659
14625906
−
DNAJB1
0x0

2803
chr19
14732536
14733997
+
CLEC17A
0x0

2804
chr19
15270591
15271715
−
NOTCH3
0x0

2805
chr19
15465179
15466371
−
AKAP8
0x2

2806
chr19
15468886
15470088
−
AKAP8
0x2

2807
chr19
15513523
15514703
−
AKAP8L
0x0

2808
chr19
16212928
16214130
+
TPM4
0x0

2809
chr19
16345227
16346378
+
AP1M1
0x0

2810
chr19
16376027
16377201
−
CIB3
0x0

2811
chr19
16470042
16471169
−
EPS15L1
0x0

2812
chr19
16651975
16653236
−
CHERP
0x0

2813
chr19
16737773
16738944
−
MED26
0x0

2814
chr19
16790289
16791467
+
TMEM38A
0x0

2815
chr19
17212335
17213596
+
MYO9B
0x0

2816
chr19
17391547
17392710
+
ANKLE1
0x0

2817
chr19
17416651
17417847
+
MRPL34
0x0

2818
chr19
17692166
17693768
+
GLT25D1
0x0

2819
chr19
17874502
17875704
+
FCHO1
0x0

2820
chr19
17972879
17974106
+
RPL18A
0x0

2821
chr19
17972879
17974106
+
SNORA68
0x0

2822
chr19
18245096
18246253
+
MAST3
0x0

2823
chr19
18390080
18391372
−
JUND
0x0

2824
chr19
18418226
18419383
−
LSM4
0x0

2825
chr19
18546682
18547816
−
ISYNA1
0x0

2826
chr19
18649873
18651098
−
FKBP8
0x0

2827
chr19
18652180
18653326
−
FKBP8
0x0

2828
chr19
18679220
18680543
+
KXD1
0x0

2829
chr19
18884271
18885435
+
CRTC1
0x2

2830
chr19
19035880
19037084
+
DDX49
0x0

2831
chr19
19108089
19109247
−
SUGP2
0x0

2832
chr19
19120195
19121638
−
SUGP2
0x0

2833
chr19
19152147
19153382
+
ARMC6
0x0

2834
chr19
19170255
19171474
+
ARMC6
0x0

2835
chr19
19246414
19248580
−
TMEM161A
0x0

2836
chr19
19407380
19408591
−
SUGP1
0x0

2837
chr19
19515851
19517059
+
GATAD2A
0x0

2838
chr19
19565218
19566440
+
GATAD2A
0x0

2839
chr19
19606355
19607510
+
GATAD2A
0x0

2840
chr19
19618774
19619862
+
GATAD2A
0x0

2841
chr19
19641808
19642907
+
YJEFN3
0x0

2842
chr19
19709318
19710495
−
PBX4
0x0

2843
chr19
21207859
21209170
+
ZNF430
0x0

2844
chr19
21289831
21291024
+
ZNF714
0x0

2845
chr19
22877044
22878262
−
ZNF99
0x0

2846
chr19
24009538
24011365
+
RPSAP58
0x0

2847
chr19
24183115
24184722
−
LOC100101266
0x0

2848
chr19
30499618
30500671
+
URI1
0x0

2849
chr19
30824657
30825856
+
ZNF536
0x2

2850
chr19
33077622
33078844
+
PDCD5
0x0

2851
chr19
33188805
33189954
+
NUDT19
0x0

2852
chr19
33460137
33461317
−
CEP89
0x0

2853
chr19
33791628
33792820
−
CEBPA
0x1

2854
chr19
34304490
34305768
+
KCTD15
0x0

2855
chr19
34718119
34719264
+
LSM14A
0x0

2856
chr19
34858984
34860104
+
GPI
0x0

2857
chr19
34890809
34892921
+
GPI
0x0

2858
chr19
34925241
34926410
+
UBA2
0x0

2859
chr19
34940655
34941844
+
UBA2
0x0

2860
chr19
35503647
35504748
−
GRAMD1A
0x0

2861
chr19
35769770
35771106
+
USF2
0x0

2862
chr19
36065946
36067217
+
TMEM147
0x0

2863
chr19
36123827
36124926
+
RBM42
0x0

2864
chr19
36148991
36150113
+
COX6B1
0x0

2865
chr19
36212927
36214148
+
MLL4
0x0

2866
chr19
36582377
36583533
+
WDR62
0x0

2867
chr19
36631344
36632542
+
CAPNS1
0x0

2868
chr19
38431494
38432690
+
SIPA1L3
0x0

2869
chr19
39326617
39327844
−
HNRNPL
0x0

2870
chr19
39337434
39338533
−
HNRNPL
0x0

2871
chr19
39410724
39412282
−
SARS2
0x0

2872
chr19
39676724
39677915
+
PAK4
0x0

2873
chr19
39797108
39798331
−
LRFN1
0x0

2874
chr19
39888164
39889343
+
MED29
0x2

2875
chr19
39902265
39903407
−
MIR4530
0x0

2876
chr19
39923315
39924524
−
RPS16
0x0

2877
chr19
39976373
39977573
+
TIMM50
0x0

2878
chr19
40324585
40325684
−
DYRK1B
0x0

2879
chr19
40324585
40325684
−
FBI
0x0

2880
chr19
40697581
40698898
+
MAP3K10
0x0

2881
chr19
40738955
40740117
−
AKT2
0x2

2882
chr19
40783554
40784768
−
MIR641
0x0

2883
chr19
40784791
40786415
−
MIR641
0x0

2884
chr19
40789643
40791062
−
AKT2
0x2

2885
chr19
40821326
40822426
−
C19orf47
0x0

2886
chr19
40826618
40827833
−
C19orf47
0x0

2887
chr19
40871081
40872319
+
PLD3
0x0

2888
chr19
41307405
41308504
−
EGLN2
0x0

2889
chr19
41307405
41308504
+
RAB4B-EGLN2
0x0

2890
chr19
41313315
41314483
+
EGLN2
0x0

2891
chr19
41313315
41314483
+
RAB4B-EGLN2
0x0

2892
chr19
41784451
41785650
+
HNRNPUL1
0x0

2893
chr19
41800880
41802017
+
HNRNPUL1
0x0

2894
chr19
41812393
41813671
+
HNRNPUL1
0x0

2895
chr19
41815425
41816747
−
TGFB1
0x1

2896
chr19
41829951
41831140
−
CCDC97
0x0

2897
chr19
42069747
42070918
−
CEACAM4
0x0

2898
chr19
42364262
42365484
+
RPS19
0x0

2899
chr19
42375951
42377127
+
RPS19
0x0

2900
chr19
42751641
42752823
−
ERF
0x1

2901
chr19
42792581
42793913
+
CIC
0x2

2902
chr19
42838329
42840427
+
MEGF8
0x0

2903
chr19
42853211
42854995
+
MEGF8
0x0

2904
chr19
42881170
42882304
+
MEGF8
0x0

2905
chr19
42937196
42938377
+
MEGF8
0x0

2906
chr19
43909808
43910977
+
TEX101
0x0

2907
chr19
44046898
44048117
−
XRCC1
0x0

2908
chr19
44111103
44112238
−
ZNF428
0x0

2909
chr19
44677729
44678937
+
ZNF226
0x2

2910
chr19
45489903
45491113
+
CLPTM1
0x0

2911
chr19
45637271
45638417
+
PPP1R37
0x0

2912
chr19
45981284
45982504
−
RTN2
0x0

2913
chr19
46055463
46056676
−
OPA3
0x0

2914
chr19
46191155
46192341
−
SNRPD2
0x0

2915
chr19
46285399
46290500
−
DMPK
0x0

2916
chr19
46285399
46290500
−
DMWD
0x0

2917
chr19
46361925
46363145
+
FOXA3
0x0

2918
chr19
45403964
46405141
−
MYPOP
0x0

2919
chr19
46441853
46443027
−
NOVA2
0x0

2920
chr19
47112545
47113889
+
CALM3
0x0

2921
chr19
47219629
47220775
−
PRKD2
0x0

2922
chr19
47230409
47231590
−
STRN4
0x0

2923
chr19
47234518
47235724
−
STRN4
0x0

2924
chr19
47277768
47279296
−
SLC1A5
0x0

2925
chr19
47287026
47288125
−
SLC1A5
0x0

2926
chr19
47290828
47292007
−
SLC1A5
0x0

2927
chr19
47421491
47422610
+
ARHGAP35
0x1

2928
chr19
47505828
47507452
+
ARHGAP35
0x1

2929
chr19
47571603
47572761
−
ZC3H4
0x0

2930
chr19
47633618
47634854
+
SAE1
0x0

2931
chr19
47857790
47859035
+
DHX34
0x0

2932
chr19
47884204
47885407
+
DHX34
0x0

2933
chr19
47995135
47996311
−
NAPA
0x0

2934
chr19
48179700
48180894
+
GLTSCR1
0x1

2935
chr19
48258914
48260113
+
GLTSCR2
0x1

2936
chr19
48258914
48260113
+
SNORD23
0x0

2937
chr19
48287091
48288282
+
SEPW1
0x0

2938
chr19
48426524
48427748
+
SNAR-A10
0x0

2939
chr19
48426524
48427748
+
SNAR-A11
0x0

2940
chr19
48426524
48427748
+
SNAR-A14
0x0

2941
chr19
48426524
48427748
+
SNAR-A3
0x0

2942
chr19
48426524
48427748
+
SNAR-A4
0x0

2943
chr19
48426524
48427748
+
SNAR-A5
0x0

2944
chr19
48426524
48427748
+
SNAR-A6
0x0

2945
chr19
48426524
48427748
+
SNAR-A7
0x0

2946
chr19
48426524
48427748
+
SNAR-A8
0x0

2947
chr19
48426524
48427748
+
SNAR-A9
0x0

2948
chr19
48638772
48639948
−
LIG1
0x0

2949
chr19
48640427
48641526
−
LIG1
0x0

2950
chr19
48642529
48643725
−
LIG1
0x0

2951
chr19
48704862
48706055
−
CARD8
0x0

2952
chr19
48885682
48886906
−
KDELR1
0x0

2953
chr19
48893193
48894425
−
KDELR1
0x0

2954
chr19
49118619
49120644
−
RPL18
0x0

2955
chr19
49297824
49298967
−
BCAT2
0x0

2956
chr19
49303599
49304778
−
BCAT2
0x0

2957
chr19
49425423
49426724
+
NUCB1
0x0

2958
chr19
49469028
49470166
+
FTL
0x0

2959
chr19
49471950
49473128
−
GYS1
0x0

2960
chr19
49588237
49589435
+
SNRNP70
0x0

2961
chr19
49592075
49593223
+
SNRNP70
0x0

2962
chr19
49607258
49608427
+
SNRNP70
0x0

2963
chr19
49645121
49646312
+
PPFIA3
0x0

2964
chr19
49670843
49672015
+
TRPM4
0x0

2965
chr19
49863523
49864822
−
TEAD2
0x0

2966
chr19
49955965
49957142
+
ALDH16A1
0x0

2967
chr19
49992705
49993802
+
RPL13A
0x0

2968
chr19
49992705
49993802
+
RPL13AP5
0x0

2969
chr19
49992705
49993802
+
SNORD32A
0x0

2970
chr19
49994537
49995624
+
RPL13A
0x0

2971
chr19
49994537
49995624
+
RPL13AP5
0x0

2972
chr19
50000608
50001855
+
RPS11
0x0

2973
chr19
50000608
50001855
+
SNORD35B
0x0

2974
chr19
50002222
50003374
+
RPS11
0x0

2975
chr19
50028948
50030116
+
FCGRT
0x0

2976
chr19
50098847
50100070
−
PRR12
0x0

2977
chr19
50104606
50105797
+
PRR12
0x0

2978
chr19
50125677
50126919
+
PRR12
0x0

2979
chr19
50359518
50362672
−
PTOV1
0x0

2980
chr19
50409664
50411091
−
NUP62
0x0

2981
chr19
52381165
52382302
−
ZNF577
0x0

2982
chr19
52729015
52730190
+
PPP2R1A
0x2

2983
chr19
53226284
53227434
−
ZNF611
0x0

2984
chr19
54462756
54463932
+
CACNG8
0x0

2985
chr19
54605893
54607047
+
NDUFA3
0x0

2986
chr19
54704517
54705652
+
RPS9
0x0

2987
chr19
54710900
54712000
+
RPS9
0x0

2988
chr19
54969341
54970479
+
LENG8
0x0

2989
chr19
54972309
54973633
+
LENG8
0x0

2990
chr19
55559299
55560476
−
RDH13
0x0

2991
chr19
55897400
55898599
+
RPL28
0x0

2992
chr19
55899145
55900296
+
RPL28
0x0

2993
chr19
55900600
55901783
+
RPL28
0x0

2994
chr19
55945818
55947059
+
ZNF628
0x0

2995
chr19
55978495
55979717
+
ZNF628
0x0

2996
chr19
55997742
55999096
+
NAT14
0x0

2997
chr19
56090628
56091988
−
ZNF579
0x0

2998
chr19
56172904
56173985
+
U2AF2
0x2

2999
chr19
56185234
56186475
+
U2AF2
0x2

3000
chr19
56667669
56668775
+
ZNF444
0x0

3001
chr19
57725909
57727008
+
ZNF264
0x4

3002
chr19
57910640
57911792
+
ZNF548
0x0

3003
chr19
57973839
57975442
−
ZNF772
0x0

3004
chr19
57979307
57980462
−
ZNF772
0x0

3005
chr19
58217480
58218587
+
ZNF551
0x0

3006
chr19
58280064
58281258
+
ZNF586
0x0

3007
chr19
58295632
58296837
+
ZNF586
0x0

3008
chr19
58378068
58379253
+
ZNF587
0x0

3009
chr19
58455718
58456894
−
ZNF256
0x0

3010
chr19
58874297
58875496
+
A1BG-AS1
0x0

3011
chr19
58904215
58905433
+
RPS5
0x0

3012
chr19
59024596
59025774
−
ZBTB45
0x0

3013
chr19
59061179
59062583
+
TRIM28
0x0

3014
chr19
59066969
59068097
−
UBE2M
0x0

3015
chr19
59069120
59070278
−
UBE2M
0x0

3016
chr2
1216356
1217585
+
SNTG2
0x0

3017
chr2
1636731
1637920
−
PXDN
0x2

3018
chr2
2363834
2365034
−
MYTH
0x0

3019
chr2
3320034
3321188
−
TSSC1
0x0

3020
chr2
8869616
8870757
−
KIDINS220
0x0

3021
chr2
8994807
8995934
−
MBOAT2
0x0

3022
chr2
8997799
8999023
−
MBOAT2
0x0

3023
chr2
9757076
9758210
−
YWHAQ
0x2

3024
chr2
10586337
10587409
−
SNORA80B
0x0

3025
chr2
11724384
11725662
+
GREB1
0x0

3026
chr2
11906920
11908110
+
LPIN1
0x0

3027
chr2
15653200
15654333
−
NBAS
0x0

3028
chr2
16639823
16641013
+
MYCN
0x2

3029
chr2
17942106
17943268
+
GEN1
0x2

3030
chr2
20232436
20233529
−
LAPTM4A
0x0

3031
chr2
20417746
20419143
−
SDC1
0x0

3032
chr2
20501494
20502666
−
PUM2
0x0

3033
chr2
20680167
20681308
+
RHOB
0x1

3034
chr2
23629735
23630885
+
KLHL29
0x0

3035
chr2
23644452
23645882
+
KLHL29
0x0

3036
chr2
23675495
23676607
+
KLHL29
0x0

3037
chr2
24079710
24080888
−
ATAD2B
0x0

3038
chr2
24289952
24291126
−
SF3B14
0x0

3039
chr2
25004382
25005586
+
CENPO
0x0

3040
chr2
25452998
25454097
−
DNMT3A
0x2

3041
chr2
25961435
25962615
−
ASXL2
0x0

3042
chr2
26250444
26251731
−
KIF3C
0x0

3043
chr2
26256446
26257646
+
RAB10
0x0

3044
chr2
26617976
26619180
+
EPT1
0x0

3045
chr2
27273066
27274339
+
AGBL5
0x0

3046
chr2
27355797
27356988
−
PREB
0x0

3047
chr2
27456383
27457481
+
CAD
0x0

3048
chr2
27477080
27478216
−
SLC30A3
0x0

3049
chr2
28974355
28975566
+
PPP1CB
0x0

3050
chr2
29135977
29137186
+
SNORD92
0x0

3051
chr2
29135977
29137186
+
WDR43
0x0

3052
chr2
29148700
29149881
+
WDR43
0x0

3053
chr2
29150294
29151499
+
WDR43
0x0

3054
chr2
29388281
29389489
+
CLIP4
0x0

3055
chr2
30723323
30724519
+
LCLAT1
0x0

3056
chr2
32140854
32141953
−
MEMO1
0x0

3057
chr2
32248479
32249699
−
DPY30
0x0

3058
chr2
33726765
33727887
+
RASGRP3
0x0

3059
chr2
33739891
33741064
−
FAM98A
0x0

3060
chr2
35845713
35846891
−
LOC100288911
0x0

3061
chr2
36667962
36669182
+
CRIM1
0x0

3062
chr2
36669204
36670402
+
CRIM1
0x0

3063
chr2
37080343
37081493
−
STRN
0x0

3064
chr2
37326947
37328278
−
EIF2AK2
0x1

3065
chr2
37332097
37333466
−
EIF2AK2
0x1

3066
chr2
38708654
38710070
+
GALM
0x0

3067
chr2
39220563
39221718
−
SOS1
0x2

3068
chr2
39281328
39282494
−
SOS1
0x2

3069
chr2
40424638
40425802
−
SLC8A1
0x0

3070
chr2
40655162
40656518
−
SLC8A1
0x0

3071
chr2
42417346
42418501
+
EML4
0x2

3072
chr2
42469322
42470470
+
EML4
0x2

3073
chr2
42930426
42931526
+
MTA3
0x0

3074
chr2
42991030
42992261
+
MTA3
0x0

3075
chr2
43628334
43629550
+
LOC100129726
0x0

3076
chr2
43707207
43708335
−
THADA
0x0

3077
chr2
43753054
43754275
−
THADA
0x0

3078
chr2
44127543
44128682
−
LRPPRC
0x0

3079
chr2
44133422
44134551
−
LRPPRC
0x0

3080
chr2
44428084
44429242
+
PPM1B
0x0

3081
chr2
44588997
44590196
+
CAMKMT
0x0

3082
chr2
44842666
44843896
+
CAMKMT
0x0

3083
chr2
45704492
45705671
−
SRBD1
0x0

3084
chr2
45789231
45790428
−
SRBD1
0x0

3085
chr2
46113133
46114336
+
PRKCE
0x0

3086
chr2
47387070
47388219
−
CALM2
0x0

3087
chr2
47389236
47390372
−
CALM2
0x0

3088
chr2
47401791
47404187
−
CALM2
0x0

3089
chr2
54084744
54085904
+
ERLEC1
0x0

3090
chr2
55198969
55200096
−
RTN4
0x0

3091
chr2
55209139
55210248
−
RTN4
0x0

3092
chr2
55276912
55278085
−
RTN4
0x0

3093
chr2
55455389
55456529
−
C2orf63
0x0

3094
chr2
55460782
55461826
+
MIR4426
0x0

3095
chr2
55460782
55461826
+
RPS27A
0x0

3096
chr2
56256982
56258160
−
MIR216B
0x0

3097
chr2
58426661
58427856
−
FANCL
0x0

3098
chr2
60775743
60776943
+
PAPOLG
0x0

3099
chr2
61105229
61106424
+
REL
0x2

3100
chr2
61129741
61130952
+
REL
0x2

3101
chr2
61152233
61153452
+
REL
0x2

3102
chr2
61441647
61442807
−
USP34
0x0

3103
chr2
61718705
61720082
−
XPO1
0x2

3104
chr2
61729986
61731165
−
XPO1
0x2

3105
chr2
61764394
61765670
−
XPO1
0x2

3106
chr2
61891926
61893148
+
COMMD1
0x4

3107
chr2
62109913
62111078
−
CCT4
0x0

3108
chr2
63185727
63186942
+
EHBP1
0x0

3109
chr2
65496944
65498205
+
ACTR2
0x0

3110
chr2
65629603
65630801
−
SPRED2
0x0

3111
chr2
69266676
69267880
+
ANTXR1
0x0

3112
chr2
69977480
69978670
+
ANXA4
0x0

3113
chr2
69998942
70000138
+
ANXA4
0x0

3114
chr2
70065682
70066781
+
GMCL1
0x0

3115
chr2
70130919
70132148
+
SNRNP27
0x0

3116
chr2
70166448
70167626
−
ASPRV1
0x0

3117
chr2
70439959
70441087
−
TIA1
0x0

3118
chr2
70451212
70453245
−
TIA1
0x0

3119
chr2
70462729
70463934
−
TIA1
0x0

3120
chr2
70475116
70476306
−
TIA1
0x0

3121
chr2
70506910
70508076
+
PCYOX1
0x0

3122
chr2
71605045
71606241
+
2NF638
0x2

3123
chr2
71660699
71661885
+
ZNF638
0x2

3124
chr2
72403769
72404907
−
EXOC6B
0x0

3125
chr2
72880523
72881715
−
EXOC6B
0x0

3126
chr2
73314836
73316011
−
RAB11F1P5
0x0

3127
chr2
73466265
73467475
+
CCT7
0x0

3128
chr2
73471196
73472298
+
CCT7
0x0

3129
chr2
74379504
74380719
−
MOB1A
0x1

3130
chr2
74472451
74473668
−
SLC4A5
0x0

3131
chr2
74604733
74605908
−
DCTN1
0x0

3132
chr2
74651919
74653107
+
WDR54
0x0

3133
chr2
74719416
74720610
+
TTC31
0x0

3134
chr2
74756938
74758134
+
HTRA2
0x1

3135
chr2
75886605
75887676
+
MRPL19
0x0

3136
chr2
76671803
76673078
−
LRRTM4
0x0

3137
chr2
78928161
78929528
+
REG3G
0x0

3138
chr2
82813926
82815121
+
LOC1720
0x0

3139
chr2
85547533
85548789
−
TGOLN2
0x0

3140
chr2
85549172
85550284
−
TGOLN2
0x0

3141
chr2
85571106
85572305
−
RETSAT
0x0

3142
chr2
85596349
85597520
+
ELMOD3
0x0

3143
chr2
85768172
85769384
+
MAT2A
0x0

3144
chr2
85770203
85771928
+
MAT2A
0x0

3145
chr2
86362432
86363688
+
PTCD3
0x0

3146
chr2
86362432
86363688
+
SNORD94
0x0

3147
chr2
96850183
96852632
−
STARD7
0x0

3148
chr2
96873373
96874629
−
STARD7
0x0

3149
chr2
96886991
96888202
+
LOC285033
0x0

3150
chr2
96917577
96918862
−
TMEM127
0x1

3151
chr2
96934086
96935241
−
TMEM127
0x1

3152
chr2
96934811
96935966
+
CIAO1
0x0

3153
chr2
96939147
96940246
+
CIAO1
0x0

3154
chr2
96964067
96965248
−
SNRNP200
0x0

3155
chr2
97028996
97030194
+
NCAPH
0x0

3156
chr2
97271741
97273016
−
KANSL3
0x0

3157
chr2
97504664
97505839
−
ANKRD23
0x0

3158
chr2
97528436
97529590
−
SEMA4C
0x0

3159
chr2
97532383
97533489
−
SEMA4C
0x0

3160
chr2
97688627
97689804
−
FAM178B
0x0

3161
chr2
97830818
97832001
+
ANKRD36
0x0

3162
chr2
98443952
98445069
+
ZAP70
0x0

3163
chr2
98611751
98612927
+
VWA3B
0x0

3164
chr2
99213766
99214929
−
COA5
0x0

3165
chr2
99327874
99329169
−
MGAT4A
0x0

3166
chr2
100505174
100506343
−
AFF3
0x2

3167
chr2
101621869
101623334
+
RPL31
0x0

3168
chr2
101634848
101636020
+
RPL31
0x0

3169
chr2
101753040
101754214
−
TBC1D8
0x0

3170
chr2
101914253
101915427
−
RNF149
0x0

3171
chr2
102471880
102473077
+
MAP4K4
0x2

3172
chr2
105470160
105471496
+
POU3F3
0x0

3173
chr2
105546628
105547807
+
POU3F3
0x0

3174
chr2
105908127
105909296
−
TGFBRAP1
0x0

3175
chr2
109182877
109184117
+
LIMS1
0x0

3176
chr2
109350228
109351366
+
RANBP2
0x0

3177
chr2
109380433
109381480
+
RANBP2
0x0

3178
chr2
111433698
111434876
−
BUB1
0x0

3179
chr2
113278429
113279578
+
TTL
0x2

3180
chr2
113288452
113289542
+
TTL
0x2

3181
chr2
113420264
113421422
+
SLC20A1
0x0

3182
chr2
114201793
114202983
+
CBWD2
0x0

3183
chr2
114567960
114569149
−
SLC35F5
0x0

3184
chr2
114708764
114709972
+
ACTR3
0x0

3185
chr2
115694554
115695736
−
LOC389023
0x0

3186
chr2
115694749
115695961
+
DPP10
0x2

3187
chr2
116999724
117000945
+
DPP10
0x2

3188
chr2
121387744
121388900
−
LOC84931
0x0

3189
chr2
121498659
121499846
+
GLI2
0x0

3190
chr2
121572475
121573681
+
GLI2
0x0

3191
chr2
121721345
121722544
+
GLI2
0x0

3192
chr2
122158585
122159790
−
CLASP1
0x0

3193
chr2
122287903
122289168
−
RNU4ATAC
0x0

3194
chr2
122326393
122327567
−
CLASP1
0x0

3195
chr2
122363177
122364331
−
CLASP1
0x0

3196
chr2
122522653
122523768
+
TSN
0x0

3197
chr2
128014354
128015560
−
ERCC3
0x2

3198
chr2
128033246
128034430
−
ERCC3
0x2

3199
chr2
128144821
128146023
−
MIR4783
0x0

3200
chr2
128263658
128264859
−
IWS1
0x0

3201
chr2
128605078
128606215
−
POLR2D
0x0

3202
chr2
128740898
128742002
−
SAP130
0x0

3203
chr2
128916619
128917760
+
UGGT1
0x2

3204
chr2
130913803
130915004
−
SMPD4
0x0

3205
chr2
130939357
130940573
+
MZT2B
0x0

3206
chr2
131094151
131095309
−
CCDC115
0x0

3207
chr2
131104509
131105707
+
IMP4
0x2

3208
chr2
131132081
131133280
+
PTPN18
0x0

3209
chr2
131805917
131807019
−
FAM168B
0x0

3210
chr2
131899453
131900659
+
PLEKHB2
0x0

3211
chr2
132245207
132246346
−
MIR4784
0x0

3212
chr2
132273057
132274242
+
LOC150776
0x0

3213
chr2
133011758
133013847
−
MIR663B
0x0

3214
chr2
133026440
133027503
−
ANKRD30BL
0x0

3215
chr2
133027871
133029879
−
ANKRD30BL
0x0

3216
chr2
133741826
133742980
−
NCKAP5
0x0

3217
chr2
134916352
134917556
+
MIR3679
0x0

3218
chr2
135211232
135212359
+
MGAT5
0x0

3219
chr2
136508474
136509745
+
UBXN4
0x0

3220
chr2
136613864
136615023
−
MCM6
0x0

3221
chr2
138786081
138787300
+
HNMT
0x0

3222
chr2
142231057
142232282
+
KYNU
0x0

3223
chr2
142246188
142247397
+
KYNU
0x0

3224
chr2
142469274
142470500
−
LRP1B
0x1

3225
chr2
142536923
142538099
−
LRP1B
0x1

3226
chr2
142742729
142743935
−
LRP1B
0x1

3227
chr2
148729810
148730961
−
ORC4
0x0

3228
chr2
149402018
149403220
+
EPC2
0x0

3229
chr2
151218773
151219905
+
LYPD6
0x0

3230
chr2
152318973
152320151
+
RIF1
0x0

3231
chr2
152802350
152803566
−
CACNB4
0x0

3232
chr2
152846132
152847415
−
CACNB4
0x0

3233
chr2
153193327
153194477
+
FMNL2
0x0

3234
chr2
153205934
153207116
+
FMNL2
0x0

3235
chr2
153524942
153526351
−
PRPF40A
0x0

3236
chr2
154729764
154730960
+
GALNT13
0x0

3237
chr2
154818140
154819320
+
GALNT13
0x0

3238
chr2
154819642
154820805
+
GALNT13
0x0

3239
chr2
155410346
155411541
+
GALNT13
0x0

3240
chr2
157033856
157035046
−
NR4A2
0x0

3241
chr2
157312157
157313327
+
GPD2
0x0

3242
chr2
158155010
158156187
−
ERMN
0x0

3243
chr2
159346768
159348023
+
PKP4
0x0

3244
chr2
160087070
160088269
+
TANC1
0x0

3245
chr2
161130286
161131453
−
RBMS1
0x0

3246
chr2
161264377
161265530
−
MIR4785
0x0

3247
chr2
162207621
162208841
+
P5MD14
0x0

3248
chr2
162979680
162980900
+
SLC4A10
0x2

3249
chr2
164457179
164458356
−
FIGN
0x0

3250
chr2
165583619
165584827
−
COBLL1
0x0

3251
chr2
166908003
166909181
−
SCN1A
0x0

3252
chr2
167036660
167037847
−
SCN9A
0x2

3253
chr2
168004968
168006187
+
XIRP2
0x2

3254
chr2
168193128
168194318
+
XIRP2
0x2

3255
chr2
168810454
168811655
−
STK39
0x0

3256
chr2
169629883
169632194
+
CERS6
0x0

3257
chr2
169708092
169709241
−
SPC25
0x0

3258
chr2
169718770
169719869
−
SPC25
0x0

3259
chr2
170745999
170747207
+
UBR3
0x2

3260
chr2
170803991
170805188
+
UBR3
0x2

3261
chr2
171822195
171823294
+
GORASP2
0x0

3262
chr2
172513412
172514608
+
DYNC1I2
0x0

3263
chr2
172964494
172965794
−
DLX2
0x0

3264
chr2
172973378
172974581
+
DLX1
0x0

3265
chr2
174812507
174813692
−
SP3
0x0

3266
chr2
175345813
175347006
−
GPR155
0x0

3267
chr2
175584480
175585720
+
SCRN3
0x0

3268
chr2
176793434
176794543
−
KIAA1715
0x0

3269
chr2
176845051
176846246
−
KIAA1715
0x0

3270
chr2
176889001
176890223
+
HOXD13
0x2

3271
chr2
177039955
177041231
−
HOXD-AS1
0x0

3272
chr2
177065262
177066455
−
HOXD-AS1
0x0

3273
chr2
178084124
178085352
+
HNRNPA3
0x0

3274
chr2
178111555
178112777
−
MIR3128
0x0

3275
chr2
178256942
178258132
+
AGPS
0x0

3276
chr2
179403300
179404432
+
LOC100506866
0x0

3277
chr2
179468434
179469583
+
LOC100506866
0x0

3278
chr2
179487035
179488248
+
LOC100506866
0x0

3279
chr2
183595170
183596369
+
DNAJC10
0x0

3280
chr2
183789780
183790961
−
NCKAP1
0x0

3281
chr2
183887963
183889156
−
NCKAP1
0x0

3282
chr2
185472545
185473764
−
ZNF804A
0x0

3283
chr2
187072084
187073267
−
ZSWIM2
0x0

3284
chr2
187167909
187169130
−
ZSWIM2
0x0

3285
chr2
187310259
187311409
−
ZSWIM2
0x0

3286
chr2
189271930
189273039
−
GULP1
0x0

3287
chr2
190317882
190319095
+
WDR75
0x0

3288
chr2
191887589
191888807
+
GLS
0x0

3289
chr2
197657125
197658291
−
GTF3C3
0x2

3290
chr2
197752015
197753239
−
PGAP1
0x0

3291
chr2
198256448
198257650
−
SF3B1
0x2

3292
chr2
198353229
198354328
−
HSPD1
0x0

3293
chr2
198367444
198368643
+
HSPE1
0x0

3294
chr2
198399765
198400920
+
HSPE1-MOB4
0x0

3295
chr2
198399765
198400920
+
MOB4
0x0

3296
chr2
200245869
200247024
−
SATB2
0x2

3297
chr2
200297611
200298794
−
SATB2
0x2

3298
chr2
201687403
201688597
+
BZW1
0x0

3299
chr2
201845865
201847050
−
FAM126B
0x0

3300
chr2
202346553
202347750
+
STRADB
0x0

3301
chr2
202485617
202487245
−
TMEM237
0x0

3302
chr2
202490564
202491687
−
TMEM237
0x0

3303
chr2
202625507
202626945
−
ALS2
0x2

3304
chr2
203157232
203158427
+
NOP58
0x0

3305
chr2
203157232
203158427
−
SNORDll
0x0

3306
chr2
203160339
203161446
+
NOP58
0x0

3307
chr2
203729600
203730792
−
ICA1L
0x0

3308
chr2
203925103
203926329
+
NBEAL1
0x0

3309
chr2
204235230
204236550
−
ABI2
0x1

3310
chr2
204293056
204294163
+
A8I2
0x1

3311
chr2
205628833
205630031
+
PARD3B
0x0

3312
chr2
206613569
206614766
+
NRP2
0x0

3313
chr2
206765021
206766246
+
NRP2
0x0

3314
chr2
206889787
206890980
+
EEF1B2
0x0

3315
chr2
206997122
206998292
−
NDUFS1
0x0

3316
chr2
207026124
207027613
+
EEF1B2
0x0

3317
chr2
207026124
207027613
+
SNORA41
0x0

3318
chr2
207026124
207027613
+
SNORD51
0x0

3319
chr2
209221075
209222274
+
PIKFYVE
0x0

3320
chr2
211512125
211513352
+
CPS1
0x2

3321
chr2
212399831
212401039
+
CPS1
0x2

3322
chr2
212428216
212429388
−
ERBB4
0x1

3323
chr2
213214823
213215916
−
MIR548F2
0x0

3324
chr2
213238740
213239938
−
MIR548F2
0x0

3325
chr2
213329050
213330269
−
MIR548F2
0x0

3326
chr2
213336293
213337490
−
MIR548F2
0x0

3327
chr2
213390114
213391313
−
ERBB4
0x1

3328
chr2
216995072
216996232
+
XRCC5
0x0

3329
chr2
217069580
217070799
+
XRCC5
0x0

3330
chr2
217363468
217365329
+
RPL37A
0x0

3331
chr2
217365531
217366649
+
RPL37A
0x0

3332
chr2
217383074
217384232
+
RPL37A
0x0

3333
chr2
217431845
217433045
+
IGFBP2
0x0

3334
chr2
217538206
217540299
−
IGFBP5
0x1

3335
chr2
218286440
218287567
−
DIRC3
0x0

3336
chr2
218400358
218401552
−
DIRC3
0x0

3337
chr2
219109965
219111160
+
ARPC2
0x0

3338
chr2
219134612
219135878
+
PNKD
0x0

3339
chr2
219365160
219366302
−
USP37
0x0

3340
chr2
219525952
219527133
+
BCS1L
0x0

3341
chr2
220047566
220048764
+
FAM134A
0x0

3342
chr2
220083700
220085128
−
ABCB6
0x0

3343
chr2
220083700
220085128
−
ATG9A
0x0

3344
chr2
220431286
220432550
−
OBSL1
0x0

3345
chr2
223084400
223085617
−
PAX3
0x2

3346
chr2
223771341
223772508
+
ACSL3
0x2

3347
chr2
225337375
225338590
−
CUL3
0x1

3348
chr2
225357124
225358316
−
CUL3
0x1

3349
chr2
225362717
225363887
−
CUL3
0x1

3350
chr2
225449421
225450594
−
CUL3
0x1

3351
chr2
228627217
228628393
−
SLC19A3
0x0

3352
chr2
230015177
230016385
+
FBXO36
0x0

3353
chr2
230723204
230724432
−
TRIP12
0x0

3354
chr2
231684657
231685792
+
CAB39
0x0

3355
chr2
231742416
231743651
+
ITM2C
0x0

3356
chr2
231895330
231896507
−
LOC348761
0x0

3357
chr2
232319052
232321792
−
NCL
0x0

3358
chr2
232319052
232321792
−
SNORA75
0x0

3359
chr2
232319052
232321792
−
SNORD20
0x0

3360
chr2
232324517
232325714
−
NCL
0x0

3361
chr2
232324517
232325714
−
SNORD82
0x0

3362
chr2
232328602
232329702
−
NCL
0x0

3363
chr2
232576047
232577235
+
PTMA
0x0

3364
chr2
233936152
233937371
+
INPP5D
0x0

3365
chr2
234183893
234185136
+
SCARNA5
0x0

3366
chr2
234196971
234198139
+
SCARNA6
0x0

3367
chr2
234379111
234380348
+
DGKD
0x0

3368
chr2
236707724
236708823
+
AGAP1
0x0

3369
chr2
237084009
237085207
+
AGAP1
0x0

3370
chr2
237828105
237829302
−
COL6A3
0x0

3371
chr2
237994178
237995402
+
COPS8
0x0

3372
chr2
238640130
238641441
+
LRRFIP1
0x2

3373
chr2
238977416
238978680
+
SCLY
0x0

3374
chr2
238977416
238978680
+
UBE2F-SCLY
0x0

3375
chr2
240566799
240567975
+
LOC150935
0x0

3376
chr2
240927842
240929122
−
NDUFA10
0x0

3377
chr2
241438874
241440090
−
ANKMY1
0x0

3378
chr2
241463023
241464122
−
ANKMY1
0x0

3379
chr2
241464673
241465805
−
ANKMY1
0x0

3380
chr2
241537146
241538345
+
CAPN10
0x0

3381
chr2
241653284
241655521
−
KIF1A
0x2

3382
chr2
241680148
241681373
−
KIF1A
0x2

3383
chr2
241696785
241697921
−
KIF1A
0x2

3384
chr2
242168371
242169557
−
HDLBP
0x2

3385
chr2
242172844
242174023
−
ANO7
0x0

3386
chr2
242254254
242255441
+
SEPT2
0x0

3387
chr2
242280235
242282090
+
SEPT2
0x0

3388
chr2
242291056
242292245
+
SEPT2
0x0

3389
chr2
242292246
242293356
+
SEPT2
0x0

3390
chr2
242434431
242435563
−
STK25
0x0

3391
chr2
242684886
242686231
−
D2HGDH
0x0

3392
chr2
242699828
242700961
+
D2HGDH
0x0

3393
chr20
308144
309463
+
SOX12
0x0

3394
chr20
463505
464699
−
CSNK2A1
0x0

3395
chr20
1161617
1162788
−
TMEM74B
0x0

3396
chr20
1349577
1351191
−
FKBP1A
0x0

3397
chr20
1918344
1919624
+
SIRPA
0x0

3398
chr20
2443060
2444241
−
SNORD119
0x0

3399
chr20
2443060
2444241
−
SNRPB
0x0

3400
chr20
2447764
2448925
−
SNRPB
0x0

3401
chr20
2635175
2636402
+
NOP56
0x0

3402
chr20
2635175
2636402
+
SNORA51
0x0

3403
chr20
2637038
2638212
+
NOP56
0x0

3404
chr20
2637038
2638212
+
SNORD56
0x0

3405
chr20
2637038
2638212
+
SNORD57
0x0

3406
chr20
3145220
3146658
−
ProSAPiP1
0x0

3407
chr20
3733763
3734862
−
C20orf27
0x0

3408
chr20
4004220
4005516
+
PANK2
0x0

3409
chr20
4152647
4153818
−
ADRA1D
0x0

3410
chr20
5060684
5061856
−
C20orf30
0x0

3411
chr20
5164963
5166161
+
CDS2
0x0

3412
chr20
6559171
6560272
+
BMP2
0x1

3413
chr20
8864641
8865840
+
PLCB1
0x0

3414
chr20
9172099
9173278
+
PLCB4
0x2

3415
chr20
11905246
11906565
+
BTBD3
0x0

3416
chr20
11972785
11974015
+
BTBD3
0x0

3417
chr20
17930389
17931587
−
SNX5
0x0

3418
chr20
17942784
17944058
−
SNORD17
0x0

3419
chr20
18245801
18247009
−
DZANK1
0x0

3420
chr20
18485060
18486248
+
SEC23B
0x0

3421
chr20
25515364
25516505
−
NINL
0x0

3422
chr20
25845882
25847080
+
LOC100134868
0x0

3423
chr20
26188218
26190630
−
LOC284801
0x0

3424
chr20
26188218
26190630
−
MIR663A
0x0

3425
chr20
29620241
29621478
+
FRG1B
0x0

3426
chr20
30373619
30374717
+
TPX2
0x0

3427
chr20
30754487
30755598
+
TM9SF4
0x0

3428
chr20
30927750
30928849
+
KIF3B
0x0

3429
chr20
30953660
30954792
+
ASXL1
0x1

3430
chr20
31379762
31380979
+
DNMT3B
0x0

3431
chr20
31436868
31438511
+
MAPRE1
0x0

3432
chr20
31940667
31941815
−
CDK5RAP1
0x0

3433
chr20
31974725
31975863
−
CDK5RAP1
0x0

3434
chr20
32263513
32264643
−
E2F1
0x1

3435
chr20
32273238
32274483
−
E2F1
0x1

3436
chr20
32867650
32868912
−
AHCY
0x0

3437
chr20
33027471
33028640
−
ITCH
0x2

3438
chr20
33361081
33362271
−
NCOA6
0x2

3439
chr20
33530007
33531300
−
GSS
0x0

3440
chr20
33610313
33611516
−
TRPC4AP
0x0

3441
chr20
33866251
33867414
−
EIF6
0x0

3442
chr20
34091229
34092435
+
CEP250
0x0

3443
chr20
34144721
34145900
+
ERGIC3
0x0

3444
chr20
34218394
34219612
+
CPNE1
0x0

3445
chr20
34233085
34234229
−
RBM12
0x0

3446
chr20
34288156
34289329
+
ROMO1
0x0

3447
chr20
34301632
34302837
−
RBM39
0x0

3448
chr20
34312012
34313213
−
RBM39
0x0

3449
chr20
34430845
34432061
+
PHF20
0x0

3450
chr20
34633445
34634576
−
LOC647979
0x0

3451
chr20
34636380
34637538
−
LOC647979
0x0

3452
chr20
35221533
35222724
+
TGIF2
0x0

3453
chr20
35281129
35282335
−
NDRG3
0x0

3454
chr20
35422398
35423497
−
KIAA0889
0x0

3455
chr20
35443437
35444575
−
KIAA0889
0x0

3456
chr20
35466846
35467976
−
KIAA0889
0x0

3457
chr20
35485069
35486168
−
KIAA0889
0x0

3458
chr20
35519588
35520734
−
SAMHD1
0x0

3459
chr20
35857418
35858593
+
RPN2
0x0

3460
chr20
36064875
36066076
−
BLCAP
0x5

3461
chr20
36145828
36146964
−
BLCAP
0x5

3462
chr20
36147195
36148377
−
BLCAP
0x5

3463
chr20
36603038
36604247
−
TTI1
0x0

3464
chr20
37047754
37049031
−
LOC388796
0x0

3465
chr20
37053360
37054538
−
SNORA71B
0x0

3466
chr20
37055441
37056553
−
SNORA71A
0x0

3467
chr20
37062007
37063212
−
LOC388796
0x0

3468
chr20
37062007
37063212
−
SNORA71D
0x0

3469
chr20
37189919
37191130
+
RALGAPB
0x0

3470
chr20
37389853
37390980
+
ACTR5
0x0

3471
chr20
37500902
37502082
+
PPP1R16B
0x0

3472
chr20
37960926
37962082
−
LOC339568
0x0

3473
chr20
39652337
39653562
+
TOP1
0x2

3474
chr20
39751537
39752686
+
TOP1
0x2

3475
chr20
39755510
39756646
+
TOP1
0x2

3476
chr20
42086469
42087562
+
SRSF6
0x2

3477
chr20
42101122
42102269
+
SRSF6
0x2

3478
chr20
42139312
42140444
−
GTSF1L
0x0

3479
chr20
42142857
42143994
+
L3MBTL1
0x0

3480
chr20
42225881
42227031
+
IFT52
0x0

3481
chr20
42320252
42321487
+
MYBL2
0x0

3482
chr20
42635354
42636553
+
TOX2
0x0

3483
chr20
43380554
43381761
−
RIMS4
0x0

3484
chr20
43535683
43536777
+
YWHAB
0x2

3485
chr20
44469990
44471179
−
ACOT8
0x0

3486
chr20
44498416
44499609
+
ZSWIM3
0x0

3487
chr20
44557368
44558519
−
PLTP
0x0

3488
chr20
45892219
45893412
−
ZMYND8
0x0

3489
chr20
47896310
47897875
+
SNORD12
0x0

3490
chr20
47896310
47897875
+
SNORD12B
0x0

3491
chr20
47896310
47897875
+
ZNFX1-AS1
0x0

3492
chr20
47964535
47965725
+
ZNFX1-AS1
0x0

3493
chr20
48288304
48289481
−
B4GALT5
0x0

3494
chr20
48697546
48698670
−
TMEM189-UBE2V1
0x0

3495
chr20
48697546
48698670
−
UBE2V1
0x0

3496
chr20
48706461
48707619
−
TMEM189-UBE2V1
0x0

3497
chr20
48706461
48707619
−
UBE2V1
0x0

3498
chr20
49541256
49542400
−
ADNP
0x0

3499
chr20
50216789
50217980
−
ATP9A
0x0

3500
chr20
50512575
50513768
−
SALL4
0x0

3501
chr20
50556896
50658253
−
ZFP64
0x2

3502
chr20
50702728
50703853
−
ZFP64
0x2

3503
chr20
50704408
50705579
−
ZFP64
0x2

3504
chr20
51687704
51688904
+
TSHZ2
0x2

3505
chr20
57022743
57023963
+
VAPB
0x0

3506
chr20
57233979
57235189
+
STX16
0x0

3507
chr20
57233979
57235189
+
STX16-NPEPL1
0x0

3508
chr20
57465380
57466479
+
GNAS
0x6

3509
chr20
57479961
57481011
+
GNAS
0x6

3510
chr20
57483814
57485692
+
GNAS
0x6

3511
chr20
57608841
57609971
−
SLMO2
0x0

3512
chr20
60513126
60514302
−
MIR1Z57
0x0

3513
chr20
60588238
60589418
−
TAF4
0x0

3514
chr20
60639005
60640133
−
TAF4
0x0

3515
chr20
60848232
60849342
+
OSBPL2
0x0

3516
chr20
60906798
60907895
−
LAMA5
0x0

3517
chr20
60906798
60907895
−
MIR4758
0x0

3518
chr20
60934764
60935941
−
LAMA5
0x0

3519
chr20
60941458
60942635
−
LAMA5
0x0

3520
chr20
60962350
60964070
+
RPS21
0x0

3521
chr20
61431286
61432436
+
C20orf20
0x4

3522
chr20
61478722
61479897
−
TCFL5
0x0

3523
chr20
61907455
61908654
+
ARFGAP1
0x0

3524
chr20
62289653
62290799
+
RTEL1
0x0

3525
chr20
62289653
62290799
+
RTEL1-TNFRSF6B
0x0

3526
chr20
62338006
62339157
−
ARFRP1
0x0

3527
chr20
62365427
62366595
+
ZGPAT
0x0

3528
chr20
62373279
62374403
+
SLC2A4RG
0x0

3529
chr20
62527170
62528378
+
DNAJC5
0x0

3530
chr20
62545422
62546619
+
MIR941-1
0x0

3531
chr20
62573549
62574693
−
MIR647
0x0

3532
chr20
62582519
62583704
−
UCKL1
0x0

3533
chr20
62599061
62600188
−
ZNF512B
0x0

3534
chr20
62612010
62613160
+
PRPF6
0x0

3535
chr21
16016413
16017631
+
ABCC13
0x0

3536
chr21
17691360
17692529
+
LINC00478
0x0

3537
chr21
17923872
17925099
+
MIRLET7C
0x1

3538
chr21
18939729
18940861
+
CXADR
0x0

3539
chr21
18965434
18966673
−
BTG3
0x0

3540
chr21
19808934
19810061
−
TMPRSS15
0x0

3541
chr21
20716989
20718110
+
CHODL
0x0

3542
chr21
27096387
27097500
−
ATP5J
0x0

3543
chr21
27253244
27254417
−
APP
0x0

3544
chr21
27422807
27423993
−
APP
0x0

3545
chr21
27483816
27484951
−
APP
0x0

3546
chr21
27542144
27543260
−
APP
0x0

3547
chr21
28127783
28128979
+
MIR4759
0x0

3548
chr21
28208989
28210463
−
ADAMTS1
0x2

3549
chr21
28216087
28217212
−
ADAMTS1
0x2

3550
chr21
28337808
28339033
−
ADAMTS5
0x0

3551
chr21
30425923
30427216
+
USP16
0x2

3552
chr21
30698361
30699558
+
BACH1
0x0

3553
chr21
31014916
31016114
+
GRIK1-AS2
0x0

3554
chr21
32638350
32639765
−
TIAM1
0x2

3555
chr21
33036141
33037340
+
SOD1
0x0

3556
chr21
33040334
33041539
+
SOD1
0x0

3557
chr21
33089295
33090522
−
SCAF4
0x0

3558
chr21
33748942
33750183
−
SNORA80
0x0

3559
chr21
33984133
33985269
−
C21orf59
0x0

3560
chr21
34719386
34720535
+
IFNAR1
0x0

3561
chr21
35030387
35031585
+
ITSN1
0x0

3562
chr21
35127217
35128385
+
ITSN1
0x0

3563
chr21
35275722
35276821
−
ATP50
0x0

3564
chr21
35466827
35468201
+
SLC5A3
0x0

3565
chr21
36145165
36146372
+
LOC100506385
0x0

3566
chr21
37717977
37719131
+
MORC3
0x0

3567
chr21
37784041
37785217
+
CHAF1B
0x0

3568
chr21
37788598
37789672
+
CHAF1B
0x0

3569
chr21
38567541
38568686
+
TTC3
0x0

3570
chr21
38574002
38575432
+
TTC3
0x0

3571
chr21
38596923
38598132
−
DSCR3
0x0

3572
chr21
38632627
38633808
−
DSCR3
0x0

3573
chr21
40197423
40198595
+
ETS2
0x0

3574
chr21
40517282
40518471
−
PSMG1
0x0

3575
chr21
40718385
40719530
−
HMGN1
0x0

3576
chr21
42749811
42750988
+
MX2
0x2

3577
chr21
44268392
44269583
+
WDR4
0x0

3578
chr21
44479625
44480758
−
CBS
0x0

3579
chr21
44984500
44985920
+
RRP1B
0x0

3580
chr21
45090405
45091504
+
RRP1B
0x0

3581
chr21
45179520
45180696
+
PDXK
0x0

3582
chr21
45221421
45222618
+
RRP1
0x0

3583
chr21
45337879
45339028
+
AGPAT3
0x0

3584
chr21
45393639
45394947
+
AGPAT3
0x0

3585
chr21
45559550
45560770
+
C21orf33
0x0

3586
chr21
46188735
46189879
−
UBE2G2
0x2

3587
chr21
46225809
46226932
−
SUMO3
0x0

3588
chr21
46708339
46709547
+
LOC642852
0x0

3589
chr21
46893600
46894927
+
COL18A1
0x1

3590
chr21
46949302
46950441
−
SLC19A1
0x0

3591
chr21
46952281
46953369
−
SLC19A1
0x0

3592
chr21
46955505
46956592
−
SLC19A1
0x0

3593
chr21
47424319
47425504
+
COL6A1
0x0

3594
chr21
47547608
47548806
+
COL6A2
0x0

3595
chr21
47608898
47610162
−
LSS
0x0

3596
chr21
47738047
47739198
−
C21orf58
0x0

3597
chr22
18314151
18315281
−
MICAL3
0x0

3598
chr22
18571125
18572217
+
PEX26
0x0

3599
chr22
18954229
18955424
+
DGCR5
0x0

3600
chr22
19162785
19163956
−
SLC25A1
0x0

3601
chr22
19283535
19284762
+
MRPL40
0x0

3602
chr22
19362273
19363409
−
HIRA
0x0

3603
chr22
19822965
19824171
−
C22orf29
0x0

3604
chr22
19946011
19947236
+
COMT
0x0

3605
chr22
19949534
19950733
+
COMT
0x0

3606
chr22
19967218
19968536
−
ARVCF
0x0

3607
chr22
20842383
20843522
−
KLHL22
0x0

3608
chr22
21287555
21289058
+
CRKL
0x0

3609
chr22
21306986
21308085
+
CRKL
0x0

3610
chr22
21742936
21744308
+
RIMBP3B
0x0

3611
chr22
21742936
21744308
+
RIMBP3C
0x0

3612
chr22
22210386
22211557
−
MAPK1
0x0

3613
chr22
22672503
22673700
+
LOC96610
0x0

3614
chr22
23522226
23523427
+
BCR
0x1

3615
chr22
23980518
23981697
−
GUSBP11
0x0

3616
chr22
24236041
24237608
+
MIF
0x0

3617
chr22
24438704
24439858
+
CABIN1
0x0

3618
chr22
24907612
24908737
+
UPB1
0x0

3619
chr22
24936646
24937830
−
C22orf13
0x0

3620
chr22
24967397
24968547
+
SNRPD3
0x0

3621
chr22
25529046
25530177
+
KIAA1671
0x0

3622
chr22
25776890
25778026
−
LRP5L
0x0

3623
chr22
26104005
26105227
+
ADRBK2
0x0

3624
chr22
27282576
27283773
−
CRYBB1
0x0

3625
chr22
28248228
28249383
−
PITPNB
0x0

3626
chr22
28629801
28630944
−
TTC28
0x0

3627
chr22
28763509
28764779
−
TTC28
0x0

3628
chr22
28814029
28815169
−
TTC28
0x0

3629
chr22
28852585
28853737
−
TTC28
0x0

3630
chr22
28888395
28889599
−
TTC28
0x0

3631
chr22
29356334
29357530
+
ZNRF3
0x0

3632
chr22
29538797
29539902
+
KREMEN1
0x2

3633
chr22
29541059
29542208
+
KREMEN1
0x2

3634
chr22
29725923
29727091
−
AP1B1
0x0

3635
chr22
29727713
29730500
−
AP1B1
0x0

3636
chr22
29727713
29730500
−
MIR3653
0x0

3637
chr22
29727713
29730500
−
SNORD125
0x0

3638
chr22
31371430
31372477
+
TUG1
0x0

3639
chr22
31556509
31557707
+
RNF18S
0x0

3640
chr22
32226093
32227273
−
DEPDC5
0x0

3641
chr22
32894134
32895276
+
FBXO7
0x0

3642
chr22
33777348
33778521
−
LARGE
0x0

3643
chr22
34297389
34298523
−
LARGE
0x0

3644
chr22
34315651
34316828
−
LARGE
0x0

3645
chr22
35681160
35682395
+
HMGXB4
0x0

3646
chr22
35690280
35691464
+
HMGXB4
0x0

3647
chr22
35839585
35840776
+
MCM5
0x0

3648
chr22
36137244
36138456
−
RBFOX2
0x0

3649
chr22
36138942
36140500
−
RBFOX2
0x0

3650
chr22
36214874
36216032
−
RBFOX2
0x0

3651
chr22
36395321
36396462
−
RBFOX2
0x0

3652
chr22
36677011
36678199
−
MYH9
0x2

3653
chr22
36680665
36681891
−
MYH9
0x2

3654
chr22
36704808
36705986
−
MYH9
0x2

3655
chr22
37803544
37804731
−
ELFN2
0x0

3656
chr22
38007253
38008489
+
GGA1
0x2

3657
chr22
38200770
38201857
+
H1F0
0x0

3658
chr22
38313130
38314351
+
MICALL1
0x0

3659
chr22
38616456
38617636
−
TMEM184B
0x0

3660
chr22
38690099
38691306
−
CSNK1E
0x0

3661
chr22
38691643
38692846
−
CSNK1E
0x0

3662
chr22
38851091
38852298
+
KDELR3
0x0

3663
chr22
38879086
38881782
−
DDX17
0x0

3664
chr22
38896636
38897754
−
DDX17
0x0

3665
chr22
39079245
39080420
+
TOMM22
0x0

3666
chr22
39126436
39127627
+
GTPBP1
0x0

3667
chr22
39258060
39259789
−
CBX6
0x0

3668
chr22
39709252
39710490
−
RP13
0x0

3669
chr22
39709252
39710490
−
SNORD83B
0x0

3670
chr22
39710669
39711896
−
RPL3
0x0

3671
chr22
39710669
39711896
−
SNORD83A
0x0

3672
chr22
39713023
39714106
−
RPL3
0x0

3673
chr22
39714525
39715679
−
RPL3
0x0

3674
chr22
39714525
39715679
−
SNORD43
0x0

3675
chr22
39824331
39825448
+
TAB1
0x0

3676
chr22
40603841
40604999
+
TNRC6B
0x0

3677
chr22
41032643
41033828
+
MCHR1
0x2

3678
chr22
41322022
41323150
+
XPNPEP3
0x0

3679
chr22
41348974
41350206
+
RBX1
0x1

3680
chr22
41367993
41369234
+
RBX1
0x1

3681
chr22
41650943
41652115
−
RANGAP1
0x0

3682
chr22
41672402
41673555
−
RANGAP1
0x0

3683
chr22
41830391
41831584
−
TOB2
0x0

3684
chr22
41921316
41922493
−
POLR3H
0x0

3685
chr22
41931206
41932394
−
POLR3H
0x0

3686
chr22
41989044
41990224
−
PMM1
0x0

3687
chr22
42017457
42018631
+
XRCC6
0x0

3688
chr22
42031586
42032802
+
XRCC6
0x0

3689
chr22
42070194
42071398
−
NHP2L1
0x0

3690
chr22
42205327
42206535
+
CCDC134
0x0

3691
chr22
42224006
42225166
+
CCDC134
0x0

3692
chr22
42228697
42229797
+
SREBF2
0x0

3693
chr22
42244116
42245325
+
SREBF2
0x0

3694
chr22
42301585
42303689
+
SREBF2
0x0

3695
chr22
42390611
42391960
+
SEPTS
0x0

3696
chr22
42605304
42606458
−
TCF20
0x0

3697
chr22
42911537
42912665
−
RRP7A
0x0

3698
chr22
42960739
42961876
−
RRP7B
0x0

3699
chr22
43010681
43011963
+
RNU12
0x0

3700
chr22
43014427
43015900
−
CYB5R3
0x0

3701
chr22
44403105
44404301
+
PARVB
0x0

3702
chr22
45364086
45365225
−
PHF21B
0x0

3703
chr22
45568661
45569815
+
NUP50
0x0

3704
chr22
45580847
45581958
+
NUP50
0x0

3705
chr22
45921134
45922335
+
FBLN1
0x0

3706
chr22
46088330
46089523
+
ATXN10
0x0

3707
chr22
46124715
46126044
+
ATXN10
0x0

3708
chr22
46134049
46135230
+
ATXN10
0x0

3709
chr22
46156733
46157865
+
MIR4762
0x0

3710
chr22
46268284
46269464
+
ATXN10
0x0

3711
chr22
46483698
46484878
+
MIRLET7BHG
0x0

3712
chr22
46494420
46495618
+
MIRLET7BHG
0x0

3713
chr22
46634509
46635753
+
PPARA
0x0

3714
chr22
46781824
46783035
−
CELSR1
0x0

3715
chr22
46946646
46947830
−
CELSR1
0x0

3716
chr22
47270127
47271321
+
TBC1D22A
0x0

3717
chr22
50205194
50206352
−
BRD1
0x0

3718
chr22
50210282
50211470
−
BRD1
0x0

3719
chr22
50713376
50714569
−
PLXNB2
0x0

3720
chr22
50719855
50721037
−
PLXNB2
0x0

3721
chr22
50831729
50832913
+
PPP6R2
0x0

3722
chr22
50904081
50906314
−
SBF1
0x0

3723
chr22
50970887
50972085
+
NCAPH2
0x0

3724
chr22
51063279
51064390
−
ARSA
0x0

3725
chr3
3186604
3187841
+
TRNT1
0x0

3726
chr3
8024180
8025374
−
LOC100288428
0x0

3727
chr3
8265114
8266333
+
LMCD1
0x0

3728
chr3
9431261
9432805
−
LOC440944
0x0

3729
chr3
9486201
9487428
+
SETD5
0x0

3730
chr3
9857220
9858434
+
TTLL3
0x0

3731
chr3
10167287
10168486
+
BRK1
0x0

3732
chr3
10321861
10323056
+
TATDN2
0x0

3733
chr3
11401512
11402751
+
ATG7
0x0

3734
chr3
11597538
11598649
−
VGLL4
0x0

3735
chr3
12064814
12066017
+
SYN2
0x2

3736
chr3
12147964
12149112
+
SYN2
0x2

3737
chr3
12560059
12561224
+
TSEN2
0x0

3738
chr3
12625214
12626361
−
RAF1
0x2

3739
chr3
12844503
12845700
+
CAND2
0x0

3740
chr3
12881152
12882451
−
RPL32
0x0

3741
chr3
12881152
12882451
−
SNORA7A
0x0

3742
chr3
12982633
12983771
−
IQSEC1
0x0

3743
chr3
13035839
13037016
−
IQSEC1
0x0

3744
chr3
13280722
13281919
−
NUP210
0x2

3745
chr3
13313379
13314536
−
NUP210
0x2

3746
chr3
13357743
13359380
−
NUP210
0x2

3747
chr3
13783339
13784537
+
LOC285375
0x0

3748
chr3
14199493
14200692
−
XPC
0x2

3749
chr3
15483124
15484230
+
EAF1
0x0

3750
chr3
15779482
15780795
+
BTD
0x0

3751
chr3
15885578
15886855
−
ANKRD28
0x0

3752
chr3
16275601
16276775
+
GALNTL2
0x0

3753
chr3
16459402
16460560
−
RFTN1
0x0

3754
chr3
17052965
17054111
+
PICL2
0x0

3755
chr3
20025601
20026775
+
RAB5A
0x0

3756
chr3
23383956
23385109
+
MIR548AC
0x0

3757
chr3
23436605
23437832
+
MIR548AC
0x0

3758
chr3
23925735
23926895
+
UBE2E1
0x0

3759
chr3
23932123
23933247
+
UBE2E1
0x0

3760
chr3
23960126
23962663
+
RPL15
0x0

3761
chr3
23995512
23996762
+
NR1D2
0x0

3762
chr3
25639039
25640283
−
TOP2B
0x0

3763
chr3
29587021
29588218
+
RBMS3
0x0

3764
chr3
31269659
31270890
+
STT3B
0x0

3765
chr3
31620850
31622065
+
STT3B
0x0

3766
chr3
31699275
31700456
+
STT3B
0x0

3767
chr3
31945766
31946935
+
OSBPL10
0x0

3768
chr3
32078480
32079674
+
ZNF860
0x0

3769
chr3
32411082
32412230
+
CMTM8
0x0

3770
chr3
32599973
32601163
−
DYNC1LI1
0x0

3771
chr3
32609995
32611224
−
DYNC1LI1
0x0

3772
chr3
32938215
32939410
+
TRIM71
0x0

3773
chr3
33128714
33129913
−
TMPPE
0x0

3774
chr3
33173472
33174713
+
CRTAP
0x0

3775
chr3
33643362
33644461
−
CLASP2
0x0

3776
chr3
33873618
33874717
+
PDCD6IP
0x0

3777
chr3
36726163
36727403
+
STAC
0x0

3778
chr3
37080825
37081931
+
MLH1
0x1

3779
chr3
37189849
37191014
−
LRRFIP2
0x0

3780
chr3
37465287
37466386
+
C3orf35
0x0

3781
chr3
38427202
38428303
+
XYLB
0x0

3782
chr3
38668691
38669899
−
SCN5A
0x2

3783
chr3
39449312
39450619
+
RPSA
0x0

3784
chr3
39449312
39450619
+
SNORA6
0x0

3785
chr3
39452000
39454062
+
RPSA
0x0

3786
chr3
39452000
39454062
+
SNORA62
0x0

3787
chr3
40352965
40354173
+
EIF1B
0x0

3788
chr3
40504882
40506079
+
RPL14
0x0

3789
chr3
40522637
40523826
+
ZNF619
0x0

3790
chr3
40713594
40714769
+
ZNF621
0x0

3791
chr3
41268246
41269401
+
CTNNB1
0x2

3792
chr3
41280979
41282170
+
CTNNB1
0x2

3793
chr3
42172215
42173420
+
TRAK1
0x0

3794
chr3
42262814
42263984
+
TRAK1
0x0

3795
chr3
42627709
42628944
+
SS18L2
0x0

3796
chr3
42661569
42662722
+
NKTR
0x0

3797
chr3
42825272
42826470
−
HIGD1A
0x0

3798
chr3
43369372
43370583
+
SNRK
0x0

3799
chr3
43513438
43514642
+
SNRK
0x0

3800
chr3
43735287
43736484
+
ABHD5
0x0

3801
chr3
44534839
44536016
−
ZNF445
0x0

3802
chr3
44672062
44673163
+
ZNF197
0x0

3803
chr3
44879232
44880427
+
KIF15
0x0

3804
chr3
45532675
45533841
+
LARS2
0x0

3805
chr3
45696671
45697833
+
LIMD1
0x1

3806
chr3
45729920
45731109
−
LOC644714
0x0

3807
chr3
47030877
47031967
+
NBEAL2
0x0

3808
chr3
47050355
47051532
+
NBEAL2
0x0

3809
chr3
47450648
47451750
+
PTPN23
0x0

3810
chr3
47466455
47467633
−
SCAP
0x0

3811
chr3
47469475
47470674
−
SCAP
0x0

3812
chr3
47529404
47530562
−
C3orf75
0x0

3813
chr3
47603307
47604405
−
CSPG5
0x0

3814
chr3
47627164
47629184
−
SMARCC1
0x0

3815
chr3
47703473
47704650
−
SMARCC1
0x0

3816
chr3
47719118
47720319
−
SMARCC1
0x0

3817
chr3
47892891
47895011
−
MAP4
0x0

3818
chr3
47932060
47933280
−
MAP4
0x0

3819
chr3
47985416
47986611
−
MAP4
0x0

3820
chr3
48313866
48315070
+
ZNF589
0x0

3821
chr3
48455708
48456825
−
PLXNB1
0x0

3822
chr3
48460349
48461527
−
PLXNB1
0x0

3823
chr3
48730604
48732071
−
IP6K2
0x0

3824
chr3
48784557
48786041
−
PRKAR2A
0x0

3825
chr3
48978026
48979203
+
ARIH2
0x0

3826
chr3
49049998
49051180
+
WDR6
0x0

3827
chr3
49059757
49060931
+
NDUFAF3
0x0

3828
chr3
49298828
49299995
−
C3orf62
0x0

3829
chr3
49306933
49308097
+
MIR4271
0x0

3830
chr3
49396629
49397880
−
RHOA
0x1

3831
chr3
49462515
49463654
−
NICN1
0x0

3832
chr3
49515374
49516569
+
DAG1
0x0

3833
chr3
49570399
49571592
+
DAG1
0x0

3834
chr3
49736551
49737732
+
RNF123
0x0

3835
chr3
50263689
50264867
+
SLC38A3
0x2

3836
chr3
50773542
50774742
+
DOCK3
0x0

3837
chr3
51042193
51043377
+
DOCK3
0x0

3838
chr3
51242911
51244156
+
DOCK3
0x0

3839
chr3
51347120
51348316
+
DOCK3
0x0

3840
chr3
51572431
51573592
+
RAD54L2
0x0

3841
chr3
51697732
51698844
+
RAD54L2
0x0

3842
chr3
51727913
51729115
−
IQCF6
0x0

3843
chr3
52002235
52003383
−
ABHD14B
0x0

3844
chr3
52027879
52028994
−
RPL29
0x0

3845
chr3
52561632
52562808
−
NT5DC2
0x0

3846
chr3
52569766
52570959
+
C3orf78
0x0

3847
chr3
52635477
52636633
−
PBRM1
0x1

3848
chr3
52713144
52714273
−
PBRM1
0x1

3849
chr3
52728009
52729194
−
GLT8D1
0x0

3850
chr3
53260228
53261442
−
TKT
0x0

3851
chr3
53327386
53328534
−
DCP1A
0x0

3852
chr3
53893275
53894463
−
ACTR8
0x0

3853
chr3
56105579
56106778
+
CCDC66
0x0

3854
chr3
56253146
56254314
−
ERC2
0x0

3855
chr3
56657136
56658267
−
FAM208A
0x0

3856
chr3
56692410
56693565
+
CCDC66
0x0

3857
chr3
56712433
56713636
−
FAM208A
0x0

3858
chr3
58066827
58068032
+
FLNB
0x2

3859
chr3
59526653
59527853
−
FHIT
0x1

3860
chr3
59803894
59805090
−
FHIT
0x1

3861
chr3
60392540
60393686
−
FHIT
0x1

3862
chr3
60740685
60741849
−
FHIT
0x1

3863
chr3
61079221
61080390
−
FHIT
0x1

3864
chr3
61684302
61685482
−
ID2B
0x0

3865
chr3
61728103
61729326
−
ID2B
0x0

3866
chr3
61781350
61782617
+
PTPRG
0x0

3867
chr3
61821361
61822559
+
PTPRG
0x0

3868
chr3
62252507
62253654
+
PTPRG
0x0

3869
chr3
63530565
63531774
+
SYNPR
0x0

3870
chr3
63898015
63899478
+
ATXN7
0x0

3871
chr3
64081176
64082354
−
PRICKLE2
0x0

3872
chr3
65581623
65582779
−
MAGI1
0x0

3873
chr3
69061262
69062419
−
C3orf64
0x0

3874
chr3
69109074
69110269
−
UBA3
0x0

3875
chr3
69383812
69385009
−
FRMD4B
0x0

3876
chr3
69937863
69939029
+
MITF
0x2

3877
chr3
71049846
71051051
−
FOXP1
0x1

3878
chr3
71310174
71311273
−
FOXP1
0x1

3879
chr3
71803897
71805392
+
GPR27
0x0

3880
chr3
72440865
72442047
−
RYBP
0x0

3881
chr3
73159615
73160858
+
PPP4R2
0x0

3882
chr3
75467516
75468695
−
FAM86DP
0x0

3883
chr3
75778673
75780352
−
ZNF717
0x0

3884
chr3
76067180
76068297
+
MIR4273
0x0

3885
chr3
76116679
76117859
+
MIR4273
0x0

3886
chr3
77588421
77589624
−
ROBO1
0x2

3887
chr3
78210509
78211683
+
ROBO2
0x2

3888
chr3
78725364
78726526
−
ROBO1
0x2

3889
chr3
78776220
78777399
−
ROBO1
0x2

3890
chr3
78965685
78966835
−
ROBO1
0x2

3891
chr3
79746721
79747916
+
ROBO2
0x2

3892
chr3
87302575
87303778
+
CHMP2B
0x2

3893
chr3
88188033
88189234
+
ZNF654
0x0

3894
chr3
93845492
93846677
+
NSUN3
0x0

3895
chr3
96070305
96071474
+
EPHA6
0x0

3896
chr3
96336252
96337451
−
MINA
0x0

3897
chr3
96706235
96707403
+
EPHA6
0x0

3898
chr3
98298899
98300073
−
CPOX
0x0

3899
chr3
98514482
98515659
−
DCBLD2
0x0

3900
chr3
99674284
99675721
+
C3orf26
0x0

3901
chr3
100083078
100084175
−
TOMM70A
0x0

3902
chr3
101294947
101296226
−
SENP7
0x0

3903
chr3
101311953
101313173
+
PCNP
0x0

3904
chr3
101427409
101428630
+
LOC285359
0x0

3905
chr3
101523677
101524892
−
FAM55C
0x0

3906
chr3
105577927
105579124
−
CBLB
0x2

3907
chr3
112728872
112730023
−
C3orf17
0x0

3908
chr3
112731024
112732187
−
C3orf17
0x0

3909
chr3
113351035
113352266
+
SIDT1
0x0

3910
chr3
113409806
113410988
−
KIAA2018
0x0

3911
chr3
113437715
113438865
−
NAA50
0x0

3912
chr3
113439795
113440972
−
NAA50
0x0

3913
chr3
113528980
113530968
+
ATP6V1A
0x0

3914
chr3
113782739
113783838
+
QTRTD1
0x0

3915
chr3
114068620
114069796
−
ZBTB20
0x0

3916
chr3
119247667
119248873
+
TIMMDC1
0x0

3917
chr3
119509622
119510841
+
NR1I2
0x0

3918
chr3
119812267
119813380
−
GSK3B
0x2

3919
chr3
120434017
120435211
−
RABL3
0x0

3920
chr3
120955706
120956915
−
POLQ
0x0

3921
chr3
122841602
122842804
+
PDIA5
0x0

3922
chr3
124988538
124989715
−
ZNF148
0x0

3923
chr3
125165792
125166986
−
SNX4
0x2

3924
chr3
125797486
125798706
−
SLC41A3
0x0

3925
chr3
125833502
125834789
−
ALDH1L1
0x4

3926
chr3
126180019
126181440
−
ZXDC
0x0

3927
chr3
126183659
126184858
−
ZXDC
0x0

3928
chr3
126322569
126323774
−
TXNRD3
0x0

3929
chr3
126707552
126708763
+
PLXNA1
0x0

3930
chr3
127380537
127381652
+
PODXL2
0x0

3931
chr3
127788558
127790058
+
SEC61A1
0x0

3932
chr3
127793410
127794585
−
RUVBL1
0x2

3933
chr3
128198861
128200036
−
GATA2
0x2

3934
chr3
128207961
128209161
+
DNAJB8-AS1
0x0

3935
chr3
128338243
128339419
−
RPN1
0x2

3936
chr3
128451591
128452997
+
RAB7A
0x0

3937
chr3
128531822
128533064
+
RAB7A
0x0

3938
chr3
128953745
128954950
+
COPG1
0x0

3939
chr3
129273522
129274695
−
PLXND1
0x0

3940
chr3
129296466
129297816
−
PLXND1
0x0

3941
chr3
129309709
129310948
+
H1FOO
0x2

3942
chr3
130462865
130464003
−
P1K3R4
0x0

3943
chr3
131197366
131198647
−
SNORA58
0x0

3944
chr3
131947407
131948608
−
CPNE4
0x0

3945
chr3
132293236
132294410
−
ACAD11
0x0

3946
chr3
132293236
132294410
−
NPHP3-ACAD11
0x0

3947
chr3
132394900
132396036
+
UBA5
0x0

3948
chr3
132809501
132810699
+
TMEM108
0x0

3949
chr3
133361690
133362902
−
TOPBP1
0x0

3950
chr3
133875654
133876850
−
RYK
0x0

3951
chr3
134501746
134502960
−
KY
0x0

3952
chr3
134713228
134714454
+
EPHB1
0x2

3953
chr3
136676705
136677925
+
IL20RB
0x0

3954
chr3
141324383
141325571
+
RASA2
0x0

3955
chr3
141644100
141645202
+
ATP1B3
0x0

3956
chr3
142047179
142048291
−
XRN1
0x1

3957
chr3
142391861
142393182
+
PLS1
0x0

3958
chr3
142774866
142776027
+
U2SURP
0x0

3959
chr3
143553099
143554255
−
SLC9A9
0x0

3960
chr3
148748280
148749431
−
HLTF
0x1

3961
chr3
148757934
148759261
−
HLTF
0x1

3962
chr3
149672385
149673561
−
PFN2
0x0

3963
chr3
149682334
149684418
−
PFN2
0x0

3964
chr3
149685647
149686790
−
PFN2
0x0

3965
chr3
149699572
149700765
−
PFN2
0x0

3966
chr3
150261659
150262838
−
SERP1
0x0

3967
chr3
150381802
150383036
+
SELT
0x0

3968
chr3
150905323
150906552
+
MED12L
0x2

3969
chr3
152019844
152021041
+
MBNL1
0x0

3970
chr3
152525159
152526317
−
TMEM14E
0x0

3971
chr3
154006950
154008133
−
DHX36
0x0

3972
chr3
154017847
154018991
−
DHX36
0x0

3973
chr3
155610832
155611932
+
GMPS
0x2

3974
chr3
156258040
156259216
−
SSR3
0x0

3975
chr3
156259638
156260819
−
SSR3
0x0

3976
chr3
159505029
159506215
+
IQCJ-SCHIP1
0x0

3977
chr3
159505029
159506215
+
SCHIPl
0x0

3978
chr3
160101112
160102239
−
IFT80
0x0

3979
chr3
160135040
160136208
+
SMC4
0x0

3980
chr3
160145967
160147164
+
SMC4
0x0

3981
chr3
160151049
160152148
+
SMC4
0x0

3982
chr3
160232247
160233581
−
KPNA4
0x0

3983
chr3
160232247
160233581
−
SCARNA7
0x0

3984
chr3
161146335
161147562
−
SPTSSB
0x0

3985
chr3
162751663
162752835
+
OTOL1
0x0

3986
chr3
167812547
167813770
−
GOLIM4
0x0

3987
chr3
168916004
168917153
−
MECOM
0x0

3988
chr3
169016868
169018187
−
MECOM
0x0

3989
chr3
169248357
169249556
−
MECOM
0x0

3990
chr3
169257396
169258572
−
MECOM
0x0

3991
chr3
169276218
169277388
−
MECOM
0x0

3992
chr3
169300966
169302116
−
MECOM
0x0

3993
chr3
169321337
169322504
−
MECOM
0x0

3994
chr3
169481843
169483395
−
TERC
0x0

3995
chr3
169489439
169490639
+
MYNN
0x0

3996
chr3
169712126
169713251
+
SEC62
0x0

3997
chr3
169811003
169812221
−
PHC3
0x0

3998
chr3
170113003
170114159
+
SKIL
0x0

3999
chr3
173662250
173663437
+
NLGN1
0x2

4000
chr3
174095052
174096268
+
NLGN1
0x2

4001
chr3
174689747
174690921
−
SPATA16
0x0

4002
chr3
175180913
175182083
+
NAALADL2
0x0

4003
chr3
176738627
176739772
−
TBL1XR1
0x2

4004
chr3
178724112
178725336
−
ZMAT3
0x0

4005
chr3
178897509
178898703
+
PIK3CA
0x2

4006
chr3
179040437
179041633
+
ZNF639
0x2

4007
chr3
179089083
179090273
+
MFN1
0x0

4008
chr3
179113461
179114610
−
GNB4
0x2

4009
chr3
179117003
179118152
−
GNB4
0x2

4010
chr3
179305509
179306667
+
ACTL6A
0x0

4011
chr3
179879102
179880325
−
PEX5L
0x0

4012
chr3
180631103
180632281
−
DNAJC19
0x0

4013
chr3
181540082
181541351
−
FU46066
0x0

4014
chr3
182582782
182583964
+
ATP11B
0x0

4015
chr3
182750101
182751276
−
MCCC1
0x0

4016
chr3
183169134
183170340
+
LOC100505687
0x0

4017
chr3
183353570
183354694
+
KLHL24
0x0

4018
chr3
183398003
183399122
+
KLHL24
0x0

4019
chr3
183580621
183581759
−
PARL
0x0

4020
chr3
183744592
183745798
−
ABCC5
0x0

4021
chr3
183854121
183855271
+
EIF2B5
0x0

4022
chr3
183867148
183868604
+
EIF2B5
0x0

4023
chr3
183890038
183891239
+
DVL3
0x0

4024
chr3
183900738
183902213
+
AP2M1
0x0

4025
chr3
184039630
184040778
+
EIF4G1
0x0

4026
chr3
184042919
184044133
+
EIF4G1
0x0

4027
chr3
184042919
184044133
+
SNORD66
0x0

4028
chr3
184051974
184053512
+
EIF4G1
0x0

4029
chr3
184084326
184085542
+
POLR2H
0x0

4030
chr3
184427867
184429119
−
MAGEF1
0x0

4031
chr3
184429133
184430288
−
MAGEF1
0x0

4032
chr3
184563055
184564277
+
VPS8
0x0

4033
chr3
185347678
185348961
+
SENP2
0x0

4034
chr3
185361867
185363192
−
IGF2BP2
0x0

4035
chr3
185439837
185441123
−
IGF2BP2
0x0

4036
chr3
185505712
185506895
−
IGF2BP2
0x0

4037
chr3
185634368
185635555
−
TRA2B
0x0

4038
chr3
185649515
185650644
−
TRA2B
0x0

4039
chr3
185653526
185654615
−
TRA2B
0x0

4040
chr3
186503929
186505190
+
EIF4A2
0x2

4041
chr3
186503929
186505190
+
MIR1248
0x0

4042
chr3
186503929
186505190
+
SNORA63
0x0

4043
chr3
186503929
186505190
+
SNORA81
0x0

4044
chr3
186507201
186508333
−
RFC4
0x0

4045
chr3
186617309
186618709
+
ST6GAL1
0x0

4046
chr3
186759892
186761084
+
ST6GAL1
0x0

4047
chr3
187388143
187389326
+
LOC100131635
0x0

4048
chr3
192515576
192516752
−
MB21D2
0x0

4049
chr3
193855605
193856801
+
HES1
0x4

4050
chr3
194125256
194126390
−
ATP13A3
0x0

4051
chr3
194171170
194172310
−
ATP13A3
0x0

4052
chr3
194386411
194387704
−
LSG1
0x0

4053
chr3
195776095
195777234
−
TFRC
0x2

4054
chr3
195962385
195963505
−
PCYT1A
0x0

4055
chr3
196074014
196075163
−
UBXN7
0x0

4056
chr3
196081421
196082538
−
UBXN7
0x0

4057
chr3
196118165
196119364
−
UBXN7
0x0

4058
chr3
196119861
196121051
−
UBXN7
0x0

4059
chr3
196511321
196512475
−
CEP19
0x0

4060
chr3
196728214
196729390
−
MFI2
0x0

4061
chr3
196842301
196843472
−
DLG1
0x1

4062
chr3
197281533
197282691
+
FYTTD1
0x0

4063
chr3
197679722
197680920
+
RPL35A
0x0

4064
chr3
197682245
197683345
+
RPL35A
0x0

4065
chr4
1209320
1210535
−
CTBP1
0x1

4066
chr4
1218742
1219931
−
CTBP1
0x1

4067
chr4
1231531
1232630
−
CTBP1
0x1

4068
chr4
1234606
1235835
−
CTBP1
0x1

4069
chr4
1342835
1343966
+
KIAA1530
0x4

4070
chr4
1672052
1673244
−
FAM53A
0x0

4071
chr4
1694014
1695533
−
SLBP
0x0

4072
chr4
1713372
1714566
−
SLBP
0x0

4073
chr4
1726499
1727631
+
TACC3
0x0

4074
chr4
1738532
1739923
+
TACC3
0x0

4075
chr4
1746121
1747254
+
TACC3
0x0

4076
chr4
1805357
1806534
+
FGFR3
0x2

4077
chr4
1813767
1815003
−
LETM1
0x2

4078
chr4
1824830
1826025
−
LETM1
0x2

4079
chr4
1918109
1919304
+
WHSC1
0x2

4080
chr4
1936420
1937586
+
WHSC1
0x2

4081
chr4
1957214
1958422
+
WHSC1
0x2

4082
chr4
1975823
1977043
+
SCARNA22
0x0

4083
chr4
1975823
1977043
+
WHSC1
0x2

4084
chr4
1981796
1982993
+
WHSC1
0x2

4085
chr4
2067921
2069165
+
NAT8L
0x0

4086
chr4
2077034
2078212
−
POLN
0x0

4087
chr4
2248957
2250057
−
MXD4
0x0

4088
chr4
2581395
2582619
+
FAM193A
0x0

4089
chr4
2827638
2829176
+
SH3BP2
0x0

4090
chr4
2906074
2907292
+
ADD1
0x0

4091
chr4
2940758
2941861
−
NOP14
0x0

4092
chr4
3252082
3253256
−
HTT-AS1
0x0

4093
chr4
4683894
4685085
+
LOC100507266
0x0

4094
chr4
5818067
5819249
+
EVC
0x0

4095
chr4
6200362
6201539
−
JAKMIP1
0x0

4096
chr4
6642990
6644560
+
MRFAP1
0x0

4097
chr4
6709345
6710474
−
MRFAP1L1
0x0

4098
chr4
6998419
6999606
+
TBC1D14
0x0

4099
chr4
7033051
7034321
+
TBC1D14
0x0

4100
chr4
7583649
7584931
+
SORCS2
0x0

4101
chr4
8459163
8460338
+
METTL19
0x0

4102
chr4
11684050
11685227
−
HS3ST1
0x0

4103
chr4
13426350
13427562
−
RAB28
0x0

4104
chr4
13731061
13732284
+
LOC152742
0x0

4105
chr4
17625172
17626370
+
MED28
0x0

4106
chr4
17819468
17820625
+
NCAPG
0x0

4107
chr4
17838682
17839842
+
NCAPG
0x0

4108
chr4
17841200
17842430
+
NCAPG
0x0

4109
chr4
18013434
18014610
−
LCORL
0x0

4110
chr4
18576184
18577360
−
LCORL
0x0

4111
chr4
20253069
20255107
+
SLIT2
0x1

4112
chr4
20357968
20359022
+
SLIT2-IT1
0x0

4113
chr4
20377297
20378395
+
SLIT2-IT1
0x0

4114
chr4
20414007
20415155
+
SLIT2-IT1
0x0

4115
chr4
20420764
20421861
+
SLIT2-IT1
0x0

4116
chr4
20526965
20528169
+
SLIT2
0x1

4117
chr4
20554935
20556122
+
SLIT2
0x1

4118
chr4
20590724
20591907
+
SLIT2
0x1

4119
chr4
20621379
20622480
+
SLIT2
0x1

4120
chr4
25251620
25252796
+
PI4K2B
0x0

4121
chr4
25278154
25279346
+
PI4K2B
0x0

4122
chr4
25748638
25749824
−
SEL1L3
0x0

4123
chr4
26416536
26417741
+
RBPJ
0x0

4124
chr4
27023705
27024866
+
STIM2
0x0

4125
chr4
30525911
30527106
−
CCKAR
0x2

4126
chr4
30724060
30725257
+
PCDH7
0x2

4127
chr4
30732429
30733530
+
PCDH7
0x2

4128
chr4
30737453
30738629
+
PCDH7
0x2

4129
chr4
30755239
30756386
+
PCDH7
0x2

4130
chr4
37437853
37439050
−
RELL1
0x0

4131
chr4
37634961
37637224
−
RELL1
0x0

4132
chr4
38618668
38619867
+
KLF3
0x0

4133
chr4
39114266
39115366
+
KLHL5
0x0

4134
chr4
39276035
39277181
+
WDR19
0x0

4135
chr4
39286725
39287909
+
WDR19
0x0

4136
chr4
39708907
39710122
+
UBE2K
0x0

4137
chr4
39782183
39783294
+
UBE2K
0x0

4138
chr4
39978528
39979627
−
PDS5A
0x0

4139
chr4
40601188
40602333
−
RBM47
0x0

4140
chr4
41259046
41260283
+
UCHL1
0x1

4141
chr4
41264120
41265319
+
UCHL1
0x1

4142
chr4
41269710
41270980
+
UCHL1
0x1

4143
chr4
42088879
42090056
+
SLC30A9
0x0

4144
chr4
42202449
42203618
+
SLC30A9
0x0

4145
chr4
43411605
43412801
−
ATP8A1
0x0

4146
chr4
46893136
46894294
−
COX7B2
0x0

4147
chr4
47708099
47709348
+
ATP10D
0x0

4148
chr4
47882394
47883542
−
NFXL1
0x0

4149
chr4
48413731
48414890
+
SLAIN2
0x0

4150
chr4
48438539
48439739
+
SLAIN2
0x0

4151
chr4
48862472
48863658
+
OCIAD1
0x0

4152
chr4
52734129
52735328
+
DCUN1D4
0x0

4153
chr4
53461921
53463125
−
USP46
0x0

4154
chr4
54283388
54284590
+
FIP1L1
0x2

4155
chr4
54953571
54954744
+
GSX2
0x0

4156
chr4
55841774
55842881
−
KDR
0x2

4157
chr4
56280443
56281494
+
TMEM165
0x0

4158
chr4
56962978
56964223
+
CEP135
0x0

4159
chr4
57325750
57327992
+
PAICS
0x0

4160
chr4
58383343
58384447
+
LOC255130
0x0

4161
chr4
59221215
59222390
−
IGFBP7
0x1

4162
chr4
62093328
62094523
+
LPHN3
0x2

4163
chr4
62551899
62553121
+
LPHN3
0x2

4164
chr4
62774206
62775380
+
LPHN3
0x2

4165
chr4
66438864
66440463
+
LOC100144602
0x0

4166
chr4
68294835
68295976
−
CENPC1
0x0

4167
chr4
68321540
68322718
−
CENPC1
0x0

4168
chr4
69097071
69098228
−
TMPRSS11B
0x0

4169
chr4
70296091
70297349
−
UGT2B4
0x0

4170
chr4
71553746
71554940
+
UTP3
0x0

4171
chr4
73941209
73942338
−
ANKRD17
0x0

4172
chr4
73955544
73957661
−
ANKRD17
0x0

4173
chr4
73986039
73987204
−
ANKRD17
0x0

4174
chr4
74079369
74080510
−
ANKRD17
0x0

4175
chr4
74102690
74103817
−
ANKRD17
0x0

4176
chr4
74109735
74110834
−
ANKRD17
0x0

4177
chr4
76569124
76570342
−
G3BP2
0x0

4178
chr4
76648143
76649358
−
G3BP2
0x0

4179
chr4
76660425
76661657
+
USO1
0x0

4180
chr4
76733874
76735088
+
USO1
0x0

4181
chr4
76806599
76808121
+
USO1
0x0

4182
chr4
77265081
77266329
+
FAM47E-STBD1
0x0

4183
chr4
77265081
77266329
+
STBD1
0x0

4184
chr4
77372618
77373794
+
SHROOM3
0x2

4185
chr4
77766703
77767861
−
SOWAHB
0x0

4186
chr4
77768802
77770022
+
SHROOM3
0x2

4187
chr4
77958275
77959447
+
SEPT11
0x0

4188
chr4
77967833
77969064
−
CCNI
0x0

4189
chr4
77969179
77970319
−
CCNI
0x0

4190
chr4
77976650
77978723
−
CCNI
0x0

4191
chr4
79053658
79054798
−
CNOT6L
0x0

4192
chr4
79175849
79177015
+
FRAS1
0x0

4193
chr4
79205034
79206238
+
FRAS1
0x0

4194
chr4
79410767
79411878
+
FRAS1
0x0

4195
chr4
79438573
79439806
+
FRAS1
0x0

4196
chr4
79734146
79735341
+
BMP2K
0x0

4197
chr4
79840005
79841132
−
PAQR3
0x0

4198
chr4
80274113
80275302
−
NAA11
0x0

4199
chr4
83268298
83269488
−
HNRNPD
0x0

4200
chr4
83274558
83275765
−
HNRNPD
0x0

4201
chr4
83280150
83281278
−
HNRNPD
0x0

4202
chr4
83343963
83345140
−
HNRPDL
0x0

4203
chr4
83347069
83348169
−
HNRPDL
0x0

4204
chr4
83550678
83551963
−
SCD5
0x0

4205
chr4
83818751
83819908
−
LOC100499177
0x0

4206
chr4
86021366
86022519
+
WDFY3-AS2
0x0

4207
chr4
87393257
87394403
−
MAPK10
0x0

4208
chr4
87515041
87516221
+
PTPN13
0x0

4209
chr4
87653247
87654357
+
PTPN13
0x0

4210
chr4
87870545
87871718
−
LOC100506746
0x0

4211
chr4
87940038
87941259
+
AFF1
0x0

4212
chr4
88099083
88100238
−
KLHL8
0x0

4213
chr4
88137806
88138917
−
KLHL8
0x0

4214
chr4
89777339
89778499
−
FAM13A
0x2

4215
chr4
89954916
89956116
−
FAM13A
0x2

4216
chr4
90663937
90665134
+
LOC644248
0x0

4217
chr4
93531591
93532768
+
GRID2
0x0

4218
chr4
95416050
95417252
+
PDLIM5
0x0

4219
chr4
95575127
95576327
+
PDLIM5
0x0

4220
chr4
96396095
96397271
−
UNC5C
0x1

4221
chr4
99563213
99564313
−
TSPAN5
0x0

4222
chr4
99850331
99851505
+
METAP1
0x0

4223
chr4
100868849
100870090
−
H2AFZ
0x0

4224
chr4
103717651
103719025
−
UBE2D3
0x0

4225
chr4
104725398
104726574
−
TACR3
0x0

4226
chr4
106026648
106027830
+
TET2
0x1

4227
chr4
106057841
106059021
−
PPA2
0x0

4228
chr4
106344162
106345353
−
PPA2
0x0

4229
chr4
106852779
106853976
+
NPNT
0x0

4230
chr4
107208670
107209801
−
TBCK
0x0

4231
chr4
107868851
107870051
−
DKK2
0x2

4232
chr4
107923941
107925121
−
DKK2
0x2

4233
chr4
109564721
109565921
+
OSTC
0x0

4234
chr4
109760830
109762023
−
COL25A1
0x2

4235
chr4
110104521
110105697
−
COL25A1
0x2

4236
chr4
110608918
110610063
+
CCDC109B
0x0

4237
chr4
110650525
110651689
−
PLA2G12A
0x0

4238
chr4
111068841
111070012
−
EL0VL6
0x2

4239
chr4
113708823
113709979
−
MIR3O2B
0x0

4240
chr4
113785324
113786500
+
ANK2
0x2

4241
chr4
114146722
114148054
+
ANK2
0x2

4242
chr4
114341014
114342181
+
ANK2
0x2

4243
chr4
114437818
114438997
−
CAMK2D
0x0

4244
chr4
114662153
114663347
−
CAMK2D
0x0

4245
chr4
119199757
119201059
+
SNHG8
0x0

4246
chr4
119199757
119201059
+
SNORA24
0x0

4247
chr4
120157972
120159202
+
USP53
0x0

4248
chr4
120476269
120477447
−
PDE5A
0x0

4249
chr4
121587880
121589054
+
PP12613
0x0

4250
chr4
122588643
122590042
−
ANXA5
0x0

4251
chr4
122606909
122608071
−
ANXA5
0x0

4252
chr4
123750558
123751842
+
FGF2
0x0

4253
chr4
128754661
128755882
+
HSPA4L
0x0

4254
chr4
128850808
128851989
−
MFSD8
0x0

4255
chr4
136916515
136917744
−
PCDH18
0x2

4256
chr4
140045828
140047021
−
ELF2
0x0

4257
chr4
140300081
140301298
−
NAA15
0x0

4258
chr4
140427948
140429133
−
SETD7
0x0

4259
chr4
140429601
140430909
−
SETD7
0x0

4260
chr4
140618700
140619799
−
MAML3
0x0

4261
chr4
140805551
140806871
−
MAML3
0x0

4262
chr4
141349704
141350880
−
CLGN
0x0

4263
chr4
142154608
142155762
+
ZNF330
0x0

4264
chr4
143315717
143316925
−
INPP4B
0x1

4265
chr4
144257623
144258821
+
GAB1
0x6

4266
chr4
144270075
144271461
−
FREM3
0x0

4267
chr4
144346149
144347318
+
GAB1
0x6

4268
chr4
146018918
146020143
+
ABCE1
0x2

4269
chr4
146427241
146428425
+
SMAD1
0x0

4270
chr4
146822800
146823918
−
ZNF827
0x0

4271
chr4
149180417
149181814
−
NR3C2
0x0

4272
chr4
149265208
149266372
−
NR3C2
0x0

4273
chr4
149356392
149357576
−
NR3C2
0x0

4274
chr4
151185305
151186711
−
LRBA
0x0

4275
chr4
151871001
151872180
−
LRBA
0x0

4276
chr4
152024415
152025614
+
RPS3A
0x0

4277
chr4
152024415
152025614
+
SNORD73A
0x0

4278
chr4
152041252
152042409
−
SH3D19
0x0

4279
chr4
152591367
152592570
−
PET112
0x0

4280
chr4
153448757
153449897
−
FBXW7
0x1

4281
chr4
154169920
154171208
+
TRIM2
0x0

4282
chr4
154472765
154473974
+
KIAA0922
0x0

4283
chr4
155457250
155458379
−
PLRG1
0x0

4284
chr4
158688599
158689776
−
FAM198B
0x0

4285
chr4
159636841
159637978
−
PPID
0x0

4286
chr4
164045004
164046132
−
NAF1
0x0

4287
chr4
164077750
164078946
−
NAF1
0x0

4288
chr4
166213819
166215040
−
GK3P
0x0

4289
chr4
166263567
166264776
+
MSMO1
0x0

4290
chr4
167021877
167023098
+
TLL1
0x0

4291
chr4
167063135
167064378
+
TLL1
0x0

4292
chr4
169925827
169927030
+
PALLD
0x0

4293
chr4
170332145
170333366
−
NEK1
0x0

4294
chr4
170427527
170428695
−
NEK1
0x0

4295
chr4
174252351
174253786
−
HMGB2
0x0

4296
chr4
174254588
174255755
−
HMGB2
0x0

4297
chr4
175219945
175221126
+
CEP44
0x0

4298
chr4
175275109
175276324
+
CEP44
0x0

4299
chr4
176423626
176424847
+
ADAM29
0x2

4300
chr4
176842074
176843173
−
GPM6A
0x0

4301
chr4
177240631
177241730
+
SPCS3
0x0

4302
chr4
177252721
177253795
+
SPCS3
0x0

4303
chr4
177495908
177497008
−
VEGFC
0x0

4304
chr4
181405460
181406582
−
LINC00290
0x0

4305
chr4
183403106
183404347
+
ODZ3
0x0

4306
chr4
183608768
183609957
+
ODZ3
0x0

4307
chr4
184185650
184186805
+
WWC2
0x0

4308
chr4
184206594
184207757
+
WWC2
0x0

4309
chr4
184236991
184238138
+
WWC2
0x0

4310
chr4
185598395
185599560
+
CCDC111
0x0

4311
chr4
185612026
185613243
+
CCDC111
0x0

4312
chr4
186284166
186285356
+
SNX25
0x0

4313
chr4
187548781
187550336
−
FAT1
0x1

4314
chr4
187595179
187596294
−
FAT1
0x1

4315
chr4
187627324
187628579
−
FAT1
0x1

4316
chr4
187628672
187630961
−
FAT1
0x1

4317
chr5
256042
257241
+
SDHA
0x1

4318
chr5
465016
466156
+
EXOC3
0x0

4319
chr5
475184
476283
+
EXOC3
0x0

4320
chr5
616400
617529
+
CEP72
0x0

4321
chr5
619661
620917
+
CEP72
0x0

4322
chr5
855260
856450
−
ZDHHC11
0x0

4323
chr5
881928
883115
−
BRD9
0x0

4324
chr5
984575
985775
−
LOC100506688
0x0

4325
chr5
1011265
1012552
+
NKD2
0x0

4326
chr5
1059288
1060478
+
NKD2
0x0

4327
chr5
1317484
1318925
−
CLPTM1L
0x0

4328
chr5
2099419
2100621
+
NDUFS6
0x0

4329
chr5
5433872
5435049
+
KIAA0947
0x0

4330
chr5
6367854
6369079
+
MED10
0x0

4331
chr5
6599311
6600462
−
NSUN2
0x0

4332
chr5
6732256
6733453
+
PAPD7
0x0

4333
chr5
6742830
6744075
+
PAPD7
0x0

4334
chr5
6847884
6849102
−
MIR4278
0x0

4335
chr5
7054525
7055680
−
MIR4454
0x0

4336
chr5
10277925
10279202
−
CMBL
0x0

4337
chr5
10374162
10375376
+
MARCH6
0x0

4338
chr5
10379681
10380780
+
MARCH6
0x0

4339
chr5
10400598
10401855
+
MARCH6
0x0

4340
chr5
10415135
10416313
+
MARCH6
0x0

4341
chr5
10425959
10427183
+
MARCH6
0x0

4342
chr5
14420879
14422105
+
TRIO
0x0

4343
chr5
14482958
14484167
+
TRIO
0x0

4344
chr5
14508432
14509594
+
TRIO
0x0

4345
chr5
14701374
14702535
−
ANKH
0x0

4346
chr5
14750666
14751845
−
ANKH
0x0

4347
chr5
15822964
15824180
+
FBXL7
0x0

4348
chr5
18800477
18801690
+
BASP1
0x0

4349
chr5
20304100
20305276
−
CDH18
0x4

4350
chr5
21527696
21528894
+
GUSBP1
0x0

4351
chr5
31455998
31457175
−
DROSHA
0x2

4352
chr5
31488619
31489794
−
DROSHA
0x2

4353
chr5
32124537
32125869
−
GOLPH3
0x0

4354
chr5
32143298
32144538
−
GOLPH3
0x0

4355
chr5
32378698
32379827
−
ZFR
0x0

4356
chr5
32601050
32602364
+
SUB1
0x0

4357
chr5
33161873
33163111
+
LOC340113
0x0

4358
chr5
33452823
33453991
+
TARS
0x0

4359
chr5
34068024
34069192
−
C1QTNF3
0x0

4360
chr5
34801788
34803022
+
RAI14
0x0

4361
chr5
36146478
36147695
−
MIR580
0x0

4362
chr5
36931288
36932498
+
NIPBL
0x0

4363
chr5
37107160
37108354
−
C5orf42
0x0

4364
chr5
37290557
37291656
−
NUP155
0x0

4365
chr5
37644395
37645575
+
WDR70
0x0

4366
chr5
38966651
38967862
−
RICTOR
0x0

4367
chr5
40714019
40715191
−
PE33
0x0

4368
chr5
40834076
40835225
−
RPL37
0x0

4369
chr5
41920550
41921732
+
C5orf51
0x0

4370
chr5
43290478
43291600
−
HMGCS1
0x0

4371
chr5
44816488
44817669
+
MRPS30
0x0

4372
chr5
53348060
53349257
−
ARL15
0x0

4373
chr5
54964571
54965747
−
SLC38A9
0x0

4374
chr5
55281035
55282211
−
IL6ST
0x2

4375
chr5
56239517
56240829
−
MIER3
0x2

4376
chr5
56464363
56465567
−
MIER3
0x2

4377
chr5
60163431
60164583
−
ERCC8
0x0

4378
chr5
60195168
60196367
−
ERCC8
0x0

4379
chr5
60280264
60281431
+
NDUFAF2
0x0

4380
chr5
60454911
60456125
−
C5orf43
0x0

4381
chr5
60629614
60630713
+
ZSWIM6
0x0

4382
chr5
60778117
60779343
+
ZSWIM6
0x0

4383
chr5
60838057
60839254
+
ZSWIM6
0x0

4384
chr5
64017997
64019153
−
SREK1IP1
0x0

4385
chr5
64826677
64827834
−
CENPK
0x0

4386
chr5
64854223
64855425
−
CENPK
0x0

4387
chr5
65474521
65475620
+
SREK1
0x0

4388
chr5
65929854
65931080
+
MAST4
0x0

4389
chr5
68169262
68170459
+
SLC30A5
0x0

4390
chr5
68470301
68471848
+
CCNB1
0x0

4391
chr5
68534620
68535809
+
CDK7
0x0

4392
chr5
71146171
71147505
+
CARTPT
0x0

4393
chr5
71501197
71502296
+
MAP1B
0x2

4394
chr5
71558941
71560151
−
MRPS27
0x0

4395
chr5
72153426
72154546
+
TNPO1
0x2

4396
chr5
72188374
72189602
+
TNPO1
0x2

4397
chr5
72206009
72207217
+
TNPO1
0x2

4398
chr5
72293664
72294858
+
FCHO2
0x0

4399
chr5
72798331
72799514
+
BTF3
0x0

4400
chr5
73923248
73924390
−
ENC1
0x0

4401
chr5
75630962
75632158
−
F2RL2
0x2

4402
chr5
75775909
75777085
−
F2RL2
0x2

4403
chr5
76375769
76376916
−
SNORA47
0x0

4404
chr5
76727954
76729712
−
WDR41
0x0

4405
chr5
77301561
77302684
−
AP3B1
0x0

4406
chr5
77435096
77436266
−
AP3B1
0x0

4407
chr5
77528492
77529643
−
AP3B1
0x0

4408
chr5
78734358
78735466
−
HOMER1
0x0

4409
chr5
79548465
79549683
+
SPZ1
0x0

4410
chr5
80183593
80184748
+
MSH3
0x2

4411
chr5
80484785
80485962
−
LOC100131067
0x0

4412
chr5
80628317
80629455
−
ACOT12
0x0

4413
chr5
81570830
81571946
−
RPS23
0x0

4414
chr5
81573146
81574245
−
RPS23
0x0

4415
chr5
82254994
82256171
−
TMEM167A
0x0

4416
chr5
82359469
82360601
−
SCARNA18
0x0

4417
chr5
86569424
86570609
+
RASA1
0x2

4418
chr5
89768753
89769931
−
M8LAC2
0x0

4419
chr5
90105888
90107164
+
GPR98
0x0

4420
chr5
92929548
92930740
+
NR2F1
0x0

4421
chr5
93018311
93019965
−
POUSF2
0x0

4422
chr5
93131269
93132417
−
FAM172A
0x0

4423
chr5
94173902
94175063
−
MCTP1
0x0

4424
chr5
95158511
95159640
+
RHOBTB3
0x0

4425
chr5
95239923
95241132
−
ELL2
0x0

4426
chr5
96323354
96324453
+
INPEP
0x0

4427
chr5
100068452
100069649
+
FAM174A
0x0

4428
chr5
101637845
101639040
+
PAM
0x0

4429
chr5
102087133
102088329
−
SLCO6A1
0x0

4430
chr5
102212164
102213379
+
PAM
0x0

4431
chr5
107002182
107003311
−
EFNA5
0x1

4432
chr5
108229675
108230841
−
HP07349
0x0

4433
chr5
108349997
108351209
−
HP07349
0x0

4434
chr5
109034853
109036078
−
PJA2
0x0

4435
chr5
109146662
109147860
+
MAN2A1
0x0

4436
chr5
109930841
109932041
+
TMEM232
0x0

4437
chr5
110458675
110459862
+
WDR36
0x0

4438
chr5
111496683
111497883
+
EPB41L4A-AS1
0x0

4439
chr5
111496683
111497883
+
SNORA13
0x0

4440
chr5
112349145
112350420
+
DCP2
0x0

4441
chr5
112382879
112384028
−
MCC
0x1

4442
chr5
112599748
112600940
−
MCC
0x1

4443
chr5
118172992
118174184
−
DTWD2
0x0

4444
chr5
118417262
118418446
+
DMXL1
0x0

4445
chr5
118499717
118500922
+
DMXL1
0x0

4446
chr5
122358764
122359921
−
PPIC
0x0

4447
chr5
122698012
122699206
−
CEP120
0x0

4448
chr5
122880801
122882021
+
CSNK1G3
0x0

4449
chr5
122990432
122991632
+
CSNK1G3
0x0

4450
chr5
123981877
123983264
−
ZNF608
0x0

4451
chr5
123998470
123999607
−
ZNF608
0x0

4452
chr5
126112381
126113578
+
LMNB1
0x0

4453
chr5
126153331
126154530
+
LMNB1
0x0

4454
chr5
126889467
126890663
+
PRRC1
0x0

4455
chr5
127276736
127277912
−
FLJ33630
0x0

4456
chr5
129449539
129450732
+
CHSY3
0x0

<4457
chr5
130524747
130525947
+
LYRM7
0x0

4458
chr5
130746679
130747856
−
RAPGEF6
0x0

4459
chr5
130760870
130762039
−
RAPGEF6
0x0

4460
chr5
130771334
130772508
−
RAPGEF6
0x0

4461
chr5
130959540
130960717
−
RAPGEF6
0x0

4462
chr5
130977720
130978819
−
FNIP1
0x0

4463
chr5
131515897
131517099
+
PDLIM4
0x1

4464
chr5
131803299
131804500
+
C5orf56
0x0

4465
chr5
132202774
132203870
+
UQCRQ
0x0

4466
chr5
133307460
133308834
−
VDAC1
0x0

4467
chr5
133311749
133312912
−
VDAC1
0x0

4468
chr5
133492617
133493834
−
SKP1
0x0

4469
chr5
133532291
133533413
−
PPP2CA
0x0

4470
chr5
134076563
134077772
+
CAMLG
0x0

4471
chr5
134115176
134117473
+
DDX46
0x0

4472
chr5
134159669
134160855
+
DDX46
0x0

4473
chr5
134259234
134260405
+
MIR4461
0x0

4474
chr5
134262142
134263369
−
PITX1
0x0

4475
chr5
134355468
134356654
−
PITX1
0x0

4476
chr5
134570673
134571870
+
CATSPER3
0x0

4477
chr5
134669500
134670677
−
H2AFY
0x0

4478
chr5
137033418
137034620
−
KLHL3
0x0

4479
chr5
137087973
137089077
−
HNRNPAO
0x0

4480
chr5
137289730
137290854
−
FAM13B
0x0

4481
chr5
137666391
137667527
−
CDC25C
0x2

4482
chr5
137771267
137772439
+
KDM3B
0x1

4483
chr5
137781466
137783078
+
REEP2
0x0

4484
chr5
137842197
137843338
−
ETF1
0x0

4485
chr5
137896165
137897367
−
HSPA9
0x0

4486
chr5
137896165
137897367
−
SNORD63
0x0

4487
chr5
138119261
138120454
+
CTNNA1
0x0

4488
chr5
138613928
138615224
+
MATR3
0x0

4489
chr5
138613928
138615224
+
SNHG4
0x0

4490
chr5
138613928
138615224
+
SNORA74A
0x0

4491
chr5
138664683
138665785
+
MATR3
0x0

4492
chr5
138697052
138698264
+
PAIP2
0x0

4493
chr5
138955660
138956759
+
UBE2D2
0x0

4494
chr5
139907953
139909087
+
ANKHD1
0x0

4495
chr5
139907953
139909087
+
ANKHD1-EIF4EBP3
0x0

4496
chr5
139935676
139936843
−
SRA1
0x0

4497
chr5
139942922
139944119
−
APBB3
0x0

4498
chr5
139947150
139948368
+
SLC35A4
0x0

4499
chr5
140026517
140027657
−
NDUFA2
0x0

4500
chr5
140090322
140091532
+
VTRNA1-1
0x0

4501
chr5
140097951
140099191
+
VTRNA1-2
0x0

4502
chr5
140105202
140106473
+
VTRNA1-3
0x0

4503
chr5
140697652
140699013
−
TAF7
0x0

4504
chr5
140882980
140884167
+
PCDHGA1
0x0

4505
chr5
140882980
140884167
+
PCDHGA10
0x0

4506
chr5
140882980
140884167
+
PCDHGA11
0x0

4507
chr5
140882980
140884167
+
PCDHGA12
0x0

4508
chr5
140882980
140884167
+
PCDHGA2
0x0

4509
chr5
140882980
140884167
+
PCDHGA3
0x0

4510
chr5
140882980
140884167
+
PCDHGA4
0x0

4511
chr5
140882980
140884167
+
PCDHGA5
0x0

4512
chr5
140882980
140884167
+
PCDHGA6
0x0

4513
chr5
140882980
140884167
+
PCDHGA7
0x0

4514
chr5
140882980
140884167
+
PCDHGA8
0x0

4515
chr5
140882980
140884167
+
PCDHGA9
0x0

4516
chr5
140882980
140884167
+
PCDHGB1
0x0

4517
chr5
140882980
140884167
+
PCDHGB2
0x0

4518
chr5
140882980
140884167
+
PCDHGB3
0x0

4519
chr5
140882980
140884167
+
PCDHGB4
0x0

4520
chr5
140882980
140884167
+
PCDHGB5
0x0

4521
chr5
140882980
140884167
+
PCDHGB6
0x0

4522
chr5
140882980
140884167
+
PCDHGB7
0x0

4523
chr5
140882980
140884167
+
PCDHGC3
0x0

4524
chr5
140882980
140884167
+
PCDHGC4
0x0

4525
chr5
140882980
140884167
+
PCDHGC5
0x2

4526
chr5
140894240
140895404
−
DIAPH1
0x2

4527
chr5
140958099
140959290
−
DIAPH1
0x2

4528
chr5
141005206
141006359
−
HDAC3
0x1

4529
chr5
141313659
141314784
+
KIAA0141
0x0

4530
chr5
141379710
141380830
−
GNPDA1
0x0

4531
chr5
142659520
142660619
−
NR3C1
0x0

4532
chr5
145485049
145486259
−
PLAC8L1
0x0

4533
chr5
145828942
145830154
+
TCERG1
0x2

4534
chr5
145934974
145936167
+
TCERG1
0x2

4535
chr5
146770912
146772858
−
DPYSL3
0x0

4536
chr5
147695170
147696363
+
SPINK7
0x1

4537
chr5
149221294
149222492
+
PPARGC1B
0x0

4538
chr5
149379189
149380405
+
HMGXB3
0x0

4539
chr5
149391310
149392467
+
HMGXB3
0x0

4540
chr5
149409668
149410825
+
HMGXB3
0x0

4541
chr5
149823257
149824472
−
RPS14
0x0

4542
chr5
149826726
149827839
−
RPS14
0x0

4543
chr5
149933323
149934522
+
NDST1
0x0

4544
chr5
150088157
150089605
−
DCTN4
0x0

4545
chr5
150305903
150307127
+
IRGM
0x0

4546
chr5
151166977
151168088
+
G3BP1
0x2

4547
chr5
151176282
151177428
+
G3BP1
0x2

4548
chr5
151183068
151184445
+
G3BP1
0x2

4549
chr5
151988029
151989202
+
G3BP1
0x2

4550
chr5
154184861
154185960
+
LARP1
0x0

4551
chr5
154194245
154195970
+
LARP1
0x0

4552
chr5
155271898
155273116
+
SGCD
0x0

4553
chr5
157258473
157259663
−
CLINT1
0x0

4554
chr5
157403274
157404503
−
CLINT1
0x0

4555
chr5
159519658
159520837
−
PWWP2A
0x0

4556
chr5
162917770
162918943
+
HMMR
0x0

4557
chr5
164286793
164287987
+
MAT2B
0x0

4558
chr5
167979735
167980834
−
PANK3
0x0

4559
chr5
170532740
170533963
+
RANBP17
0x2

4560
chr5
170631767
170632976
+
RANBP17
0x2

4561
chr5
170650569
170651816
+
RANBP17
0x2

4562
chr5
170814307
170815505
+
NPM1
0x2

4563
chr5
170833000
170834240
+
NPM1
0x2

4564
chr5
170836987
170838202
+
NPM1
0x2

4565
chr5
170864262
170865494
+
FGF18
0x0

4566
chr5
171636089
171637261
−
UBTD2
0x0

4567
chr5
172402266
172403402
+
RPL26L1
0x0

4568
chr5
172447180
172448424
+
ATP6V0E1
0x0

4569
chr5
172447180
172448424
+
SNORA74B
0x0

4570
chr5
174541243
174542729
−
FLI16171
0x0

4571
chr5
174954262
174955476
+
SFXN1
0x0

4572
chr5
175046803
175047922
−
DRD1
0x0

4573
chr5
176348311
176349451
−
UIMC1
0x0

4574
chr5
176729779
176730956
−
RAB24
0x2

4575
chr5
176868941
176870106
+
GRK6
0x0

4576
chr5
176881538
176882733
+
PRR7
0x0

4577
chr5
176883596
176884716
−
DBN1
0x2

4578
chr5
176964393
176966567
−
FAM193B
0x0

4579
chr5
177058987
177060287
−
LOC202181
0x0

4580
chr5
177310372
177311573
+
LOC728554
0x0

4581
chr5
177379634
177380812
+
FAM153C
0x0

4582
chr5
177656564
177657732
−
AGXT2L2
0x0

4583
chr5
179049534
179050703
−
HNRNPH1
0x0

4584
chr5
179132092
179133317
+
CANX
0x0

4585
chr5
179155733
179157832
+
CANX
0x0

4586
chr5
179251620
179252771
+
SQSTM1
0x0

4587
chr5
179673716
179674848
−
MAPK9
0x0

4588
chr5
180206560
180207717
−
MGAT1
0x0

4589
chr5
180528261
180529516
+
BTNL9
0x0

4590
chr5
180634178
180635408
+
TRIM41
0x0

4591
chr5
180644693
180645829
−
MIR4638
0x0

4592
chr5
180665592
180666691
−
GNB2L1
0x0

4593
chr5
180667997
180669448
−
GN82L1
0x0

4594
chr5
180667997
180669448
−
SNORD96A
0x0

4595
chr5
180669745
180671450
−
GN82L1
0x0

4596
chr5
180669745
180671450
−
SNORD95
0x0

4597
chr6
350525
351808
+
DUSP22
0x1

4598
chr6
694363
695593
+
IRF4
0x2

4599
chr6
1392055
1393297
+
FOXF2
0x0

4600
chr6
2249565
2250764
+
LOC100508120
0x0

4601
chr6
2959958
2961063
−
SERPINB6
0x0

4602
chr6
2999751
3000981
+
NQO2
0x0

4603
chr6
3224108
3225372
−
TUBB2B
0x0

4604
chr6
3343107
3344230
+
SLC22A23
0x0

4605
chr6
4061321
4062476
+
PRPF4B
0x2

4606
chr6
4427628
4428908
+
CDYL
0x2

4607
chr6
4891386
4893097
+
CDYL
0x2

4608
chr6
5305109
5306287
−
LYRM4
0x0

4609
chr6
5819194
5820380
+
FARS2
0x0

4610
chr6
6006440
6007652
−
NRN1
0x0

4611
chr6
7281986
7283116
−
SSR1
0x0

4612
chr6
7289208
7290341
−
SSR1
0x0

4613
chr6
7312770
7313892
−
SSR1
0x0

4614
chr6
7338944
7340205
−
CAGE1
0x0

4615
chr6
7417091
7418291
+
RIOK1
0x0

4616
chr6
7567486
7568687
+
DSP
0x0

4617
chr6
10397277
10398503
−
TFAP2A
0x1

4618
chr6
10790794
10791948
+
TMEM14B
0x0

4619
chr6
11120447
11121644
+
C6orf228
0x0

4620
chr6
11135447
11136546
+
C6orf228
0x0

4621
chr6
12094830
12095971
+
HIVEP1
0x0

4622
chr6
12513934
12515138
+
PHACTR1
0x0

4623
chr6
13213750
13214999
+
PHACTR1
0x0

4624
chr6
13374363
13375494
−
GFOD1
0x0

4625
chr6
13486586
13487751
−
GFOD1
0x0

4626
chr6
13646093
13647202
−
RANBP9
0x0

4627
chr6
13787360
13788567
−
CCDC90A
0x0

4628
chr6
15011581
15012776
+
JAR1D2
0x2

4629
chr6
15416602
15417810
+
JARID2
0x2

4630
chr6
16326605
16327827
−
ATXN1
0x0

4631
chr6
16747172
16748334
−
ATXN1
0x0

4632
chr6
17615189
17616505
−
NUP153
0x0

4633
chr6
18224189
18225654
−
DEK
0x2

4634
chr6
18264094
18265258
−
DEK
0x2

4635
chr6
19839163
19840388
+
ID4
0x1

4636
chr6
20452761
20453860
+
E2F3
0x2

4637
chr6
20556060
20557162
+
CDKAL1
0x0

4638
chr6
21593746
21594950
+
SOX4
0x0

4639
chr6
21595334
21596486
+
SOX4
0x0

4640
chr6
24417797
24418997
+
MRS2
0x0

4641
chr6
24718988
24720133
−
C6orf62
0x0

4642
chr6
26020508
26021702
+
HIST1H3A
0x0

4643
chr6
26026615
26027821
−
HIST1H4B
0x0

4644
chr6
26031448
26032740
−
HIST1H3B
0x0

4645
chr6
26056020
26057248
−
HIST1H1C
0x2

4646
chr6
26103864
26105124
+
H1ST1H4C
0x0

4647
chr6
26156035
26157248
+
HIST1H1E
0x2

4648
chr6
26157864
26159045
+
HIST1H2BD
0x0

4649
chr6
26198776
26199974
−
HIST1H2AD
0x0

4650
chr6
26198776
26199974
−
HIST1H3D
0x0

4651
chr6
26204313
26205679
+
HIST1H4E
0x0

4652
chr6
26216601
26217833
+
HIST1H2AE
0x0

4653
chr6
26250095
26251233
−
HIST1H3F
0x0

4654
chr6
26284906
26286305
−
HIST1H4H
0x0

4655
chr6
26305137
26306335
−
HIST1H4H
0x0

4656
chr6
26327842
26329088
+
BTN3A2
0x0

4657
chr6
26520899
26522108
+
HCG11
0x0

4658
chr6
26537187
26538396
+
HMGN4
0x0

4659
chr6
26553894
26554993
+
HMGN4
0x0

4660
chr6
26556236
26557446
+
HMGN4
0x0

4661
chr6
26568500
26569739
+
HMGN4
0x0

4662
chr6
26575282
26576489
+
ABT1
0x0

4663
chr6
26576788
26577992
+
ABT1
0x0

4664
chr6
26594507
26595750
+
ABT1
0x0

4665
chr6
27077095
27078239
−
HIST1H2BJ
0x0

4666
chr6
27100256
27101388
+
HIST1H2AG
0x0

4667
chr6
27114034
27115196
−
HIST1H2BK
0x0

4668
chr6
27125338
27126535
+
MIR3143
0x0

4669
chr6
27177100
27178332
+
PRSS16
0x0

4670
chr6
27181083
27182248
−
HIST1H2BK
0x0

4671
chr6
27182391
27183627
+
PRSS16
0x0

4672
chr6
27197707
27198928
−
POM121L2
0x0

4673
chr6
27261107
27262319
+
VN1R10P
0x0

4674
chr6
27262686
27263839
+
VN1R10P
0x0

4675
chr6
27265242
27266405
+
VN1R10P
0x0

4676
chr6
27470978
27472096
+
ZNF391
0x2

4677
chr6
27514942
27516154
−
ZNF184
0x0

4678
chr6
27520641
27521851
−
ZNF184
0x0

4679
chr6
27550661
27551841
−
ZNF184
0x0

4680
chr6
27569815
27570892
−
ZNF184
0x0

4681
chr6
27572845
27574055
−
ZNF184
0x0

4682
chr6
27618069
27619288
−
HIST1H2BL
0x0

4683
chr6
27637768
27638977
−
HIST1H2BL
0x0

4684
chr6
27758556
27759782
−
HIST1H2BL
0x0

4685
chr6
27860016
27861423
−
HIST1H2AM
0x0

4686
chr6
27860839
27861988
+
HIST1H2BO
0x2

4687
chr6
28180242
28181509
+
ZNF193
0x0

4688
chr6
28426989
28428187
−
ZSCAN23
0x0

4689
chr6
28625465
28626614
−
SCAND3
0x0

4690
chr6
28641012
28642197
−
SCAND3
0x0

4691
chr6
28663157
28664356
−
SCAND3
0x0

4692
chr6
28677791
28678990
+
GPX5
0x0

4693
chr6
28696501
28697715
+
GPX5
0x0

4694
chr6
28702649
28703851
−
LOC401242
0x0

4695
chr6
28714933
28716164
+
GPX5
0x0

4696
chr6
28725595
28726811
−
LOC401242
0x0

4697
chr6
28757006
28758172
−
LOC401242
0x0

4698
chr6
28769969
28771216
−
LOC401242
0x0

4699
chr6
28784408
28785655
−
LOC401242
0x0

4700
chr6
28863440
28864678
−
TRIM27
0x2

4701
chr6
28865423
28866591
−
TRIM27
0x2

4702
chr6
28908284
28909530
+
LOC100129636
0x0

4703
chr6
28911814
28913011
+
LOC100129636
0x0

4704
chr6
28918286
28919467
+
LOC100129636
0x0

4705
chr6
29593377
29594477
−
GABBR1
0x2

4706
chr6
29912705
29913935
+
HLA-A
0x2

4707
chr6
30174258
30175638
−
TRIM26
0x0

4708
chr6
30513886
30515122
−
GNL1
0x0

4709
chr6
30680109
30681208
−
MDC1
0x0

4710
chr6
30681230
30682456
−
MDC1
0x0

4711
chr6
30691823
30693561
+
TUBB
0x2

4712
chr6
30831650
30832824
+
DDR1
0x0

4713
chr6
30846909
30848085
+
DDR1
0x0

4714
chr6
31130402
31131596
+
TCF19
0x0

4715
chr6
31496068
31497234
−
ATP6V1G2-DDX39B
0x0

4716
chr6
31496068
31497234
−
DDX39B
0x0

4717
chr6
31501739
31502906
−
ATP6V1G2-DDX39B
0x0

4718
chr6
31501739
31502906
−
DDX39B
0x0

4719
chr6
31507750
31508843
−
ATP6V1G2-DDX39B
0x0

4720
chr6
31507750
31508843
−
DDX39B
0x0

4721
chr6
31588657
31589786
+
PRRC2A
0x0

4722
chr6
31590298
31591538
+
PRRC2A
0x0

4723
chr6
31590298
31591538
+
SNORA38
0x0

4724
chr6
31613730
31614837
−
BAG6
0x0

4725
chr6
31703631
31704808
−
CLIC1
0x0

4726
chr6
31746849
31748039
−
VARS
0x0

4727
chr6
31760008
31761205
−
VARS
0x0

4728
chr6
31782864
31784065
+
HSPA1A
0x0

4729
chr6
31784919
31786234
+
HSPA1A
0x0

4730
chr6
31797179
31798469
+
HSPA1B
0x0

4731
chr6
31804278
31805485
+
C6orf48
0x0

4732
chr6
31804278
31805485
+
SNORD52
0x0

4733
chr6
32086135
32087386
−
ATF6B
0x0

4734
chr6
32148451
32149554
+
RNF5
0x0

4735
chr6
32148451
32149554
+
RNF5P1
0x0

4736
chr6
33239916
33241022
+
RPS18
0x0

4737
chr6
33243018
33244197
+
RPS18
0x0

4738
chr6
33266967
33268141
−
RGL2
0x0

4739
chr6
33266967
33268141
−
TAPBP
0x0

4740
chr6
33654767
33655866
+
ITPR3
0x2

4741
chr6
33738948
33740183
−
LEMD2
0x0

4742
chr6
34204449
34205642
+
HMGA1
0x2

4743
chr6
34213068
34214379
+
HMGA1
0x2

4744
chr6
34249271
34250682
−
NUDT3
0x0

4745
chr6
34249271
34250682
−
RPS10-NUDT3
0x0

4746
chr6
34388259
34389415
−
RPS10
0x0

4747
chr6
34388259
34389415
−
RPS10-NUDT3
0x0

4748
chr6
34390262
34391440
−
RPS10
0x0

4749
chr6
34390262
34391440
−
RPS10-NUDT3
0x0

4750
chr6
34556452
34557600
−
C6orf106
0x0

4751
chr6
34826547
34827779
+
UHRF1BP1
0x0

4752
chr6
35032311
35033701
+
ANKS1A
0x0

4753
chr6
35451550
35452727
−
TEAD3
0x0

4754
chr6
35523396
35524603
+
RPL10A
0x0

4755
chr6
35853153
35854414
−
SRPK1
0x0

4756
chr6
36198642
36199909
+
BRPF3
0x0

4757
chr6
36569808
36571036
+
SRSF3
0x2

4758
chr6
36894856
36896000
+
C6orf89
0x0

4759
chr6
37358228
37359440
+
RNF8
0x0

4760
chr6
38041182
38042392
+
ZFAND3
0x0

4761
chr6
41761912
41763042
−
USP49
0x0

4762
chr6
42236613
42237790
−
TRERF1
0x0

4763
chr6
42423307
42424509
+
UBR2
0x0

4764
chr6
42856085
42857313
+
RPL7L1
0x0

4765
chr6
42923667
42925068
−
PEX6
0x0

4766
chr6
42988024
42989312
−
KLHDC3
0x0

4767
chr6
43025492
43027669
−
MRPL2
0x0

4768
chr6
43037667
43038876
+
KLC4
0x0

4769
chr6
43095792
43096991
+
PTK7
0x0

4770
chr6
43171690
43172872
+
CUL9
0x0

4771
chr6
44081319
44082523
−
MRPL14
0x0

4772
chr6
44094272
44095453
−
MRPL14
0x0

4773
chr6
44219220
44220481
+
HSP90AB1
0x2

4774
chr6
44266391
44267567
−
AARS2
0x0

4775
chr6
44408477
44410722
+
CDC5L
0x0

4776
chr6
44995610
44996776
−
SUPT3H
0x0

4777
chr6
46111643
46112793
+
ENPP4
0x0

4778
chr6
46622408
46623507
+
SLC25A27
0x0

4779
chr6
47251283
47252411
−
TNFRSF21
0x0

4780
chr6
47253341
47254576
−
TNFRSF21
0x0

4781
chr6
52349296
52350448
+
EFHC1
0x0

4782
chr6
52849480
52850704
−
GSTA4
0x0

4783
chr6
52855044
52856169
−
GSTA4
0x0

4784
chr6
52859885
52861330
+
FBXO9
0x0

4785
chr6
52957213
52958430
+
FBXO9
0x0

4786
chr6
53083552
53084753
+
FBXO9
0x0

4787
chr6
53132185
53133289
−
ELOVL5
0x0

4788
chr6
56399463
56400610
−
OST
0x2

4789
chr6
57034314
57035512
+
ZNF451
0x0

4790
chr6
57053896
57055230
−
RAB23
0x2

4791
chr6
63921356
63922581
+
PTP4A1
0x0

4792
chr6
64290668
64291881
+
PTP4A1
0x0

4793
chr6
71225073
71226176
+
FAM135A
0x0

4794
chr6
73448473
73449706
+
KCNQ5
0x2

4795
chr6
74197008
74198113
−
EEF1A1
0x1

4796
chr6
74227963
74229055
−
EEF1A1
0x1

4797
chr6
74229688
74230876
−
EEF1A1
0x1

4798
chr6
74309553
74310681
−
SLC17A5
0x2

4799
chr6
75946972
75948118
−
COX7A2
0x0

4800
chr6
77993678
77994796
−
HTR1B
0x0

4801
chr6
79665318
79666472
−
PHIP
0x2

4802
chr6
79769656
79770833
−
PHIP
0x2

4803
chr6
80656541
80657733
−
ELOVL4
0x0

4804
chr6
80751306
80752707
+
TTK
0x2

4805
chr6
83706974
83708136
−
UBE3D
0x0

4806
chr6
83787687
83788905
+
DOPEY1
0x0

4807
chr6
84942245
84943434
−
KIAA1009
0x0

4808
chr6
86323454
86325410
−
SYNCRIP
0x0

4809
chr6
86333179
86334327
−
SYNCRIP
0x0

4810
chr6
86339754
86340907
−
SYNCRIP
0x0

4811
chr6
86386454
86387828
−
SNHG5
0x0

4812
chr6
86386454
86387828
−
SNORD50A
0x1

4813
chr6
86385454
86387828
−
SNORD50B
0x0

4814
chr6
87896838
87898031
+
ZNF292
0x0

4815
chr6
88268955
88270163
−
RARS2
0x0

4816
chr6
88271871
88273026
−
RARS2
0x0

4817
chr6
89512421
89513595
−
RNGTT
0x0

4818
chr6
89772705
89773936
−
SRSF12
0x0

4819
chr6
90036427
90037576
−
UBE2J1
0x0

4820
chr6
90103175
90104299
−
RRAGD
0x0

4821
chr6
90180489
90181711
+
ANKRD6
0x0

4822
chr6
90190795
90191990
+
ANKRD6
0x0

4823
chr6
90319964
90321150
+
ANKRD6
0x0

4824
chr6
90352660
90354462
−
MDN1
0x0

4825
chr6
90377219
90378421
−
MDN1
0x0

4826
chr6
91224962
91226062
−
MAP3K7
0x0

4827
chr6
91327958
91329132
+
MIR4464
0x0

4828
chr6
94045719
94046894
−
EPHA7
0x2

4829
chr6
94268127
94269325
+
TSG1
0x0

4830
chr6
97632526
97633664
−
MMS22L
0x0

4831
chr6
97683639
97684802
−
IMMS22L
0x0

4832
chr6
97685918
97687017
−
MMS22L
0x0

4833
chr6
97719552
97720728
−
MMS22L
0x0

4834
chr6
100028547
100029746
−
CCNC
0x1

4835
chr6
100905416
100906563
−
SIM1
0x0

4836
chr6
101135519
101136729
−
ASCC3
0x0

4837
chr6
101146910
101148133
−
ASCC3
0x0

4838
chr6
105544496
105545608
−
BVES
0x0

4839
chr6
106730913
106732080
−
ATG5
0x0

4840
chr6
106896710
106897932
+
AIM1
0x4

4841
chr6
107388384
107389560
−
BEND3
0x0

4842
chr6
107969104
107970332
+
SOBP
0x0

4843
chr6
108984597
108986174
+
FOXO3
0x1

4844
chr6
109688249
109689435
−
CD164
0x0

4845
chr6
111193860
111195060
+
AMD1
0x0

4846
chr6
111210899
111212106
+
AMD1
0x0

4847
chr6
111588017
111589142
+
KIAA1919
0x0

4848
chr6
111653808
111654975
−
REV3L
0x0

4849
chr6
111793412
111794582
−
REV3L
0x0

4850
chr6
111904428
111905605
+
TRAF3IP2-AS1
0x0

4851
chr6
111982194
111983390
−
FYN
0x0

4852
chr6
113292154
113293373
+
RFPL4B
0x0

4853
chr6
114178112
114179330
+
MARCKS
0x0

4854
chr6
114181875
114183039
+
MARCKS
0x0

4855
chr6
116579247
116580527
−
TSPYL4
0x0

4856
chr6
116598668
116599891
−
TSPYL1
0x0

4857
chr6
117034886
117036007
+
KPNA5
0x2

4858
chr6
118031778
118032913
+
NUS1
0x0

4859
chr6
118332249
118333446
+
SLC35F1
0x0

4860
chr6
118554121
118555276
−
CEP85L
0x0

4861
chr6
119177072
119178279
−
MCM9
0x0

4862
chr6
119393192
119394423
−
MIR548B
0x0

4863
chr6
121007221
121008447
+
GJA1
0x1

4864
chr6
121769727
121770978
+
GJA1
0x1

4865
chr6
121900967
121902148
−
C6orf170
0x2

4866
chr6
123065973
123067206
+
PKIB
0x0

4867
chr6
124217186
124218234
+
NKAIN2
0x0

4868
chr6
125596639
125597850
−
HDDC2
0x0

4869
chr6
126299287
126300490
+
HINT3
0x0

4870
chr6
126359698
126360815
+
TRMT11
0x0

4871
chr6
126371294
126372445
+
TRMT11
0x0

4872
chr6
126500603
126501839
+
TRMT11
0x0

4873
chr6
126524483
126525677
+
CENPW
0x0

4874
chr6
131215651
131216815
−
EPB41L2
0x0

4875
chr6
131337192
131338291
−
EPB41L2
0x0

4876
chr6
131517695
131518893
+
AKAP7
0x0

4877
chr6
131978592
131979749
+
ENPP3
0x0

4878
chr6
132381098
132382233
+
LOC100507254
0x0

4879
chr6
133135538
133137071
+
RPS12
0x0

4880
chr6
133135538
133137071
+
SNORD101
0x0

4881
chr6
133137377
133138573
+
RPS12
0x0

4882
chr6
133137377
133138573
+
SNORA33
0x0

4883
chr6
133137377
133138573
+
SNORD100
0x0

4884
chr6
135776476
135777666
−
AHI1
0x0

4885
chr6
135792205
135793369
−
AHI1
0x0

4886
chr6
136580786
136583058
−
BCLAF1
0x2

4887
chr6
136609769
136610922
−
BCLAF1
0x2

4888
chr6
136950837
136951945
+
PEX7
0x0

4889
chr6
136985366
136986559
−
MAP3K5
0x2

4890
chr6
137516718
137517919
+
IFNGR1
0x0

4891
chr6
138411876
138413053
−
PERP
0x0

4892
chr6
139471071
139472211
+
HECA
0x1

4893
chr6
143770410
143771612
+
PEX3
0x0

4894
chr6
144024630
144025793
+
PHACTR2
0x0

4895
chr6
144080177
144081352
+
PHACTR2
0x0

4896
chr6
144092907
144094059
+
PHACTR2
0x0

4897
chr6
144415589
144416776
−
SF3B5
0x0

4898
chr6
144691525
144692844
−
SF3B5
0x0

4899
chr6
145503291
145504468
+
UTRN
0x0

4900
chr6
148180382
148181555
+
SAMDS
0x0

4901
chr6
148864652
148865751
+
SASH1
0x1

4902
chr6
149114303
149115527
+
UST
0x0

4903
chr6
149373105
149374324
−
UST
0x0

4904
chr6
149731584
149732938
−
TAB2
0x0

4905
chr6
149771073
149772242
−
ZC3H12D
0x0

4906
chr6
149887280
149888487
+
C6orf72
0x0

4907
chr6
150070386
150071604
+
PCMT1
0x0

4908
chr6
150131824
150133021
+
PCMT1
0x0

4909
chr6
151007810
151008958
+
PLEKHG1
0x0

4910
chr6
151230797
151231991
−
MTHFD1L
0x0

4911
chr6
151715338
151716552
+
AKAP12
0x1

4912
chr6
153602990
153604390
−
RGS17
0x0

4913
chr6
153741015
153742253
+
OPRM1
0x0

4914
chr6
154510891
154512064
+
OPRM1
0x0

4915
chr6
157099272
157100482
+
ARID1B
0x2

4916
chr6
157297408
157298585
+
ARID1B
0x2

4917
chr6
158501709
158502885
+
SYNJ2
0x0

4918
chr6
158732582
158734565
+
TULP4
0x0

4919
chr6
158836738
158837951
+
TULP4
0x0

4920
chr6
159005798
159006993
+
TMEM181
0x0

4921
chr6
159010147
159011345
+
TMEM181
0x0

4922
chr6
159222196
159223361
−
EZR
0x2

4923
chr6
160100679
160101871
−
SOD2
0x1

4924
chr6
160147489
160148641
−
LOC100129518
0x0

4925
chr6
160199235
160200470
−
TCP1
0x0

4926
chr6
160200704
160201944
−
SNORA20
0x0

4927
chr6
160200704
160201944
−
TCP1
0x0

4928
chr6
161574255
161575389
−
AGPAT4
0x0

4929
chr6
161693681
161694857
−
AGPAT4
0x0

4930
chr6
163729635
163730813
−
LOC285796
0x0

4931
chr6
163992894
163994954
+
QKI
0x0

4932
chr6
167096615
167097792
−
RPS6KA2
0x1

4933
chr6
167232349
167233545
−
RPS6KA2
0x1

4934
chr6
167431288
167432414
+
FGFR1OP
0x2

4935
chr6
169717516
169718713
−
THBS2
0x0

4936
chr6
169959010
169960179
−
WDR27
0x0

4937
chr6
170063733
170065042
−
WDR27
0x0

4938
chr6
170107201
170108322
−
PHF10
0x0

4939
chr6
170108331
170109430
−
PHF10
0x0

4940
chr6
170109684
170110800
−
PHF10
0x0

4941
chr6
170715138
170716380
−
FAM120B
0x0

4942
chr6
170793708
170794808
−
TBP
0x0

4943
chr7
716322
717533
−
PRKAR1B
0x0

4944
chr7
793397
794759
−
HEATR2
0x0

4945
chr7
882031
883164
+
SUN1
0x0

4946
chr7
1114643
1115856
−
C7orf50
0x0

4947
chr7
1148073
1149265
−
C7or(50
0x0

4948
chr7
2209517
2210716
−
MAD1L1
0x1

4949
chr7
2335042
2336261
−
SNX8
0x0

4950
chr7
2419510
2420742
+
EIF3B
0x0

4951
chr7
2653169
2654343
+
IQCE
0x0

4952
chr7
2702439
2704021
+
TTYH3
0x0

4953
chr7
2762696
2763886
−
GNA12
0x0

4954
chr7
2765610
2766723
−
GNA12
0x0

4955
chr7
3038321
3039532
+
AMZ1
0x0

4956
chr7
3152398
3153597
−
CARD11
0x2

4957
chr7
3297158
3298337
−
CARD11
0x2

4958
chr7
3347392
3348543
+
SDK1
0x0

4959
chr7
3613078
3614275
+
SDK1
0x0

4960
chr7
3998820
4000014
+
SDK1
0x0

4961
chr7
4118598
4119714
+
SDK1
0x0

4962
chr7
5253679
5254827
+
WIPI2
0x0

4963
chr7
5269929
5271252
+
WIPI2
0x0

4964
chr7
5347601
5348689
−
TNRC18
0x0

4965
chr7
5351989
5353124
−
TNRC18
0x0

4966
chr7
5395880
5397015
−
TNRC18
0x0

4967
chr7
5433553
5434723
−
TNRC18
0x0

4968
chr7
5450755
5451944
−
TNRC18
0x0

4969
chr7
5536480
5537661
−
MIR589
0x0

4970
chr7
5540860
5542057
−
FBXL18
0x0

4971
chr7
5566668
5567958
−
ACTB
0x2

4972
chr7
5685864
5687035
−
RNF216
0x0

4973
chr7
6025876
6027098
−
PMS2
0x1

4974
chr7
6098042
6099244
−
EIF2AK1
0x0

4975
chr7
6380025
6381233
−
C7orf70
0x0

4976
chr7
6441838
6444007
+
RAC1
0x0

4977
chr7
6500568
6501811
−
KDELR2
0x0

4978
chr7
7882404
7883601
+
LOC729852
0x0

4979
chr7
8112486
8113702
+
GLCCI1
0x0

4980
chr7
8127283
8128479
+
GLCCI1
0x0

4981
chr7
11137465
11138681
+
PHF14
0x0

4982
chr7
12024744
12025924
−
THSD7A
0x0

4983
chr7
12915824
12917060
+
ARL4A
0x0

4984
chr7
15781909
15783031
−
LOC100506025
0x0

4985
chr7
16739862
16741056
−
BZW2
0x0

4986
chr7
16823462
16824630
+
TSPAN13
0x0

4987
chr7
22895658
22896857
+
SNORD93
0x0

4988
chr7
23224278
23225503
+
NUPL2
0x0

4989
chr7
23239252
23240488
−
NUPL2
0x0

4990
chr7
23446198
23447358
−
IGF2BP3
0x0

4991
chr7
23530465
23531648
+
RPS2P32
0x0

4992
chr7
24731533
24732682
+
MPP6
0x0

4993
chr7
25988340
25989530
−
MIR148A
0x0

4994
chr7
26230917
26232469
−
HNRNPA2B1
0x2

4995
chr7
26236459
26237797
−
HNRNPA2B1
0x2

4996
chr7
26239671
26241083
−
HNRNPA2B1
0x2

4997
chr7
26241519
26242615
+
CBX3
0x0

4998
chr7
26364063
26365261
+
SNX10
0x0

4999
chr7
26706811
26708082
−
SKAP2
0x0

5000
chr7
27202973
27204085
−
HOXA10-HOXA9
0x0

5001
chr7
27202973
27204085
−
HOXA9
0x2

5002
chr7
27205067
27206183
−
HOXA9
0x2

5003
chr7
28081190
28082374
−
JAZF1
0x2

5004
chr7
28179077
28180280
−
JAZF1
0x2

5005
chr7
28832876
28834100
+
CREB5
0x0

5006
chr7
28843490
28844709
+
CREB5
0x0

5007
chr7
29960439
29961649
−
SCRN1
0x0

5008
chr7
30199055
30200368
+
C7orf41
0x0

5009
chr7
30201709
30202892
+
C7or(41
0x0

5010
chr7
30401633
30402869
+
ZNRF2
0x0

5011
chr7
32602085
32603255
+
AVL9
0x0

5012
chr7
32768061
32769271
+
ZNRF2P1
0x0

5013
chr7
34970565
34971769
−
DPY19L1
0x0

5014
chr7
35187334
35188527
−
DPY19L2P1
0x0

5015
chr7
35943851
35945050
+
SEPT7
0x0

5016
chr7
37474190
37475366
+
GPR141
0x0

5017
chr7
38764683
38766032
−
VPS41
0x0

5018
chr7
38767749
38768941
−
VPS41
0x0

5019
chr7
40046956
40048149
+
CDK13
0x0

5020
chr7
40122300
40123482
+
CDK13
0x0

5021
chr7
40716495
40717647
+
C7orf10
0x0

5022
chr7
43664776
43665987
−
C7orf44
0x0

5023
chr7
43676994
43678133
−
C7orf44
0x0

5024
chr7
43688077
43689239
−
C7orf44
0x0

5025
chr7
43755954
43757114
−
C7orf44
0x0

5026
chr7
44017403
44018614
−
POLR2J4
0x0

5027
chr7
44156210
44157388
−
POLD2
0x0

5028
chr7
44252240
44253901
+
YKT6
0x0

5029
chr7
44422977
44425078
−
NUDCD3
0x0

5030
chr7
44506929
44508226
+
OGDH
0x0

5031
chr7
44615133
44616293
−
DDX56
0x0

5032
chr7
44867630
44869296
−
H2AFV
0x0

5033
chr7
44869491
44870653
−
H2AFV
0x0

5034
chr7
44871384
44872476
−
H2AFV
0x0

5035
chr7
45024431
45025655
−
SNHG15
0x0

5036
chr7
45024431
45025655
−
SNORA9
0x0

5037
chr7
45055716
45056839
+
CCM2
0x0

5038
chr7
45143432
45145126
−
SNORA5A
0x0

5039
chr7
45143432
45145126
−
SNORA5C
0x0

5040
chr7
45143432
45145126
−
TBRG4
0x0

5041
chr7
45631850
45633046
+
ADCY1
0x2

5042
chr7
45687751
45688961
+
ADCY1
0x2

5043
chr7
47883015
47884214
−
PKD1L1
0x0

5044
chr7
48329866
48330965
+
ABCA13
0x0

5045
chr7
51125959
51127160
−
COBL
0x0

5046
chr7
51140419
51141571
+
COBL
0x0

5047
chr7
53573745
53575001
+
POM121L12
0x0

5048
chr7
53843321
53844539
+
POM121L12
0x0

5049
chr7
55712928
55714027
+
LANCL2
0x0

5050
chr7
55992166
55993377
+
ZNF713
0x0

5051
chr7
56047818
56048984
+
GBAS
0x0

5052
chr7
56050957
56052136
+
GBAS
0x0

5053
chr7
56066418
56067572
+
GBAS
0x0

5054
chr7
56111114
56112302
−
PSPH
0x0

5055
chr7
56122829
56124002
+
CCT6A
0x0

5056
chr7
56125566
56126665
+
CCT6A
0x0

5057
chr7
56130833
56132038
+
CCT6A
0x0

5058
chr7
56130833
56132038
+
SUMF2
0x0

5059
chr7
56168775
56169951
−
CHCHD2
0x0

5060
chr7
63806388
63807524
+
ZNF736
0x0

5061
chr7
64512487
64513689
+
CCT6P3
0x0

5062
chr7
65220022
65221173
+
CCT6P1
0x0

5063
chr7
65220022
65221173
+
SNORA22
0x0

5064
chr7
66444580
66445777
+
TYW1
0x0

5065
chr7
66452731
66453910
−
SBDS
0x2

5066
chr7
66461505
66462727
+
TYW1
0x0

5067
chr7
66696321
66697506
−
PMS2P4
0x0

5068
chr7
66732088
66733253
−
PMS2P4
0x0

5069
chr7
68526830
68528282
+
AUTS2
0x0

5070
chr7
69137623
69139895
+
AUTS2
0x0

5071
chr7
69150855
69152052
+
AUTS2
0x0

5072
chr7
69890680
69891884
+
AUTS2
0x0

5073
chr7
69944884
69946122
+
AUTS2
0x0

5074
chr7
70095006
70096231
+
AUTS2
0x0

5075
chr7
70158630
70159729
+
AUTS2
0x0

5076
chr7
70162406
70163506
+
AUTS2
0x0

5077
chr7
70228678
70229863
+
AUTS2
0x0

5078
chr7
72210226
72211362
−
TYW1B
0x0

5079
chr7
72384475
72385573
+
POM 121
0x0

5080
chr7
72855521
72856620
−
BAZ1B
0x0

5081
chr7
72892223
72893442
−
BAZ1B
0x0

5082
chr7
73028896
73030065
−
MLXIPL
0x0

5083
chr7
73609735
73611412
+
EIF4H
0x0

5084
chr7
74011007
74012204
+
GTF21RD1
0x0

5085
chr7
75013767
75014967
+
TRIM73
0x0

5086
chr7
75013767
75014967
+
TRIM74
0x0

5087
chr7
75616282
75617424
−
TMEM120A
0x0

5088
chr7
75677085
75678284
+
MDH2
0x0

5089
chr7
75695075
75696451
+
MDH2
0x0

5090
chr7
76183802
76184974
+
LOC100133091
0x0

5091
chr7
77288076
77289291
+
PTPN12
0x1

5092
chr7
77325584
77329262
+
RSBN1L
0x0

5093
chr7
77409754
77411102
+
RSBN1L
0x0

5094
chr7
77444662
77445817
+
PHTF2
0x0

5095
chr7
77819775
77820999
+
RPL13AP17
0x0

5096
chr7
84217800
84218994
−
SEMA3A
0x0

5097
chr7
85957572
85958791
+
GRM3
0x2

5098
chr7
91745871
91747042
−
CYP51A1
0x0

5099
chr7
92121693
92122871
−
PEX1
0x0

5100
chr7
94259800
94260938
−
SGCE
0x4

5101
chr7
94277985
94279186
−
SGCE
0x4

5102
chr7
95182157
95183355
+
ASB4
0x4

5103
chr7
97500925
97502164
−
ASNS
0x0

5104
chr7
97822980
97824146
+
LMTK2
0x0

5105
chr7
98571475
98572623
+
TRRAP
0x2

5106
chr7
98580407
98581636
+
TRRAP
0x2

5107
chr7
99040246
99041345
−
CPSF4
0x0

5108
chr7
99055334
99056509
−
ATP5J2
0x0

5109
chr7
99063102
99064286
−
ATP5J2
0x0

5110
chr7
99063102
99064286
−
ATP5J2-PTCD1
0x0

5111
chr7
99070753
99071852
+
ZNF789
0x0

5112
chr7
99090314
99091491
−
ZNF394
0x0

5113
chr7
99164579
99165769
+
ZNF655
0x0

5114
chr7
99620568
99621775
+
ZKSCAN1
0x0

5115
chr7
99696493
99697583
−
MCM7
0x0

5116
chr7
99766778
99767983
−
GPC2
0x0

5117
chr7
100027125
100028311
+
MEPCE
0x0

5118
chr7
100171876
100172981
−
LRCH4
0x0

5119
chr7
100177762
100178920
−
LRCH4
0x0

5120
chr7
100880641
100881974
−
CLDN15
0x0

5121
chr7
100895195
100896397
+
ZNHIT1
0x0

5122
chr7
101518509
101519697
−
CUX1
0x2

5123
chr7
101614007
101615204
+
CUX1
0x2

5124
chr7
101870302
101871497
+
CUX1
0x2

5125
chr7
102090409
102091726
+
ORAI2
0x0

5126
chr7
102103915
102105079
−
ALKBH4
0x0

5127
chr7
102273284
102274466
−
POLR2J2
0x0

5128
chr7
102776284
102777472
−
RPL19P12
0x0

5129
chr7
102956740
102957866
−
DNAJC2
0x0

5130
chr7
102959728
102960926
−
DNAJC2
0x0

5131
chr7
102987648
102988747
+
PSMC2
0x0

5132
chr7
103017293
103018395
+
PSMC2
0x0

5133
chr7
104183926
104185102
−
LOC645591
0x0

5134
chr7
104989419
104990519
−
SRPK2
0x0

5135
chr7
105130826
105131959
−
PUS7
0x0

5136
chr7
105730920
105732237
−
SYPL1
0x0

5137
chr7
106966970
106968196
−
COG5
0x0

5138
chr7
107392326
107393492
+
CBLL1
0x0

5139
chr7
107579969
107581118
−
LAMB1
0x0

5140
chr7
107604477
107605657
−
LAMB1
0x0

5141
chr7
107641647
107642890
−
LAMB1
0x0

5142
chr7
107788055
107789246
−
NRCAM
0x1

5143
chr7
109647779
109648956
−
EIF3IP1
0x0

5144
chr7
111928314
111929569
+
ZNF277
0x0

5145
chr7
112094112
112095341
+
IFRD1
0x0

5146
chr7
113813661
113814849
+
FOXP2
0x0

5147
chr7
113873613
113874725
+
FOXP2
0x0

5148
chr7
116655877
116657135
+
ST7-OT4
0x0

5149
chr7
116864291
116865488
−
ST7
0x1

5150
chr7
121022060
121023221
−
FAM3C
0x0

5151
chr7
123181470
123182631
−
NDUFA5
0x0

5152
chr7
126826996
126828167
−
GRM8
0x2

5153
chr7
127002369
127003478
−
ZNF800
0x0

5154
chr7
127011169
127012346
−
ZNF800
0x0

5155
chr7
127292221
127293424
+
SND1
0x0

5156
chr7
127304238
127305368
−
SND1
0x0

5157
chr7
127717944
127719181
−
SND1
0x0

5158
chr7
128045356
128046535
−
IMPDH1
0x0

5159
chr7
128144617
128145843
−
METTL2B
0x0

5160
chr7
128268899
128270067
+
FU45340
0x0

5161
chr7
128294201
128295432
+
FU4S340
0x0

5162
chr7
128336957
128338351
+
FAM71F2
0x0

5163
chr7
128410338
128411503
+
CALU
0x0

5164
chr7
128626267
128627427
−
TNPO3
0x0

5165
chr7
128804197
128805297
+
TSPAN33
0x0

5166
chr7
128828291
128829490
+
SMO
0x1

5167
chr7
128844598
128846620
+
SMO
0x1

5168
chr7
128956910
128958109
+
AHCYL2
0x0

5169
chr7
129249052
129250217
−
MIR182
0x0

5170
chr7
129771754
129772914
+
KLHDC10
0x0

5171
chr7
132719105
132721265
−
CHCHD3
0x0

5172
chr7
134126762
134127961
−
AKR1B1
0x1

5173
chr7
134446424
134447609
−
AKR1B1
0x1

5174
chr7
134653877
134655027
+
CALD1
0x0

5175
chr7
135262978
135264232
+
NUP205
0x0

5176
chr7
135299192
135300395
−
NUP205
0x0

5177
chr7
135564469
135565613
−
LUZP6
0x0

5178
chr7
135564469
135565613
−
MTPN
0x0

5179
chr7
135612497
135613615
−
LUZP6
0x0

5180
chr7
135612497
135613615
−
MTPN
0x0

5181
chr7
135631923
135633117
−
LUZP6
0x0

5182
chr7
135631923
135633117
−
MTPN
0x0

5183
chr7
137561561
137562688
−
CREB3L2
0x2

5184
chr7
137593795
137594957
−
CREB3L2
0x2

5185
chr7
137641335
137642504
−
CREB3L2
0x2

5186
chr7
138229348
138230509
+
TRIM24
0x1

5187
chr7
138601353
138602530
−
KIAA1549
0x0

5188
chr7
138708377
138709573
−
ZC3HAV1L
0x0

5189
chr7
139060142
139061336
+
LUC7L2
0x0

5190
chr7
139091472
139092571
+
LUC7L2
0x0

5191
chr7
139163207
139164420
−
KLRG2
0x0

5192
chr7
139252540
139254304
−
HIPK2
0x1

5193
chr7
139255381
139257357
−
HIPK2
0x1

5194
chr7
139415555
139417089
−
HIPK2
0x1

5195
chr7
139991958
139993146
−
SLC37A3
0x0

5196
chr7
140578969
140580149
−
BRAF
0x2

5197
chr7
140608227
140609407
−
BRAF
0x2

5198
chr7
140949281
140950478
+
LOC100507421
0x0

5199
chr7
140989729
140990945
+
LOC100507421
0x0

5200
chr7
141427256
141428517
−
WEE2
0x0

5201
chr7
142828739
142829949
−
OR6W1P
0x0

5202
chr7
148517064
148518265
−
EZH2
0x2

5203
chr7
148637989
148639256
+
CUL1
0x1

5204
chr7
148683652
148684931
−
PDIA4
0x2

5205
chr7
148815628
148816762
−
ZNF425
0x0

5206
chr7
148822219
148823398
−
ZNF425
0x0

5207
chr7
148875639
148876808
+
ZNF398
0x0

5208
chr7
149187521
149188679
−
ZNF746
0x0

5209
chr7
149281240
149282410
+
KRBA1
0x0

5210
chr7
149361344
149362611
+
KRBA1
0x0

5211
chr7
149387704
149388911
−
ZNF767
0x0

5212
chr7
149411854
149413217
+
KRBA1
0x0

5213
chr7
149575886
149577679
+
ATP6V0E2
0x0

5214
chr7
150070282
150071455
+
REPIN1
0x0

5215
chr7
150815954
150817053
+
AGAP3
0x0

5216
chr7
150910175
150911551
−
ABCF2
0x0

5217
chr7
150967839
150969008
−
SMARCD3
0x0

5218
chr7
151215094
151216312
−
RHEB
0x0

5219
chr7
151921067
151922240
−
MLL3
0x2

5220
chr7
152097427
152098632
−
MLL3
0x2

5221
chr7
155099915
155101047
+
INSIG1
0x0

5222
chr7
155250236
155251340
+
EN2
0x0

5223
chr7
155572294
155573527
+
RBM33
0x0

5224
chr7
156473215
156474319
−
LMBR1
0x0

5225
chr7
157131140
157132337
+
DNAJB6
0x0

5226
chr7
157207302
157208421
+
DNAJB6
0x0

5227
chr7
158482226
158483355
−
NCAPG2
0x0

5228
chr7
158523818
158524891
−
ESYT2
0x0

5229
chr7
158526068
158527207
−
ESYT2
0x0

5230
chr8
171812
172992
−
RPL23AP53
0x0

5231
chr8
650437
651644
−
ERICH1
0x0

5232
chr8
1728071
1729269
+
CLN8
0x2

5233
chr8
1851872
1853143
+
ARHGEF10
0x2

5234
chr8
1892421
1893656
+
ARHGEF10
0x2

5235
chr8
8719116
8720272
−
MFHAS1
0x1

5236
chr8
9522657
9523873
+
TNKS
0x0

5237
chr8
10543587
10544750
+
C8orf74
0x0

5238
chr8
10553225
10554430
−
SOX7
0x1

5239
chr8
10989659
10990816
−
XKR6
0x0

5240
chr8
11018991
11020365
−
XKR6
0x0

5241
chr8
11179720
11180920
+
MTMR9
0x0

5242
chr8
14088163
14089374
−
SGCZ
0x0

5243
chr8
14466831
14468007
−
SGCZ
0x0

5244
chr8
15608483
15609698
+
TUSC3
0x1

5245
chr8
16969800
16970982
+
EFHA2
0x0

5246
chr8
16973468
16974591
+
EFHA2
0x0

5247
chr8
17020725
17021901
+
ZDHHC2
0x1

5248
chr8
17528806
17529982
−
MTUS1
0x1

5249
chr8
17600589
17601753
−
MTUS1
0x1

5250
chr8
21783081
21784262
+
XPO7
0x2

5251
chr8
22273079
22274302
+
SLC39A14
0x0

5252
chr8
22278525
22279701
+
SLC39A14
0x0

5253
chr8
22993341
22994750
−
TNFRSF10D
0x0

5254
chr8
23001245
23002452
−
TNFRSF10D
0x0

5255
chr8
23118432
23119876
+
CHMP7
0x0

5256
chr8
23933949
23935207
−
STC1
0x2

5257
chr8
26466443
26467884
+
DPYSL2
0x0

5258
chr8
26513085
26514287
+
DPYSL2
0x0

5259
chr8
27626561
27627757
−
CCDC25
0x0

5260
chr8
27642609
27643794
+
ESCO2
0x0

5261
chr8
27661194
27662353
+
ESCO2
0x0

5262
chr8
28610258
28611360
+
EXTL3
0x1

5263
chr8
28925365
28926640
−
K1F13B
0x0

5264
chr8
28973920
28975219
−
KIF13B
0x0

5265
chr8
29191850
29193027
−
DUSP4
0x0

5266
chr8
29926842
29927959
−
TMEM66
0x0

5267
chr8
30535411
30536703
−
GSR
0x0

5268
chr8
30918443
30919643
+
WRN
0x2

5269
chr8
30941596
30942794
+
WRN
0x2

5270
chr8
30973889
30975103
+
WRN
0x2

5271
chr8
33307984
33309159
−
FUT10
0x0

5272
chr8
33370435
33371696
+
MAK16
0x0

5273
chr8
33405399
33406500
−
RNF122
0x0

5274
chr8
37351279
37352488
−
LOC728024
0x0

5275
chr8
37548760
37549962
−
LOC728024
0x0

5276
chr8
37555657
37556832
+
ZNF703
0x0

5277
chr8
37610997
37612138
+
ERLIN2
0x0

5278
chr8
37734373
37735537
−
RAB11FIP1
0x0

5279
chr8
37896767
37897965
+
EIF4EBP1
0x0

5280
chr8
37964730
37965937
+
ASH2L
0x0

5281
chr8
38238788
38240521
−
WHSC1L1
0x1

5282
chr8
41789279
41790380
−
KAT6A
0x2

5283
chr8
42069466
42070659
+
AP3M2
0x0

5284
chr8
42751527
42752702
−
RNF170
0x0

5285
chr8
48454145
48455421
+
KIAA0146
0x0

5286
chr8
48690474
48691581
−
PRKDC
0x0

5287
chr8
48719526
48720712
−
PRKDC
0x0

5288
chr8
56698693
56699907
+
TGS1
0x0

5289
chr8
56702837
56704080
+
TGS1
0x0

5290
chr8
56792545
56793692
+
LYN
0x0

5291
chr8
56986406
56987620
−
RPS20
0x0

5292
chr8
56986406
56987620
−
SNORD54
0x0

5293
chr8
59361453
59362789
+
UBXN2B
0x0

5294
chr8
59495823
59497028
−
NSMAF
0x0

5295
chr8
60367861
60369092
+
SDCBP
0x0

5296
chr8
61141149
61142305
−
CAS
0x0

5297
chr8
61380988
61382139
−
CA8
0x0

5298
chr8
61428976
61430164
+
RAB2A
0x0

5299
chr8
62558694
62559890
−
ASPH
0x0

5300
chr8
65062889
65064025
−
LOC401463
0x0

5301
chr8
67025014
67026251
+
DNAJC5B
0x0

5302
chr8
67834131
67835343
−
SNHG6
0x0

5303
chr8
67834131
67835343
−
SNORD87
0x0

5304
chr8
67854441
67855579
−
TCF24
0x0

5305
chr8
69218262
69219475
+
C8orf34
0x0

5306
chr8
69628958
69630158
+
C8orf34
0x0

5307
chr8
70601758
70603154
−
SLC05A1
0x0

5308
chr8
71015648
71016846
−
NCOA2
0x2

5309
chr8
71485199
71486420
−
TRAM1
0x0

5310
chr8
72549549
72550725
−
MSC
0x0

5311
chr8
73557323
73558542
+
KCNB2
0x0

5312
chr8
74558696
74559805
−
STAU2
0x0

5313
chr8
77776192
77777558
+
ZFHX4
0x2

5314
chr8
80676493
80677670
−
HEY1
0x2

5315
chr8
80708218
80709377
+
STMN2
0x0

5316
chr8
81039463
81040687
−
TPD52
0x0

5317
chr8
84510943
84512141
−
C8orf59
0x0

5318
chr8
86191435
86192537
+
CAB
0x0

5319
chr8
87528903
87530098
+
CPNE3
0x0

5320
chr8
95406717
95407924
−
RAD54B
0x0

5321
chr8
95854520
95855619
+
INTS8
0x0

5322
chr8
98672727
98573911
+
MTDH
0x0

5323
chr8
98817057
98818222
+
LAPTM4B
0x0

5324
chr8
98827727
98828903
+
LAPTM4B
0x0

5325
chr8
101485556
101486759
−
ANKRD46
0x0

5326
chr8
101714872
101716041
−
PABPC1
0x2

5327
chr8
101724361
101725581
−
PABPC1
0x2

5328
chr8
101727184
101728357
−
PABPC1
0x2

5329
chr8
101729540
101730664
−
PABPC1
0x2

5330
chr8
101733058
101734450
−
PABPC1
0x2

5331
chr8
102149814
102150984
+
FU42969
0x0

5332
chr8
103423528
103424664
−
UBR5
0x2

5333
chr8
103845897
103847028
−
AZIN1
0x0

5334
chr8
106914349
106915532
−
ABRA
0x0

5335
chr8
107709298
107710494
−
ABRA
0x0

5336
chr8
110281595
110282791
−
NUDCD1
0x0

5337
chr8
110353471
110354647
+
ENY2
0x0

5338
chr8
116563419
116564599
−
TRPS1
0x0

5339
chr8
119396638
119397854
−
SAMD12
0x0

5340
chr8
120743496
120744716
−
TAF2
0x2

5341
chr8
120874372
120875604
+
DEPTOR
0x0

5342
chr8
121501990
121503167
+
MTBP
0x0

5343
chr8
124025136
124026313
−
DERL1
0x0

5344
chr8
124053823
124055003
−
DERL1
0x0

5345
chr8
124095937
124097121
+
WDR67
0x0

5346
chr8
124250286
124251573
−
C8orf76
0x0

5347
chr8
124250286
124251573
−
ZHX1-C8ORF76
0x0

5348
chr8
124511119
124512309
−
FBXO32
0x1

5349
chr8
124826019
124827118
+
FAM91A1
0x0

5350
chr8
125503049
125504257
+
RNF139
0x0

5351
chr8
126257758
126258960
+
NSMCE2
0x0

5352
chr8
126467614
126468814
+
TRIB1
0x2

5353
chr8
126584427
126585626
+
TRIB1
0x2

5354
chr8
128752709
128753881
+
MYC
0x2

5355
chr8
128878369
128879800
+
PVT1
0x0

5356
chr8
128902427
128903666
+
PVT1
0x0

5357
chr8
129006031
129007240
+
PVT1
0x0

5358
chr8
129232188
129233396
+
MIR1208
0x0

5359
chr8
131369782
131370944
−
ASAP1
0x0

5360
chr8
134249222
134250405
−
NDRG1
0x1

5361
chr8
135602264
135603445
−
ZFAT
0x4

5362
chr8
136484515
136485664
+
KHDRBS3
0x0

5363
chr8
141539629
141540966
−
EIF2C2
0x0

5364
chr8
141706964
141708108
−
PTK2
0x0

5365
chr8
144390951
144392074
−
TOP1MT
0x0

5366
chr8
144589736
144590895
−
ZC3H3
0x0

5367
chr8
144623760
144624957
+
GSDMD
0x0

5368
chr8
144656550
144657716
−
NAPRT1
0x0

5369
chr8
144665432
144666631
−
EEF1D
0x0

5370
chr8
144668416
144669512
−
EEF1D
0x0

5371
chr8
144671344
144672503
−
EEF1D
0x0

5372
chr8
144872867
144874212
−
SCRIB
0x1

5373
chr8
144995170
144996345
−
PLEC
0x0

5374
chr8
144996673
144997860
−
PLEC
0x0

5375
chr8
145512299
145513597
−
BOP1
0x0

5376
chr8
145514906
145516064
+
HSF1
0x0

5377
chr8
145735164
145736323
+
MFSD3
0x0

5378
chr8
145975673
145976844
−
ZNF251
0x0

5379
chr8
146014646
146015821
−
RPL8
0x0

5380
chr8
146016941
146018035
−
RPL8
0x0

5381
chr9
579222
580422
+
KANK1
0x1

5382
chr9
583912
585146
+
KANK1
0x1

5383
chr9
2358753
2359971
−
SMARCA2
0x1

5384
chr9
3214212
3215432
−
KCNV2
0x0

5385
chr9
3508378
3509541
−
RFX3
0x0

5386
chr9
4826335
4827507
+
RCL1
0x0

5387
chr9
4833549
4834747
−
RCL1
0x0

5388
chr9
5734043
5735202
+
KIAA1432
0x0

5389
chr9
9441508
9442749
−
KDM4C
0x0

5390
chr9
13124573
13125772
−
MPDZ
0x0

5391
chr9
14611622
14612784
−
ZDHHC21
0x0

5392
chr9
14640065
14641279
−
ZDHHC21
0x0

5393
chr9
14921661
14922812
−
FREM1
0x0

5394
chr9
15482841
15484138
−
PSIP1
0x2

5395
chr9
15505342
15506551
−
PSIP1
0x2

5396
chr9
16828016
16829203
−
BNC2
0x0

5397
chr9
17413189
17414414
−
CNTLN
0x0

5398
chr9
17440398
17441554
−
BNC2
0x0

5399
chr9
19055113
19056309
−
HAUS6
0x0

5400
chr9
19063173
19064362
−
HAUS6
0x0

5401
chr9
19063173
19064362
−
SCARNA8
0x0

5402
chr9
19372260
19373473
+
DENNO4C
0x0

5403
chr9
19375853
19377070
−
RPS6
0x0

5404
chr9
19377873
19380410
−
RPS6
0x0

5405
chr9
19383288
19384499
+
DENND4C
0x0

5406
chr9
20429737
20430924
−
MLLT3
0x2

5407
chr9
20548245
20549446
−
MIR4474
0x0

5408
chr9
20786340
20787535
+
KIAA1797
0x0

5409
chr9
20810807
20811984
−
MLLT3
0x2

5410
chr9
20896813
20898020
+
KIAA1797
0x0

5411
chr9
20923117
20924315
+
KIAA1797
0x0

5412
chr9
21332177
21333335
−
KLHL9
0x0

5413
chr9
21698742
21700024
+
MTAP
0x1

5414
chr9
21861943
21863042
+
MTAP
0x1

5415
chr9
21867924
21869151
+
MTAP
0x1

5416
chr9
21903931
21905084
+
MTAP
0x1

5417
chr9
22081029
22082228
+
CDKN2B-AS1
0x0

5418
chr9
25676769
25677898
−
TUSC1
0x0

5419
chr9
26658888
26660011
+
IFT74
0x0

5420
chr9
26935048
26936169
−
PLAA
0x0

5421
chr9
28707158
28708331
−
LINGO2
0x0

5422
chr9
28846936
28848152
−
MIR876
0x0

5423
chr9
33011499
33012677
−
APTX
0x0

5424
chr9
33023893
33025172
−
SMU1
0x0

5425
chr9
33038376
33039941
+
DNAJA1
0x0

5426
chr9
33318207
33319380
+
NFX1
0x0

5427
chr9
33916595
33917697
+
UBE2R2
0x0

5428
chr9
33952273
33953373
−
SNORD121A
0x0

5429
chr9
33952273
33953373
−
UBAP2
0x0

5430
chr9
33955557
33956731
−
UBAP2
0x0

5431
chr9
33960256
33961456
−
UBAP2
0x0

5432
chr9
33963170
33964252
−
UBAP2
0x0

5433
chr9
34011964
34013151
−
UBAP2
0x0

5434
chr9
34016524
34017695
−
UBAP2
0x0

5435
chr9
34049409
34050630
−
SNORD121B
0x0

5436
chr9
34087271
34088491
−
DCAF12
0x0

5437
chr9
34185383
34186545
−
UBAP1
0x0

5438
chr9
34282012
34283214
−
KIF24
0x0

5439
chr9
34634177
34635546
−
SIGMAR1
0x0

5440
chr9
35101379
35102543
−
STOML2
0x0

5441
chr9
35398409
35399768
+
UNC13B
0x0

5442
chr9
35547214
35548291
+
RUSC2
0x0

5443
chr9
35657197
35658583
−
RMRP
0x0

5444
chr9
35705464
35707665
−
TLN1
0x2

5445
chr9
35712376
35713551
−
TLN1
0x2

5446
chr9
35737757
35738923
−
GBA2
0x0

5447
chr9
35748405
35749597
−
GBA2
0x0

5448
chr9
36211270
36212469
−
CLTA
0x0

5449
chr9
36215412
36216592
−
GNE
0x0

5450
chr9
37161890
37162980
+
ZCCHC7
0x0

5451
chr9
37180719
37181818
−
ZCCHC7
0x0

5452
chr9
37394697
37395893
+
GRHPR
0x0

5453
chr9
37425972
37427149
+
GRHPR
0x0

5454
chr9
37757009
37758131
+
RG9MTD3
0x0

5455
chr9
37776759
37777892
−
EXOSC3
0x0

5456
chr9
38392326
38393556
+
ALDH1B1
0x0

5457
chr9
38406249
38407526
−
IGFBPL1
0x1

5458
chr9
38408287
38409466
−
IGFBPL1
0x1

5459
chr9
38542057
38543182
−
ANKRD18A
0x0

5460
chr9
38548716
38549888
−
ANKRD18A
0x0

5461
chr9
45454163
45455328
+
FAM27A
0x0

5462
chr9
66862489
66863606
−
LOC286297
0x0

5463
chr9
72276359
72277573
−
APBA1
0x4

5464
chr9
72802958
72804155
−
LOC100507244
0x0

5465
chr9
74319441
74320649
−
TMEM2
0x0

5466
chr9
77639260
77640400
−
C9orf41
0x0

5467
chr9
79000589
79001744
−
RFK
0x0

5468
chr9
79186185
79187441
+
GCNT1
0x0

5469
chr9
80333954
80335131
−
GNAQ
0x2

5470
chr9
80461575
80462760
−
GNAQ
0x2

5471
chr9
80526971
80528160
−
GNAQ
0x2

5472
chr9
80624392
80625619
−
GNAQ
0x2

5473
chr9
81149233
81150432
+
PSAT1
0x0

5474
chr9
82201319
82202535
+
TIE4
0x2

5475
chr9
84036070
84037267
+
FAM75D5
0x0

5476
chr9
84250539
84251853
−
TLE1
0x0

5477
chr9
84486792
84487991
−
TLE1
0x0

5478
chr9
85827443
85828601
−
FRMD3
0x0

5479
chr9
86186741
86188057
−
FRMD3
0x0

5480
chr9
86292867
86294079
−
UBQIN1
0x0

5481
chr9
86582599
86583805
−
HNRNPK
0x0

5482
chr9
86598602
86599787
+
RMI1
0x0

5483
chr9
88260737
88261915
−
AGTPBP1
0x0

5484
chr9
88307117
88308237
−
AGTPBP1
0x0

5485
chr9
90115188
90116387
+
DAPK1
0x1

5486
chr9
91925658
91926817
+
CKS2
0x0

5487
chr9
94053627
94054823
−
AUH
0x0

5488
chr9
94666775
94667954
−
ROR2
0x0

5489
chr9
95017779
95019585
−
IARS
0x0

5490
chr9
95026780
95027945
−
IARS
0x0

5491
chr9
95148146
95149332
+
CENPP
0x0

5492
chr9
95289868
95290971
+
CENPP
0x0

5493
chr9
96054324
96055449
+
WNK2
0x1

5494
chr9
96259226
96260410
+
FAM120A
0x1

5495
chr9
96260521
96261610
+
FAM120A
0x1

5496
chr9
96304540
96306154
+
FAM120A
0x1

5497
chr9
96425818
96426994
+
PHF2
0x0

5498
chr9
97626912
97628116
+
MIR2278
0x0

5499
chr9
97747161
97748371
+
C9orf3
0x0

5500
chr9
98205195
98206341
−
PTCH1
0x1

5501
chr9
98665745
98667943
+
C9orf102
0x0

5502
chr9
98703213
98704414
+
C9orf102
0x0

5503
chr9
98864832
98866024
−
LOC158434
0x0

5504
chr9
99541077
99542255
−
ZNF510
0x0

5505
chr9
100434963
100436183
+
NCBP1
0x0

5506
chr9
100443119
100444445
+
NCBP1
0x0

5507
chr9
100777282
100778579
+
ANP32B
0x0

5508
chr9
101495339
101496482
−
ANKS6
0x0

5509
chr9
103086818
103087997
−
TEX10
0x0

5510
chr9
105967533
105968751
+
CYLC2
0x0

5511
chr9
108456322
108457519
+
TMEM38B
0x0

5512
chr9
108535853
108537110
+
TMEM38B
0x0

5513
chr9
108651081
108652249
+
TMEM38B
0x0

5514
chr9
110089577
110090784
+
RAD23B
0x0

5515
chr9
111650030
111651171
−
IKBKAP
0x0

5516
chr9
111778364
111779477
−
C9orf5
0x0

5517
chr9
111780160
111781373
−
C9orf5
0x0

5518
chr9
111790148
111791333
−
C9orf5
0x0

5519
chr9
111812360
111813518
−
C9orf5
0x0

5520
chr9
113016565
113017668
−
TXN
0x0

5521
chr9
113170031
113171232
+
AKAP2
0x0

5522
chr9
113170031
113171232
+
PALM2-AKAP2
0x0

5523
chr9
113740724
113741947
−
LPAR1
0x0

5524
chr9
114176345
114177492
−
KIAA0368
0x0

5525
chr9
114696644
114697810
+
UGCG
0x0

5526
chr9
114796115
114797308
−
SUSD1
0x0

5527
chr9
114802856
114804030
−
SUSD1
0x0

5528
chr9
114980670
114981806
−
PTBP3
0x0

5529
chr9
114993295
114994445
−
PTBP3
0x0

5530
chr9
115013987
115015217
+
HSDL2
0x0

5531
chr9
115248759
115249937
+
KIAA1958
0x0

5532
chr9
115260536
115261678
+
KIAA1958
0x0

5533
chr9
115335902
115337364
+
KIAA1958
0x0

5534
chr9
115346600
115347807
+
KIAA1958
0x0

5535
chr9
115424721
115426125
+
KIAA1958
0x0

5536
chr9
115448029
115450211
−
C9orf80
0x0

5537
chr9
115469920
115471091
−
C9orf80
0x0

5538
chr9
115531377
115532567
+
SNX30
0x0

5539
chr9
115682177
115683415
+
SNX30
0x0

5540
chr9
116023582
116024730
+
SLC31A1
0x0

5541
chr9
116792285
116793484
+
ZNF618
0x0

5542
chr9
116815803
116817028
+
ZNF618
0x0

5543
chr9
116991103
116992232
+
COL27A1
0x0

5544
chr9
117068821
117069994
+
COL27A1
0x0

5545
chr9
117359969
117361206
+
ATP6V1G1
0x0

5546
chr9
117370634
117371856
−
LOC100S0S478
0x0

5547
chr9
120844756
120846132
−
ASTN2
0x0

5548
chr9
123227241
123228507
−
CDK5RAP2
0x0

5549
chr9
123618193
123619372
−
PHF19
0x0

5550
chr9
124101279
124102449
−
STOM
0x0

5551
chr9
124544477
124545706
+
DAB2IP
0x1

5552
chr9
124546847
124548061
+
DAB2IP
0x1

5553
chr9
125641926
125643151
−
RC3H2
0x0

5554
chr9
125641926
125643151
−
SNORD90
0x0

5555
chr9
125842673
125843822
+
RABGAP1
0x0

5556
chr9
126021388
126022620
−
STRBP
0x0

5557
chr9
127115305
127116453
−
PSMB7
0x0

5558
chr9
127194668
127195860
+
GPR144
0x0

5559
chr9
127362373
127363500
+
NR6A1
0x0

5560
chr9
127619641
127620905
−
RPL35
0x0

5561
chr9
128099141
128100376
+
GAPVD1
0x0

5562
chr9
128620793
128622016
+
PBX3
0x0

5563
chr9
128985818
128987014
−
NRON
0x0

5564
chr9
129456477
129457634
+
LMX1B
0x4

5565
chr9
129461350
129462503
+
LMX1B
0x4

5566
chr9
129567385
129568582
+
ZBTB43
0x0

5567
chr9
130209656
130210776
−
RPL12
0x0

5568
chr9
130547783
130548996
+
CDK9
0x0

5569
chr9
130547783
130548996
+
MIR2861
0x0

5570
chr9
130547783
130548996
+
MIR3960
0x0

5571
chr9
130630132
130631339
−
AK1
0x0

5572
chr9
130647627
130648808
−
ST6GALNAC6
0x0

5573
chr9
130886273
130887511
−
PTGES2
0x0

5574
chr9
131101823
131103019
−
TRUB2
0x0

5575
chr9
131369703
131371031
+
SPTAN1
0x2

5576
chr9
131457332
131458528
+
SET
0x2

5577
chr9
131517208
131518346
−
ZER1
0x0

5578
chr9
131668747
131669926
+
LRRC8A
0x0

5579
chr9
131679585
131680770
+
LRRC8A
0x0

5580
chr9
131727918
131729140
+
NUP188
0x0

5581
chr9
131732532
131733679
+
NUP188
0x0

5582
chr9
131770371
131771456
−
SH3GLB2
0x0

5583
chr9
131773181
131774253
−
SH3GLB2
0x0

5584
chr9
131832278
131833404
+
FAM73B
0x0

5585
chr9
132266292
132267491
+
LOC100506190
0x0

5586
chr9
132395806
132396981
+
METTLUA
0x0

5587
chr9
132400461
132402140
−
ASB6
0x0

5588
chr9
132650535
132651858
−
FNBP1
0x2

5589
chr9
132899707
132901024
+
GPR107
0x0

5590
chr9
132995682
132998198
+
NCS1
0x0

5591
chr9
133576846
133578028
+
EXOSC2
0x0

5592
chr9
133580429
133581619
+
EXOSC2
0x0

5593
chr9
133690736
133691950
+
ABL1
0x2

5594
chr9
133924803
133925919
+
LAMC3
0x0

5595
chr9
133996060
133997384
+
AIF1L
0x0

5596
chr9
134287069
134288195
+
PRRC2B
0x0

5597
chr9
134304953
134306142
+
PRRC2B
0x0

5598
chr9
134313808
134315037
+
PRRC2B
0x0

5599
chr9
134319022
134320189
+
PRRC2B
0x0

5600
chr9
134371214
134373009
+
PRRC2B
0x0

5601
chr9
134374644
134375968
+
PRRC2B
0x0

5602
chr9
134451766
134453602
−
RAPGEF1
0x0

5603
chr9
134857136
134858315
−
MED27
0x0

5604
chr9
134913794
134914897
−
MED27
0x0

5605
chr9
135139556
135140719
−
SETX
0x0

5606
chr9
135275910
135277087
−
TTF1
0x0

5607
chr9
135483943
135485086
−
DDX31
0x0

5608
chr9
135784782
135785881
−
TSC1
0x1

5609
chr9
135924729
135925906
−
GTF3C5
0x0

5610
chr9
135973592
135974691
−
RALGDS
0x2

5611
chr9
135998700
136000170
−
RALGDS
0x2

5612
chr9
136020317
136021667
−
RALGDS
0x2

5613
chr9
136203824
136205001
−
SURF6
0x0

5614
chr9
136216397
136217914
+
RPL7A
0x0

5615
chr9
136216397
136217914
+
SNORD36A
0x0

5616
chr9
136216397
136217914
+
SNORD36B
0x0

5617
chr9
136216397
136217914
+
SNORD36C
0x0

5618
chr9
136228108
136230784
−
SURF4
0x0

5619
chr9
136474800
136475979
−
FAM163B
0x0

5620
chr9
137023421
137024790
+
WDR5
0x0

5621
chr9
137029029
137030228
−
RNU6ATAC
0x0

5622
chr9
137305770
137306997
−
RXRA
0x0

5623
chr9
138264957
138266133
+
PPP1R26
0x0

5624
chr9
138651228
138652408
−
CAMSAP1
0x0

5625
chr9
138772916
138775474
−
CAMSAP1
0x0

5626
chr9
138835556
138836655
−
UBAC1
0x0

5627
chr9
139098581
139099758
−
QSOX2
0x0

5628
chr9
139248624
139249755
+
GPSM1
0x0

5629
chr9
139252436
139253615
+
GPSM1
0x0

5630
chr9
139270387
139271514
−
SNAPC4
0x0

5631
chr9
139300843
139302303
−
SDCCAG3
0x0

5632
chr9
139306000
139307223
+
PMPCA
0x0

5633
chr9
139326284
139327462
−
INPP5E
0x0

5634
chr9
139334317
139335518
−
SEC16A
0x0

5635
chr9
139355237
139356585
−
SEC16A
0x0

5636
chr9
139369167
139370266
−
SEC16A
0x0

5637
chr9
139608470
139609690
+
FAM69B
0x0

5638
chr9
139618664
139619796
−
SNHG7
0x0

5639
chr9
139620014
139621238
−
SNHG7
0x0

5640
chr9
139620014
139621238
−
SNORA17
0x0

5641
chr9
139620014
139621238
−
SNORA43
0x0

5642
chr9
139686353
139687562
+
TMEM141
0x0

5643
chr9
139716292
139717458
+
C9orf86
0x0

5644
chr9
139725678
139726811
+
C9orf86
0x0

5645
chr9
139734812
139735981
+
C9orf86
0x0

5646
chr9
139743402
139744501
+
PHPT1
0x4

5647
chr9
139827010
139828223
+
TRAF2
0x0

5648
chr9
139901384
139902524
−
ABCA2
0x0

5649
chr9
139904579
139905686
−
ABCA2
0x0

5650
chr9
139908105
139909204
−
ABCA2
0x0

5651
chr9
139911510
139912639
−
ABCA2
0x0

5652
chr9
139916992
139918141
−
ABCA2
0x0

5653
chr9
139936983
139939048
−
NPDC1
0x0

5654
chr9
139939110
139940262
−
NPDC1
0x0

5655
chr9
139956840
139958016
−
SAPCD2
0x0

5656
chr9
139972957
139974872
+
UAP1L1
0x0

5657
chr9
140001474
140002681
+
MAN1B1
0x0

5658
chr9
140078233
140079809
−
ANAPC2
0x0

5659
chr9
140082995
140084194
+
SSNA1
0x0

5660
chr9
140100452
140101634
+
NDOR1
0x0

5661
chr9
140136707
140137882
+
TUBB4B
0x0

5662
chr9
140147472
140148671
+
C9orf173
0x0

5663
chr9
140169601
140170815
+
C9orf167
0x0

5664
chr9
140279070
140280213
−
EXD3
0x0

5665
chr9
140342309
140343845
−
NELF
0x0

5666
chr9
140351347
140352478
−
NELF
0x0

5667
chr9
140375375
140376591
−
PNPLA7
0x0

5668
chr9
140481200
140482329
−
ZMYND19
0x0

5669
chr9
140484130
140485265
−
ZMYND19
0x0

5670
chr9
140637806
140638965
+
EHMT1
0x0

5671
chr9
140729130
140730908
+
EHMT1
0x0

5672
chr9
141054281
141055394
+
TUBBP5
0x0

5673
chr9
141132390
141133605
+
FAM157B
0x0

5674
chrX
3522243
3523476
−
PRKX
0x2

5675
chrX
6340101
6341264
−
MIR4770
0x0

5676
chrX
8326354
8327513
+
VCX3B
0x2

5677
chrX
9543660
9544882
+
TBL1X
0x0

5678
chrX
9571405
9572643
+
TBL1X
0x0

5679
chrX
9862050
9863191
+
SHROOM2
0x0

5680
chrX
11010346
11011488
−
ARHGAP6
0x0

5681
chrX
14629215
14630428
−
FANCB
0x0

5682
chrX
14876727
14877909
−
FANCB
0x0

5683
chrX
15421374
15422561
−
PIR-FIGF
0x0

5684
chrX
17091194
17092417
+
REP52
0x0

5685
chrX
17300438
17301635
+
NHS
0x0

5686
chrX
18372174
18373364
−
SCML2
0x0

5687
chrX
20153607
20154922
−
EIF1AX
0x0

5688
chrX
20153607
20154922
−
SCARNA9L
0x0

5689
chrX
21576566
21577762
+
CNKSR2
0x0

5690
chrX
22229861
22231058
+
PHEX
0x0

5691
chrX
24095005
24096156
+
EIF2S3
0x0

5692
chrX
24175280
24176442
+
ZFX
0x0

5693
chrX
24196894
24198305
+
ZFX
0x0

5694
chrX
24761177
24763241
+
POLA1
0x0

5695
chrX
24761177
24763241
+
SCARNA23
0x0

5696
chrX
24977492
24978688
+
POLA1
0x0

5697
chrX
27399828
27401046
−
SMEK3P
0x0

5698
chrX
29000399
29001566
−
DCAF8L1
0x0

5699
chrX
30648152
30649398
+
GK
0x0

5700
chrX
34233500
34234721
+
FAM47B
0x0

5701
chrX
39645752
39646886
−
BCOR
0x2

5702
chrX
40464569
40465726
+
ATP6AP2
0x0

5703
chrX
41092038
41093252
+
USP9X
0x0

5704
chrX
41207726
41208825
+
DDX3X
0x1

5705
chrX
44736213
44737379
+
KDM6A
0x2

5706
chrX
46299524
46300707
−
ZNF674
0x0

5707
chrX
47081266
47082479
+
CDK16
0x0

5708
chrX
47088062
47089227
+
CDK16
0x0

5709
chrX
47495209
47496359
−
ELK1
0x0

5710
chrX
47665780
47667007
+
ZNF81
0x0

5711
chrX
47746834
47748055
+
ZNF81
0x0

5712
chrX
48435453
48436647
+
RBM3
0x0

5713
chrX
48462703
48463818
+
WDR13
0x0

5714
chrX
48831187
48832583
−
GRIPAP1
0x0

5715
chrX
49126721
49127934
−
PPP1R3F
0x0

5716
chrX
49857672
49858823
+
CLCN5
0x2

5717
chrX
51936036
51937238
+
MAGED4
0x0

5718
chrX
51936036
51937238
+
MAGED4B
0x0

5719
chrX
53106605
53107796
+
GPR173
0x0

5720
chrX
53134334
53135497
+
TSPYL2
0x0

5721
chrX
53405372
53407332
−
SMC1A
0x0

5722
chrX
53569946
53571046
−
HUWE1
0x0

5723
chrX
53618943
53620070
−
HUWE1
0x0

5724
chrX
53673766
53675041
−
HUWE1
0x0

5725
chrX
53792619
53793775
−
HUWE1
0x0

5726
chrX
54594744
54595938
+
GNL3L
0x0

5727
chrX
54596140
54597311
+
GNL3L
0x0

5728
chrX
56992161
56993336
−
SPIN3
0x0

5729
chrX
68004807
68006025
+
EFNB1
0x0

5730
chrX
68379551
68380728
−
PJA1
0x0

5731
chrX
68891771
68893024
+
EDA
0x0

5732
chrX
69380277
69381519
+
IGBP1
0x0

5733
chrX
69531191
69532421
+
KIF4A
0x0

5734
chrX
69691179
69692344
+
DLG3
0x2

5735
chrX
69720649
69721848
+
DLG3
0x2

5736
chrX
70182424
70183623
+
FOXO4
0x1

5737
chrX
70507281
70508462
−
ZMYM3
0x0

5738
chrX
70520333
70521503
+
NONO
0x2

5739
chrX
70602894
70604095
+
TAF1
0x2

5740
chrX
70861969
70863207
+
ACRC
0x0

5741
chrX
71570013
71571157
−
HDAC8
0x0

5742
chrX
71596356
71597548
−
HDAC8
0x0

5743
chrX
71769793
71770972
−
HDAC8
0x0

5744
chrX
73046559
73048327
−
XIST
0x4

5745
chrX
73052516
73053845
−
XIST
0x4

5746
chrX
73057033
73059270
−
XIST
0x4

5747
chrX
73062806
73063994
−
XIST
0x4

5748
chrX
73069685
73073030
−
XIST
0x4

5749
chrX
73170342
73171562
+
JPX
0x0

5750
chrX
73430482
73431552
−
MIR421
0x0

5751
chrX
73436680
73437810
−
MIR421
0x0

5752
chrX
73482382
73483604
−
FTX
0x0

5753
chrX
73494914
73496013
−
FTX
0x0

5754
chrX
76923431
76924656
−
ATRX
0x2

5755
chrX
77081697
77082848
−
MAGT1
0x0

5756
chrX
77105733
77106914
−
MAGT1
0x0

5757
chrX
79927079
79928302
−
BRWD3
0x0

5758
chrX
81950478
81951677
−
RPS6KA6
0x1

5759
chrX
85340420
85341609
−
CHM
0x0

5760
chrX
96438715
96439906
+
DIAPH2
0x0

5761
chrX
99410666
99411825
−
PCDH19
0x0

5762
chrX
100289732
100290890
−
TRMT2B
0x0

5763
chrX
100654698
100655907
−
GLA
0x0

5764
chrX
100668386
100669571
+
HNRNPH2
0x0

5765
chrX
100668386
100669571
+
RPL36A-HNRNPH2
0x0

5766
chrX
100678736
100679933
+
ARMCX4
0x0

5767
chrX
102108868
102110010
+
LOC100287765
0x0

5768
chrX
102185541
102186736
+
RAB40AL
0x0

5769
chrX
102632229
102633433
+
NGFRAP1
0x0

5770
chrX
102930316
102931634
−
MORF4L2
0x0

5771
chrX
103407200
103408423
+
FAM199X
0x0

5772
chrX
103416323
103417521
+
FAM199X
0x0

5773
chrX
105855261
105856451
+
CXorf57
0x0

5774
chrX
106164212
106165373
−
R1PPLY1
0x0

5775
chrX
106184082
106185253
−
MORC4
0x0

5776
chrX
106236843
106238032
−
MORC4
0x0

5777
chrX
106296930
106298133
−
RBM41
0x0

5778
chrX
106312517
106313695
−
RBM41
0x0

5779
chrX
106351735
106352899
−
RBM41
0x0

5780
chrX
106956061
106957210
−
TSC22D3
0x0

5781
chrX
107083544
107084738
+
MID2
0x0

5782
chrX
107330418
107331641
−
PSMD10
0x0

5783
chrX
107692109
107693273
+
COL4A5
0x0

5784
chrX
107755369
107756586
+
COL4A5
0x0

5785
chrX
107962711
107965128
−
IRS4
0x2

5786
chrX
107965833
107966886
+
IRS4
0x2

5787
chrX
107978161
107979977
−
IRS4
0x2

5788
chrX
108296815
108298321
+
COL4A5
0x0

5789
chrX
108885425
108886557
−
ACSL4
0x0

5790
chrX
109418043
109419259
+
TMEM164
0x0

5791
chrX
109419535
109421324
+
TMEM164
0x0

5792
chrX
109440950
109442127
−
AMMECR1
0x0

5793
chrX
110928049
110929158
+
ALG13
0x0

5794
chrX
111556247
111557485
−
ZCCHC16
0x0

5795
chrX
112018825
112019925
−
AMOT
0x0

5796
chrX
112832649
112833826
−
AMOT
0x0

5797
chrX
114388539
114389720
−
LRCH2
0x0

5798
chrX
114860238
114861417
−
LRCH2
0x0

5799
chrX
114883597
114884758
+
PLS3
0x0

5800
chrX
114937422
114938740
+
PLS3
0x0

5801
chrX
114952760
114953901
−
LRCH2
0x0

5802
chrX
115033924
115035353
−
CXorf61
0x0

5803
chrX
115051152
115052326
−
cxorf61
0x0

5804
chrX
115108241
115109440
−
CXorf61
0x0

5805
chrX
117333430
117334585
−
KLHL13
0x0

5806
chrX
117512110
117513293
+
WDR44
0x0

5807
chrX
118151592
118152740
+
LONRF3
0x0

5808
chrX
118377285
118378507
+
PGRMC1
0x0

5809
chrX
118557172
118558436
+
SLC25A43
0x0

5810
chrX
118603146
118604243
+
SLC25A5
0x0

5811
chrX
118717249
118718392
+
UBE2A
0x2

5812
chrX
118919904
118921072
−
RPL39
0x0

5813
chrX
119005351
119006450
+
NDUFA1
0x0

5814
chrX
119390792
119391981
+
ZBTB33
0x0

5815
chrX
119658057
119660511
−
CUL4B
0x0

5816
chrX
122736393
122737568
−
THOC2
0x0

5817
chrX
123041693
123042887
+
XIAP
0x0

5818
chrX
123095598
123096767
+
STAG2
0x0

5819
chrX
123234731
123236864
+
STAG2
0x0

5820
chrX
128705605
128706804
+
OCRL
0x0

5821
chrX
128725857
128727037
+
OCRL
0x0

5822
chrX
129065075
129066245
−
ZDHHC9
0x0

5823
chrX
129535551
129536727
−
GPR119
0x0

5824
chrX
129538199
129539389
+
RBMX2
0x0

5825
chrX
130882834
130884008
−
LOC286467
0x0

5826
chrX
130889093
130890323
−
LOC286467
0x0

5827
chrX
130902059
130903202
−
LOC286467
0x0

5828
chrX
130917396
130918579
−
LOC286467
0x0

5829
chrX
130927787
130929004
−
LOC286467
0x0

5830
chrX
131198110
131199259
+
MST4
0x0

5831
chrX
131337023
131338180
−
RAP2C
0x0

5832
chrX
131512145
131513234
−
MBNL3
0x0

5833
chrX
131760858
131762133
−
HS6ST2
0x0

5834
chrX
132081206
132082401
−
HS6ST2
0x0

5835
chrX
132435951
132437179
−
GPC4
0x0

5836
chrX
132804697
132805894
+
CCDC160
0x0

5837
chrX
133682855
133684020
−
MIR424
0x0

5838
chrX
133683746
133684962
+
LOC100506757
0x0

5839
chrX
133693934
133695138
+
LOC100506757
0x0

5840
chrX
133750415
133751607
−
PLAC1
0x0

5841
chrX
133904208
133905344
−
FAM122B
0x0

5842
chrX
134169327
134170543
+
FAM127A
0x0

5843
chrX
134685389
134686586
+
DDX26B
0x0

5844
chrX
134700591
134701697
+
DDX26B
0x0

5845
chrX
134704442
134705586
+
DDX26B
0x0

5846
chrX
135044994
135047017
−
MMGT1
0x0

5847
chrX
135292161
135293316
+
FHL1
0x0

5848
chrX
135894541
135895736
−
ARHGEF6
0x0

5849
chrX
135960801
135962006
−
RBMX
0x1

5850
chrX
135960801
135962006
−
SNORD61
0x0

5851
chrX
138051867
138053046
+
LOC100129662
0x0

5852
chrX
138822633
138823803
−
ATP11C
0x0

5853
chrX
139806745
139807946
+
RP1-177G62
0x0

5854
chrX
144138226
144139456
+
SPANXN1
0x0

5855
chrX
147024021
147025185
+
FMR1
0x0

5856
chrX
147743371
147744594
+
AFF2
0x2

5857
chrX
148615669
148616861
−
LOC100131434
0x0

5858
chrX
148622764
148623954
+
CXorf40A
0x0

5859
chrX
149101387
149102530
−
CXorf40B
0x0

5860
chrX
149283200
149284299
+
LOC100272228
0x0

5861
chrX
149932765
149933963
+
MTMR1
0x0

5862
chrX
149934398
149936217
−
CD99L2
0x0

5863
chrX
150156335
150157614
+
HMGB3
0x0

5864
chrX
150347357
150348535
+
GPR50
0x0

5865
chrX
152138729
152139828
+
ZNF185
0x0

5866
chrX
152615120
152616281
+
ZNF275
0x0

5867
chrX
152712573
152713786
−
HAUS7
0x0

5868
chrX
152907741
152908844
+
DUSP9
0x2

5869
chrX
152931282
152932454
+
DUSP9
0x2

5870
chrX
152961002
152962294
+
SLC6A8
0x0

5871
chrX
153061339
153062580
+
SSR4
0x0

5872
chrX
153212601
153214292
−
HCFC1
0x0

5873
chrX
153229508
153230711
−
HCFC1
0x0

5874
chrX
153275908
153277630
−
IRAK1
0x0

5875
chrX
153282970
153284121
−
IRAK1
0x0

5876
chrX
153290837
153291997
−
MECP2
0x0

5877
chrX
153329200
153330332
−
MECP2
0x0

5878
chrX
153582804
153583968
−
FLNA
0x2

5879
chrX
153590352
153591533
−
FLNA
0x2

5880
chrX
153607528
153608725
+
EMD
0x0

5881
chrX
153626228
153627408
+
RPL10
0x1

5882
chrX
153648801
153649993
+
TAZ
0x0

5883
chrX
153656522
153657630
+
ATP6AP1
0x0

5884
chrX
153663803
153666133
+
ATP6AP1
0x0

5885
chrX
153663803
153666133
+
GDI1
0x0

5886
chrX
153670936
153672130
+
GDI1
0x0

5887
chrX
153677138
153678294
+
FAM50A
0x0

5888
chrX
153736962
153738109
−
FAM3A
0x0

5889
chrX
153743942
153745077
−
FAM3A
0x0

5890
chrX
153996235
153997439
+
DKC1
0x0

5891
chrX
153996235
153997439
+
SNORA36A
0x0

5892
chrX
154002693
154003854
+
DKC1
0x0

5893
chrX
154002693
154003854
+
SNORA56
0x0

Lengthy table referenced here

US20220403380A1-20221222-T00001

Please refer to the end of the specification for access instructions.

OTHER EMBODIMENTS

It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

LENGTHY TABLES

The patent application contains a lengthy table section. A copy of the table is available in electronic form from the USPTO web site (). An electronic copy of the table will also be available from the USPTO upon request and payment of the fee set forth in 37 CFR 1.19(b)(3).

	Number	Date	Country
Parent	15558974	Sep 2017	US
Child	17038425		US

RNA Interactome of Polycomb Repressive Complex 1 (PRC1)

Information

Publication Number

Date Filed

Date Published

Inventors

Original Assignees

CPC

International Classifications

Abstract

Description

Claims

CLAIM OF PRIORITY

FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

Provisional Applications (1)

Continuations (1)